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about this Publication
In 2008  Harm Reduction International released the Global State of Harm Reduction, a report that mapped 
responses to drug-related HIV and hepatitis C epidemics around the world for the first time. The report 
has since been published every two years.
The Global State of Harm Reduction 2012 presents the major developments in harm reduction policy 
adoption and programme implementation that have occurred since 2010, enabling some assessment of 
global progress. It also explores several key issues for developing an integrated harm reduction response, 
such as building effective harm reduction services for women who inject drugs, access to harm reduction 
services by young people, drug use among men who have sex with men, global progress toward drug 
decriminalisation and regulation and sustainability of services in challenging environments.
This report, and other global state of harm reduction resources, are designed to provide reference tools for 
a wide range of audiences, such as international donor organisations, multilateral and bilateral agencies, 
civil society and non-governmental organisations, including organisations of people who use drugs, as 
well as researchers and the media.
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If you would like to find out more about Harm Reduction International
and how you can support our work, please contact us at:
Harm Reduction International
Unit 2D12, South Bank Technopark
90 London Road, London, SE1 6LN
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Email: info@ihra.net
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Introduction
AHRN Asian Harm Reduction Network 
AIVL Australian Injecting and Illicit Drug Users’ League 
AIDS Acquired immunodeficiency syndrome 
ANPUD Asian Network of People who use Drugs 
ART Antiretroviral therapy 
ATS Amphetamine-type stimulants 
BMT Buprenorphine maintenance treatment 
CARICOM Caribbean Community 
CHRC Caribbean Harm Reduction Coalition 
CND Commission on Narcotic Drugs 
CPR Cardiopulmonary resuscitation 
CPT Co-trimoxazole preventive treatment 
CSO Civil society organisation 
DCR Drug consumption room 
DFID Department for International Development (UK) 
DOTS Directly Observed Treatment Short-Course 
ECOSOC Economic and Social Council (UN) 
EMCDDA European Monitoring Centre for Drugs and Drug 
Addiction 
EMRO WHO Eastern Mediterranean Regional Office 
EC European Commission 
EU European Union
EuroHRN European Harm Reduction Network 
GDP Gross Domestic Product 
GFATM Global Fund to Fight AIDS, Tuberculosis and 
Malaria 
GP General practitioner 
GTZ Deutsche Gesellschaft für Technische 
Zusammenarbeit 
HAT Heroin assisted treatment 
HBV Hepatitis B virus 
HBsAG Marker in the blood indicating active HBV 
infection 
HCV Hepatitis C virus 
HIV Human immunodeficiency virus 
HLS High Level Segment 
IDU Injecting drug use 
IHRA International Harm Reduction Association 
INCB International Narcotics Control Board 
INPUD International Network of People who Use Drugs 
MENA Middle East and North Africa 
MENAHRA Middle East and North African Harm Reduction 
Network 
MDT Mandatory drug testing 
MMT Methadone maintenance treatment 
MSM Men who have sex with men 
NASA National AIDS Spending assessment 
NGO Non-governmental organisation 
NIDU Non-injecting drug use 
NSP Needle and syringe exchange programme 
OST Opioid substitution therapy 
PAHO Pan American Health Organization (WHO) 
PEPFAR President’s Emergency Plan for AIDS Relief 
PICTs Pacific Island Countries and Territories 
PNEP Prison needle and syringe exchange programme 
SAHRN Sub-Saharan African Harm Reduction Network 
SAMHSA US Substance Abuse and Mental Health Services 
Administration 
SIF Supervised or safer injecting facility 
STI Sexually transmitted infection 
SPC Secretariat of the Pacific Community 
TB Tuberculosis
UAE United Arab Emirates 
UK United Kingdom of Great Britain and Northern 
Ireland 
UN United Nations 
UNAIDS Joint United Nations Programme on HIV/AIDS 
UNDP United Nations Development Programme 
UNESCO United Nations Economic, Social and Cultural 
Organization 
UNFPA United Nations Population Fund 
UNGASS United Nations General Assembly Special Session
UNICEF United Nations Children’s Fund 
UNODC United Nations Office on Drugs and Crime 
MENARO 
UNODC
Middle East and North Africa Regional Office 
US United States of America 
VCT Voluntary HIV counselling and testing 
WFP World Food Programme (UN) 
WHO World Health Organization
4Introductory comments from Michel Sidibé 
Executive Director, UNAIDS
The third edition of the Global State of Harm Reduction 
report comes at a pivotal time in the HIV epidemic. 
Thirty per cent of HIV infections outside sub-Saharan Africa, 
representing approximately 3 million people, are attributed 
to injecting drug use. New infections among people who 
use drugs account for an increasing share of global HIV 
incidence. In Eastern Europe and Central Asia, injecting drug 
use accounts for up to 80% of HIV infections, with the annual 
rate of new HIV infections in the region having increased 
by more than 250% between 2001 and 2010.a  In several 
countries in sub-Saharan Africa including Kenya, Tanzania 
and South Africa a new wave of infections due to drug 
injecting has emerged in recent years.
This reality serves as an urgent reminder of the commitment 
made by all United Nations Member States in the 2011 
Political Declaration on HIV/AIDS to reduce transmission 
of HIV among people who inject drugs by 50% by 2015. 
Achieving this target demands a cohesive response to 
HIV from UN agencies, states, civil society and affected 
communities alike based on the strongest available public 
health evidence and human rights principles. 
UNAIDS is unequivocal in its message to Member States 
about what works to reduce HIV transmission among 
people who inject drugs. The evidence is clear and decisive: 
sufficient provision and coverage of needle and syringe 
programmes, opioid substitution therapy and antiretroviral 
therapy as part of the nine key interventions outlined in the 
WHO, UNODC, UNAIDS technical guide work to effectively 
reduce HIV transmission among people who inject drugs, as 
well as providing other measurable benefits to individuals’ 
health and their communities.
Despite the existence of these evidence-based and cost-
effective harm reduction interventions, their coverage 
remains shockingly low. As this report highlights, fewer 
than two clean needles per month are distributed globally 
per person who injects drugs, under 13% of people who 
use drugs are enrolled in opioid substitution therapy, and 
only 4% of people who inject drugs living with HIV are on 
antiretroviral treatment. b
Most alarming is that a significant number of countries 
with reported injecting drug use continue to restrict access 
to these services. Punitive laws and policies, whether via 
prohibiting the provision of sterile injecting equipment 
and opioid substitution therapy, criminalising drug use, 
a    UNAIDS (2010) Global Report. UNAIDS Report on the Global AIDS Epidemic. Geneva: UN-
AIDS.
b   Mathers BM et al. for the UN Reference Group on IDU (2010) The global epidemiology of 
injecting drug use and HIV among people who inject drugs: A systematic review, Lancet, 372 
(9651): 1733–1745.
possession of injecting paraphernalia, or denying HIV 
treatment to people who use drugs, violate people’s right to 
health and harm the community. Such punitive policies not 
only fail to reduce HIV transmission but create unintended 
harms – for instance, by driving people who inject drugs 
away from prevention and care and resulting in prison 
overcrowding. Responses to HIV should transcend ideology 
and be based on scientific evidence and sound human rights 
principles; they should support, not punish, those affected. 
UN Secretary-General Ban Ki-Moon stated that “No one 
should be stigmatised or discriminated against because 
of their dependence on drugs” and called on UN Member 
States to ensure that people who use drugs have equal 
access to health and social services. An important function of 
UNAIDS is to highlight the adverse human rights and public 
health impacts of restrictive laws and policies, and “to create 
protective social and legal environment that enable access 
to HIV programmes.”c Further, in its 2011–2015 Strategy, 
Getting to Zero, UNAIDS is explicit about reducing by half 
the number of “countries with punitive laws and practices 
around HIV transmission, drug use or homosexuality that 
block effective responses”. 
The need for legal reform aligned with HIV prevention and 
treatment, complemented by the meaningful involvement 
of people who use drugs in service and policy formulation 
and implementation, has never been more imperative than 
it is now for achieving the goal of universal access. 
On behalf of the UNAIDS Secretariat and our co-sponsors, 
I am proud to say that UNAIDS is committed to playing 
the leading role in a coordinated, unambiguous and bold 
UN response to HIV among people who inject drugs. In 
an increasingly hostile policy climate, we must replace 
dangerous complacency with decisive action when it 
comes to HIV-related harm reduction. Without firm global 
leadership, evidence and human rights-based national 
policies, bold resource replenishment for harm reduction 
and urgent scale-up of harm reduction interventions, there 
will be no “getting to zero”. 
The original Global State of Harm Reduction report, 
published in 2008, provided the first global snapshot 
of harm reduction service availability and coverage, 
reflecting the contributions of civil society organisations, 
multilateral agencies and researchers in the drug-related 
HIV response. Since then, the biennial reports have become 
an indispensable reference tool and authoritative resource 
for a wide range of agencies and individuals engaging in 
advocacy for harm reduction worldwide. The latest edition 
c   UNAIDS (2010) Strategy 2011–2015: Getting to Zero. Geneva: UNAIDS
5of the report includes important data on viral hepatitis, 
and a timely focus on intersections between drug use, HIV 
and harm reduction services among other key affected 
populations, including women, children and men who have 
sex with men. These sub-populations of people who inject 
drugs are often the most marginalised in the global AIDS 
response, requiring immediate services and a proportionate 
allocation of HIV prevention resources. The promotion of 
harm reduction as part of a bolder, more united and more 
comprehensive global effort will be essential to halving HIV 
infections among people who inject drugs by 2015. 
Michel Sidibé
Executive Director, UNAIDS
Introductory comments from Michel Kazatchkine 
Member of the Global Commission on Drug Policy
People who inject drugs remain a key population in global 
health, accounting for around 3 million HIV infections 
and 10 million hepatitis C infections. This is in addition to 
the numerous financial, social and public health burdens 
associated with overdose and drug dependence. But if you 
are reading this report, you probably know this all too well.
However, these issues – and the proven harm reduction 
interventions that can address them – are more important 
now than ever before. In a global economic downturn the 
burden of drug use is likely to increase, while the finances to 
deal with these problems become ever more limited. In 2011, 
United Nations Member States committed to reducing HIV 
transmission among people who inject drugs by 50% in the 
next four years, and yet we now face a major crossroads in 
the response. It is essential that people who use drugs are not 
forgotten or overlooked.
The Global State of Harm Reduction reports have fast become 
an integral tool in the ongoing advocacy for people who inject 
drugs. These biennial documents are helping us to track the 
progress that has been made. Grassroots projects to protect 
people who inject drugs in the 1980s have been developed, 
scaled up and integrated into mainstream healthcare in many 
diverse countries around the world. The evidence base has 
also grown, allowing harm reduction to become standard 
jargon for the key international bodies: including the United 
Nations General Assembly, the Office of the United Nations 
High Commissioner for Human Rights, the World Health 
Organization, the Joint United Nations Programme on HIV/
AIDS, and the United Nations Office on Drugs and Crime. 
I will always be proud to say that the Global Fund to Fight AIDS, 
Tuberculosis and Malaria explicitly supports harm reduction 
and is the leading international donor for this approach.d The 
Global Fund faces its own challenges in the current financial 
climate but remains committed to funding essential services 
including those for people who inject drugs. This report is a 
d   Bridge J et al. (2012) Global Fund Investments in Harm Reduction from 2002 to 2009, 
International Journal of Drug Policy (23): 279–285.
timely reminder of the urgent need for continued and reliable 
financing for harm reduction. 
This report also highlights huge anomalies in the international 
response. In 2009, at the International Harm Reduction 
Conference in Bangkok, I stated that some countries “seem 
determined to swim against the tide with their wilful blindness 
to the evidence”. This remains the case. For example, there are 
120 countries that report HIV transmission among people who 
inject drugs, yet only 86 countries implement official needle 
and syringe programmes to some degree in order to prevent 
this transmission. In a majority of settings, coverage of such 
programmes is far below the level needed to have an impact. 
Too often we have seen inexpensive and cost-effective harm 
reduction approaches being overlooked, overshadowed or 
undermined by expensive and often ineffectual approaches 
with a ‘war on drugs’ rhetoric. The compulsory detention, 
forced treatment, execution, torture and corporal punishment 
of people who use drugs simply have to stop. They are 
violations of human rights and international law. 
This is the third edition of this flagship publication, which 
provides the latest data on harm reduction, expanded 
regional updates and key thematic chapters. I would like 
to thank Harm Reduction International for giving me the 
opportunity to provide these introductory comments, and 
I wish you all the best in using this valuable resource to 
promote harm reduction in your own settings.
Professor Michel Kazatchkine
Former Executive Director of the Global Fund to Fight AIDS, 
Tuberculosis and Malaria
Member of the Global Commission on Drug Policy
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6Introductory comments by Eliot Ross Albers
Executive Director, International Network of People who Use Drugs (INPUD)
On behalf of the International Network of People Who Use 
Drugs (INPUD), I welcome this third edition of the Global State 
of Harm Reduction, and thank Harm Reduction International 
for giving me the chance to add these opening remarks to 
what has become an essential tool used by INPUD and our 
members in their advocacy for the provision of essential harm 
reduction services for our community. 
The evidence base for the efficacy of harm reduction 
programmes is irrefutable and widely supported by 
international agencies including UNAIDS, the Global Fund 
to Fight AIDS, Tuberculosis and Malaria, the World Health 
Organization (WHO) and the Office of the United Nations 
High Commissioner for Human Rights.
Despite the overwhelming evidence in favour of harm 
reduction programmes, this report shows that there remains 
a significant discrepancy between what we know should be 
providede and what actually is.
The publication of this report is especially timely, as not only 
are we in the grip of a global recession, but we are also seeing 
a political retreat from harm reduction on the domestic front 
by several states that have historically been strong supporters 
(e.g. the Netherlands and the United Kingdom); on the other 
hand, their international support for harm reduction remains 
strong. In many countries in Eastern Europe where the HIV 
and viral hepatitis epidemics are especially acute among 
people who inject drugs and largely driven by the sharing 
of syringes, harm reduction is scorned. For example, Russia, 
which has a population of 2 million injecting opiate users, 
of whom 37.2% are estimated to be living with HIV (in some 
regions prevalence reaches up to 75%),f refuses to provide 
needle and syringe exchange and prohibits the provision of 
methadone. The USA has also reinstated its ban on spending 
federal funds on needle and syringe programmes. This is a 
highly retrogressive step, as it applies not just to the USA 
but to all programmes, no matter where they are based, that 
receive federal funds.
e WHO, UNODC, UNAIDS (2009) Technical Guide for Countries to Set Targets for Universal 
Access to HIV Prevention, Treatment and Care for Injecting Drug Users. Geneva: World Health 
Organization.
f Federal Service on Customers’ Rights and Human Well-being Surveillance of the Russian 
Federation (2010) Country Progress Report on the progress of implementing the Declaration of 
Commitment on HIV/AIDS adopted at the 26th United Nations General Assembly Special Session 
on HIV/AIDS. Reporting period: January 2008 – December 2009. Moscow: Federal Service on 
Customers’ Rights and Human Well-being Surveillance of the Russian Federation.
Far from being provided with the services that we need, 
people who inject drugs remain criminalised, marginalised, 
repressed and discriminated against. We face human rights 
abuses including torture and corporal punishment, execution, 
arbitrary violence and abuse, compulsory detention and 
forced treatment in facilities that provide no medical services 
but that do subject their inmates to forced labour and often 
cruel and inhuman treatment.g h  In spite of a recent call for 
their immediate closure sponsored by 12 UN bodies,i these 
facilities remain open and are often applauded, or simply 
ignored, by the guardians of the international system of 
punitive prohibition.
The Global State of Harm Reduction 2012 shows that where 
progress has taken place, it has often been at an insufficiently 
low level to have an impact on viral hepatitis and HIV 
epidemics among people who inject drugs, and the new 
programmes that have been implemented are  generally 
small-scale pilots. The universal provision of harm reduction 
services is just the first step in righting the systematic human 
rights abuses to which people who use drugs are subjected. 
INPUD will continue to advocate and organise to make the 
voices of the illegal-drug-using community heard. 
The Global State of Harm Reduction is an invaluable tool in 
INPUD’s advocacy work and a strident wake-up call to anyone 
who believes that the work of harm reduction is done. We 
have known for more than 20 years what measures need to be 
taken to prevent HIV transmission among people who inject 
drugs, but we are facing a barrier of intransigent ignorance, 
prejudice and a refusal on the part of many governments 
around the world to accept the science. This is unacceptable 
and should be called what it is – wilful neglect and a breach of 
basic human rights, not least of all, the inalienable right to the 
highest standard of health to which all people, whether they 
use illegal drugs or not, are entitled. 
Eliot Ross Albers
Executive Director, INPUD
g Stevens A (2012) The ethics and effectiveness of coerced treatment of people who use 
drugs, Human Rights and Drugs, 2(1) 7–16.
h Hall W et al. (2012) Compulsory detention, forced detoxification and enforced la-
bour are not ethically acceptable or effective ways to treat addiction, Addiction, pp. 1-3. 
doi:10.1111/j.1360-0443.2012.03888.x, http://onlinelibrary.wiley.com/doi/10.1111/j.1360-
0443.2012.03888.x/pdf Accessed 9 July 2012.
i United Nations (2012) Joint Statement: Compulsory drug detention and rehabilitation 
centres. New York: UN, http://www.unaids.org/en/media/unaids/contentassets/documents/
document/2012/JC2310_Joint%20Statement6March12FINAL_en.pdf Accessed 20 May 2012.
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About the Global State of Harm Reduction 2012
In 2008 Harm Reduction International (HRI) released the Global 
State of Harm Reduction, a report that mapped responses 
to drug-related HIV and hepatitis C epidemics around the 
world for the first time.j The information gathered for the 
report provided a critical baseline against which progress 
could be measured in terms of the international, regional 
and national recognition of harm reduction in policy and 
practice. The second edition, Global State of Harm Reduction 
2010: Key Issues for Broadening the Response, documented 
major developments in harm reduction policy adoption and 
programme implementation that had occurred since 2008, 
enabling some assessment of global progress. It also explored 
several key issues for harm reduction, such as the response 
to amphetamine-related harms; harm reduction in prisons; 
the reduction of various drug-related health harms including 
bacterial infections, tuberculosis, viral hepatitis and overdose; 
and the extent to which financial resources for harm reduction 
are available.k
The Global State of Harm Reduction 2012 presents the 
major developments in harm reduction policy adoption 
and programme implementation that have occurred since 
2010. It also explores several major topics for developing an 
integrated harm reduction response, such as effective harm 
reduction services for women who inject drugs; access to 
harm reduction services by young people; drug use among 
men who have sex with men and implications for harm 
reduction; global progress toward building an enabling policy 
environment for harm reduction implementation through 
drug decriminalisation and regulation; case studies on 
sustainability and scale-up of services; and promotion of harm 
reduction approaches in challenging environments. 
This report, and other Global State of Harm Reduction 
resourcesl are designed to provide advocacy and reference 
tools for a wide range of audiences, such as international 
donor organisations, multilateral and bilateral agencies, 
civil society and non-governmental organisations (NGOs), 
including organisations of people who use drugs, as well as 
researchers and the media.
j        Cook C and Kanaef N (2008) Global State of Harm Reduction 2008: Mapping the 
Response to Drug-Related HIV and Hepatitis C Epidemics. London: Harm Reduction Inter-
national.
k  Cook C (2010) The Global State of Harm Reduction: Key Issues for Broadening the Re-
sponse. London: International Harm Reduction Association.
l  See www.ihra.net for more details.
Methodology
The information in Sections 1 and 2 of this report was gathered 
using existing data sources, including research papers and 
reports from multilateral agencies, international NGOs, 
civil society and harm reduction networks, as well as expert 
opinion from organisations of people who use drugs and 
those working in the harm reduction field. Within each region, 
HRI enlisted support from regional harm reduction networks 
and researchers to gather qualitative information on key 
developmentsm and to review population size estimates, data 
on the epidemiology of HIV and viral hepatitis among people 
who inject drugs, and the extent of provision of needle and 
syringe exchange programmes (NSPs) and opioid substitution 
therapy (OST). 
Quantitative data for the tables at the beginning of each 
regional update in Section 2 were obtained from a variety of 
sources. These data seek to reflect the most recent available 
estimates within each country at the time of the data 
collection exercise (January–April 2012). Sources used include 
global systematic reviews conducted by the Reference Group 
to the United Nations on HIV/ AIDS and Injecting Drug Use 
(UN Reference Group) on the epidemiology of injecting 
drug use and HIV and the coverage of key harm reduction 
interventions in 2008n and 2010,o updated reports since then 
by the UN Reference Group (including forthcoming articles),p 
national Global AIDS Progress reports submitted to UNAIDS 
in March 2012 and national surveillance studies conducted 
since 2010.q Where none of these sources were available, the 
data were unpublished or their reliability was questioned by 
civil society, researchers or other experts, expert opinion was 
sought to identify additional sources of information and verify 
their reliability. Unless HRI was able to identify newer data, 
prevalence estimates for viral hepatitis were sourced from 
the review of reviews published by Nelson and colleagues 
in the Lancet in 2011. Data for Western Europe and several 
countries in Eastern Europe were sourced from the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
2012 statistical bulletin, unless otherwise stated in the text.r 
Sources are provided for all of the estimates reported, and any 
discrepancies in data are noted in footnotes within the tables 
or in the text. 
m  A copy of the information collection questionnaire for the Global State of Harm 
Reduction 2012 can be obtained by contacting info@ihra.net.
n  Mathers B et al. (2008). The global epidemiology of injecting drug use and HIV among 
people who inject drugs: A systematic review, Lancet, 372 (9651): 1733-1745.
o  Mathers B et al. (2010). HIV prevention, treatment, and care services for people who 
inject drugs: A systematic review of global, regional, and national coverage, Lancet, 375, 
DOI:10.1016/S0140-6736(10)60232-2.
p  Petersen Z, Pluddemann A, van Hout MC, Dada S, Parry C & Myers B on behalf of the 
Secretariat to the United Nations Reference Group on Injecting Drug Use and HIV (2012) 
The prevalence of HIV among people who inject drugs and availability of prevention and 
treatment services: findings from 21 countries. A brief report. Parow: South African Medical 
Research Council.
q  Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D & Degenhardt 
L (2011) Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: 
results of systematic reviews, Lancet, 378(9791): 571–583.
r  See http://www.emcdda.europa.eu/stats12 for more details. 
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8Figures published through international reporting systems, 
such as those undertaken by the World Health Organization 
and UNAIDS, may differ from those collated here due the 
different scope of monitoring surveys, varying reliability 
criteria and focus on regions that may include different 
country classifications. 
Regions were largely identified using the coverage of the 
regional harm reduction networks. Therefore, this report 
examines the regions of Oceania, Asia, Eurasia (Central and 
Eastern Europe and Central Asia), Western Europe, Sub-
Saharan Africa, Middle East and North Africa, Latin America, 
the Caribbean and North America. 
Where possible, the regional updates were peer reviewed by 
the regional harm reduction networks and other experts in 
the field (see Acknowledgements).
This report also contains chapters on major topics for the harm 
reduction response, which were identified through feedback 
on the second report and consultation with HRI’s Scientific 
Review Committee and key partners of the organisation. 
These chapters have been prepared by representatives from 
civil society, research and multilateral agencies with specific 
expertise in the area, and reviewed by peers in the field. 
Although some of the issues covered are fairly new areas 
with relatively little research to report on, these chapters aim 
to present what is currently known and raise issues for the 
international harm reduction community to consider. 
Data quality
For global population size estimates of people who inject 
drugs and HIV epidemiology, this report draws heavily on 
global systematic reviews conducted by the UN Reference 
Group. That review presented only data that fitted with 
reliability criteria established by the UN Reference Group, 
resulting in data gaps for many countries with HIV epidemics 
among people who inject drugs. 
Given that this remains the most reliable assessment of the 
state of the epidemic, HRI has presented the UN Reference 
Group data where these data were the most recent available 
estimates, and provided data from other sources for those 
countries and territories for which other reliable sources 
were available. These included bio-behavioural surveillance 
reports, academic studies and, for information on the most 
recent number of NSP and OST sites, expert opinion was also 
consulted. The data collection process involved regional harm 
reduction networks and other regional experts reviewing the 
regional data gathered, including the figures reported in the 
tables. The data tables were additionally shared for review 
with researchers and members of the UN Reference Group 
from around the world. Where the accuracy of data was 
questioned but no alternate, reliable figures were provided, 
this is noted in footnotes or within the text.
Although population size estimates for people who inject 
drugs have become available at the national level for several 
countries since 2008 (for instance, through UNAIDS Global 
AIDS Progress reports), a systematic calculation of global 
population size estimates was not conducted in the context 
of this report. Differences in data sources and year of estimate 
between the epidemiology and service coverage figures 
rendered global and regional comparisons challenging. 
The significant data gaps are an important reminder of the 
need for improved monitoring systems and data reporting on 
HIV and drug use around the world. 
In reporting on the existence and coverage of harm reduction, 
this report sought input from harm reduction networks, 
researchers and other experts in the field. Where no updates 
were available, 2010 data was reported. 
The data presented here on epidemiology and coverage 
represent the most recent, verifiable estimates currently 
available; however, lack of uniformity in measures, data 
collection methodologies and definitions for the estimates 
provided renders cross-national and regional comparisons 
challenging.
Limitations
This report attempts to provide a global snapshot of harm 
reduction policies and programmes and, as such, has several 
limitations. It does not provide an extensive evaluation of the 
services or policies in place. It must be recognised that the 
existence of a service does not necessarily denote adequate 
quality and coverage to have an impact on drug-related 
harms.
While this report aims to cover some important areas for harm 
reduction, it focuses largely on the public health aspects of 
the response and does not document the full spectrum of 
social and legal harms faced by people who use drugs. Neither 
does it cover the full spectrum of harms related to substance 
use – for example, those related to alcohol and tobacco use.
A significant gap in the current edition of the report is the 
omission of a thematic focus on the intersection between sex 
work and drug use. HRI is presently in the process of developing 
a separate publication and web resources addressing drug 
use among sex workers and broader implications for harm 
reduction. 
9Report structure
Section 1 provides a global overview of harm reduction 
policy and programming.
Section 2 contains nine brief regional updates – Asia, Eurasia, 
Western Europe, the Caribbean, Latin America, North America, 
Oceania, Middle East and North Africa, and Sub-Saharan Africa 
– that examine the developments for harm reduction since 
2010.
Section 3 comprises six chapters that explore themes relevant 
to developing an integrated harm reduction response, 
including specific barriers to service access faced by women 
and young people who inject drugs, drug use among men 
who have sex with men and implications for harm reduction, 
a global overview of drug decriminalisation policies around 
the world, and an exploration of sustaining and scaling up 
services in challenging social and political environments.
Introduction
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Harm Reduction: A Global Update
Harm reduction is increasing in recognition around the world. 
This is demonstrated by several significant developments in 
policy, implementation and research in the last two years. 
Among these are increases in the number of countries 
addressing harm reduction in national policies and strategic 
plans, as well as those gathering epidemiology and coverage 
monitoring data among people who inject drugs (PWID) and 
implementing harm reduction programmes. However, the 
availability and coverage of harm reduction programmes 
remains uneven among and within regions, and is particularly 
limited in low- and middle- income countries. In many parts 
of the world, harm reduction programmes face widespread 
challenges in the context of economic and donor uncertainty 
(see below for more details).
Injecting drug use (IDU) has been documented in at least 158 
countries and territories globally.1 The latest available global 
population size estimates indicate that 15.9 million (range 
11–21 million) people inject drugs around the world.2 The 
most significant numbers of PWID reside in China, the USA 
and Russia. Reports of HIV among PWID are documented in 
120 countries.3 In 2010, nearly half (47%) of people who inject 
drugs living with HIV in low- and middle-income countries 
came from five nations – China, Vietnam, Malaysia, Russia and 
Ukraine.32 Specific sub-populations of PWID, including young 
people and women who inject drugs, experience elevated 
barriers to service access (see Sections 2 and 3 for more 
details).
PWID also face elevated rates of viral hepatitis and tuberculosis. 
Recent estimates indicate that approximately 10 million PWID 
worldwide may have hepatitis C, a figure that surpasses HIV 
infection among this population.3 China is home to more than 
half (1.6 million, range 1.1–2.2 million) of PWID living with 
hepatitis C worldwide, followed by the USA (1.5 million) and 
Russia (1.3 million).3 Asia has the largest populations of PWID 
with active hepatitis B (HbsAg)a (300,000, range 100,000–
700,000). People living with HIV who also inject drugs have a 
two- to six-fold increased risk of developing TB compared to 
non-injectors, and commonly have co-infection with hepatitis 
B (HBV) and C (HCV) viral infection.4 This risk is on average 
twenty-three times higher in prisons than in the general 
population5 (see Section 2 for more details).
a  HbsAg indicates active (either acute or chronic) infection. Approximately 95% of 
adults with acute HBV infection clear the virus and develop anti-HBc and hepatitis B 
surface antibodies (anti-HBs). People who inject drugs may have lower clearance rates for 
HBV than the general population because more PWID may become chronically infected. 
For more information, see Nelson PK et al (2011) Global epidemiology of hepatitis B and 
hepatitis C in people who inject drugs: results of systematic reviews, Lancet, 378(9791): 
571–583.
The global harm reduction response
International policy developments for harm 
reduction 
In the past two years since 2010, several developments 
in international policy have occurred, with important 
implications for harm reduction: 
 » On 16 December 2011 the US Congress reinstated the 
ban on federal funding for needle and syringe exchange 
programmes (NSPs).6 The decision comes just two years 
after the 21-year-old ban was repealed and signed into 
law by President Barack Obama in December 2009, 
thereby allowing states and local public health officials to 
use federal funds for sterile syringe access. The decision 
includes reinstatements of bans on both domestic and 
international use of US federal funds for NSPs as part of 
the 2012 omnibus spending bill. 
 » At the UN High Level Meeting on AIDS in June 2011, 
states adopted a new declaration with revised targets 
for measuring progress in the global response, the 
Political Declaration on HIV and AIDS: Intensifying Our 
Efforts to Eliminate HIV and AIDS.7 The text of the final 
outcome document reflects ongoing tensions between 
evidence and human rights-based approaches, and 
relativist stances by some states, which emphasise 
‘local circumstances, ethics and cultural values’ at the 
expense of public health-based strategies.8 However, 
the document also reflected negotiation successes, 
including the explicit mention of the WHO/UNAIDS/
UNODC comprehensive harm reduction package, a 
pledge to reduce HIV among PWID by 50% by 2015 and 
concrete, time-bound coverage and funding targets. 
 » Countries submitted their first reports to monitor 
progress against commitments in the 2011 Political 
Declaration on HIV/AIDS to UNAIDS in March 2012, 
which will form the basis of an end-of-year report on the 
state of the global HIV epidemic. The core indicators for 
country progress reporting have been revised to reflect 
the new targets set out in the 2011 Political Declaration, 
and represent one of the most comprehensive tools to 
date for monitoring the epidemiology of HIV and service 
coverage among PWID by multilateral agencies.9 
 » In March 2012, twelve UN agencies called on states to 
close compulsory drug detention and rehabilitation 
centres and implement voluntary, evidence-informed 
and rights-based health and social services in the 
community.10 This is a particularly relevant development 
for countries in Asia, where the continued commitment 
to compulsory detention by some countries remains 
a serious human rights concern.11-12 During a meeting 
with civil society at the 55th Session of the Commission 
on Narcotic Drugs (CND), however, the International 
Narcotics Control Board (INCB) refused to denounce such 
13
centres, or ‘any atrocity’ committed in the name of drug 
control.13 The INCB President also refused to refrain from 
referring to people who use drugs (PWUD) as ‘abusers’ 
and ‘drug abusing offenders’ when asked to do so by the 
International Network of People who Use Drugs (INPUD), 
who explained the terms were seen as stigmatising and 
offensive.
 » The role of naloxone in addressing opioid overdose 
was recognised for the first time in a high-level 
international resolution in March 2012. Members at the 
55th CND unanimously endorsed a resolution promoting 
evidence-based strategies to address opioid overdose.14 
Introduced by the Czech Republic and co-sponsored by 
Israel and Denmark (the latter on behalf of the European 
Union), the resolution calls on UNODC, WHO and other 
international organisations to work with member states 
to address the global overdose epidemic. 
 » Also at the 55th session of the CND in March 2011, a 
resolution was adopted, co-sponsored by the USA, 
entitled ‘Achieving zero new infections of HIV among 
injecting and other drug users.’15 Following tense 
debates, with Russia in particular being resistant to the 
resolution, member states finally endorsed the WHO, 
UNAIDS, UNODC comprehensive package on HIV and 
IDU – a first at the CND.
 » The emerging issue of new psychoactive substances, 
commonly known as ‘legal highs’, and the need to explore 
considered, evidence-informed approaches other 
than criminal justice, was recognised in a progressive 
resolution adopted at the 55th CND.16 Originally proposed 
by Australia, the resolution did not call for ‘legal highs’ to 
be banned or criminalised, but rather urged countries 
‘to consider a wide variety of evidence-based control 
measures to tackle the emergence of new psychoactive 
substances, including the use of consumer protection, 
legislation regarding medicine and legislation 
regarding hazardous substances.’ Advocates welcomed 
the resolution, noting that an acknowledgement of 
alternative means of regulating illicit substances is an 
important step forward for member states at the CND.17 
 » The World Health Organization (WHO) has developed 
new guidanceb on prevention strategies for viral 
hepatitis B and C in PWID planned for release at the 19th 
International AIDS Conference Washington, DC, in July 
2012. Recommendations will comprise three distinct but 
interlinked areas: surveillance, screening and antiretroviral 
therapy (ART) management in people with HIV and 
viral Hepatitis B and C co-infections. Recommendations 
include strengthening hepatitis monitoring systems 
through standardising case definitions of viral hepatitis, 
integrating hepatitis with HIV, TB and STI surveillance, 
and considering sentinel surveillance for acute hepatitis 
among key populations at higher risk, including PWID.
b  The new guidance can be downloaded from http://www.who.int/hiv/pub/guidelines/
hepatitis/en/.
 » Since 2010 the leadership of the UN Office on Drugs 
and Crime (UNODC) on HIV-related harm reduction 
has deteriorated. As the lead UNAIDS co-sponsor with 
responsibility for HIV and IDU, this is a considerable 
concern. Since taking the office of Executive Director, Mr 
Yury Fedotov has failed to endorse basic HIV prevention 
measures related to IDU and has questioned whether 
his agency has a harm reduction mandate18 or an official 
position on OST.19 HIV/AIDS organisations took the 
occasion of World AIDS Day in 2011 to write to Mr Fedotov 
to seek clarification on these issues. They received no 
reply from Mr Fedotov, rather an ambiguous reply from 
another senior member of staff.
 » During the 55th session of the CND, the UNODC 
Executive Director’s report to member states on HIV 
and IDU reworded the agreed WHO, UNAIDS, UNODC 
comprehensive package to give prominence to 
abstinence-based drug treatment and to downplay 
opioid substitution therapy (OST).20 Throughout the 
report, HIV prevention was seen as a subset of drug 
treatment, while the phrases ‘opioid substitution therapy’ 
and ‘needle and syringe programmes’ were avoided. 
Following an intervention by the European Union, UNODC 
had to correct the actual wording of the comprehensive 
package at the plenary of the Commission. To date the 
document remains unchanged.
 » Within the European Union, Sweden and Italy continued 
to play negative roles on harm reduction. As a group, 
the European Union has weakened in its harm reduction 
position. This was evident at the High Level Meeting on 
HIV at the UN, and despite some important progress, also 
at the 55th CND. This is due in part to harm reduction being 
seen as a less important diplomatic issue for countries 
that previously adopted leadership roles internationally, 
including the United Kingdom and the Netherlands. This 
is despite strong, ongoing harm reduction programming 
nationally and funding for harm reduction internationally 
from those same countries.
An enabling environment for harm reduction
In 2012 there are 97 countries and territories that support a 
harm reduction approach, four morec than reported in 2010 
(see Table 1.1.1).21d This support is explicit either in national 
policy documents (eighty-three countries – four more than 
in 2010), and/or through the implementation or tolerance 
of harm reduction interventions such as NSPs (eighty-six 
countries – four more than in 2010)e or OST (seventy-seven 
countries – seven more than in 2010).f 
c  Macau, Jordan, Syria, Tunisia. 
d  Inclusion in this list refers both to countries or territories that have newly supported 
a harm reduction approach in policy and/or practice since 2010, and to countries or 
territories for which ‘not known’ was reported in 2010 (i.e. Macau).
e  South Africa, Tanzania, Macau and Laos PDR.
f  Cambodia, Bangladesh, Tajikistan, Kenya, Tanzania, Macau and Kosovo.
Global Overview
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There is a trend towards less punitive responses toward 
PWID in some countries and regions, with between 25 and 
30 countries adopting some form of decriminalisation of 
possession of drugs for personal use.g Although significant 
variations in such reforms and how they are implemented and 
evaluated makes generalisations difficult, emerging evidence 
indicates that decriminalisation provides an enabling 
environment supporting implementation and take-up of 
harm reduction programmes proven to reduce HIV and viral 
hepatitis transmission.
Table 1.1.1: Countries or territories employing a harm 
reduction approach in policy or practiceh
Country or territory
Explicit 
supportive 
reference 
to harm 
reduction in 
national policy 
documents
Needle 
exchange 
programmes 
operational
Opioid 
substitution 
programmes 
operational
Drug 
consumption 
room(s)
ASIA
Afghanistan ✓ ✓ ✓ x
Bangladesh ✓ ✓ ✓ x
Cambodia ✓ ✓ x x
China ✓ ✓ ✓ x
Hong Kong ✓ x ✓ x
India ✓ ✓ ✓ x
Indonesia ✓ ✓ ✓ x
Macau ✓ ✓ ✓ x
Malaysia ✓ ✓ ✓ x
Maldives x x ✓ x
Mongolia x ✓ x x
Myanmar ✓ ✓ ✓ x
Nepal ✓ ✓ ✓ x
Pakistan ✓ ✓ x x
PDR Laos ✓ x x x
Philippines ✓ ✓ x x
Taiwan ✓ ✓ ✓ x
Thailand ✓ ✓ ✓ x
Vietnam ✓ ✓ ✓ x
CARIBBEAN
Puerto Rico x ✓ ✓ x
Trinidad and Tobago ✓ x x x
EURASIA
Albania ✓ ✓ ✓ x
Armenia ✓ ✓ ✓ x
Azerbaijan x ✓ ✓ x
Belarus ✓ ✓ ✓ x
Bosnia & Herzegovina ✓ ✓ ✓ x
Bulgaria ✓ ✓ ✓ x
Croatia ✓ ✓ ✓ x
Czech Republic ✓ ✓ ✓ x
Estonia ✓ ✓ ✓ x
g  See Chapter 3.4 of this publication for a global summary of drug decriminalisation 
policies.
h  This includes countries that have harm reduction in their national policies or strategy 
documents on HIV, viral hepatitis and/or drug use. In many countries, harm reduction 
may appear in one or more of such policies, but not all. Inclusion in this table of NSP, OST 
and DCRs indicates only the availability of these interventions, rather than their scope or 
coverage.
Country or territory
Explicit 
supportive 
reference 
to harm 
reduction in 
national policy 
documents
Needle 
exchange 
programmes 
operational
Opioid 
substitution 
programmes 
operational
Drug 
consumption 
room(s)
Georgia ✓ ✓ ✓ x
Hungary ✓ ✓ ✓ x
Kazakhstan ✓ ✓ ✓ x
Kosovo ✓ ✓ ✓ x
Kyrgyzstan ✓ ✓ ✓ x
Latvia ✓ ✓ ✓ x
Lithuania ✓ ✓ ✓ x
Macedonia ✓ ✓ ✓ x
Moldova ✓ ✓ ✓ x
Montenegro ✓ ✓ ✓ x
Poland ✓ ✓ ✓ x
Romania ✓ ✓ ✓ x
Russia x ✓ x x
Serbia ✓ ✓ ✓ x
Slovakia ✓ ✓ ✓ x
Slovenia ✓ ✓ ✓ x
Tajikistan ✓ ✓ ✓ x
Turkmenistan x ✓ x x
Ukraine ✓ ✓ ✓ x
Uzbekistan ✓ ✓ x x
LATIN AMERICA
Argentina ✓ ✓ x x
Brazil ✓ ✓ x x
Colombia ✓ x ✓ x
Mexico ✓ ✓ ✓ x
Paraguay ✓ ✓ x x
Uruguay ✓ ✓ x x
MIDDLE EAST and NORTH AFRICA
Egypt x ✓ x x
Iran ✓ ✓ ✓ x
Israel ✓ ✓ ✓ x
Jordan ✓ x x x
Lebanon ✓ ✓ ✓ x
Morocco ✓ ✓ x x
Oman x ✓ x x
Palestine x ✓ x x
Syria ✓ x x x
Tunisia ✓ ✓ x x
NORTH AMERICA
Canada ✓ ✓ ✓ ✓
United States ✓ ✓ ✓ x
OCEANIA
Australia ✓ ✓ ✓ ✓
New Zealand ✓ ✓ ✓ x
SUB-SAHARAN AFRICA
Kenya ✓ x ✓ x
Mauritius ✓ ✓ ✓ x
Senegal x x ✓ x
Seychelles x x x x
South Africa x ✓ ✓ x
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Country or territory
Explicit 
supportive 
reference 
to harm 
reduction in 
national policy 
documents
Needle 
exchange 
programmes 
operational
Opioid 
substitution 
programmes 
operational
Drug 
consumption 
room(s)
Tanzania ✓ ✓ ✓ x
Zanzibar ✓ x x x
WESTERN EUROPE
Austria ✓ ✓ ✓ x
Belgium ✓ ✓ ✓ x
Cyprus ✓ ✓ ✓ x
Denmark ✓ ✓ ✓ x
Finland ✓ ✓ ✓ x
France ✓ ✓ ✓ x
Germany ✓ ✓ ✓ ✓
Greece ✓ ✓ ✓ x
Iceland nk x ✓ x
Ireland ✓ ✓ ✓ x
Italy ✓ ✓ ✓ x
Luxembourg ✓ ✓ ✓ ✓
Malta ✓ ✓ ✓ x
Netherlands ✓ ✓ ✓ ✓
Norway ✓ ✓ ✓ ✓
Portugal ✓ ✓ ✓ x
Spain ✓ ✓ ✓ ✓
Sweden ✓ ✓ ✓ x
Switzerland ✓ ✓ ✓ ✓
United Kingdom ✓ ✓ ✓ x
Civil society and networks 
Harm reduction networks continue to operate in every region 
of the world, and are making important contributions at 
national, regional and international levels. Regional networks 
include the AHRN Federation, Caribbean Harm Reduction 
Coalition (CHRC), Eurasian Harm Reduction Network (EHRN), 
European Harm Reduction Network (EuroHRN), Middle East 
and North African Harm Reduction Association (MENAHRA), 
Intercambios Asociación Civil (Latin America) and a nascent 
Sub-Saharan Africa Network. There are also numerous 
national and local level networks that continue to advocate 
for harm reduction at these levels. 
In recent years, there have been a number of notable 
developments among regional harm reduction networks. 
These include the expansion of EuroHRN, which was formed 
in 2009. The major outputs of the network have been the 
publication of the first civil society audit in Europe and a report 
detailing a mapping of drug user organisations throughout 
the region.22 The research into drug user organisations was 
particularly significant as it led to the formation of the first 
pan-European network of PWUD. EuroHRN held its first 
European Harm Reduction Meeting in Marseille in 2011.
The Asian Harm Reduction Network has gone through 
significant modifications including a name change to 
the AHRN Federation. It has undergone organisational 
restructuring to develop a federation model, which aims to 
allow national harm reduction organisations and networks to 
have a key role in determining the future and priorities of the 
network. The federation consists of national and sub-national 
harm reduction networks, as well as key focal organisations, 
and focuses its efforts in India, Indonesia, Thailand, Cambodia, 
Myanmar, China, Malaysia and Nepal. 
MENAHRA has been a significant catalyst for increasing 
attention to harm reduction in the MENA region since its 
founding in 2007.23 In January 2012, MENAHRA began 
implementation of its round 10 Global Fund grant to expand 
harm reduction in twelve countriesi across the region through 
capacity building, training, advocacy and networking 
activities. The overall aim of this project is to create a conducive 
environment for the scale-up and implementation of HIV and 
harm reduction programmes across the region. 
Global networks that include harm reduction as a key 
component of their work continue to operate at the 
international level. These include YouthRISE, International 
Network of People Who Use Drugs (INPUD), International 
Nursing Harm Reduction Network (INHRN), International 
Doctors for Healthy Drug Policies (IDHDP), International 
Centre for Science in Drug Policy (ICSDP), Law Enforcement 
and HIV Network (LEAHN), Women’s Harm Reduction Network 
(WHRIN) and the International Drug Policy Consortium (IDPC). 
IDPC has developed a strong membership base and produced 
several publications since 2010, including the Second Edition 
of the IDPC Drug Policy Guide and over twenty drug policy 
briefings. IDPC facilitates strong civil society involvement and 
engagement with policy makers at regional and international 
forums, particularly at the CND, and works at national and 
international levels to promote open dialogue around a 
human rights and public health approach to drug policy.
There has been some progress in the engagement of civil 
society in international policy-making. During the 54th 
CND session, a resolution was adopted on improving civil 
society engagement at the Commission. During informal 
negotiations it was one of the most contested resolutions, 
reflecting many member states’ ongoing discomfort with civil 
society engagement. The following year, however, the first 
official civil society hearing was held at the CND: an important 
and positive development. Despite this improvement, the 
2012 session of the CND was marred by the secretariat’s 
censorship of civil society statements. Two oral statements – 
one criticising the UNODC’s Executive Director for a lack of 
leadership on HIV, and the other on human rights concerns 
about the International Narcotics Control Board’s annual 
report – were not permitted and had to be amended. 
i  Iran, Pakistan, Libya, Lebanon, Syria, Jordan, Bahrain, Morocco, Egypt, Afghanistan, 
Oman and Palestine.
Global Overview
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Civil society launched a number of significant declarations that 
sought to mobilise international support for key international 
forums in 2010 and 2011. The Vienna Declaration,24 a global 
initiative supported by the Open Society Foundations, was 
launched at the 18th International AIDS conference in July 
2010. Calling for drug policy to be based on scientific evidence, 
the Declaration received over 17,000 endorsements in less 
than three months. Notable signatories include three former 
Latin American presidents, as well as cities, Nobel laureates, 
scientists, lawyers, academics, researchers, and activists from 
around the world. 
In advance of the UN High Level Meeting (HLM) on AIDS held 
in June 2011, Harm Reduction International (HRI) launched 
the Beirut Declaration on HIV and Injecting Drug Use: A Global 
Call for Action, an initiative aimed at increasing support for 
harm reduction and related drug policy reform within the 
proceedings and outputs of the HLM, and raising awareness of 
the limited international support for harm reduction and the 
drug policy reforms necessary for its optimal implementation. 
The Declaration was endorsed by over 200 organisations 
in the broader HIV/AIDS and development fieldsj and was 
featured in prominent forums. For example, the 9 April 2011 
edition of the scientific journal the Lancet featured the HLM 
and the Beirut Declaration in its editorial, calling for increased 
attention to harm reduction, IDU and drug policy reform 
within the proceedings of the HLM.25 
The visibility of regional networks of PWUD has also increased 
in recent years; new networks have been established in 
Eurasia, Europe and the MENA regions. The Eurasiank and 
MENA networks were established in 2010, and the Europeanl 
network in 2011. 
INPUD has undergone significant changes since 2010 with 
the selection of a new executive director, a full-time staff 
team and a newly elected board. INPUD’s increased capacity 
has allowed its staff and members to engage actively in 
international forums such as the CND and the UNAIDS 
Programme Coordinating Board (PCB), and at the community 
level in Afghanistan, Kenya, Tanzania, Eastern Europe, and 
Central Asia through the delivery of capacity-building 
workshops and technical assistance. Since 2010, INPUD has 
become an increasingly important partner representing the 
perspective of drug using and injecting populations to civil 
society and multilateral agencies. 
The harm reduction ‘network of networks’ continues to work 
collectively and share information. It is made up of regional 
and global networks as well as national harm reduction 
networks, which include the Canadian Harm Reduction 
Network (CHRN), Colectivo por Una Politicia Integral Hacia las 
j  For a complete list of endorsements visit www.ihra.net/endorsements.
k  Refer to Chapter 2.2 of this publication for further information on the development 
of this network.
l  Refer to Chapter 2.3 of this publication for further information of the development of 
this network.
Drogues (CUPIHD, based in Mexico) and the Harm Reduction 
Coalition (HRC, based in the USA).
Community Action on  
Harm Reduction  
Community Action on Harm Reduction (CAHR) is a new 
and ambitious five-year project led by the International 
HIV/AIDS Alliance and made possible by a grant from 
the Dutch Ministry of Internal Affairs (BUZA). It aims to 
significantly improve HIV and harm reduction services for 
people who inject drugs, their partners and children, in 
China, India, Indonesia, Kenya and Malaysia. The project 
works to introduce essential harm reduction interventions 
in Kenya, improve access to community-based support 
services in China, increase the quality of behavioural 
change programming in India and Malaysia, and expand 
quality harm reduction services to new communities 
within PWID populations in Indonesia. Overall, it aims to 
reach more than 180,000 people who inject drugs, their 
partners and children. There is a strong focus on building 
the capacity of community-based organisations as well 
as the meaningful engagement of people who use drugs 
in the development, implementation and evaluation of 
services within each country.
Global coverage of harm reduction services 
The lack of reliable population size estimates for PWID 
in several countries, and inconsistencies in the quality of 
available data, make accurate assessments of progress since 
2010 challenging. Generally, where data is available, harm 
reduction service provision has increased in countries where 
it was already being implemented. Several countries in sub-
Saharan Africa, Asia and parts of Eastern Europe and Central 
Asia have NSPs and/or OST. Despite these improvements, 
expansion of programmes has been slow and many new 
programmes are small-scale pilots. The last two years have 
also witnessed significant scale-down of services in countries 
with some of the highest HIV burdens among PWID. In 
most low- and middle-income countries, coverage remains 
insufficient to stabilise and reverse HIV and viral hepatitis 
epidemics among PWID.
Needle and syringe exchange programmes
In 2012 there are eighty-six countries and territories that 
implement NSPs to varying degrees. Models of provision 
include fixed and specialist NSP sites, community-based 
outreach, pharmacy provision and vending machines. Three 
countries have newly implemented NSPs since 2010 -- South 
Africa, Tanzania and Laos PDR.m 
m  Macau is not included, although it is newly reported to provide NSP and OST in this 
report. Provision of harm reduction services in Macau started prior to 2010. However, in 
past reports, information on Macau was not known/not reported.
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Global Overview
The  number of operational NSP sites, and the coverage 
provided through existing services, varies widely among 
countries and regions. According to internationally 
recommended  targets,n coverage is high in only a few 
countries such as Australia, several Western European 
countries, as well as in Bangladesh, where over 200 needle/
syringes per PWID are reached per year. 
Generally coverage is lower in low- and middle-income 
countries, with few changes in provision since 2010 in Latin 
America and the Caribbean, which distribute less than one 
needle per person per year.26 An increasing number of sites 
provide sterile injecting equipment around the world, 
including in countries that have high HIV and viral hepatitis 
prevalence among PWID such as the Ukraine and several 
countries in Asia. Despite increases in provision, existing 
services in most low and middle-income countries do not 
reach coverage levels sufficient to stabilise and reverse HIV 
epidemics among this population. For instance, just an 
estimated 10% of PWID in Eastern Europe, and 36% in Central 
Asia, access NSPs.27
Since 2010, NSP provision was scaled back in several countries 
in Asiao and Eurasia.p Seventy-two countries and territories 
with reported IDU (thirty-eight of them with HIV reported 
among this population) remain without any NSP provision.
Drug consumption rooms 
In 2012 there are fifty-eight cities around the world that 
operate at least one drug consumption room (DCR). DCRs 
form a vital part of harm reduction services in some parts of 
Western Europe, allowing PWUD to inject in a safe space and 
under medical supervision. They are eighty-six operational 
DCRs implemented across seven European countries 
(Denmark, Germany, Luxembourg, the Netherlands, Norway, 
Spain, and Switzerland), as well as one in Sydney, Australia and 
one in Vancouver, Canada. Denmark is the latest country to 
implement the intervention. In 2011, an NGO in Copenhagen 
began operating a mobile DCR without explicit permission or 
interference from authorities. Ten months later, in June 2012, 
the Danish parliament officially gave municipalities the legal 
mandate to operate DCRs, making Denmark the first country 
globally to implement legally regulated DCRs.28 
Opioid substitution therapy
OST is provided in seventy-seven countries worldwide – seven 
more than reported in 2010.q Methadone and buprenorphine 
are the substances of choice for substitution, but in some 
countries other formulations are also provided, including 
slow-release morphine and codeine, and heroin-assisted 
treatment (HAT).
n  The 2009 WHO, UNAIDS, UNODC Technical Guide for countries to set targets 
for universal access to HIV prevention, treatment and care for injecting drug users 
categorises NSP coverage levels as follows: low (<100 needles/syringes per injector 
per year), medium (>100–<200 needles/syringes per injector per year) and high (≥200 
needles/syringes per injector per year).
o  For example, Pakistan, Nepal and Cambodia.
p  For example, Belarus, Hungary, Kazakhstan, Lithuania and Russia.
q  Cambodia, Bangladesh, Tajikistan, Kenya, Tanzania, Macau and Kosovo.
The number of sites providing OST and the proportion of 
people that receive substitution therapy, is substantially 
higher in high-income countries. For example, an estimated 
61% of PWID are receiving OST in Western Europe.26 Among 
low and middle-income countries, high coverage has also 
been reported in Iran, where 42.6% of PWID are receiving 
OST,27 and in the Czech Republic, with 40% OST coverage.30 
Provision of OST has been scaled up in several countries in 
Asia, Eurasia and the Middle East and North Africa. Since 2010, 
OST provision has been newly introduced in Tajikistan, Kosovo, 
Kenya, Tanzania, Cambodia, and Bangladesh. However, the 
coverage of existing programmes remains substantially below 
minimum levels recommended by international guidance, 
and improvements in scale and quality are urgently needed 
to ensure that interventions achieve the greatest impact.r 
The latest global estimates of OST coverage, from 2010, 
indicate that 6–12% of PWID are receiving OST, with wide 
variations among regions.26 OST coverage remains very 
limited in parts of sub-Saharan Africa, Latin America and Asia. 
Available data suggest that less than 3% of PWID receive 
OST in countries such as Cambodia, Indonesia, Myanmar 
and Vietnam, where IDU has contributed significantly to HIV 
epidemics.31 
OST remains unavailable in eighty-one countries with 
reported IDU (fifty of them with reports of HIV among PWID). 
Integrated HIV, viral hepatitis and TB services for 
people who inject drugs
Data on the extent to which interventions other than NSP and 
OST, such as treatment for HIV, viral hepatitis and tuberculosis, 
reach PWID around the world is less available on a global 
basis. Comprehensive estimates of HIV, viral hepatitis and 
tuberculosis needs and access among PWID are not available. 
Existing research suggests that access to ART by people who 
inject drugs and live with HIV remains disproportionately 
low compared with other key populations at higher risk of 
HIV, particularly in low- and middle-income countries.32-33 
For example, PWID comprise 67% of cumulative HIV cases in 
China, Vietnam, Russia, Ukraine, Malaysia, but only 25% of ART 
recipients.32 
Critical barriers affecting the delivery of and access to TB 
and HIV services for PWID include separate management 
of TB, HIV, viral hepatitis and drug use, high levels of stigma 
and discrimination and the criminalisation of drug use in 
many countries around the world.4, 34 Increased research and 
surveillance efforts are also critical to better understand the 
true burden of HIV, viral hepatitis and TB among PWID in 
communities and prisons and the scale of services required.
r  The 2009 WHO, UNAIDS, UNODC Technical Guide for countries to set targets 
for universal access to HIV prevention, treatment and care for injecting drug users 
categorises OST coverage levels as follows: low: <20% of opioid dependent PWID on 
OST; medium: 20–40% of opioid dependent PWID on OST; and high: >40% of opioid 
dependent PWID on OST.
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There is an urgent need for greater integration of ART 
provision with harm reduction services, including OST, as well 
as with TB and viral hepatitis treatment.32, 35 The provision of 
coordinated and tailored service delivery models, along with 
peer involvement in treatment delivery, are key to achieving 
sufficient coverage of these interventions among PWID.33 
Overdose 
Overdose remains a leading cause of death globally among 
PWUD, particularly those who inject. Research from an 
increasing number of countries has examined overdose-
related mortality among people who use opioids, including 
among PWID.36 However, estimates on the occurrence of 
overdose mortality and non-fatal overdose outside of high-
income countries remains very limited, and usually requires 
consultation of qualitative data sources and expert opinion.37-38 
A recent global meta-analysis of prospective studies on 
mortality associated with heroin and other opioid use found 
that Asia had the highest crude mortality rate (CMR) at 5.23 
deaths per 100 person-years, and Australasia had the lowest 
(1.08), with overdose most commonly cited as the cause 
of death.38 Research since 2010 has also shown that PWUD 
have a 74% greater risk of overdose if they are HIV-positive 
compared to their HIV-negative counterparts.39 There is a clear 
need to conduct more research and to improve standardised 
reporting to obtain an accurate picture of overdose among 
this population in low and middle-income countries. 
The urgent need to address overdose among PWUD was 
recognised in 2011 by the Global Fund to Fight AIDS, 
Tuberculosis and Malaria, which has encouraged grant 
applicants to include overdose services in national proposals 
since 2010.40 The US President’s Emergency Plan for AIDS 
Relief (PEPFAR) has also recently included naloxone provision 
as part of their revised guidance on PWID.41 
Naloxone, an effective opioid antagonist used to reverse the 
effects of opiate overdose, remains limited for distribution 
by peers and family members of PWUD, especially in low- 
and middle-income countries. As of 2012, community-based 
naloxone distribution programmes are present to varying 
degrees in at least sixteen countries, including Afghanistan, 
Australia, Canada, China, Germany, Georgia, India, Kazakhstan, 
Kyrgyzstan, Tajikistan, Thailand, the UK, USA, Ukraine, Russia 
and Vietnam.
Harm reduction in prisons
The provision of harm reduction interventions including 
NSPs and OST in prisons and other closed settings, remains 
extremely limited compared with responses in the community. 
As of 2012, ten countriess around the world implement NPSs 
in prison, including Iran and countries in Eastern Europe, 
s  Armenia, Belarus, Kyrgyzstan, Moldova, Romania, Iran, Germany, Luxembourg, Spain 
and Switzerland.
Central Asia and Western Europe. Forty-one countriest provide 
OST in prisons. Among these, sixteen are countries in Western 
Europe, twelve in Eurasia and four in Asia, in addition to 
Canada, the USA, Puerto Rico, Australia, New Zealand, Iran 
and Mauritius. 
Considering the high rates of IDU and the complex interaction 
of HIV, viral hepatitis and tuberculosis in prison settings 
worldwide,42-43 there is an urgent need to implement and 
expand the provision of harm reduction services in these 
settings. This is especially urgent for Eastern Europe and 
Central Asia where this interaction in prison settings is most 
marked.4
Resourcing the harm reduction response
The funding landscape has changed drastically since the 
first comprehensive analysis of harm reduction funding 
and resourcing gaps was published by HRI in 2010.44 The 
international financial crisis, combined with a shift in 
aid priorities toward low-income countries and resource 
constraints at the Global Fund to Fight AIDS, Tuberculosis and 
Malaria, pose a major threat to the future and sustainability of 
harm reduction. 
HRI previously estimated that approximately US$160 million 
(or US$0.03 per PWID per day) was invested in HIV-related 
harm reduction in low and middle-income countries in 
2007, of which US$136 million (90%) was from international 
donors.45 This amounted to 7% of the US$2.13 billion in 2009 
and 5% of the US$3.29 billion in 2010 estimated by UNAIDS to 
meet the basic HIV prevention needs of PWID. 46 
In June 2011 a group of international experts, including from 
UNAIDS, the Global Fund, PEPFAR, WHO, the Bill and Melinda 
Gates Foundation, and the World Bank, launched a new 
framework for investment in the global HIV response, which 
has since been endorsed widely by multilateral agencies and 
researchers.47 The investment framework argues for setting 
priorities based on country-specific epidemiology and calls for 
the scale-up of investments in evidence-based, high-impact 
interventions, including NSP and OST for PWID. Modelling 
of the framework’s potential impact indicates that, to avert 
12.2 million new infections and 7.4 million AIDS-related 
deaths between 2011 and 2020, annual resource needs must 
increase from US$16.6 billion in 2011 to US$22–24 billion in 
2015.48 To achieve the proposed reduction in transmission and 
AIDS-related deaths among PWID, US$2.3 billion is required 
by 2015 (falling to US$1.5 billion by 2020 through savings in 
treatment and economies of scale) compared to the US$0.5 
billion estimated to be available in 2011.47 
t  India, Indonesia, Malaysia, Thailand, Albania, Croatia, Czech Republic, Georgia, 
Hungary, Macedonia, Moldova, Montenegro, Poland, Romania, Serbia, Slovenia, Iran, 
Canada, USA, Puerto Rico, Australia, New Zealand, Mauritius, Austria, Belgium, Denmark, 
Finland, Germany, Ireland, Italy, Luxembourg, Malta, Netherlands, Norway, Portugal, 
Spain, Sweden, Switzerland, UK and Latvia.
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During the past decade, and particularly in recent years, the 
Global Fund has emerged as the largest funder for harm 
reduction programmes targeting PWID. Between Round 1 in 
2002 and Round 9 in 2009, an estimated US$430 million was 
approved for this population.49 Two-thirds of the budgeted 
funds were allocated to the core package of harm reduction 
interventions as defined by WHO, UNODC and UNAIDS,50 
including needle and syringe distribution and OST. More than 
half of the funds (US$236 million) were granted to countries in 
Eastern Europe and Central Asia. Global Fund support for harm 
reduction has grown steadily since 2009, and has particularly 
risen in Round 10, when it introduced a funding reserve for 
grants targeting most-at-risk populations51 and released 
the first harm reduction guidance note for applicants.40 
Subsequent analysis indicates that an additional estimated 
investment of US$152 million for PWID was committed in 
Round 10, taking the ten-year total to nearly US$580 million 
(see Table 1.1.2). Although the need for harm reduction 
services still far outweighs current provision, and hostile 
policy environments in some countries continue to prevent 
effective programmes from scaling up,26 commitment to harm 
reduction improved significantly during this period, both in 
national level HIV and drug strategies and internationally. 
Table 1.1.2: Approved Global Fund investments targeting 
people who inject drugs, Round 1 (2002) to Round 10 (2010)52
COuNtry / tErritOry tOtAL (uS$)
ASiA 166,700,000
Afghanistan 1,300,000  
Bangladesh 10,800,000 *
Bhutan <100,000  
Cambodia 5,800,000 *
China 23,400,000  
india 20,800,000 *
indonesia 14,000,000 *
Malaysia 6,100,000 *
Mongolia 100,000  
Maldives 500,000  
Myanmar 7,700,000 *
Nepal 7,600,000 *
Pakistan 13,800,000 *
Philippines 1,500,000  
Sri Lanka 200,000 *
thailand 28,000,000 *
timor Leste <100,000 *
Viet Nam 25,100,000 *
EAStErN EurOPE AND CENtrAL ASiA 366,100,000
Albania 1,400,000
Armenia 3,100,000 *
Azerbaijan 6,000,000 *
Belarus 17,500,000 *
Bosnia & Herzegovina 9,800,000 *
Bulgaria 9,500,000  
Croatia 600,000  
Estonia 2,700,000  
COuNtry / tErritOry tOtAL (uS$)
Georgia 12,700,000 *
Kazakhstan 29,800,000 *
Kosovo 2,000,000  
Kyrgyzstan 25,800,000 *
Macedonia 15,600,000 *
Moldova 7,200,000 *
Montenegro 1,600,000 *
romania 4,200,000  
russian Federation 38,400,000  
Serbia 6,500,000 *
tajikistan 15,600,000  
ukraine 143,900,000 *
uzbekistan 12,200,000 *
LAtiN AMEriCA 10,200,000
Argentina 1,600,000  
Mexico 7,000,000 *
Paraguay 1,600,000 *
MiDDLE EASt AND NOrtH AFriCA 24,000,000
Algeria 500,000  
Egypt 800,000  
iran 8,200,000 *
Jordan 300,000  
MENAHrA 6,200,000 * †
Morocco 4,600,000 *
Syrian Arab republic 1,200,000 *
tunisia 1,400,000  
West Bank and Gaza 800,000  
SuB-SAHArAN AFriCA 7,800,000
Burundi 600,000 *
Cape Verde 700,000 *
Kenya 1,900,000 *
Madagascar 1,300,000 *
Mauritius 1,500,000 *
Nigeria 1,300,000 *
Zanzibar 500,000 ‡
Western Europe 900,000
turkey 900,000  
total (all regions) 575,900,000  
Notes
Figures are rounded. Data are correct as of March 2012. Data are based 
on detailed grant budgets submitted to the Global Fund and may not 
reflect actual expenditures.
* Figure includes projections for future years of grants that have not 
yet been formally committed.
† The Middle East and North Africa Harm Reduction Association 
(MENAHRA) received a multi-country grant that covers Afghanistan, 
Bahrain, Egypt, Iran, Jordan, Lebanon, Libya, Morocco, Oman, Pakistan, 
Syrian Arab Republic, Tunisia, and the West Bank and Gaza.
‡ Zanzibar, a semi-autonomous part of Tanzania, receives separate 
grants from the Global Fund.
In November 2011, however, the Global Fund announced the 
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cancellation of its next funding round (Round 11) along with 
the imposition of additional cost-cutting measures. These 
structural changes at the Global Fund have severe short and 
long-term implications for harm reduction programme start-
up, sustainability and expansion.u The Transitional Funding 
Mechanism (TFM) was established by the Global Fund to 
support the continuation of existing, essentialv programmes, 
but does not allow for further scale-up or start-up of services. 
This affected several countries in Asia, Eastern Europe and 
Central Asia with significant HIV and IDU burdens or emerging 
epidemics among PWID.27 In addition, several countries that 
may have planned to submit grant proposals in 2012 and 
2013 cannot now do so until 2014. 
In November 2011, the Global Fund board also passed the 
‘55% rule’, requiring that total funding approved for grant 
renewals for low-income countries be no less than 55% of 
any annual funding window.53 As an interim measure, it 
placed a 75% ceiling on grant renewals funding for lower-
middle income countries, further limiting available funds. 
The new rules, based solely on income status, affected many 
states with prominent injecting-driven epidemics such as 
Indonesia, Thailand and Malaysia. In response to concerns 
voiced by several delegations, the Global Fund Board passed 
a decision at its 26th Board meeting in May 2012 to freeze 
the implementation of the ‘55% rule.’53 A critical component 
informing this decision was the mobilisation of civil society 
organisations to document evidence of the short-term effects 
brought on by the ‘55% rule’ at country level, and to bring 
this evidence into high-level discussions.27, 54 At the time of 
writing, it is unclear how financing for harm reduction will be 
prioritised as part of the new Global Fund funding model that 
is being developed. 
The limited donor landscape for harm reduction approaches 
is further undermined by a shift in bilateral aid priorities and 
a narrowing of international aid budgets in some countries. 
Between them, the main bilateral donors for harm reduction – 
the UK, Australia and the Netherlands – accounted for US$67.4 
million in 2007.45 Recently however, these donors too have 
shifted their priorities away from middle-income countries, 
and in some cases have noticeably reduced spending on 
HIV/AIDS. For example, the UK Department for International 
Development’s (DFID) bilateral HIV programmes will be cut by 
30% over the next three years, and remaining funds will largely 
focus on low-income countries.55 The President’s Emergency 
Plan for AIDS Relief (PEPFAR) increased its investment in HIV 
programmes targeting PWID from US$18.1 million in 200956 to 
US$27.7 million in 2011.57 However, PEPFAR’s funding for harm 
reduction represents only 0.65% of this budget.54 The recent 
u  For a more in-depth discussion of repercussions internationally see McLean S, 
Wong F & Konopka S (2012) HIV, Drug Use and The Global Fund: Don’t Stop Now. Brighton: 
International HIV/AIDS Alliance. For a detailed discussion in relation to Eastern Europe 
and Central Asia, see Raminta S, Votyagov S and Pinkham S (2012) Quitting While Not 
Ahead: The Global Fund’s retrenchment and the looming crisis for harm reduction in Eastern 
Europe & Central Asia. Vilnius: EHRN. 
v  According to official Global Fund guidance, the term ‘essential’ for the purposes of 
the Transitional Funding Mechanism includes programmes for PWID.
re-instatement of a federal funding ban on needle exchange 
programmes, both domestically and abroad, places further 
constraints on global harm reduction resources. 6
Few national governments have been willing or able to finance 
the implementation and scale-up of HIV and harm reduction 
interventions within their own borders, with a few notable 
exceptions (such as Malaysia and Taiwan).44 For example, when 
Romania became ineligible for Global Fund resources in 2010, 
the government failed to support existing NGO-run harm 
reduction programmes. As a result, the percentage of PWID 
reached by harm reduction programmes decreased from 76% 
in 2009 to 49% in 2010. In 2011, the number of newly reported 
HIV infections among PWID was higher than in previous years, 
and cases attributed to IDU increased as a proportion of new 
infections.27 Numerous countries with IDU-driven epidemics 
are likely to experience a lack of government support 
following the exodus of international donor funds. Some 
private donors including the Gates Foundation and Open 
Society Foundations (OSF) have stepped in to support harm 
reduction approaches in the absence of national, bilateral and 
Global Fund support in certain settings. However, this support 
remains insufficient to maintain and allow sufficient scale-up 
to halt and reverse existing and emerging epidemics among 
PWID in the long-term.
Although there is no accurate estimation of the total spend 
on harm reduction globally, nor the shortfall in 2012, it is clear 
that recent developments significantly limit potential progress 
toward international commitments, such as halving HIV 
transmission among PWID by 201558 and achieving universal 
access to HIV prevention, treatment, care and support for 
PWID.59 There is an urgent need for civil society (including 
international and local NGOs, organisations of PWUD) as well 
as donors and national governments to mobilise as a matter of 
urgency in order to ensure the continuation and sustainability 
of programmes and avoid reversing gainsw already made in 
preventing HIV and other blood-borne viruses among PWID. 
The regional updates in Section 2 of this report provide a 
more detailed documentation of the state of harm reduction 
in different parts of the world, particularly highlighting 
developments since 2010. Section 3 explores key thematic 
areas for building an integrated harm reduction response, 
including specific barriers to access faced by women and 
young people who inject drugs, and drug use among men 
who have sex with men, and implications for harm reduction 
service provision. Additional chapters provide a global 
overview of drug decriminalisation policies around the world, 
and an exploration of sustaining and scaling up services in 
challenging social and political environments.
w  Please see Section 2.2 of this report for a discussion of the situation in Greece as 
an example of a setting where HIV can re-emerge in the absence of well-resourced 
responses.
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Table 2.1.1: Epidemiology of HIV and Viral Hepatitis, 
and Harm Reduction Responses in Asia 
Country/territory 
with reported 
injecting  
drug use
People who  
inject drugsa
HIV prevalence 
among people 
who inject drugs 
(%)
Hepatitis C (anti-
HCV) prevalence 
among people 
who inject drugs 
(%)1
Hepatitis B 
(anti-HBsAg) 
prevalence among 
people who inject 
drugs 
(%)1
Harm reduction responseb
 NSPc OSTd
Afghanistan
20,000 
(18,000–23,000)2
72 36 5.8 (19)3 (NP) (1)(M)3
Bangladesh 21,800–23,8002 5.32 >50e  9.4 (120)4 (P) (1)
Bhutan nk nk nk nk
Brunei Darussalam nk nk nk  nk
Cambodia 1900f 2 24.12 nk nk (2)  (1)5
China 2,350,0002 6.4g 2  67 (60.9–73.1)  9.6 (3.8–15.4) (>900)2 (738)2(B,M)       
Hong Kong 30,0006 nk -- -- 7 1
India 177,000–180,0004 9.24  41  10.2    (2.7–17.8) (261)4 (72)h 8 (M,B,O)
Indonesia
105,784  
(73,663–201,131)i 9
362 77.3 2.9 (194)2  (74)2(B,M) 
Japan 400,000 nk 64.8 (55–74.5)  3.2 (2–4.3)
Korea (Republic of) nk nk 57 4  
Laos PDR 17002 nk nk  nk 2
Macau 23810 1.3211 80.411 10.711  (4)11(P) (4)11(B,M)
Malaysia 170,0002 8.72 67.1 nk (297)2 j (P) (674)
2 k(B,M)
Maldives 793 (690–896)2 0l 12  0.7i 12 0.8i 12 (1) (M)
Mongolia nk nk nk nk  (1)
Myanmar 75,0002 21.92 79.2  9.1 (40)2(P) (10)(M)2
Nepal  (30,155–33,742)13 6.32 87.3 (80.5–94) 5.8        (5.5–6)  (43) (3)2 m (B,M) 
Pakistan 91,0002 c 27.22 84 (75–92.9)  6.8          (6–7.5) (81)  
Philippines 15,506 13.62 70 nk  (3)
Singapore nk nk  42.5  8.5
Sri Lanka nk nk nk nk n
Taiwan nk 13.8 (2–25.6)  41  16.7 (1103) (90)(B,M)
Thailand 40,30014 21.92 o 89.8 nk (10)(P) (147)p (M)
Vietnam 158,4142 13.42 f 74.1  19.5 (297)2(P) (41)2(M) 
nk= not known
 
a Unless otherwise stated, data are sourced from Mathers B. et al for the Reference Group to the UN on HIV and Injecting Drug Use (2008) Global epidemiology of injecting drug use and 
HIV among people who inject drugs: a systematic review, Lancet, 372( 9651):1733–1745.
b Unless otherwise stated, data on NSP and OST coverage are sourced from Mathers B, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, Myers B, Ambekar A & Strathdee SA for the 
Reference Group to the United Nations on HIV and Injecting Drug Use (2010) HIV prevention, treatment and care for people who inject drugs: A systematic review of global, regional and 
country level coverage, Lancet, 375(9719):1014-28.
c The number in brackets represents the number of operational NSP sites, including fixed sites, vending machines and mobile NSPs operating from a vehicle or through outreach workers. 
(P) = needles and syringes reported to be available for purchase from pharmacies or other outlets, and (NP) = needles and syringes not available for purchase.
d The number in brackets represents the number of operational OST programmes, including publicly and privately funded clinics and pharmacy dispensing programmes. (M) = metha-
done, (B) = buprenorphine, (O) = any other form (including morphine and codeine).
e HIV Serological Surveillance conducted in six cities, with the highest prevalence reported among PWID in Kanshat at 95.7% (Bangladesh, Ministry of Health and Family Welfare, 2011).
f Year of estimate: 2007.
g Figure represents national average only and may significant regional variations.
h Figure represents the number of sites managed by the National AIDS Control Organisation (NACO). Researchers in the region estimate that at least 80 additional sites are implemented 
by external development partners.
i Figure has been queried by civil society sources, with some estimating that it is closer to 60,000. A World Bank survey was underway at the time of writing.
j The total number of NSP sites includes 221 NGO sites and 76 government-run sites.
k Total number of OST sites includes 218 in government hospitals and clinics and 406 private health care practitioners.
l Based on 2009 surveillance in two cities, Addu and Male.
m At least two additional sites were not included as part of this figure since anecdotal reports from civil society indicate that these sites provide buprenorphine for detoxification only 
rather than for maintenance therapy.
n Although there are no official programmes operating in Sri Lanka, anecdotal reports indicate that some psychiatrists and general practitioners prescribe methadone as OST.
o Estimate based on men who inject drugs only.
p Civil society and experts in the region have suggested that this estimate is too high and may not be representative of the actual level of OST provision in Thailand. It has been suggested 
that numbers may include clinics which require periodic detoxification and re-enrolment.
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Map 2.1.1: Availability of needle and syringe exchange programmes (NSP) 
and opioid substitution therapy (OST)
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Harm Reduction in Asia
At least one quarter (4.5 million) of the total estimated 
number of people who inject drugs (PWID) live in the Asia 
region, with over half of these residing in China.47 At the 
regional level approximately 16% of PWID are living with HIV,47 
but significantly higher rates have been detected at local level 
within several countries. In five countries with updated figures 
as of 2012 – Cambodia, Indonesia, Myanmar, Pakistan and 
Thailand – over one fifth to one half of PWID may be living 
with HIV.2
Regionally, most countries in Asia now offer essential harm 
reduction services for PWID, although current data do not assess 
their quality (see Table 2.1.1). Seventeen countries implement 
needle and syringe exchange programmes (NSPs) to varying 
degrees, including new programmes in border regions within 
Laos PDR.15 Provision of opioid substitution therapy (OST) has 
expanded in several countries including Myanmar, Malaysia, 
Indonesia, China, Vietnam and the Maldives, and two countries 
– Cambodia and Bangladesh – have newly established 
programmes since last reported in 2010. However, coverage 
of both interventions remain substantially below minimum 
levels recommended by international guidance.38 Despite 
progress made in recent years in improving HIV surveillance, 
the continued lack of or controversy over reliable data on the 
size of PWID populations in some parts of the region limit the 
accuracy of available coverage estimates, knowledge of the 
true burden of tuberculosis (TB), HIV and viral hepatitis among 
PWID, evaluation of impacts and planning for scale-up and 
resourcing needs.
Co-infection with HIV, viral hepatitis (B and C) and/or TB 
among PWID pose significant challenges across Asia. Greater 
integration of antiretroviral therapy (ART) with OST services, 
TB and viral hepatitis treatment, and peer involvement in 
treatment delivery, are key to achieving sufficient intervention 
coverage among this population.16, 48 Increased prevalence of 
injection as the route of drug administration for amphetamine-
type stimulants (ATS), the most commonly used drugs in 
Thailand, Laos, South Korea, Cambodia and Japan, has been 
documented in some countries.17 Cross-border mobility of 
PWID may contribute to epidemics among PWID, requiring 
increasingly collaborative prevention efforts in border areas 
within Bangladesh, Myanmar, China and Laos. The increasing 
overlap between injecting drug use (IDU) and sex work may 
pose an emerging challenge in several local and national 
contexts, including Sri Lanka, Pakistan and Malaysia.2 
There is increased awareness of harm reduction as an 
evidence-based public health approach to reduce HIV and 
other co-infections and address the health needs of PWID in 
the region. Nineteen countries or territoriesq identify PWID as 
q  Afghanistan, Bangladesh, Cambodia, China, Hong Kong, India, Indonesia, Macau, 
Malaysia, Maldives, Mongolia, Myanmar, Nepal, Pakistan, Laos PDR, Philippines, Taiwan, 
Thailand, Vietnam. 
a target population for the HIV response and explicitly include 
harm reduction in their national plans and/or drug policies, 
pointing to clear progress since 200918 when this was the 
case for only 14 countries. However, despite these significant 
improvements, 61% of countries in Asia Pacific still have laws 
and policies that pose major impediments to the provision of 
effective HIV prevention, care, treatment and support services 
for PWID.19 
The funding environment in Asia has become increasingly 
precarious in the last two years due to the withdrawal of 
support for harm reduction services by key bilateral donors 
and a reduction in Global Fund funds. There is an urgent need 
for strategic investment of available funds in the coverage 
and quality of high-impact, cost-effective interventions such 
as NSPs and OST.20-21
Developments in harm reduction 
implementation
Needle and syringe exchange programmes
Of the 25 countries and territories in Asia where IDU has been 
reported, 17 – two more than reported in 2010r – implement 
NSPs to varying degrees (see Table 2.1.1). In Cambodia, 
Mongolia, the Philippines and Thailand, NSP provision 
remains small-scale. In August 2011, the first NSPs in Laos 
were established at four remote health centres in the northern 
districts of Phongsaly and Houaphanh Provinces bordering 
Vietnam.15 
NSPs are delivered through various modalities across the 
region. In some settings there has been a shift from provision 
through stand-alone sites targeted at PWID to service delivery 
integrated within existing facilities, such as health clinics 
and pharmacies.26 Additional examples include 24-hour 
anonymous provision of sterile injecting equipment and 
condoms through self-service boxes at commune health 
stations and community hotspots in Vietnam,2 and harm 
reduction services and provision through a grocery store on 
the China/Myanmar border.15
In some countries in Asia, the number of NSP sites has 
increased: for example, in Bangladesh (from 93 in 2010 to 
120 in 2012), India (from 200–219 in 2010 to 261 in 2012), 
Indonesia (from 120 in 2006 to 194 in 2011) and Malaysia 
(from 117–130 to 297 in 2012).2, 4 Despite these increases, NSP 
coverage in most Asian countries remains insufficient to have 
an impact on HIV and viral hepatitis epidemics among PWID.s 
Coverage of NSPs varies widely across the region, from 263.7 
r  Laos PDR and Macau. Although NSPs started operating in Macau before 2010, this 
information was reported as ‘not known’ in the 2010 edition of this report.
s  The 2009 WHO, UNAIDS, UNODC Technical Guide for countries to set targets for universal 
access to HIV prevention, treatment and care for injecting drug users categorises NSP 
coverage levels as follows: low (<100 needles/syringes per injector per year), medium 
(>100–<200 needles/syringes per injector per year) and high (≥200 needles/syringes per 
injector per year).
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needle-syringes per PWID per year distributed in Bangladesh 
– the highest level of needle-syringe distribution among 
low- and middle-income countries worldwide – to less than 
10 needle-syringes per PWID per year in Thailand, Indonesia 
and the Philippines. New estimates since 2010 suggest that 
NSP coverage reaches medium levels in Malaysia (116 needle-
syringes per PWID per year), Myanmar (118 needle-syringes 
per PWID per year), Cambodia (120.2 needle-syringes per 
PWID per year), Vietnam (140 needle-syringes per PWID per 
year) t and China (180 needle-syringes per PWID per year). 
Coverage remains low in Pakistan and Nepal, where provision 
amounts to less than 100 needle-syringes per PWID per year.2 
In eight countriesu in Asia with reported IDU there are no 
operational NSP sites. Since 2010, NSP provision was scaled 
back or interrupted in Pakistan,22 Nepal23-24 and Cambodia. In 
Pakistan and Nepal site closures were due to the withdrawal 
of national funding support.25-26 In Cambodia, the provision 
of needles and syringes is dependent upon the availability of 
NSP licences issued at the discretion of the National Authority 
for Combating Drugs (NACD).84 In 2011 the government 
revoked or failed to renew licences for existing NSP services, 
as part of a move to relocate services to the government.26 As 
of December 2011, there were no licensed NSP sites operating 
in Cambodia, leading to a drastic downturn in service 
coverage.27 At the time of writing, a small number of services 
run by non-governmental organisations (NGOs) in Cambodia 
had resumed provision of sterile injecting equipment, but the 
reach of existing programmes remains restricted.28 
Fear of arrest and detention in compulsory detoxification 
centres that violate the human rights of PWID and fail to 
provide evidence-based programmes continues to deter 
many individuals from accessing NSP services and carrying 
sterile injecting equipment.29 
Geographical distance, costly transportation, inappropriate 
size of needle-syringes, lack of adequate training and limited 
capacity of peer outreach workers pose further barriers to 
access. Legal age restrictions for accessing NSPs in some 
Asian countries pose obstacles for PWID under 18 years 
old, despite evidence that age of initiation to injecting is 
gradually decreasing in some areas (see Chapter 3.2 for a 
broader discussion of legal age restrictions for harm reduction 
services).30 
t  2011 estimate based on men who inject drugs only.
u  Bhutan, Brunei-Darussalam, Hong Kong, Japan, Republic of Korea, Maldives, 
Singapore, Sri Lanka.
Service provision cuts in Pakistan
Harm reduction service provision to a sizeable portion 
of PWID in Pakistan has been severely threatened since 
2010. The largest harm reduction project in the country, 
running since 2005 with support from the World Bank, 
was suddenly terminated by the Government of Punjab 
using discretionary powers in May 2010. At the time of 
cancellation, the programme had reached over 14,000 
PWID across eight cities in Punjab, and plans were in 
progress to scale up services to an additional four cities, 
reaching up to an estimated 22,000 PWID. Although 
no official reason for the programme’s termination was 
provided, civil society advocates cite the refusal on the 
part of the implementing organisation (Nai Zindagi) to 
disclose personal details of the project’s beneficiaries to 
government officials as part of an accountability audit 
as a potential trigger for subsequent official decisions. 
Recent surveillance data suggest that the closure of 
services has already begun to reverse important gains 
made in the past five years of implementation.31 
A portion of the gap in harm reduction service delivery 
will be filled by Pakistan’s Global Fund Round 9 grant 
scheduled to begin in 2012 and covering an estimated 
28,000 people with NSP services across 24 districts in 
Punjab and Sindh provinces over four years. However, the 
crisis persists, as the eight cities in which programmes 
were originally terminated continue to lack harm 
reduction provision and will not be covered by this grant.
Opioid substitution therapy
Availability and coverage of OST has been scaled up in several 
Asian countries since 2010 (see Table 2.1.1). For example, 
provision was expanded in Myanmar (from 7 sites in 2010 
to 10 by December 2011, reaching 1637 PWID),2 Malaysia 
(from 95 in 2010 to 674 sites reaching 44,428 PWID in 2012),v 
Indonesia (from 11 sites in 2006 to 74 in 2011), China (from 
600–675 sites in 2010 to 738 across 28 provinces currently 
reaching 140,000 PWID) and India (from 61–63 in 2010 to 
at least 72 in 2012).w8 In Vietnam a small-scale methadone 
programme has been significantly scaled up from four clinics 
in two provinces in 200939 to 41 clinics across 11 provinces 
presently reaching 6900 PWID.32 Plans are underway to 
further expand access to 80,000 PWID across 30 provinces 
by 2015.2 As of June 2011 the Ministry of Labour, Invalids and 
Social Affairs (MOLISA) has contributed to financing the first 
methadone maintenance therapy (MMT) clinic, an important 
development for harm reduction in the country considering 
the increasingly narrow resourcing landscape for PWID.32 In 
v  This includes provision through government hospitals and clinics (218 sites), private 
health care practitioners (406 sites), National Anti-Drug Agency (NADA) service centres 
(32 sites) and prisons (18 sites).
w  This includes four MMT pilot sites initiated by UNODC between January and April 
2012.
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the Maldives, the second phase of OST was initiated in 2011 
following a pilot methadone project established in 2009 
with support from the UNODC Regional Office for South Asia 
(ROSA).2, 33 Thailand’s Department of Medical Services reports 
that there were 6085 patients enrolled on MMT during the 
period of April 2010 to April 2011.x34 Community-based and 
civil society organisations (CSOs) play an important role in 
service implementation and success in Myanmar, China and 
Bangladesh. 
Two countries in the region have initiated OST since last 
reported in 2010.35 The first pilot methadone clinic in Phnom 
Penh, Cambodia, began dosing in July 2010.26 As of December 
2011, 113 PWID, 20% of whom are women, were receiving 
methadone, with imminent plans to scale up to three sites.5, 
27 In Dhaka, Bangladesh, an OST pilot with methadone was 
implemented in June 2010 by the International Centre for 
Diarrheal Disease Research (iccr-b) in collaboration with the 
Government of Bangladesh. To date, 150 PWID are receiving 
methadone, with another 150 to be enrolled at a second site 
being planned through funds from Save the Children under 
the Global Fund RCC programme.2 
Although rollout of OST to 6000 PWID in Pakistan is 
supported under Global Fund Round 9, implementation will 
be dependent upon successful piloting by UNODC planned 
to commence in late 2012.25 In Nepal, plans to scale up the 
national OST programme and revise guidelines and training 
curricula on OST in collaboration with the German Agency for 
International Cooperation (GIZ) were underway at the time of 
writing.2 Malaysia has gradually moved away from supporting 
compulsory detention since 2010, instead focusing its efforts 
on scaling up existing NSP and OST programmes, including 
a rare MMT programme that operates inside a mosque.36-37 
Recognising the lack of services for female PWID in 
Afghanistan, UNODC, in partnership with Médecins du Monde 
(MdM) and local Afghan NGO Nejat, has recently initiated a 
referral mechanism to facilitate access to MMT by women who 
inject drugs, and expand the capacity of local NGOs to start up 
and implement MMT.3
Despite recent increases in service coverage, OST provision 
remains very limited in some countries. Where reported, 
measures of OST coverage remain imprecise, using PWID as a 
denominator, although not all PWID inject opiates or require 
OST.38 Available data suggest that less than 3% of PWID 
receive OST in Cambodia, Indonesia, Myanmar and Vietnam.39 
In Nepal, coverage has remained the same since last reported 
in 2010 (349 PWID on OST at three sites).35 The only existing 
methadone pilot programme in Afghanistan implemented by 
MdM reached 63 male clients as of November 2011.3 Scale-
up was on hold as of June 2012 pending an independent 
evaluation conducted by Johns Hopkins University as 
requested by Afghanistan’s Ministry of Counter Narcotics.3 
OST remains unavailable in ten countries with reported 
IDU: Bhutan, Brunei Darussalam, Republic of Korea, Japan, 
x  Estimate refers to the cumulative total and may include duplicates of individuals who 
dropped out and re-registered.
Laos PDR, Mongolia, Pakistan, the Philippines, Sri Lanka and 
Singapore. 
The availability and scope of OST is constrained by several 
factors. The poor quality of programmes, including inadequate 
or insufficient information on OST and its benefits, lack of 
proper follow-up among drop-outs and inappropriate dosing 
are commonly cited reasons for lack of retention in OST across 
the region.26 In Indonesia, despite increases in the number of 
PWID receiving OST since 2010, a significant proportion of 
PWID (39%) continue to inject while on MMT, particularly in the 
early months following the start of treatment.40 Programme 
quality requires increased documentation across the region 
and significant strengthening if harm reduction interventions 
are to produce measurable results. 
Legal and policy barriers that prohibit or restrict OST pose 
significant obstacles to implementation and scale-up in 
Asia.41 For example, policies requiring government approval 
of methadone quotas for provision in Afghanistan can cause 
emergency stock-outs and restrict programme scale-up.2 
In Vietnam, a barrier to access is posed by the requirement 
to register as a drug user with law enforcement authorities 
to receive OST.42 Limited service provider capacity, fear of 
arrest and detention, geographical distance to sites and high 
transportation costs,y lack of gender-sensitive programmes43 
and the absence of clear strategies to reach young PWID all 
restrict the reach of existing programmes.26 
Amphetamine-type stimulant 
use in Asia
Use of amphetamine-type stimulants (ATS), and 
particularly that of methamphetamines, has significantly 
increased in recent years in East and Southeast Asia. 
ATS use is associated with a range of harms including 
HIV, viral hepatitis, TB and other sexually transmitted 
infections (STIs).44 ATS use is predominantly found within 
vulnerable groups such as women, young people, sex 
workers and migrants.45
ATS users tend not to access ‘traditional’ harm reduction 
services, as these are predominately aimed at people 
who use opiates. Moreover, services generally do not 
reach this group, due to differences in their drug user 
networks as compared with people who use opiates.45
To meet the needs of people who use amphetamines, 
further research and investment is needed,46 as well 
as the development of a comprehensive package of 
evidence-based interventions specifically tailored to the 
needs of amphetamine users and developed with input 
from the community.45
y  As OST programmes in most Asian countries require daily visits by clients, 
transportation costs and time spent travelling pose significant barriers to access. For 
example, it is estimated that in Myanmar and Bangladesh travel time to dispensing sites 
for some PWID exceeds two and three hours daily. 
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Antiretroviral treatment
Wide variations in HIV epidemics among PWID exist among 
and within Asian countries. For instance, although an overall 
decrease in HIV prevalence among men who inject drugs from 
33.85% in 2010 to 13.4% in 2012 was detected in Vietnam, 
prevalence continued to exceed 50% in Dien Bien and Quang 
Ninh provinces, while in Da Nang it was only 1% – the lowest 
prevalence in the country.2 Rising prevalence has been 
recently documented in numerous cities in Pakistan,2 two 
northern border provinces and Vientiane in Laos PDR,2 and in 
Jakarta, Indonesia, where prevalence among PWID rose from 
33% to 44% from 2007 to 2011 despite decreases in the rest 
of the country.9 The heterogeneity of the HIV epidemic in the 
region is similarly highlighted by the Philippines, where new 
estimates suggest that 13.56% of PWID are living with HIV, yet 
prevalence among women who inject drugs (26.98%) is more 
than twice as high as among their male counterparts (12.87%).2 
On the island of Cebu in the Philippines an emerging epidemic 
among PWID – HIV has shot up significantly from 0.40% in 
2007 to 53.8% in 20102 – has been attributed by experts to the 
delayed implementation of harm reduction programmes.39 
Conversely, reductions in HIV prevalence among PWID in 
some countries in the region have been largely attributed to 
the early implementation and scale-up of key harm reduction 
programmes such as NSP and OST.39 HIV prevalence among 
PWID has decreased significantly in Kathmandu, Nepal (from 
68% in 2003 to 20.7% in 2009 and 6.3 % in 2011), in China 
(from 9.3% in 2009 to 6.4% in 2011) and in Indonesia (from 
52% in 2007 to 36% in 2011).2 
Although regional and global monitoring mechanisms have 
improved,z disaggregated data on ART access, coverage and 
treatment needs among PWID in Asia are scarce. According 
to the World Health Organization (WHO), 22 of 26 countries 
surveyed in Asia in 2010 reported ART availability for PWID.39 
Nevertheless, the scope and coverage of ART in the region 
remains limited. In 2010, the Reference Group to the UN on 
HIV and Injecting Drug Use reported that ART was accessed 
by only a small proportion of PWID living with HIV in nine 
countries in Asia.47 For example, in Indonesia, the country with 
the highest level of coverage in the region, only 6% of PWID 
living with HIV were receiving ART.47 In Afghanistan, the only 
two available ART centres located in Kabul and Herat are not 
accessed by most ART-eligible individuals due to geographical 
distance,2 and over 40 existing drug treatment centres 
z  For example, in March 2012, countries reported to UNAIDS on updated indicators 
to monitor progress towards the targets set in the 2011 Political Declaration on HIV/AIDS, 
including halving HIV transmission among people who inject drugs by 2015. While the 
new set of indicators includes indicators measuring uptake of HIV testing and counselling 
and coverage of NSP among PWID, it does not include coverage indicators for other 
interventions in the WHO comprehensive harm reduction package. For more information, 
see UNAIDS (2011) AIDS Response Progress Reporting 2012 Guidelines:  Construction of 
Core Indicators for Monitoring the 2011 Political Declaration on HIV/AIDS. Geneva: UNAIDS.
Additionally, there was an increase of 18% between 2009 and 2010 in the number of 
countries reporting to the WHO in preparation for its 2011 report, Epidemic update and 
health sector progress towards Universal Access. A total of 109 low- and middle-income 
countries reported information on the existence of programmes and policies targeted at 
and engaging people who inject drugs in 2010, compared with the 92 countries providing 
data in 2009. See WHO, UNAIDS, UNICEF (2011) Global HIV/AIDS Response: Epidemic update 
and health sector progress towards Universal Access. Geneva: WHO.
(providing treatment other than OST) across the country lack 
any voluntary counselling and testing (VCT) services.3 
Access to ART by PWID is disproportionately low compared 
with other key populations at higher risk of HIV, and remains 
restricted by systemic and structural barriers.48 In 2010, 47% 
of PWID living with HIV in low- and middle-income countries 
came from five nations,aa three of which (China, Vietnam and 
Malaysia) are in Asia.48 PWID comprise 67% of cumulative HIV 
cases in these five countries, but only 25% of ART recipients. 
Systemic and structural barriers such as the continuing policy 
in some countries to detain people who use drugs (PWUD) 
in compulsory detention centres, and imprisonment for 
drug possession for personal use, severely restrict access 
to prevention and treatment services among PWID in the 
region.48-49 Other barriers to ART access for PWID in Asia 
include the lack of quality adherence counselling, effective 
support or follow-up plans, which are essential for treatment 
success among PWID,16 stock-outs50 and lack of access to OST, 
among several obstacles.51 
Recent studies point to increased access to HIV testing, ART 
and improved treatment outcomes for PWID in Vietnam52 and 
Bangladesh.2 In Bangladesh, nine VCT centres designated for 
PWID across five cities provided ART to 2316 PWID between 
October 2009 and September 2011. 
According to recent estimates submitted by eight Asian 
countriesab to UNAIDS as part of the 2012 Global AIDS Progress 
reporting mechanism, uptake of HIV testing and counsellingac 
ranges from less than 10% in the Philippines and Pakistan to 
over 50% in Indonesia – the country with the highest reported 
percentage of PWID accessing HIV testing.ad2 The generally 
low levels of testing among PWID in the region corroborate 
global data from the WHO and UNICEF, who reported in 2011 
that the median uptake of VCT was only 25% in 13 reporting 
countries in the previous 12 months.39 Given the small 
number of countries worldwide, and in the region specifically, 
that monitor and report on this indicator, greater efforts and 
investments are required to adequately track access to and 
increase uptake of VCT among PWID.
Viral hepatitis
Rates of hepatitis C (HCV) and hepatitis B (HBV) in PWID vary 
widely among countries in Asia. A recent systematic review 
reported Asia is the world region with the largest populations 
aa  China, Vietnam, Russia, Ukraine, Malaysia.
ab  Vietnam, Thailand, the Philippines, Pakistan, Nepal, Myanmar, Indonesia and 
Cambodia. 
ac  According to Global AIDS Progress Reporting 2012 guidance, this indicator is 
measured as the percentage of PWID that have received an HIV test in the past 12 months 
and know their results.
ad  Figures from Indonesia are based on NSP and OST attendees. Among NSP 
participants, 56% had undertaken an HIV test. HIV test uptake among methadone 
clients was nearly 100%, as enrolment in MMT requires an HIV test. The high update of 
HIV testing among PWID in Indonesia is partly attributed to the increase in supportive 
legislation on harm reduction and to the integration of NSP into primary health 
services. For more information see: UNAIDS (2012) Indonesia Global AIDS Progress Report. 
Geneva: UNAIDS, http://www.unaids.org/en/dataanalysis/monitoringcountryprogress/
progressreports/2012countries/ ce_ID_Narrative_Report.pdf Accessed 24 June 2012.
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of PWID with hepatitis B surface antigen (HbsAg)ae (300,000, 
range 100,000–700,000) and HCV (2.6 million, range 1.8–3.6 
million). China is home to more than half (1.6 million, range 
1.1–2.2 million) of PWID living with HCV worldwide.1 
Where estimates are available, all countries report an HCV 
prevalence of over 30% among PWID, and in four countries 
or territoriesaf rates exceed 80%. HBV prevalence among PWID 
ranges from 2.9% in Indonesia to 10–20% in India, Macau, 
Taiwan and Vietnam.1 The quality of existing global data on 
viral hepatitis is variable. The large ranges of available figures 
indicate inexact estimates resulting from varying prevalence 
between different sub-populations of PWID and different 
recruitment settings (see Table 2.1.1).1 Co-infection of HIV 
and HCV is a significant challenge in some parts of the region, 
particularly Bangladesh, India, Indonesia, Myanmar, Nepal 
and Thailand, where 50–100% of PWID living with HIV are also 
co-infected with HCV.53 Research indicates that co-infection 
with HIV and HCV and/or HBV is highly prevalent among PWID 
in the China–Myanmar border region.54 
Viral hepatitis testing and treatment is rarely state-funded 
in countries in Asia. The main medicine used in the current 
standard treatment for hepatitis C is Pegylated Interferon-alfa, 
which is patent protected by two pharmaceutical companies, 
Roche and Merck, and remains beyond the means of the 
majority of PWID in Asia, costing between US$11,255 and 
$18,202 in the region.55ag Despite the inclusion of viral hepatitis 
diagnostics and treatment in the ‘comprehensive package’ of 
harm reduction services recommended by UNODC, WHO and 
UNAIDS for PWID, HCV is rarely addressed in the HIV response 
for this population.38
Tuberculosis
In addition to experiencing a high burden of co-infections 
such as HBV and HCV, PWID living with HIV are at increased 
risk of developing TB, including multi-drug resistant strains 
(MDR-TB).56 South-East Asia accounts for nearly 15% of the 
global burden of new cases of HIV/TB co-infection.57 Although 
no systematic prevalence figures exist among PWID in the 
region, individual studies indicate that they experience high 
prevalence of TB and other co-infections. For example, TB 
rates among PWID living with HIV were 33.9% in Chennai, 
South India,58 and 4.8% in Pokhara, Nepal.59 In Vietnam, HIV 
infection was concentrated among PWUD with TB, particularly 
young men aged 15–34 years,60 and was the most common 
cause of death (40%) within six months of starting ART among 
a cohort of PWID living with HIV.61 Transmission of TB among 
PWID living with HIV has been linked with a lack of adherence 
ae  HbsAg indicates active (either acute or chronic) infection. Approximately 95% of 
adults with acute HBV infection clear the virus and develop anti-HBc and hepatitis B 
surface antibodies (anti-HBs). People who inject drugs may have lower clearance rates for 
HBV than the general population because more PWID may become chronically infected. 
For more information see Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, 
Horyniak D & Degenhardt L (2011) Global epidemiology of hepatitis B and hepatitis C in 
people who inject drugs: results of systematic reviews, Lancet, 378(9791): 571–583.
af  Macau, Nepal, Pakistan and Thailand. 
ag  Generally to manage HIV/HCV co-infection, a year-long treatment with Pegylated 
Interferon and Ribavarine (peg-IFN/RBV) is required.
support and inadequate prescription of ART, as well as with 
having been incarcerated.62-63
Although several countries in Asia including India, Nepal, 
Thailand and Myanmar have increasingly taken steps to 
address TB/HIV co-infection more generally,53 it is unclear to 
what extent activities target PWID specifically. For instance, 
in Pakistan, TB testing and treatment services can only be 
offered to PWID via direct linkages through harm reduction 
services providers, as PWID tend not to access general health 
services in the same manner as the general population.25 
Barriers to addressing TB among PWID include poor health 
infrastructure, administrative obstacles to effective TB and 
HIV programme collaboration, low awareness, stigma and 
discrimination by service providers and criminalisation of 
drug use.57, 64 For example, in Bangladesh, PWID are generally 
referred for testing and treatment to specialised TB clinics, 
where they are often refused anti-TB treatment due to service 
providers’ flawed perception that PWID have low rates of 
adherence.25 While referrals from harm reduction services to 
TB centres are reported to be robust in Afghanistan, there is a 
need to strengthen referral systems for HIV screening from TB 
centres.3 Additional obstacles are posed by lack of access to 
methadone or buprenorphine therapy in some settings, which 
may cause PWID to drop out of treatment when admitted to 
in-patient TB wards due to opioid withdrawal symptoms that 
go unaddressed. 
Overdose
Although studies from an increasing number of countries 
have examined mortality among people who use opioids,65 
estimates on the occurrence of overdose mortality and non-
fatal overdose outside high-income countries remains very 
limited.66-67 A recent global meta-analysis of prospective 
studies on mortality associated with heroin and other opioid 
use found that Asia had the highest crude mortality rate 
(CMR) at 5.23 deaths per 100 person-years, with overdose 
most commonly cited as the cause of death.65 In a prospective 
cohort of PWID in Liangshan, Sichuan province in China, 
64.3% deaths during a one-year period were attributed to 
overdose.68 In Thai Nguyen province, Vietnam, drug overdose 
accounted for 27% of deaths among a cohort of PWID 
between 2005 and 2007.69 Rates of non-fatal overdose among 
people who inject opioids are similarly high. For instance, in 
local studies 30% of heroin injectors in Bangkok, Thailand,70 
83% in Ban Ninh, Vietnam,71 and 12% in Southwestern China72 
reported experiencing at least one overdose.66 
The quality of available data is highly variable. Common 
limitations include the reporting of mortality risk estimates 
among PWUD and PWID derived from retrospective cohort 
studies, which greatly reduces their reliability, lack of 
standardised reporting of mortality cause among this group, 
and small sample sizes largely drawn from treatment centres, 
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which may not be representative of out-of-treatment PWID, 
thus limiting the strength of international comparisons.65-66
Responses to overdose have only recently been recognised 
as integral components of harm reduction programmes in 
some Asian countries. For example, naloxone is available in a 
majority of hospitals and ambulances in China and Sri Lanka, 
and through pharmacies, harm reduction drop-in centres 
and outreach workers in Afghanistan.3 Although the national 
MMT programme in China requests that each clinic keep 
naloxone readily available, it is unclear to what extent this 
is implemented in practice.26 In 2011, community naloxone 
distribution programmes have been piloted in Vietnam73 and 
in four provinces in China.74 
Despite these increases in provision, availability of naloxone 
for peer distribution in community settings remains limited 
in Asia.66 Five countries in the region (Afghanistan, China, 
India, Thailand and Vietnam) implement community-based 
naloxone programmes to some extent.67 In most settings in 
Asia, naloxone is classified as a scheduled drug and cannot be 
sold over the counter. Shortages of naloxone, even in licensed 
government-run health care facilities, and a lack of skills in 
addressing overdose among service providers pose ongoing 
obstacles to the prevention and management of overdose. 
In Vietnam, a law prohibiting laypeople from providing 
injections hampers scale-up of community-based naloxone 
programmes.42 In some countries, it is challenging for NGOs to 
procure naloxone for distribution, whether due to high prices 
or due to special licences (i.e. medical licences) needed to 
purchase medications. Intranasal naloxone is very costly and 
remains unavailable throughout Asia.75 
Harm reduction in prisons
IDU is widespread in prisons and other places of detention 
across the region. For instance, a study on prisoners for drug-
related crimes in nine prisons across Indonesia found that 
almost 90% had consumed an illicit drug, and more than one-
third had injected heroin.76 While some prisoners continued 
to inject drugs with decreased frequency, and others stopped 
injecting while incarcerated, 0.5–4% of PWID actually injected 
for the first time while in prison.2 Among PWID in three cities 
in Afghanistan, 62.9% had previously been imprisoned, of 
whom 17.2% reported injecting while in prison.77 Similarly, 
in a sample of 252 PWID in Bangkok, Thailand, 78% reported 
a history of incarceration, and approximately 30% of them 
injected drugs while in prison.78 
A 2010 national survey in Indonesian prisons and detention 
centres detected higher HIV rates among a subset of male 
prisoners with a history of injecting drugs (6.7%) compared 
with the general male prison population surveyed (1.1%). 
Rates were higher among women than among their male 
counterparts, and twice as high among women with an 
injecting history (12.0%) compared with incarcerated women 
with no history of IDU (6.0%).2 Rising HIV prevalence among 
Afghanistan’s 23,800 prisoners and detainees also appears to 
be linked to the high proportion of PWID in prison.2 A new 
report by the Cambodian human rights group LICADHO 
indicated that imprisonments for drug-related charges 
(including drug use) increased by 163% in 2011. In the 
13 prisons surveyed by LICADHO, this number has nearly 
quadrupled since 2008.79 
Implementation of harm reduction programmes in prisons 
and other closed settings remains a serious challenge in most 
countries in Asia. There are no NSPs operating in prisons in the 
region. In some countries, such as Bangladesh, the distribution 
of needles and syringes in prisons is considered a criminal 
offence. OST programmes operate in four Asian countries: 
India, Indonesia, Malaysia and Thailand. In India, the only 
existing prison OST pilot launched in 2008 has been scaled up, 
reaching nearly 120 inmates in one prison.8 However, where 
they do exist, prison harm reduction services remain limited: 
only four prisons in Indonesia and 11 in Malaysia implement 
the intervention.80 
As of March 2012, discussions were ongoing among 
government and police officials in the Maldives to introduce 
a comprehensive harm reduction package in prisons.2 Plans 
to initiate OST in prisons are also underway in Vietnam.2 In 
Bangladesh, the 3rd National Strategic Plan for HIV and AIDS 
Response 2011–2015 now supports implementation of prison 
OST, noting, however, that policy advocacy and reform will be 
required to facilitate programme start-up.81 
In Pakistan, Bangladesh and Afghanistan, limited drug 
treatment (other than NSP and OST) and HIV prevention 
services are provided in some prisons. This includes an 
UNODC-supported project that provides drug treatment and 
other health services (other than OST) to 450 female inmates 
out of approximately 500 female prisoners in six female 
prisons in Afghanistan.3 
In Japan, a proposed amendment will allow PWUD in prison 
to qualify for early release and undergo abstinence-based 
drug treatment in the community. Although harm reduction 
services remain unavailable in both settings, the proposed 
amendment represents an important shift away from 
treating drug dependence as a crime.82 In June 2011 a ruling 
by the Supreme Court in Indonesia strengthened diversion 
sentencing to rehabilitation instead of prison for non-violent 
drug users not convicted of drug trafficking or other felony 
charges in the country’s otherwise highly criticised narcotics 
law.83 Diversion sentencing for PWUD in Indonesia is an 
important development since 2010, considering that drug-
related offences greatly contribute to prison overcrowding.ah 
ah  According to Indonesia’s Ministry of Law and Human Rights, the number of 
prisoners for drug-related crimes in Indonesia has increased steadily as a proportion 
of the general prison population from 7122 (10% of prisoners) in 2002 to 37,295 (26% of 
prisoners) by the end of September 2009. 
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Policy developments for harm 
reduction
Harm reduction is an important component of HIV and drug 
strategies in most countries in Asia. Nineteen countries 
or territoriesai identify PWID as a target population for the 
HIV response and explicitly include harm reduction in their 
national plans and/or drug policies (see Table 2.1.1). This is a 
clear improvement since 2009 when this was the case for only 
14 countries.18 
Despite significant improvements in policy that have 
facilitated implementation and scale-up of harm reduction 
services, the existence of national policy on harm reduction 
does not equate to the provision of an adequate response in 
either scope or quality. Nearly two-thirds (61%) of countries 
in Asia Pacific still have laws and policies that pose major 
impediments to the provision of effective HIV prevention, 
care, treatment and support services for PWID.19 
In many countries in the region, harm reduction efforts are 
undermined by inconsistencies in drug control policy, which 
often conflicts directly with national HIV or drug plans. For 
example, the government of Vietnam removed Article 199 of 
the Penal Code in 2009, effectively decriminalising drug use.32 
However, under the new regulations PWID can still be sent to 
compulsory treatment centres for two years.32 In Cambodia 
the Commune Safety Policy introduced in August 2010 and 
enforced in April 2011 by the Deputy Prime Minister applies a 
zero tolerance approach to drug use, has further stigmatised 
PWID and greatly undermined harm reduction efforts.aj84-85 
Additionally, in December 2011, the National Assembly of 
Cambodia approved a drug law that mandates up to two years 
of compulsory treatment for PWUD, and fails to recognise 
essential harm reduction interventions, leaving NSPs and OST 
programmes vulnerable to arbitrary closure.84 Civil society 
advocates have strongly criticised the new drug law, pointing 
out that the term ‘drug addict’ is too broadly defined and can 
feasibly include anybody under the influence of drugs at any 
point.84 A new amendment to Thailand’s national drug policy 
in 2010 explicitly mentions harm reduction, yet this nominal 
improvement is overshadowed by the Deputy Prime Minister 
Chalerm Yubamrung’s recent proposal to ‘solve’ the drug crisis 
in Thailand within one year.86 This is a concerning approach to 
drug use and trafficking that echoes the disastrous 2003 ‘war 
on drugs’ and could have serious implications for access to 
and scale-up of harm reduction programmes.87
ai  Afghanistan, Bangladesh, Cambodia, China, Hong Kong, India, Indonesia, Macau, 
Malaysia, Maldives, Mongolia, Myanmar, Nepal, Pakistan, Laos PDR, Philippines, Taiwan, 
Thailand and Vietnam. 
aj  Anecdotal reports indicate that in efforts to enforce the Commune Safety Policy 
guideline, Cambodian police have recently become increasingly active in rounding 
up people who use drugs, who are in principle referred to compulsory rehabilitation 
treatment. If they decline treatment or are found to be engaged in crime, they are 
imprisoned. For further information, see Azariah S (2011) HAARP Cambodia Annual Review 
2011. Canberra: HAAARP.84
The continued commitment to compulsory treatment centres 
for PWID in several countries in the region undermines harm 
reduction efforts, elevates the risk of HIV transmission and 
violates international human rights law.88-89 Over 400,000 
people in the region are arbitrarily detained in drug detention 
centres,47 and up to 1000 people are executed for drug 
offences each year, in direct violation of international law.90 
Efforts have been taken in some Asian countries to mitigate 
the unintended consequences of drug policies and improve 
utilisation of harm reduction services through dialogue and 
negotiation with law enforcement officers. For example 
improved police practices reflecting a less punitive approach 
and increased understanding of harm reduction approaches 
have been observed in Kaski and Morang districts in Nepal 
as a result of joint programme implementation between law 
enforcement agencies and civil society.2 
Civil society and advocacy 
developments for harm reduction
Civil society advocates in the region have played an increasingly 
visible role in informing and liaising with governments, 
law enforcement and donors on the importance of harm 
reduction service scale-up and the need for an enabling 
policy environment. 
In 2010 the Asian Network of People Who Use Drugs (ANPUD) 
was registered in Hong Kong, a new regional coordinator 
was selected, and the Secretariat office was established in 
Bangkok, Thailand. ANPUD has since focused on developing 
and strengthening the network through a number of 
meetings and workshops, and providing its members with 
an avenue to become more meaningfully involved in policy 
and programming at the national, regional and international 
levels. 
The Asian Harm Reduction Network
The Asian Harm Reduction Network (AHRN) has continued 
to develop, successfully making the transition to a 
federation structure with ten initial members throughout 
the Asian region. Since 2010 a separate organisation, 
Access Quality International (AQI), has emerged to take 
on service delivery, technical assistance and capacity-
building roles previously held by AHRN, while AHRN has 
repositioned itself as a regional network. Following a 
series of strategic planning consultations between 2010 
and 2011 that brought together key experts from around 
the world, AHRN recently launched its new five-year 
strategic plan for 2012–2016. In its newly defined role, 
AHRN seeks to provide a platform for harm reduction 
policy dialogue and collaboration throughout Asia 
and facilitate networking and communication among 
member networks and other key stakeholders.
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At the regional level, notable events included the Asian 
launch of the Lancet special series on HIV in PWUD, organised 
by the University of Malaya’s Centre of Excellence for Research 
in AIDS (CERiA) in December 2010 in Kuala Lumpur, Malaysia. 
The symposium featured panel discussions with local, 
regional and international experts on topics particularly 
important to region including, among others, structural risk 
environments, women who use drugs, human rights, drug 
policy reform and compulsory drug detention centres.91 
The ‘10th International Congress on AIDS in Asia and the 
Pacific’ (ICAAP) was held in Busan, South Korea, in August 
2011. Despite widely condemned clashes between local law 
enforcement and community activists in Busan,92 the event 
provided an opportunity around which regional civil society 
groups could mobilise. AHRN, supported by the Open Society 
Foundations’ Global Drug Policy Program (GDPp), organised a 
satellite session exploring how the ‘war on drugs’ impacts the 
current response to drugs and HIV in the region. The meeting 
was well attended by more than 100 international delegates. 
Developments at the national level include the establishment 
of the first Afghan Drug Users’ Group (ADUG) in Kabul, 
Afghanistan, in 2011. ADUG is a movement of Afghan current 
and former PWUD, representing users’ interests and promoting 
their participation in decision-making, policy and service 
planning. ADUG participated in the ‘22nd International Harm 
Reduction Conference’ in Beirut, Lebanon, and is a recognised 
member of the International Network of People Who Use 
Drugs (INPUD). A new group comprised of several member 
organisations from across Vietnam, the Vietnam Network of 
People Who Use Drugs (VNPUD), was established in late 2011.
Civil society in Nepal has continued to engage actively in 
advocacy at the local, national and regional levels. In August 
2011, Nepalese civil society and local groups of PWUD 
produced a joint statement93 responding to poor government–
donor coordination that often led to interruptions to harm 
reduction services and serious concerns about programme 
sustainability.94 In January 2011, Recovering Nepal, in 
partnership with the government, organised the first national 
harm reduction media conference, bringing together 144 
active media representatives along with civil society networks, 
government officials and technical partners to highlight the 
need for sustainable and accelerated HIV and harm reduction 
services.95 
In an increasingly precarious funding environment, financial 
support for civil society advocacy in the region is extremely 
scarce and poses considerable challenges to sustainable and 
coordinated actions. 
Multilaterals and donors: 
developments for harm reduction
The international economic crisis, combined with a shift in aid 
priorities toward lower-income countries (LICs), and structural 
changes at the Global Fund to Fight AIDS, Tuberculosis and 
Malaria have had a considerable impact on existing and future 
harm reduction funding commitments in the region. 
Bilateral aid to the region has decreased markedly as countries, 
particularly in Southeast Asia, have transitioned to middle-
income country (MIC) status. There has been a general exodus 
of funding from donor countries such as the UK (DFID), the 
Netherlands (Dutch Development Cooperation Program) and 
Sweden (Swedish International Development Agency). The 
Australian government’s overseas aid programme’s (AusAID) 
HIV/AIDS Asia Regional Program (HAARP) remained one of the 
most significant donors funding harm reduction in the region 
as of early 2012, shouldering an estimated 30–50% of harm 
reduction costs.36 The Global Fund has played an important 
role in financing harm reduction programmes in the region, 
committing a total of US$166.7 million for interventions 
targeted at PWID between 2002 and 2010 (see Table 2.1.2). 
Major private donors such as the Gates Foundation and OSF 
have filled in some of the resource gaps, but funding levels 
remain far below what is needed to sustain and scale up 
programmes. 
Table 2.1.2: Approved Global Fund investments targeting 
people who inject drugs in Asia, Round 1 (2002) to Round 10 
(2010)96
Country / territory totAL (uS$)
Afghanistan 1,300,000  
Bangladesh 10,800,000 *
Bhutan <100,000  
Cambodia 5,800,000 *
China 23,400,000  
india 20,800,000 *
indonesia 14,000,000 *
Malaysia 6,100,000 *
Mongolia 100,000  
Maldives 500,000  
Myanmar 7,700,000 *
nepal 7,600,000 *
Pakistan 13,800,000 *
Philippines 1,500,000  
Sri Lanka 200,000 *
thailand 28,000,000 *
timor Leste <100,000 *
Vietnam 25,100,000 *
totAL 166,700,000
Notes
Figures are rounded. Data are correct as of March 2012. Data are 
based on detailed grant budgets submitted to the Global Fund and 
may not reflect actual expenditures.
* Figure includes projections for future years of grants that have not 
yet been formally committed.
Some governments such as China, India, Malaysia and 
Taiwan are filling in the gap and investing in harm reduction 
programmes within their own borders. In its national strategic 
plan 2011–2015, Laos PDR earmarks $3.6 million to reach 
60% of PWID with sterile injecting equipment and condom 
provision.2 However, core national funding for harm reduction 
in the region remains comparatively low, small-scale and 
short-term. Sustainable financing strategies, and prioritisation 
of investment in high-impact, cost-effective interventions 
such as NSP and OST, involving increasing contributions from 
national governments, are essential to enable countries to 
develop and bring harm reduction interventions for PWID 
to scale. Even as there are shortfalls for harm reduction 
funding, new research by Harm Reduction International has 
documented international donor support for drug detention 
centres and the death penalty for drug offences in several 
Asian countries.85 For example, Australia, Luxembourg and 
Sweden contributed US$1,649,800 for a UNODC project on 
capacity-building for drug detention centre staff in Vietnam, 
while the USA, Japan, Thailand, China, Brunei, Singapore, 
Sweden and Germany contributed funds to drug detention 
centre infrastructure in Laos PDR. Additionally, several 
countries that apply capital punishment for drug offences, 
such as China and Vietnam, continue to receive international 
funding and UN assistance for drug enforcement.85 
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After the Global Fund in China: a future for civil society 
in the harm reduction response?
Compiled by Sarah Konopka, International HIV/AIDS Alliance
In light of a worsening HIV epidemic among increasing 
numbers of people who inject drugs, the Chinese government 
has gradually advanced a harm reduction approach and 
in 2004 invested in the piloting of eight OST clinics in five 
provinces.96 Despite the scale-up of China’s harm reduction 
programme in recent years, coverage remains low, and 
recruitment and retention are ongoing challenges. Drop-
out rates are high, particularly where outreach, psychosocial 
support and community engagement are lacking.97-99
Harm reduction resources from the Global Fund began to 
fill the service provision gap in China in 2003,100 directing 
funds through the Chinese Centre for Disease Control 
(CDC) for capacity development of local community-based 
organisations (CBOs) to supplement the government’s clinic-
based OST programme with peer-led interventions including 
outreach, peer education, drug user support groups, family 
support services and community education. The impact 
of such services on quality has been documented: CDC-
affiliated OST clinics receiving funding from the national HIV 
prevention programme have better adherence rates and 
coverage than non-CDC-affiliated clinics.97 This demonstrates 
how valuable CBOs are in making MMT programmes work.
In 2011 the Global Fund announced that it would no longer 
fund upper-middle-income countries. Remaining Global 
Fund monies in China will expire in the end of 2012, and with 
that, the end of resources for the community-based harm 
reduction efforts. The Chinese government has pledged to fill 
the HIV resource gap,101 but civil society groups are unclear 
about what their priorities will be and what this will mean 
for the future of a civil society role in the harm reduction 
response.  
After 2012 it is anticipated that the government will contract 
the services of some CBOs and organisations/communities 
of people who use drugs to provide HIV and harm reduction 
services. Government-imposed restrictions on the NGO 
registration process remain an important concern.102-103 For 
CBOs to register as an NGO and, therefore, be eligible to receive 
government funding directly, they must have a sponsoring 
government organisation that will share responsibility for 
the management of funds.102-103 With Global Fund resources, 
some drug-user-led CBOs were able to strengthen internal 
systems and structures and build relationships with local 
government agencies. This has been vital to their success. 
As the response in China shifts to a primarily government-
funded response, civil society groups are concerned that 
their capacity development needs will be overlooked and 
that they will find it more difficult to engage and negotiate 
with local agencies.  
Commitments from other donors, including AusAID, Levis 
Foundation and the government of the Netherlands (BUZA), 
will contribute to maintaining a space for the engagement 
of communities of people who use drugs and CBOs. For 
example, the multi-country Community Action on Harm 
Reduction (CAHR) project of the International HIV/AIDS 
Alliance, funded by BUZA, works with Alliance China and drug 
user groups in Sichuan province to partner with the local CDC 
to improve MMT and NSP provision and access to peer-led 
services.104 Small-scale efforts like these will make a difference 
to the lives of the drug user groups involved and people who 
use drugs enrolled in their programme. But this will not be 
enough to influence policy on a national scale.
Experience in China shows that civil society engagement will 
be essential to the delivery of a comprehensive national harm 
reduction programme. With the exiting of the Global Fund, 
it will now be up to the Chinese government to support 
community-based and peer-led models of service delivery 
and work with communities of people who use drugs to 
ensure that peer-led and community-based interventions are 
an essential feature of the national programme.
In February 2011 the UN Regional Task Force held its meeting 
on IDU and HIV/AIDS in India.105 Key topics discussed included 
compulsory rehabilitation centres, the regional strategy for 
harm reduction in Asia Pacific 2010–2015 and key findings 
and recommendations of the external review of the UNRTF. A 
particular need was identified around the need for a regional 
advocacy strategy, including a feasible estimate of costs 
required to realise advocacy goals, to complement national 
strategies. 
The ‘Asia-Pacific High-level Intergovernmental Meeting on 
the Assessment of Progress against Commitments in the 
2011 Political Declaration on HIV/AIDS and the Millennium 
Development Goals (MDGs)’ was held in Bangkok in February 
2012. IDU and harm reduction were addressed in the context 
of insufficient coverage, continuing stigma and discrimination 
and legal and policy barriers that affect PWUD living with HIV, 
such as those that criminalise the possession of injecting 
equipment.106
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Table 2.2.1: Epidemiology of HIV and Viral Hepatitis, 
and Harm Reduction Responses in Eurasia 
Country/territory with 
reported injecting  
drug use
People who  
inject drugsa
HIV prevalence 
among people 
who inject drugs 
(%)a
Hepatitis C (anti-
HCV) prevalence 
among people 
who inject drugs 
(%)b
Hepatitis B 
(anti-HBsAg) 
prevalence among 
people who inject 
drugs 
(%)b
Harm reduction responsec
 NSPd OSTe
Albania 4,500–5,0001 f <1%2 29.21 nk  (3)  (6)3(M)
Armenia
3310
(2797–4057)4
10.75 nk nk  (7)  (4)3(M)
Azerbaijan 300,000h 9.55 62.95 10.95  (12–14)  (2)(M)
Belarus 50,0005 135 nk nk  (33)5  (13)6(M)
Bosnia and Herzegovina nk nk nk nk  (6) (8)(BN,M)
Bulgaria
20,250     
(16,200–24,300) 
2.2(s) 7 62.3(s) 8 3.1(s) 9 (100) (31)3(BN, M,O)
Croatia 8,500g 0.01 27.1(s) 8 2.4(s) 9 (42) (B,M)
Czech Republic
29,000
(25,494–33,823)(s) 
  0.0–0.67  13.68 15.1 (109) (P) (150–240)3(B,M, BN)
Estonia
13,801
(8178–34,732)
 54.3–89.9(s) h 7 90.5 21.3 (36) (10)10(B,M)
Georgia 40,00011 3.95 58.2 7.2 (10) (16)13(BN,M)
Hungary 5,69912 0.07 21.4(s) 8 0.3(s) 9 (25) (10)3(BN,M)
Kazakhstan 119,14013 3.85 61.3  7.9 (155)5  (3)3(M)
Kosovo nk 0 -- -- (3)14(M)
Kyrgyzstan 25,00015 14.65 5016 nk (29–49)5 (P) (17–20)3(M)
Latvia nk 11.25 50.0(s) 8 nk (18)5  (10)3(B,M)
Lithuania 5,45816 0.0–21.4(s) 7   70.3–89.7i (s) 8  3.3–8.9h 9 (12)17  (21)17(B,M)
Macedonia 15,000-20,00017 nk 7018 nk (15) (10)(M, B)3
Moldova 31,5625 16.45 42.7 nk (31) (10) j (M)
Montenegro nk nk 37.8 (22–53.6) 0  (18) (3)3(M)
Poland nk 6.87  44.3–72.4(s) 8 2.5-3.89 (27) (22)(B,M)
Romania 17,0005 4.218 82.9(s) 8 4.79 (3) (7)(B,M)
Russia 1,815,000 37.15 (0.3–74)k  72.5 (49–96)  9 (4) 
Serbia
30,383  
(2682–48,083)5
2.4–4.5 (s) 5 60.5–77.4(s) 5 nk (13) (30)3(B,BN,M)
Slovakia
18,841
(13,732–34,343)
0.37  40.3(s) 8 nk (20) (2)(BN,B,M)
Slovenia 7,310 0.47 21.58 3.4l (17)(P) (20)(BN,B,M,O)
Tajikistan
25,000 
(20,000–30,000)19
16.320 61.3 nk (49) (3)3(M)
Turkmenistan nk nk nk nk (2)
Ukraine 296,0005 21.55 67 (60.9–73)  6.7 (1667)5  (131)3(B,M)
Uzbekistan 83,500 8.45  51.7 nk (235)
nk= not known
(s) = sub-national data 
a Unless otherwise stated, data on the estimated number of people who inject drugs in each country are sourced from Mathers B et al. for the Reference Group to the UN on HIV and 
Injecting Drug Use (2008) Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review, Lancet, 372( 9651):1733–1745. The year of estimate is 
provided for each figure that is sourced from 2007 or earlier.
b Unless otherwise stated, estimates for hepatitis B and C are sourced from Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D & Degenhardt L (2011) Global 
epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews, Lancet, 378(9791): 571–583.
c Unless otherwise stated, data on NSP and OST coverage are sourced from Mathers B, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, Myers B, Ambekar A & Strathdee SA for the 
Reference Group to the United Nations on HIV and Injecting Drug Use (2010) HIV prevention, treatment and care for people who inject drugs: A systematic review of global, regional and 
country level coverage, Lancet, 375(9719):1014–28.
d The number in brackets represents the number of operational NSP sites, including fixed sites, vending machines and mobile NSPs operating from a vehicle or through outreach workers. 
(P) = needles and syringes reported to be available for purchase from pharmacies or other outlets, and (NP) = needles and syringes not available for purchase.
e  The number in brackets represents the number of operational OST programmes, including publicly and privately funded clinics and pharmacy dispensing programmes. (M) = 
methadone, (B) = buprenorphine, (BN) = buprenorphine-naloxone combination, (O) = any other form (including morphine and codeine). 
f Figure based on expert opinion and based on problem drug use rather than injecting only.
g   Year of estimate: 2007. 
h   Year of estimate: 2005.
i Year of estimate: 2006.
j    Seven of these are prison NSPs.
k   Year of estimate: 2003. 
l    Year of estimate: 2002.
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Harm reduction in Eurasia
Of the estimated 15.9 million (11–21.2 million) people who 
inject drugs (PWID) worldwide,20 3.7 million – nearly a quarter 
– live in Eastern Europe and Central Asia (Eurasia). Based on 
national-level estimates, the largest PWID populations are 
reported in Russia (1.8 million)21 and Ukraine (296,000).22 m 
Eurasia is the only region in the world where the number of 
people living with HIV has almost tripled since 2000, reaching 
an estimated total of 1.4 million (1.3 million–1.6 million) in 
2009 compared with 760,000 (670,000–890,000) in 2001.20 
Injecting drug use (IDU) remains the leading route of HIV 
transmission in Eurasia.23 An estimated one quarter of the 
3.7 million PWID in Eurasia are living with HIV.21 In several 
countries, particularly in Eastern Europe, HIV prevalence 
among PWID in prisons is substantially higher than prevalence 
in the general population.24 
Viral hepatitis is considerably more widespread than HIV among 
PWID in Eurasia, with five countries in the region reporting 
hepatitis C (HCV) prevalence higher than 70% among this 
population. Estonia has the highest HCV prevalence among 
PWID (>90%), followed by Romania (82.9%), Serbia (77.4%), 
Russia (72.5%) and Lithuania (>70%).25 The disproportionately 
high burden of HCV among PWID is exacerbated by limited 
access to testing and treatment, particularly for incarcerated 
PWID, who experience higher rates of viral hepatitis than 
PWID in the community.26 
Increasing rates of HIV/tuberculosis (TB) co-infection and 
limited access to treatment for both diseases contribute to 
the increased vulnerability of PWID in Eurasia. Fatal overdose 
caused approximately 21% of deaths among all people living 
with HIV in Russia in 2007, second only to TB.27 
Although harm reduction programmes across Eurasia have 
generally expanded since 2010, coverage remains low 
to medium by international targets.n Needle and syringe 
exchange programmes (NSPs) are available in all 25 countries 
of the region, but coverage varies widely among countries, 
from 19 syringes distributed per PWID per year in Latvia28 to 
174 per person per year in Estonia.29 None of the 12 countries 
in the region for which coverage data are available reached 
the international recommended level of 200 syringes per 
person per year,30 although five countries distributed between 
100 and 200 syringes per person per year: Estonia, Kazakhstan, 
Kyrgyzstan, Slovakia31 and Tajikistan.o 
Twenty-six countries in the region, with the exception of Russia, 
Turkmenistan and Uzbekistan, implement opioid substitution 
m  This report included both 250,000 and 296,000 PWIDs as population size estimates.
n  According to the 2009 WHO, UNODC, UNAIDS target-setting guide, <100 syringes 
distributed per person who injects drugs per year is considered low coverage, 100–200 is 
medium coverage, and >200 is high coverage. 
o  Data extracted from UNGASS country reports, Country questionnaires, Petersen et 
al. (2012),16 Latypov et al. (2012)3 for: Armenia, Azerbaijan, Belarus, Estonia, Kazakhstan, 
Kyrgyzstan, Latvia, Lithuania, Moldova, Romania, Tajikistan and Ukraine.
therapy (OST). Substantial scale-up of OST provision since 
2010 has occurred in Bulgaria, the Czech Republic, Georgia, 
Lithuania, Moldova and Serbia, and new programmes were 
established in Tajikistan in 2010 and Kosovo in 2012. 
Despite progress in several areas, harm reduction remains 
politically marginalised in some countries in the region, 
particularly Russia and Uzbekistan. Since 2010, Hungary’s 
national drug strategy has been amended to exclude harm 
reduction as a priority and limit access to drug treatment 
instead of criminal sanctions for people who use drugs 
(PWUD).32
The international financial crisis and the restructuring of the 
Global Fund to Fight AIDS, Tuberculosis and Malaria (the 
Global Fund) has significantly affected harm reduction efforts 
in many countries in Eurasia, with the notable exception 
of successful Round 10 applicants Kazakhstan, Kyrgyzstan, 
Ukraine and Uzbekistan.33 Since the cancellation of Round 
11 in November 2011, a number of countries in the region, 
namely Armenia, Azerbaijan and Belarus, face a different set 
of eligibility criteria for new funding and potentially long-
term funding cuts, as is the case of Albania.33 Despite the 
inclusion of harm reduction in national HIV or drug strategies 
in 26 countries,p34 the majority of governments in Eurasia do 
not financially support harm reduction programmes. Five 
countries reported non-governmental and non-Global Fund 
funding sources for harm reduction, while another 11 reported 
some governmental contributions toward the delivery of 
harm reduction programmes.q35 Overall, non-governmental 
organisations (NGOs) are the main implementers of NSPs, 
either through stand-alone sites or in the context of broader 
HIV prevention services, while governmental institutions 
tend to manage OST provision. However, in several countries, 
including Tajikistan and Uzbekistan, more governmental 
institutions have initiated NSP provision with support from 
the Global Fund. 
Civil society organisations (CSOs) and regional networks 
have played an increasingly important role in advocacy for 
harm reduction in Eurasia. Since 2010 the European Harm 
Reduction Network (EuroHRN)r which includes 13 countries 
in Eastern Europe,s was newly established with support from 
the European Commission, and the International Drug Policy 
Consortium (IDPC) initiated a new drug policy network for 
South East Europe.36 In 2011, several important events took 
place in European capitals as part of the Count the Costs 
Campaign,t on the occasion of the 50th anniversary of the 
p  Figure includes Azerbaijan, which passed a new HIV law in 2010.
q  Kyrgyzstan, Latvia, Romania, Russia, and Tajikistan reported additional funding 
sources in addition to government and GFATM, while Azerbaijan, Bulgaria, Bosnia & 
Herzegovina, Estonia, Kazakhstan, Latvia, Lithuania, Macedonia, Montenegro, Poland and 
Serbia reported governmental funding for OST/NSP and related activities.
r  The European Harm Reduction Network (EuroHRN) has been recently formed by ten 
organisations with a shared interest in advocating for and sharing knowledge on harm 
reduction within Europe. It is made up of three sub-regional networks covering North, 
South and Eastern Europe and managed by a coordinator based at the Harm Reduction 
International in the UK. For more information see www.eurohrn.eu.
s  Albania, Bosnia and Herzegovina, Bulgaria, Czech Republic, Estonia, Hungary, Latvia, 
Macedonia, Poland, Romania, Serbia, Slovakia, Slovenia. 
t  To learn more about Count the Costs, see www.countthecosts.org.
43
Single Convention on Narcotic Drugs on 30 March 2011. 
‘Urban Drug Policies in the Globalized World’, an international 
workshop conference that took place in Prague, Czech 
Republic, in 2010, brought together civil society partners 
and networks from Eurasia, enabling them to exchange 
information on policy and best practices. 
Developments in harm reduction 
implementation
Needle and syringe exchange programmes (NSPs)
NSPs operate in all 29 countries and territories in Eastern 
Europe and Central Asia (see Table 2.2.1). Since 2010, three 
countries have scaled up provision: Kyrgyzstan, Tajikistan and 
Ukraine: for example, the number of NSP sites in Ukraine has 
increased significantly from 985–1323 reported in 2010 to 
1667 in 2011.5 During the same period, five countries have 
scaled back provision due to funding cuts: Belarus, Hungary, 
Kazakhstan, Lithuania and Russia. 
Several countries reported that an increased proportion 
of PWID are being reached by NSP services. These include 
Armenia, Croatia and Kosovo, with coverage rates ranging 
from 10% in Georgia37 to 72% in Belarus.35 A recent report by 
the Eurasian Harm Reduction Network (EHRN) estimates that 
on average only 10% of PWID in Eastern Europe and 36% in 
Central Asia access NSPs.33 New data covering the period from 
January 2010 to December 2011 submitted by countries to 
UNAIDS as part of Global AIDS Progress reporting indicate 
that sharing of injecting equipment varies widely across 
the region. The number of PWID who report using sterile 
equipment during their last injection ranges from only 15.58% 
in Romania to 95.5% in Ukraine.5 New models of service 
delivery are applied in some countries including a pilot NSP in 
a prison in Tajikistan and a mobile NSP in Albania.u 
However, even in countries that report increased availability 
of NSPs, research and consultations with PWID indicate that 
many actively avoid seeking health services due to the risk 
of being stigmatised, ostracised or discriminated against 
by health care providers.16, 35, 38 Additional barriers to service 
access include limited or uneven geographical reach of 
programmes,35, 39 fear of being threatened, abused, extorted 
or arrested by the police,35, 41-43 criminalisation of possession 
of illicit substances or injecting equipment with traces of 
substances,44 lack of political will and funding,45 and limited or 
insufficient supply of injecting equipment.13, 35, 46 
Overall, harm reduction programmes that focus on women 
who use drugs are in place in Georgia, Kyrgyzstan, Russia and 
Ukraine with the support of the Open Society Foundation, 
u  The NSP in Albania has been newly integrated into the Break the Cycle (BTC) 
intervention model, which aims to enable PWID to use drugs safely by providing of 
services, skills and information and encouraging their commitment to not recruit others 
to drug use.
UNICEF and GIZ. However, in most cases, although NSPs do 
not openly discriminate against women, gender-specific 
NSP services that recognise and address the specific barriers 
faced by women who inject drugs are limited or difficult to 
access. In Romania, cultural stereotypes and stigma prevent 
many women from accessing NSP.35 In Tajikistan women 
who use drugs experience high levels of stigma, especially 
from male PWID.47 Anecdotal reports from Macedonia 
and Albania indicate that the lack of NSP programmes 
sensitive to women’s needs limits women’s access to these 
services.35 The intersection between drug use and sex work, 
particularly in the case of Roma sex workers in Hungary and 
Romania, renders addressing the needs of women drug users 
particularly challenging.35, 48
Access also appears to be limited for young PWID. Legal 
age restrictions or required parental consent prevent young 
people from accessing NSPs in Czech Republic, Estonia, 
Lithuania, Macedonia, Moldova and Romania.49-51 However, 
since NSP services are often anonymous and client ages 
unrecorded, it is hard to assess whether some PWID are under 
18.49 There are no legal age restrictions reported for accessing 
NSPs in 16 countries in the region.v In Serbia a new law due 
to be implemented beginning in August 2012 will allow 
minors aged 15 and above to have exclusive privacy over 
their medical charts and consent rights regarding their health 
issues, meaning that parental consent will be no longer be 
required when accessing harm reduction services.52
Opioid substitution therapy (OST)
OST is available in various forms in 26 countries and territories, 
with the exception of Russia, Turkmenistan and Uzbekistan. 
Despite the increased availability of OST at the national level, 
programmes continue to have limited reach, and coverage 
varies significantly among and within states. Ukraine has the 
highest number of clients on OST (6517),3 while the Czech 
Republic has the highest estimated OST coverage in the 
region, with 40% of people who inject opiates enrolled in OST.3 
It is followed by Lithuania, Bulgaria and Poland, with rates of 
13.1%,53 12% and 7% of PWID enrolled in OST, respectively.3 
In the majority of former Soviet countries coverage remains 
extremely limited, with under 5% of PWID accessing OST.3 
Although most programmes continue to have limited reach 
and are still in pilot stages,16 the number of OST sites has 
increased in 16 countries and territoriesw since 2010.
Greater coverage in the Czech Republic and Croatia can 
be partially attributed to the fact that medications used 
for OST (except methadone) can be prescribed by general 
practitioners and purchased in pharmacies.3 The opposite is 
the case in Estonia and Latvia, where prescription regulations 
limit access.35, 46 Positive developments in OST delivery have 
v  Slovakia, Croatia, Bulgaria, Albania, Slovenia, Serbia, Hungary, Bosnia, Kosovo, 
Armenia, Belarus, Kazakhstan, Kyrgyzstan, Russia, Tajikistan and Ukraine.
w  Albania, Armenia, Bosnia & Herzegovina, Bulgaria, Czech Republic, Estonia, Georgia, 
Hungary, Kazakhstan, Kyrgyzstan, Macedonia, Moldova, Poland, Romania, Serbia and 
Ukraine.
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been reported in Serbia and Bosnia and Herzegovina, where 
services have recently been decentralised.35 Additional forms 
of OST in addition to methadone have been introduced 
in Serbia (buprenorphine and buprenorphine-naloxone 
combination), as well as in Czech Republic and Georgia 
(buprenorphine-naloxone combination).37 In Bulgaria the 
quality of OST services is presently being addressed in a new 
set of guidelines for good clinical practice planned to come 
into force in 2012.3
Despite encouraging developments in OST provision in the 
region, a number of barriers remain around implementation 
and scale-up. Only nine countries – Albania, Bulgaria, 
Kyrgyzstan, Latvia, Lithuania, Macedonia, Poland, Serbia and 
Ukraine – reported access to takeaway doses. However, even 
in countries where takeaway OST is available, access is limited 
by strict regulations:3 strict admission criteria are in place in at 
least seven countries, including proving a past history of opiate 
use, as well as one or several failed treatment attempts.55-57 
Scarce provision of OST outside major urban centres results 
in uneven coverage within countries,35 and the cost of existing 
OST services, limited funding3, 40, 58 and long waiting lists35 pose 
additional barriers. Limited funding was cited as the reason 
why some services reportedly prescribe methadone doses 
below WHO recommendations in Kyrgyzstan55 and Moldova.40 
In several Eurasian countries, protocols for administering OST 
are inappropriate or non-existent, and there is a need for 
increased capacity-building among staff. 
Access to OST is also subject to strict age restrictions, with 
legal age restrictions in place in at least ten countries and 
parental consent needed for young people under 16 years old 
in Bosnia and Herzegovina and Slovakia.35 Barriers faced by 
women who inject drugs are similar to those faced by men, 
although the limitation of civil rights, particularly the removal 
of parental rights, affects women disproportionally in several 
countries including Macedonia and Ukraine.59-60 Often this is 
executed through the implementation of registries of PWUD 
at harm reduction services for women who inject drugs, 
rendering them vulnerable to discrimination and the loss of 
parental rights during child custody cases. Fear of stigma and 
discrimination remains a barrier to access for all PWID.35
Antiretroviral therapy (ART)
Eurasia is home to nearly 1 million PWID living with HIV.61 
PWID comprise 62% of people living with HIV in the region 
but only 22% of those receiving antiretroviral therapy (ART).33 
The proportion of PWID living with HIV who receive ART 
in Eurasia varies between 3.5% in Kazakhstan and 10% in 
Moldova, although it should be noted that new data on exact 
coverage since 2010 were only available for three countries.16 
The highest numbers of PWID living with HIV who access ART 
are in Ukraine (1732)16 and Poland (1372).61 Providing PWID 
with fully comprehensive prevention, treatment and care 
services is particularly important given the high rates of co-
infection with TB and viral hepatitis among this population.62 
Accessing confidential voluntary counselling and testing 
(VCT) is an important element in increasing the uptake of 
ART for PWID. Recent country-level data from 2012 Global 
AIDS Progress reports submitted to UNAIDS indicate that the 
percentage of PWID who tested and are aware of their status 
ranged between 3.9% in Azerbaijan, 64.4% in Lithuania and 
64.7% in Kazakhstan.63 Barriers to testing for HIV included 
non-confidential VCT, parental consent requirements for 
those less than 18 years old,35 availability of testing only in 
medical facilities, procedural delays,35 funding issues for VCT 
programmes35 and discrimination against PWID by health care 
providers.
Due to relatively low rates of HIV in Albania, Croatia, Georgia, 
Kosovo, Macedonia, Slovakia and Slovenia, most individuals 
in need of ART are reported to access it.35 The requirement 
to undergo additional tests prior to initiating ART, the need 
for mandatory documentation that PWID have difficulty 
accessing such as local registration, national identity card and 
fixed residence, and lack of ART treatment guidelines for PWID 
all act as deterrents to their accessing ART in several countries 
in the region.35
Challenges with adherence to ART are generally linked to 
limited access to OST, stigma and discrimination by police 
and health care providers, a lack of counselling and support, 
limited funding for ART, geographical distance from treatment 
centres and complexity of ART regimens.10, 64 Adherence 
among PWID is facilitated by socio-emotional support by 
family and friends and access to OST, such as methadone or 
buprenorphine, which attenuate the impact of active drug 
use on the uptake of ART.16 Fears that adherence rates among 
PWID will be lower than among the general population are 
not supported by a recent systematic review and meta-
analysis, which found rates of 60% adherence among PWID, 
which are similar to adherence rates found among the general 
adult population living with HIV that do not inject drugs.65
Viral hepatitis
A recent systematic review of the global epidemiology of 
viral hepatitis (B and C) among PWID concluded that Eastern 
Europe was home to the largest population of PWID with HCV, 
or 2.3 million of the total estimated 10 million PWID living with 
HCV globally in 2010 (range 6.0–15.2 million).25 Following HIV 
infection trends, Russia, where the largest PWID population 
in Eurasia resides, had the second largest population of PWID 
living with HCV in the world, after China. Prevalence data for 
HCV are available for 24 of the 29 countries and territories in 
Eurasia, ranging from 13.6% in the Czech Republic to 90.5% 
in Estonia. Lithuania, Romania and Estonia were the three 
countries with the highest recorded prevalence: 76.3–89.7% 
among PWID in two cities in 2006,66 82.9% among PWID in 
Bucharest in 200966 and 90.5% in 2002, respectively.25 
Of the 1.2 million PWID living with hepatitis B (HBV) worldwide 
in 2010, 300,000 live in Eurasia; however, it should be noted 
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that25 available data on HBV are of a lower quality than data 
on HCV. Only 11 of the 29 Eurasian countries and territories 
had ever conducted a prevalence study on HBV among PWID. 
Where data were available, prevalence varied widely from 
less than 1% in Montenegro and Hungary to over 20% in 
Estonia (see Table 2.2.1). The quality of prevalence data and 
the timing of the existing studies varied significantly among 
the 29 countries in the region, with no data available on either 
HCV or HBV from eight countriesx and several countries’ latest 
available data being from 2001 or earlier. Systematic research 
on the extent of viral hepatitis, particularly in light of the 
limited access to testing and treatment for both HCV and HBV 
among PWID,25 is urgently required. 
Access to HCV treatment among PWID remains extremely 
limited in Eurasia.67 The high cost of patented Pegylated-
Interferon used in the treatment of HCV (up to $18,000 for a 
48-week course in some countries in the region) remains a 
critical barrier to access.68 Few countries (such as Kazakhstan, 
Russia, Lithuania, Estonia and Bulgaria) are reported to provide 
any state-funded HCV treatment, but obtaining concrete data 
on the qualification criteria for receiving treatment and the 
number of people treated remains challenging. In Russia, HCV 
treatment is provided by the state for those with HCV/HIV co-
infection, but access continues to remain limited for those 
with a history of drug use, and particularly for people actively 
using drugs.68 Diagnostic tests for viral hepatitis, mainly viral 
load qualitative and quantitative tests and genotype tests, 
remain unaffordable, ranging from $10 in Ukraine to $121 in 
Georgia, and are usually paid for by the patient.68 
The WHO Regional Office for Europe (WHO-EURO) has 
developed HIV/HCV co-infection guidelines;69 however, the 
absence of HCV mono-infection or co-infection treatment 
guidelines in some countries can pose an obstacle to 
expanding treatment access. Where such guidelines do exist, 
they do not address the special needs of PWID (for example, 
guidelines often fail to address treatment adherence and 
management of side effects). Additionally, some guidelines 
are not based on internationally recognised standards of care, 
which involves dual therapy with Pegylated-Interferon and 
ribavirin.70 y 
Lack of political commitment to make viral hepatitis a 
priority poses another critical barrier to expanding access to 
treatment. Civil society organisations (CSOs), including harm 
reduction and drug user groups, have mobilised in many 
Eurasian countries to seek improved access to HCV treatment 
by demanding that national governments increase their 
commitment to address HCV, including providing treatment 
for PWUD, and that pharmaceutical companies reduce prices 
for Pegylated-Interferon.71
x  Albania, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Kyrgyzstan, 
Macedonia and Turkmenistan.
y  For example, the Russian guidelines indicate treatment with linear interferon, 
or other medicines, such as phosphoglia, which are not based on best practice or on 
guidelines developed by WHO.  
Tuberculosis (TB)
Six countries report that targeted harm reduction, HIV, viral 
hepatitis and TB testing and treatment services operate in an 
integrated manner in their country.z Most countries indicate 
that in the absence of integrated services, ‘strong referral 
systems’ between different services are in place. In Slovakia the 
NGO Odyseus has recently introduced low-threshold HIV/TB 
testing through outreach for marginalised groups, including 
migrants and mobile populations who engage in drug use.58 
Efforts to reach PWID who may require TB testing and 
treatment are limited. Few countries in the region implement 
HBV vaccination among populations at higher risk of HIV.72 
In Romania, for instance, PWID are not included in routine 
TB testing or in national TB surveillance, despite being one 
of the groups at higher risk of acquiring the infection.35 In 
some former Soviet countries, people living with HIV cannot 
start ART if they have opportunistic infections (such as TB), 
as these infections need to be treated first.16 TB services in 
some settings also deny access to TB treatment to PWID who 
are living with HIV.16 In addition to limited integration among 
services, another key barrier to TB testing and treatment is the 
lack of direct observation treatment short course (DOTS) in 
most countries, especially integrated in NSP or OST services.35, 
73 Barriers to accessing TB treatment vary by country: in 
Serbia, PWID without insurance have problems accessing TB 
treatment, in Kazakhstan PWID can only access treatment 
if they have a local registration document, and in Bulgaria, 
TB hospitals do not offer any drug dependence treatment, 
leading many PWUD to interrupt treatment and leave hospital 
early due to withdrawal symptoms.35 
Improved referral systems and integration among ART 
programmes, harm reduction services and testing and 
treatment for TB and viral hepatitis remain to be urgently 
addressed in this region.
Overdose responses
Overdose mortality in the region generally tends to be under-
estimated, and most governments in the region have not ac-
knowledged the full extent of the overdose epidemic among 
PWID. For example, while national authorities in several Cen-
tral Asian republics report conservative numbers of fatal over-
doses, 25.1% of PWID surveyed in Kazakhstan, Kyrgyzstan and 
Tajikistan in 2010 reported having witnessed someone die 
due of an overdose in the past 12 months.74 PWID in Eurasia 
also tend to have high prevalence of non-fatal overdose. For 
example, non-fatal overdose was experienced at least once 
by 59% of people injecting heroin surveyed across 16 Russian 
cities.75
z  Bosnia & Herzegovina, Croatia, Bulgaria, Poland, Slovenia and Serbia.
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For most countries where data are available, overdose 
prevention responses include limited or rare provision of 
overdose information material to PWUD, individual overdose 
risk assessment, overdose response training and risk education 
on drug-related deaths.58, 76 Across the region, overdose 
prevention programmes are often sporadic and generally run 
by local NGOs.
Naloxone, a highly effective opioid antagonist used to reverse 
the effects of opiate overdose, is registered as a medication or 
included in the essential medicine list in all Eurasian countries, 
with the exception of Albania.76 Across the region, naloxone 
is mainly available via doctors in emergency departments, 
hospitals and ambulance workers, as well as for community-
based distribution in Armenia, Belarus, Estonia, Georgia, Russia 
and Ukraine.35 Access through peers and harm reduction 
services in the community, such as NSP providers, is also 
reported in Georgia, Kazakhstan, Kyrgyzstan, Tajikistan and 
Russia; however, distribution often occurs unofficially via local 
NGOs.35, 76 Despite the availability of naloxone in emergency 
departments and ambulances, supply is not consistent across 
all types of facilities and at all times. 
Additional barriers to the effective implementation and scale-
up of overdose responses, including naloxone provision, 
include laws limiting management and transportability 
of naloxone by non-medical personnel and delays in the 
provision of emergency care responses for overdose.58 
Ongoing advocacy in several countries, including Georgia, 
Kazakhstan, Kyrgyzstan, Russia and Tajikistan, aims to expand 
access to naloxone by building political commitment, ensuring 
local or international funding for naloxone programmes 
and advocating for the removal of policy and legal barriers 
that prevent NGOs from distributing naloxone. There is an 
urgent need for advocacy around scaling up the distribution 
of naloxone beyond medical services to harm reduction 
programmes, outreach workers and PWUD, their families and 
communities. 
In December 2011, Tajikistan’s Ministry of Health approved 
the distribution of naloxone via NGOs working directly with 
PWID. Three local NGOs (Apeiron, Volonter and ROST), in 
collaboration with Soros Foundation Tajikistan and the Global 
Health Research Center of Central Asia, successfully advocated 
for authorisation to store 500 vials of naloxone at a time at 
NGO locations around the country and to distribute these 
directly to clients as needed. In addition to issuing an order to 
allow NGOs to store naloxone, the Ministry of Health has also 
endorsed guidelines developed by civil society which formalise 
and legitimise naloxone distribution through community 
harm reduction sites. Although the decision limits activity 
only to NGOs that hold a pharmaceutical activity licence, prior 
to this decision, NGOs in Tajikistan were not legally permitted 
to store naloxone on their premises, posing a major barrier to 
access by people who need it most. Similarly, in Kyrgyzstan, 
civil society reports indicate that NGOs are now permitted to 
distribute naloxone directly to their clients in Osh and Bishkek, 
through Kyrgyzstan’s Global Fund Round 10 grant. Prior to 
this, NGOs were not allowed to store or distribute naloxone.77
Harm reduction in prisons
Availability of harm reduction interventions in prisons is 
very limited across Eastern Europe and Central Asia, with 
wide variations in service coverage among countries and 
in facilities within countries. By mid-2012, five countries – 
Armenia, Kyrgyzstan, Moldova, Romania and Tajikistan – were 
implementing NSPs in prisons. OST is available in prisons in 
18 of the 26 countries and territories that also provide OST 
in the community,aa including two new OST pilots in Bosnia 
and Herzegovina and Latvia since the beginning of 2012.3 In 
several countries OST is available in prisons only to clients 
who were on treatment prior to incarceration; in others it is 
available only in custody centres, while in a third group it is 
only available in a limited number of centres.35 For example, 
some degree of OST provision is reported in prisons in 
Croatia and pre-detention trial units in Albania, Georgia and 
Kyrgyzstan, although programmes are not available as an 
integral part of health services in Albanian prisons.
The Czech Republic, Hungary, Romania and Slovenia provide 
initiation of OST on entering prison and continuation of OST in 
the community upon release from prison to varying degrees. 
Continuation of OST in prison is available in Bulgaria, Estonia, 
Poland and Montenegro provided that the inmate was already 
receiving OST prior to arrest. 
Data on prevalence of TB and HCV/HBV among PWID are 
lacking, mainly due to the lack of TB screening and HCV/
HBV testing in prisons. Nonetheless, the burden of TB, HCV/
HBV and HIV among prisoners is significant, especially given 
higher rates of co-morbidities than the general population.62 
Co-infection of HIV and TB in overcrowded prisons also poses 
significant challenges to both detention and health systems 
in Russia and post-Soviet Union countries,78 especially given 
the highly rigid level of vertical integration of each system, 
which often results in lack of coordination.62 Given the high 
proportion of PWID in prisons and correctional facilities and 
the high rate of re-offending among PWID, an important 
opportunity to reach this population is through integrated 
vaccination, testing and treatment for HCV and HBV within 
these settings.79-81
Barriers to implementation and scale-up of harm reduction 
interventions in prisons include lack of political will, denial 
of the existence of drug use in prisons, shortages of staff for 
medical services within prisons, lack of funding and data gaps 
on the extent of IDU in prisons across the region.
aa  Albania, Armenia, Bulgaria, Czech Republic, Croatia, Estonia, Georgia, Hungary, 
Kyrgyzstan, Macedonia, Moldova, Montenegro, Poland, Romania, Serbia and Slovenia.
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Policy developments for harm 
reduction
In 2010, HRI reported that 25 Eurasian countries and territories 
had national HIV or drug policies explicitly supporting harm 
reduction.34 Since then, seven countries – Belarus, Georgia, 
Kazakhstan, Kyrgyzstan, Moldova, Tajikistan and Ukraine – 
have finalised HIV strategies and national programmes that 
include harm reduction activities, in some cases focusing 
on scaling up NSP and OST, although in the case of Ukraine 
this strategy has yet to be approved.35 The HIV law passed in 
Azerbaijan in 2010, which previously had no legal provisions 
in place regarding harm reduction, now emphasises the role 
of harm reduction in HIV prevention, including NSP and OST 
provision in penitentiaries.82 Additional policy developments 
include Serbian by-laws to the new Law on Rehabilitation, 
Resocialisation and Treatment that legalise harm reduction 
and remove parental consent as a barrier for accessing NSP 
and OST, relaxation of OST criteria in Belarus and plans to 
implement community-based naloxone in Estonia.76 
The decriminalisation of drug use in Estonia and the 
amendment of penalties for drug possession for personal use 
from incarceration to administrative offences in Kazakhstan 
and Poland35, 83-84 constitute further favourable policy 
developments. 
Despite an overall trend toward a policy environment 
conducive to harm reduction implementation and scale-
up, a number of important challenges remain. Since 2010 
the policy context for harm reduction has deteriorated or 
remained highly unfavourable in Hungary, Russia and Ukraine. 
The national drug policy in Russia portrays NSP as a threat to 
effective drug control, while the 2009–2011 HIV strategic plan 
in Uzbekistan fails to recognise harm reduction and cites drug 
use and sex work as antisocial behaviours.35 
In December 2010, without prior consultation with civil 
society or medical professionals, the Hungarian government 
rejected the progressive harm-reduction-oriented drug 
strategy and introduced a new draft strategy excluding any 
mention of harm reduction. The new strategy does not list 
NSP and voluntary HIV/AIDS testing and counselling among 
its aims and refers to OST as a form of treatment that ‘may be 
necessary’ for those ‘who cannot be treated effectively with 
other methods’.85 A recent review of OST provision across 
Eurasia evaluated Lithuania to have one of the least favourable 
policy environments in the region: Lithuania’s drug policy 
does not include services for PWID, while the national HIV 
programme includes no targets for NSP and OST services.55, 
86-87 
Since 2010, stricter penaltiesab for drug possession have been 
put in place in Russia and Ukraine.88-89 For the first time, the 
Czech Republic introduced threshold quantities for possession 
of illegal drugs, with unauthorised possession for personal use 
continuing to hold an administrative penalty.90-91 Although the 
impact of this policy is unclear, evidence from other settings 
suggests that the reduction in threshold quantities for 
personal use will result in reduced access to NSP and OST due 
to fear of police harassment and raids.92 Georgia remains one 
of a few countries where the non-medical use of controlled 
drugs constitutes a criminal offence. This has a direct impact 
on both the rights and health of PWUD: currently there are 
more PWUD in prisons than there are in treatment facilities.93
New legal highs
The past two years have seen an exponential increase 
in new psychoactive substances commonly referred to 
as ‘legal highs’ across Europe. Between 1997 and 2010 
the early-warning system of the European Monitoring 
Agency on Drugs and Drug Addiction (EMCDDA) 
identified more than 150 legal highs, 65 in the past two 
years (24 in 2009 and 41 in 2010).94
Legal highs have contributed to the increased risk of HIV 
and viral hepatitis transmission in several countries in 
the region, particularly Hungary and Romania, where a 
significant proportion of heroin and amphetamine users 
have turned to injecting designer ‘legal highs’. Injection of 
‘legal highs’ is often more frequent than heroin injection, 
with the potential to increase the sharing of injecting 
equipment. 
The response from governments has generally been 
default criminalisation, even in the absence of clear 
evidence. Romania has criminalised 36 new substances in 
2010, and over 900 shops were closed down in Poland.95-96 
In 2011 the Czech Republic and Slovakia joined the race 
and criminalised 33 and 42 new substances, respectively, 
in their countries.97 ac From 1 January 2012 nine new 
substances were banned in Hungary. Although the 
Hungarian government plans to introduce generic 
legislation aimed at preventing traffickers from creating 
new legal substitutes of prohibited substances, it has 
stated that it does not aim to criminalise PWUD, but only 
the distributors of new psychoactive substances.98 This 
approach has led to the displacement of one substance 
with another, rather than a cessation of ‘legal high’ use.
ab  These included harsher penalties for drug-related crimes including administrative 
detention for drug use for up to 15 days and life sentence for large-scale drug offences 
in Russia. In March 2012 the Federal Drug Control Service of the Russian Federation 
proposed an amendment to the Criminal Code providing for up to two years of prison 
or hard labour for drug use, if the episode of drug use is repeated within a year after 
the first drug use episode has been recorded. In addition, Ukraine’s Ministry of Health 
issued a resolution in 2010 setting very low threshold amounts of illicit drugs that trigger 
criminal liability; for instance, minimum amount of heroin is set at 0.005 g, thus making all 
individuals possessing one dose of heroin without intention to sell criminals.
ac Czech Republic Act No. 167/1998 Coll., on addictive substances, was amended in the 
spring of 2011. See http://portal.gov.cz/zakon/106/2011.
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Civil society and advocacy developments 
for harm reduction
Civil society has played an increasingly important role 
in effectively advocating for harm reduction in Eurasia 
and internationally. Active lobbying and advocacy from 
national and/or regional-level CSOs and networks has been 
instrumental in amending the Slovenian Penal Code to allow 
for the establishment of settings where illicit drugs may 
consumed under medical supervision,35 the development 
of the new HIV law in Azerbaijan and actively participating 
in the working group to change the law in Romania, all with 
varying degrees of success. Advocacy for wider availability 
of naloxone in Tajikistan resulted in guidelines for overdose 
prevention and management by the Ministry of Health,35 
while an aggressive campaign in Ukraine succeeded in 
overcoming the government’s opposition to OST.3 In Bosnia 
and Herzegovina the Ministry of Security, in cooperation with 
the Ministry of Health, initiated a process of accreditation of 
harm reduction NGOs, although this process is based on the 
assumption that harm reduction programmes will be funded 
by these two ministries after the contract with Global Fund 
expires in 2014.35
Advocating for drug policy 
change in Poland
Civil society organisations in Poland have long been 
campaigning to reform the country’s drug law. During 
2010–2011 the Polish Drug Policy Network (PDPN) 
initiated a national advocacy campaign that aimed to 
amend the restrictive drug law in Poland.99 Advocacy 
activities included legal actions such as cooperation 
with the Office of the Ombudsman for Addicts, active 
participation in public debate and numerous open 
letters including one signed by a former Polish president 
and other prominent figures100 addressed to the Ministry 
of Health, Minister of Justice, Prime Minister, Polish Seim 
and Senate, and the National Bureau for Drug Prevention. 
PDPN also launched an online sign-on campaign 
targeting both Polish and international audiences to put 
pressure on Bronislaw Komorowski, the President of the 
Polish Republic, to sign the bill. 
On 25 May 2011 the President signed an amendment 
to the country’s drug law. The new amendment draws a 
greater distinction between drug dealers and drug users, 
and allows prosecutors the choice not to criminalise 
small-scale drug offenders. The next steps will be to 
ensure that the current amendment is implemented and 
to open a broader public debate on decriminalisation.
The Eurasian Network of People who Use Drugs (ENPUD) 
was established in February 2010 following a meeting of 
representatives of the drug user community and OST clients 
from Armenia, Georgia, Kyrgyzstan, Kazakhstan, Ukraine, 
Russia, Tajikistan, Uzbekistan and Moldova.101 This initiative 
represents the first attempt by people who use or have 
previously used drugs in the region to join efforts at the 
regional level. ENPUD aims to facilitate greater involvement 
of PWUD in local and international drug policy, to improve the 
quality of medical, social and legal services. A strategic follow-
up meeting and needs assessment exercise is planned to take 
place in Kiev in July 2012. 
EHRN has continued to actively promote harm reduction 
and the rights of PWUD across 29 countries in Central and 
Eastern Europe and Central Asia. In 2011, EHRN mobilised and 
supported over 30 drug user activists to testify to the Global 
Commission on HIV and the Law on a range of human rights 
violations faced by their community. Their joint statement was 
voiced at the Regional Consultation of the Global Commission 
and was delivered at the UNAIDS Programme Coordinating 
Board (PCB).92 At the 54th UN Commission on Narcotic Drugs 
(CND), EHRN organised a side event on overdose, ‘Illicit Drug 
Overdose: Major Cause of Preventable Death’, which was 
well attended by key multilateral agencies and civil society 
representatives. A key outcome of the event was the formation 
of a multisectoral initiative to develop internationally 
recognised overdose prevention guidelines.
In 2010 the South East Europe NGO Drug Policy Network, an 
initiative led by NGOs in the region and supported by the 
International Drug Policy Consortium, was launched. The 
network aims to create open and objective dialogue with 
experts, key policymakers in national governments, regional 
bodies and international organisations to promote humane 
and effective drug policies.
As part of the international Count the Costs campaign 
supported by the Open Society Foundations, the Hungarian 
Civil Liberties Union (HCLU) and the European Drug Policy 
Initiative (EDPI) coordinated actions in five European cities 
– Sofia, Bucharest, Warsaw, Oslo and Porto – to raise public 
awareness on the health and human rights costs of the war on 
drugs, to mark the 50th anniversary of the Single Convention 
on Narcotic Drugs in June 2011.102 
CSOs in Eurasia are well positioned to engage in ongoing 
advocacy to reverse the disproportionate focus on punitive 
approaches to IDU, common in countries in the region.103 In 
the current precarious funding environment, the provision of 
adequate financing for CSOs and local organisations of PWUD 
to enable them to continue this important work is particularly 
crucial.33
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Multilaterals and donors: 
developments for harm reduction
Increased engagement by multilateral agencies in harm 
reduction implementation is reported in Albania, Bosnia and 
Herzegovina, Latvia, Kyrgyzstan, Serbia and Tajikistan. UNICEF 
is an active partner in research among young PWID and in 
preparation of the new Law on Rehabilitation, Re-socialisation 
and Treatment in Serbia but plans to scale down its activities 
in Romania. UNODC supports ongoing harm reduction 
services in prisons in Latvia and Tajikistan and at the time of 
publication was investigating how to best support the scale-
up of harm reduction services in prisons in Albania, Serbia and 
Macedonia in partnership with EHRN. UNDP is the primary 
recipient for Global Fund grants in Kyrgyzstan and Tajikistan, 
both of which include support for harm reduction services. 
Funding for harm reduction responses in Eastern Europe 
and Central Asia largely originates from the Global Fund. The 
Global Fund invested over US$366 million for harm reduction 
in Eurasia alone – more than all other international sources 
combined (see Table 2.2.2).33 Other donors that support harm 
reduction in the region include the European Commission, 
OSF, UNAIDS, UNODC, UNDP and UNICEF. Along with 
international donors, additional funding for harm reduction is 
contributed by national governments in Azerbaijan, Bulgaria, 
Bosnia and Herzegovina, Czech Republic, Croatia, Estonia, 
Georgia, Hungary, Kazakhstan, Latvia, Lithuania, Macedonia, 
Montenegro, Poland, Slovenia, Slovakia and Serbia.35 Overall, 
government funding prioritises provision of medical services 
and OST, as well as NSP and OST in prisons, while CSOs and 
international partners largely support NSP and community-
based harm reduction separately or in the context of 
comprehensive HIV prevention programmes.3, 35
Table 2.2.2: Approved Global Fund investments targeting 
PWID in Eastern Europe and Central Asia Round 1 (2002) to 
Round 10 (2010)104
Country / territory totAL (uS$)
Albania 1,400,000
Armenia 3,100,000 *
Azerbaijan 6,000,000 *
Belarus 17,500,000 *
Bosnia & Herzegovina 9,800,000 *
Bulgaria 9,500,000  
Croatia 600,000  
estonia 2,700,000  
Georgia 12,700,000 *
Kazakhstan 29,800,000 *
Kosovo 2,000,000  
Kyrgyzstan 25,800,000 *
Macedonia 15,600,000 *
Moldova 7,200,000 *
Montenegro 1,600,000 *
romania 4,200,000  
russian Federation 38,400,000  
Serbia 6,500,000 *
tajikistan 15,600,000  
ukraine 143,900,000 *
uzbekistan 12,200,000 *
totAL 366,100,000
Notes
Figures are rounded. Data are correct as of March 2012. Data are based 
on detailed grant budgets submitted to the Global Fund and may not 
reflect actual expenditures.
* Figure includes projections for future years of grants that have not 
yet been formally committed.
Increased state support for harm reduction is expected 
in Macedonia; in 2011 the Ministry of Health financed the 
provision of 30,000 syringes and 50,000 condoms via NSPs 
for the first time.73 In Bosnia and Herzegovina, a new NGO 
accreditation process may result in more harm reduction 
programmes funded by the state in the coming years; 
currently only 40% of harm reduction programmes are 
funded by the national government.35 In other countries 
where the state supports harm reduction, funding is allocated 
on an annual basis, and government funds are often delayed 
and insufficient to sustain and scale-up service coverage to 
levels needed to have an impact on HIV and viral hepatitis 
epidemics.58 The financial crisis has had significant effects on 
the governmental allocations in these countries. For example, 
funds decreased by 50% in 2009–2010 in Latvia, with cuts 
disproportionally affecting populations at higher risk of HIV 
and the health budget for prisons,35 and significant cuts were 
made to the NSP budget in Lithuania.87
The cancellation of Round 11 and insufficient donor 
contributions to the Global Fund have had a major impact 
in the region. Compared with ten national and one regional 
HIV grant proposals originally planned for Round 11 and 
the second wave of National Strategy Applications (NSAs), 
only Russia (two NGO grants, including the Russian Harm 
Reduction Network/ESVERO after a special decision by the 
Global Fund Board to allow it to apply), Serbia and Tajikistan 
applied for HIV support from the Transitional Funding 
Mechanism (TFM) by the 31 March 2012 deadline.33 As of 
2012, six countries are not eligible for Global Fund funding, 
although NGOs from Bulgaria, Latvia, Lithuania and Russia can 
apply for support under the NGO scheme.ad Almost all harm 
reduction services in Azerbaijan, Bulgaria, partly in Bosnia 
and Herzegovina, Kosovo, Serbia, Azerbaijan and Macedonia 
are funded by the Global Fund.ae Of significant concern is 
the situation in Albania, Armenia and Moldova, where harm 
reduction services are at risk of closure after March 2012 when 
the Global Fund grant comes to an end. Of the five Eurasian 
countries that applied for Round 10, Georgia, Kazakhstan, 
Ukraine and Uzbekistan were successful. Harm reduction 
through Round 10 funding includes planned OST scale-up 
in Kazakhstan; HIV prevention for most-at-risk populations, 
including harm reduction services for PWID in Ukraine; as well 
as NSP, testing and vaccination for viral hepatitis, and OST for 
PWID in Uzbekistan.35 
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UK
IRELAND
FRANCE
SPAINPORTUGAL
GERMANY
ITALY
AUSTRIA
SWITZERLAND
MALTA
ANDORRA
BELGIUM
NETHERLANDS
DENMARK
NORWAY
SWEDEN
FINLAND
GREECE
CYPRUS
MONACO
TURKEY
LUXEMBOURG
ICELAND
nk= not known
(s) = sub-national data 
a    Unless otherwise stated, data are sourced from Mathers B et al. for the Reference Group to the UN on HIV and Injecting Drug Use (2008) Global epidemiology of injecting drug use and 
HIV among people who inject drugs: a systematic review, Lancet, 372(9651):1733–1745.
b    Unless otherwise stated, data are sourced from European Monitoring Centre on Drugs and Drug Addiction (EMCDDA) (2012) Statistical Bulletin 2012: Table INF-1.  Prevalence of HIV infec-
tion among injecting drug users in the EU countries, Croatia, Turkey and Norway, 2010 or most recent year available, http://www.emcdda.europa.eu/stats12#display:/stats12/inftab1.
c    Unless otherwise stated, data are sourced from EMCDDA (2012) Table INF-2. Prevalence of HCV antibody among injecting drug users in the EU countries, Croatia, Turkey and Norway,  
2010 or most recent year available, http://www.emcdda.europa.eu/stats12#display:/stats12/inftab2.
d    Unless otherwise stated, data are sourced from EMCDDA (2012) Table INF-3. Prevalence of markers for HBV infection among injecting drug users in the EU countries, Croatia, Turkey and 
Norway, 2010 or most recent year available, http://www.emcdda.europa.eu/stats12#display:/stats12/inftab3.
e    The number in brackets represents the number of operational NSP sites, including fixed sites, vending machines, pharmacy-based NSP sites and mobile NSPs operating from a vehicle or 
through outreach workers. (P) = needles and syringes reported to be available for purchase from pharmacies or other outlets, and (NP) = needles and syringes not available for purchase. 
f    The number in brackets represents the number of operational OST programmes, including publicly and privately funded clinics and pharmacy dispensing programmes. (M) = methadone, (B) = 
buprenorphine, (BN) = buprenorphine-naloxone combination, (H) = heroin-assisted therapy, (O) = any other form (including morphine and codeine).
g    DCR = drug consumption room. 
h    Year of estimate: 2000
i     Year of estimate: 2006
j     Year of estimate: 2007.
k    Year of estimate: 2003. 
l     Year of estimate: 1999.
m   Year of estimate: 1992–1995.
n    Year of estimate 2004. 
o    Year of estimate: 1992–1994.
p    Year of estimate: 1990–1993.
q    Year of estimate: 1996.
r     Year of estimate: 1990–91 and 1992–93.
s     Year of estimate 2005. 
t  Year of estimate: 1998.
u    Year of estimate: 1999–2001, 2003. 
v Year of estimate: 1997.
w   Year of estimate: 2002. 
x    Year of estimate: 2004–2010.
y    Year of estimate: 1996–2000.
Table 2.3.1: Epidemiology of HIV and Viral Hepatitis, 
and Harm Reduction Responses in Western Europe
 
Country/territory 
with reported 
injecting  
drug use
People who  
inject drugsa
HIV prevalence 
among people 
who inject drugs 
(%)b
Hepatitis C (anti-
HCV) prevalence 
among people 
who inject drugs 
(%)c
Hepatitis B 
(anti-HBsAg) 
prevalence among 
people who inject 
drugs 
(%)d
Harm reduction response
 NSP1 e OST2 f DCRg 
Andorra nk nk nk nk
Austria
17,500  
(12,000–23,000)h
0.7–5.3 43.4–65.3 nk (31) (B,M,O)
Belgium
5,125  
(3,377–7,829)3
3.4–6 (s) 28.1–80 (s) 0–2.8 (s) (69)(P) (B,H,M)
Cyprus 467 (418–539)3 0–1.3 51.3 1.7 (1)(P) (1)(B,O)
Denmark
12,754  
(10,066–16,821)i 3 
2.1i 52.5 1.3j 4 (135)i  (B,H,M)
Finland
15,650  
(12,200–19,700)
0.7 (s) 60.5 nk (40)  (B,M,O)
France 122,000l 5.1–8i (s) 41.7i (s) 4.8 (3.4–6.2)m 4 (532)(P) (19,484)(B,M,O)
Germany
94,250  
(78,000–110,500)
3.4j 75j n 7.2 (6–8.4)o 4 (250)  (2,786–6,626)(B,H,M) (27)
Greece
9,439  
(8,110–11,060)3
0.7–0.8 48.7–68.8 2.9–3.6 (6)(P) (17)(B,M,O)
Iceland nk nk 63p 4 nk (B,M)
Ireland
6,289  
(4,694–7,884)q 
5.8v 4 74.6 (72.3–76.9)4 0k 4 (32)(P) (332)(B,M,O)
Italy 326,000q 11.5 58.5 5.1 (0.9–9.3)r 4 (B,M,O)
Luxembourg
1,485  
(1,253–1,919)j 3
2.4 71.8–90.7s 3.9s (8) (B,M,O) (1)
Malta nk 0 36.3 (7) (≥2) (B,M)
Monaco nk nk nk nk
Netherlands
2,390  
(2,336–2,444)3 
0 (s) 47.6–67.4 (s) 1–13 (s) (175)5 (P) (B,H,M) (40)
Norway
10,238  
(8,810–12,480)3 
2.4 69.9 0 (s) (29)rr(P) (B,M) (1)
Portugal 10,950–21,9003 s 4.9–17.2 36.5–83.1 2–3.4 (1,620)(P) (B,M)
Spain 83,972t 32.3
79.6  
(73.3–85.9)u 4
3.6 (1.8–5.3) 4 (2,274)(P) (497–2,229)(B,H,M) (7)
Sweden nk 2 (s) 59.7(s) 2.3 4 (2) (B,M)
Switzerland
31,653  
(24,907–38,399)v 
1.4 4 78.3w 4 44 (101)(P) (B,H,M,O) (7)
Turkey nk 0.5 5.3 (s) 5.2 4
United Kingdom
133,112 (126,852–
143,278)3 x
0–4.3 (s) 26.1–61.2 8.9 (0–17.8)y 4 (1,523)(P) (B,H,M,O)
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Harm Reduction in Western Europe
Injecting drug use (IDU) remains common in Europe for both 
opioids and amphetamines, with significant user populations 
in Italy, France, Spain, the UK and Germany. Approximately 
1 million people who inject drugs (PWID) reside in Western 
European countries.6 While low HIV prevalence among PWID 
in many countries in Western Europe has been linked with the 
early implementation of harm reduction programmes, the 
scope and reach of programmes remains uneven. Almost all 
countries in the region have operational needle and syringe 
exchange programmes (NSPs) and opioid substitution 
therapy (OST), but some national programmes are too small 
to have any clear impacts, and many of the larger programmes 
are under constant threat of closure. European countries 
continue to feature among those with the highest coverage 
of harm reduction programmes globally,z but to protect 
and promote these services moving forward will require 
concerted cooperation between harm reduction advocates 
and policymakers, particularly in a time of ever-increasing 
financial hardship.7 
NSPs are available in all countries in the region except  for 
Andorra, Monaco, Iceland and Turkey. Geographical coverage, 
however, varies greatly from country to country, with only one 
NSP site reported in Cyprus, for example, compared with more 
than 1,000 in Spain and Portugal.2 No considerable expansion 
in NSPs has been reported in the region since 2010, although 
one new programme has opened in Helsingborg in Sweden, 
which is the first such development in over two decades in 
the country. 
Various forms of OST are provided across the region through 
publicly and privately funded clinics and pharmacy dispensing 
programmes. These include methadone maintenance 
treatment (MMT), buprenorphine maintenance treatment 
(BMT), heroin-assisted therapy (HAT) and other forms of 
OST including morphine and codeine. Turkey introduced 
buprenorphine-naloxone combination for substitution 
therapy in 2010. Even though regional and national OST 
coverage rates vary substantially, levels of coverage in Western 
Europe (61% of PWID receiving OST) are high compared 
with other world regions.2 In some countries, however, OST 
programmes are implemented on a very small scale. Cyprus 
and Malta operate only one and two OST sites, respectively. 
The majority of the countries in Western Europe lead in the 
provision of harm reduction services in prisons. However, 
coverage of prison NSPs and OST varies across the region, and 
there is lack of data for all countries. Extensive prison NSPs are 
in place in Spain and Luxembourg.7
z  According to the 2009 WHO, UNODC, UNAIDS target-setting guide, <100 syringes 
distributed per person who injects drugs per year is considered low coverage; 100–200 is 
medium coverage, and >200 is high coverage.
The decrease in new HIV infections within the EU over the 
last decade has been brought about by a number of factors, 
including more easily available harm reduction measures 
and a decline in IDU, as well as better prevention and 
treatment services. But while NSPs and OST have become 
widely accepted within the EU, other effective interventions 
such as drug consumption rooms (DCRs) and HAT remain 
controversial and rare. There are 85 DCRs in six countries 
across the region.8 Denmark is the first country in the world 
to have passed legislation to regulate the operation of such 
facilities via a new law adopted on 1 July 2012. 
Western Europe is reported to have the highest regional level 
of antiretroviral therapy (ART) coverage among PWID in the 
world, but considerable barriers to universal access remain. 
Coverage of ART in prisons varies across the region,7 while 
poverty and social exclusion impede access and adherence. 
In some countries (such as Portugal) it has been reported that 
doctors have refused to allow people who use drugs (PWUD) 
to initiate ART.7 
In those Western European countries that saw the first heroin 
epidemics, populations of PWID are growing older. Harm 
reduction services will need to monitor their specific health 
and social needs, as well as the challenges that an ageing 
population presents to service providers.9  
While heroin remains the most popular drug among older 
users, amphetamine-type stimulants (ATS) are the most 
popular amongst young people.9 ATS users are estimated to 
make up 28% of those entering treatment in Sweden, 17% 
in Finland10 and smaller proportions in Belgium, Denmark, 
Germany and the Netherlands.10 Solid data on prevalance of 
ATS injection, however, are not available.
Indeed, while the monitoring of drug use and related harms 
in Europe continues to be good, there are significant gaps 
in knowledge, particularly in relation to young people, 
migrants, street-involved people and other vulnerable 
populations. In the case of young people, the focus on 
home and school surveys inevitably excludes those outside 
mainstream education and outside the home, and more 
attention and funding is needed for other forms of data 
collection. Drug use studies also tend to examine imprecise 
and problematic criteria such as lifetime or last yearly use, 
which may obscure specific  patterns of use that may be 
driving drug-related harms. Service and treatment data in 
many countries, meanwhile, obscure non-service-using 
populations, contributing to a general paucity of data that 
diminishes the potential impact of harm reduction. 
Funding for drug policies, meanwhile, has been hit hard by 
European governments’ responses to the economic crisis. In 
its 2011 annual report, the European Monitoring Centre for 
Drugs and Drug Addiction estimates that from 2008 to 2011 
these cuts ranged from 2% to 44%.10 Meanwhile, the European 
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Union (EU) is becoming increasingly fragmented on a political 
level in its approach to harm reduction. Countries such as the 
UK that have championed the harm reduction approach in the 
past are beginning to shift towards more abstinence-oriented 
policies.11 How this will impact the EU as a whole is, as yet, 
uncertain, but is likely to become clearer with the drafting of 
the new EU drugs strategy due for completion at the end of 
2012.
Developments in harm reduction 
implementation
Needle and syringe exchange programmes
With a few exceptions, NSPs are widely available in Western 
Europe (see Table 2.3.1). Across the region a variety of service 
delivery models are in place including stand-alone sites, 
pharmacy-based services, vending machines (in Austria, 
Denmark, France, Germany, Italy and Spain), outreach and 
peer outreach services,1 and mobile NSPs exist in roughly 
half of the countries in the region.1 Portugal and France have 
high proportions of NSP sites with outreach workers (96 and 
91, respectively), while with 1,360 sites Portugal is leading the 
way in pharmacy-based services to supplement fixed NSP 
outlets.1 
Despite good levels of provision across most of Europe 
in comparison with other world regions, the reach of 
interventions remains uneven among and within countries. 
Only one operational NSP site is reported in Cyprus, three 
in Sweden and up to 2,274 in Spain and 1,620 in Portugal. 
The number of NSP sites has doubled in Luxembourg and 
Belgium, while in Sweden, a third NSP site was established in 
Helsingborg in 2010, and an additional site is planned to be 
opened in Kalmar in late 2012. No considerable expansion in 
other countries was reported since 2010. Furthermore, national 
NSP coverage estimates often hide dramatic geographical 
variations. This represents an important gap in accessibility in 
smaller cities and rural areas in, for example, Spain, Portugal, 
Ireland, Germany, Finland, Belgium and Austria.12 
Another measure of service coverage, however, and one 
that allows for international comparisons of available data, 
is the number of syringes distributed per PWID per year.13 
Luxembourg and Norway are the only two countries in the 
region that distribute 200 or more syringes per person per 
year, which represents high coverage according to the joint 
WHO, UNODC and UNAIDS technical target-setting guide.13 
Coverage remains low in Sweden, Cyprus and Greece, where 
less than 100 syringes are distributed per person per year.14 
Increased occurrence of non-opioid injecting, such as the 
use of anabolic steroids, has been documented in some 
parts of Europe (for example, Belgium and the UK). However, 
shortage of data on the prevalence of steroid injecting and 
its low priority within national drug budgets have prevented 
the development of targeted strategies to address this user 
group’s needs.15 
Due to service-user anonymity there are no available data on 
the average age of NSP clients, but data from EMCDDA and 
WHO Europe indicate that, as a group, the population of PWID 
across the region is growing older. 
Opioid substitution therapy
All countries in the region, with the exception of Andorra and 
Monaco, provide MMT and BMT (see Table 2.3.1). Additional 
OST options, including HAT, buprenorphine plus naloxone 
combination and slow-release morphine, are widely available 
across the region. Turkey is reported as providing licensed 
buprenorphine-naloxone combination since 2010.16 However, 
the number of clients currently enrolled in the programme 
is not known. In several countries, data on OST coverage at 
the national level are unavailable due to variation in the types 
of service provision sites, as well as a lack of strong national 
monitoring systems. 
Fifteen EU Member Statesaa provide 95% of the total OST 
in Europe, and the number of OST sites in these countries 
continues to increase.17 More than half – 700,000 – of Europe’s 
population of people who use opioids are enrolled in OST.ab 
This demonstrates a strong coverage exceeding the UN’s 
recommended target figure of 40% as sufficient to address 
the spread of HIV among PWID.18 However, within Europe 
this coverage is far from even, with some countries such as 
Germany and Italy exceeding this average, and others such as 
Cyprus far below it at 5%.19, 20 France has 19,484 OST sites, the 
highest number of any country in the region where data are 
available.2 
In many countries OST provision includes access through 
general practitioners (GPs), although levels of regulation 
governing OST prescription by GPs vary considerably. For 
example, in Norway GPs can prescribe MMT and BMT to 
patients already enrolled in OST at a specialised centre, but 
they are not legally allowed to assess a patient’s need for 
treatment. In France, experts estimate that two-thirds of GPs 
who are licensed to prescribe MMT and BMT are reluctant to 
do so, thus limiting accessibility for individuals living outside 
large cities.21 
As with NSP clients, significant changes have been noted in 
the age profile of OST clients in Europe. In Greece 61% are 
aged 40 or over, while in the Netherlands the figure is around 
75%, with the 40–49 age group making up almost half of all 
OST clients.22 This trend has also been noted, albeit to a lesser 
extent, in other countries where data are available. 
aa  Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxem-
bourg, Netherlands, Portugal, Spain, Sweden, UK.
ab  Based on estimates derived from EMCDDA regional divisions, which may be dif-
ferent than those of HRI in this report. For more information, please see www.emcdda.
europe.eu.
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Heroin-assisted treatment in 
Europe
Heroin-assisted treatment (HAT) has increasingly 
emerged as an effective second-line treatment among 
individuals for whom OST and other drug treatment 
modalities have produced limited benefit.18, 23 As of 2012, 
seven countries implemented supervised injectable 
heroin (diacetylmorphine) as maintenance treatment: 
Denmark, Germany, the Netherlands, Spain, Switzerland, 
the UK and Luxembourg (pilot programme). In 2011, 
Belgium’s pilot HAT project was expanded to deliver 
treatment nationally.24 According to the European 
Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA), overall there were approximately 1,000 HAT 
patients in EU Member States and a further 1,400 in 
Switzerland as of April 2012.18
*For more information, see EMCDDA (2012) EMCDDA 
Insights: New heroin-assisted treatment: Recent evidence 
and current practices of supervised injectable heroin 
treatment in Europe and beyond. Lisbon: EMCDDA.
Antiretroviral therapy
While Western Europe as a whole has the highest level of 
coverage across the globe, there is significant variation 
between countries.2
In Luxembourg, for example, the country with the greatest 
percentage of PWID living with HIV on treatment, 70% of 
PWID were enrolled on ART in 2010, while in Portugal only 
10% of PWID living with HIV were on treatment.2 
With early diagnosis of HIV, many more PWID are likely 
to obtain the maximum benefit from ART. For instance, a 
decrease in AIDS diagnoses in Austria, the Netherlands and 
Finland has been attributed to early diagnosis and initiation 
of ART.25 High incidence rates of AIDS in some countries may 
indicate that PWID living with HIV are not accessing ART in 
the early stages following an HIV diagnosis.2 Austria has one 
of the highest rates of HIV tests per capita in Europe, but it is 
unclear whether PWID are accessing the service in numbers 
comparable with other groups at higher risk of HIV.25
Across the region there remain significant barriers to PWID 
accessing and adhering to ART, including homelessness, 
lack of insurance, lack of support and stigma from health 
professionals.26 Moreover, national data on ART coverage for 
PWID are not universally available within Western Europe, 
limiting a full understanding of availability, coverage and 
adherence.
Responding to an HIV outbreak 
among people who inject drugs in 
Greece
In 2011 Greece reported an outbreak of new HIV 
infections among people who inject drugs.27-29 By the end 
of July 2011, 113 cases had been reported by the national 
surveillance system, compared with between three and 
19 reported cases per year from 2001 to 2010. A rapid 
situation analysis by the EMCDDA found that several 
factors may have contributed to the increased risk of 
acquiring HIV, including the absence of comprehensive 
harm reduction programmes for HIV prevention among 
PWID, as well as targeting of injectors by the police, 
which has previously been shown in other settings to 
hinder service uptake and encourage increased risk-
taking behaviour such as needle and syringe sharing. The 
rapid assessment also revealed that Greece has relatively 
few low-threshold programmes for PWID (OST waiting 
lists range from five to seven years), and coverage of NSPs 
and OST is low.30 
The response from public health authorities and civil 
society in Greece has included a major restructuring 
of the OST programme, including the immediate 
provision of 28 new OST units, a switch from high to 
low dead space syringes, and an awareness campaign 
targeted at injectors in Athens, where incident cases are 
concentrated.31
Drug consumption rooms
The provision of DCRs varies across the region, with 
nationwide coverage in Switzerland and the Netherlands, 
regional coverage in Germany and Spain, and DCRs in the 
capital cities only in Norway and Luxembourg. In total there 
are 85 DCRs across 56 cities in these six countries, the majority 
of them integrated into more general health and social service 
provision networks.32 With a widespread switch from injecting 
to sniffing drugs across the region there has been an increase 
in DCR booths dedicated to this purpose, including a pilot 
study in Luxembourg in 2012.33 
New legislation governing DCRs was introduced in Denmark 
in July 2012, making it the first country in the world to have 
legally regulated DCRs. This followed political discussion 
generated by a mobile DCR operated by an NGO without 
police interference in Copenhagen since 2011.32
Despite the progress that has been made in the 
implementation of DCRs in Europe, most countries still do 
not allow their operation. Moreover, a number of barriers 
to access remain in relation to those DCRs that do exist such 
59
Western Europe
as exclusion criteria that deny access to clients who receive 
OST (Luxembourg and Germany) and exclude non-nationals 
(Switzerland), as well as restricted opening hours, age 
restrictions for under 18s and regulations around the type of 
substance that can be consumed on the premises.7
Viral hepatitis
In contrast to low HIV prevalence among PWID in many 
countries in Western Europe, rates of viral hepatitis (HBV and 
HCV), and HCV in particular, remain disproportionately high 
among PWID. According to a recent systematic review on the 
epidemiology of viral hepatitis among PWID, there are an 
estimated 727,500 PWID with HCV and 480,000 PWID with 
HBV across the region.4 
Prevalence of HCV varies widely across the region, from a 
high of 71.8–90.7% in Luxembourg, a significant public health 
issue, to a low of 5.3% in Turkey34 (see Table 2.3.1). Rates of HCV 
among PWID in Cyprus have increased significantly between 
2004 and 2010, with a steep rise from 9.1% to 51.3%,34 based 
in part on widespread equipment sharing as well as a general 
shortage of services.35 HCV rates are particularly high among 
new injectors, and there are reported rises in prevalence 
among these populations in Greece and Portugal.34 Reported 
prevalence can also vary significantly within countries, based 
on sampling biases and regional variations.34 
Barriers to HCV testing and treatment include lack of data, 
lack of awareness among medical professionals of the risks 
of co-infection with HIV, and restrictive costs, which are 
often not covered by health insurance or unavailable to the 
uninsured. In Spain and Finland PWUD are excluded from HCV 
treatments.7 
HBV rates among PWID are similarly varied across the region, 
although general levels of prevalence are low. The highest is in 
the UK with 8.9%, while Ireland and Norway report 0%.4 HBV 
vaccination programmes targeting specific high-risk groups, 
including PWID, operate in most countries in Western Europe, 
with the exception of Malta and the Flemish part of Belgium.37 
In Portugal, the requirement to pay for HBV vaccination is 
reported to prevent many PWID from accessing this service.38 
Tuberculosis
Data on tuberculosis (TB) prevalence among PWID in Western 
Europe are scarce. Estimated incidence of TB in the general 
population vary, but are less than 24 per 100,000 population 
in almost all countries for which data are available.39 The only 
exceptions are Spain and Portugal, where TB rates exceed 
those in other Western Europe countries at 25 and 49 per 
100,000 population, respectively.39 According to the EMCDDA, 
high rates of TB were reported among PWID in treatment in 
Greece, while systematic testing in drug treatment facilities in 
Austria and Norway did not identify any cases.40 An increase in 
the number of cases of TB among migrants who use drugs has 
been reported in Ireland, Sweden and Switzerland, but data 
are not available for this population. In Portugal, distrust of 
the public health care system and fear of discrimination from 
health professionals are reported to pose barriers to TB testing 
and treatment.38
Models for delivering integrated HIV, viral hepatitis and TB 
services are not well documented across Europe. Recently, 
the WHO Regional Office for Europe prioritised investigating 
strategies for the effective delivery of integrated HIV-TB 
interventions.41 A WHO-supported assessment of existing 
strategies in Porto, Portugal, documented two modelsac and 
emphasised the importance of a client-centred approach that 
combines collaboration among existing services, outreach 
programmes and uninterrupted provision of OST and other 
drug treatment while providing TB-HIV care.42
Harm reduction in prisons
Data from the EMCDDA on HIV and viral hepatitis infection 
among PWID in prisons across the region are only available 
for four countries: Spain, Malta, Finland and Sweden.43 
HIV prevalence among prisoners who inject drugs ranges 
from 0.2% in Finland to a high of 39.7% in Spain.43 The 
highest reported HCV levels among PWID in prisons are in 
Luxembourg, where 90.7% of PWID are HCV-positive.44 
Although data on TB among prisoners who inject drugs are 
scarce, studies show that the risk of TB in prisons is on average 
23 times higher than in the general population.45 
Relative to other world regions, countries in Western Europe 
lead in the provision of harm reduction services in prisons. 
Prison NSPs are available in Spain, Luxembourg, Switzerland 
and Germany, and very limited NSP pilot programmes exist 
in Scotland. Only one prison, however, offers the service in 
Germany, and in Switzerland provision of NSP in prisons 
depends on the decision of each canton.46 The only pilot NSP 
that was available in Portuguese prisons was terminated in 
2007 due to logistical challenges and resistance from prison 
guards.1 
OST is available in prison settings to varying degrees in 
most countries in the region, with the exception of Greece. 
In Sweden, OST in prison started as a pilot project in 2007 
and was continued as a national programme in 2010, but 
coverage remains poor.47 Switzerland is the only country in 
the region which provides HAT in prisons, with two facilities 
presently offering this service.48 In Finland, Sweden and Malta 
OST cannot be initiated in prison, but PWID may continue 
treatment if they were already accessing OST in community 
settings at the time of their arrest.49, 50 
ac  The two strategies included a ‘combined model’ where all services are provided 
within a central location by a multi-disciplinary team, and a ‘collaborative’ model, charac-
terised as client-centred and informal, which involves collaboration of service providers 
and outreach teams to  deliver treatment in a location convenient to the client. 
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Overdose 
Opioid overdoses are a major cause of mortality among PWID, 
accounting for between 10% and 23% of drug-related deaths 
in the 15–49 age group.51 The most likely periods for PWID to 
overdose are after release from prison or if OST is interrupted. 
A study of 382 PWID taking part in a prison-based OST 
programme documented no deaths during OST but 13 deaths 
when OST was interrupted – eight of them overdose-related.52
Across the region, overdose prevention responses are 
implemented to varying degrees but include the provision of 
overdose information material to PWUD, individual overdose 
risk assessment and overdose response training. Naloxone is a 
registered medication in all Western European countries, but 
its availability varies across the region and within countries. In 
Scotland, for example, nurses and pharmacists can prescribe 
and dispense the Scottish Naloxone Programme’s kits, while 
elsewhere in the UK the medication is only currently available 
through limited-scale pilot programmes, with scale-up 
anticipated soon.53 In a new review released in May 2012 
the UK Advisory Council on the Misuse of Drugs (ACMD) 
recommended that the government take concrete steps to 
make naloxone more widely availablead including by easing 
restrictions on who can be supplied with naloxone and 
investigating how peers can be trained to administer it in 
emergencies. In 2011 Scotland promoted the availability of 
naloxone to approved services without prescription for use in 
emergencies.54
Naloxone is only available on a takeaway basis in Italy, 
Germany, Spain, Scotland and Norway.55 In Denmark a small-
scale trial of peer distribution of naloxone operates in the 
country’s capital, with a limited number of social workers 
prescribed the medication, and further expansion of the 
programme is still pending.56 
Policy developments for harm 
reduction 
At a national level all countries in the region,with the exception 
of Italy and Sweden, explicitly support harm reduction in 
their national drug policy strategies. Implementation of harm 
reduction services in many countries, however, is carried out 
by local governments. In Sweden, for example, the provision of 
NSPs is reliant on local political approval, which has hindered 
the scale-up of new programmes, including in the country‘s 
two largest cities.57 
Despite long-standing support for harm reduction within the 
region, however, since 2010 there have been incidences of 
ad  Although naloxone has been available under UK law since 2005, it remains a pre-
scription-only drug and is only licensed for use in injectable form. As such, non-medical 
services and people who use drugs, their families and peers, who may be more frequently 
present during the occurrence of opiate-related overdoses, are not able to legally hold 
stocks of naloxone and administer it in emergencies.
policy shifts away from harm reduction from countries that 
have traditionally been strong advocates for the approach. 
For example, the UK has one of the lowest levels of HIV 
among PWID in Europe, which is often attributed to the 
early introduction of harm reduction programmes in the 
country.58 But support for harm reduction in the UK has been 
undermined in the past two years due to leadership changes, 
although tensions remain between ministries. In March 2012 
the UK government published a new roadmap document 
entitled Putting Full Recovery First, which strongly prioritised 
an abstinence-based approach. In response to the roadmap, 
civil society organisations (CSOs) such as the Terrence Higgins 
Trust, the National AIDS Trust and Release have addressed an 
open letter to the UK government, warning that ministers will 
be putting lives at risk and reversing decades of success in HIV 
prevention if harm reduction is undermined.59
At the regional level, policy developments currently centre 
around the drafting of the new EU drugs strategy. The current 
strategy will come to an end in 2012, and the new drug policy 
framework will be the first adopted under the Lisbon Treaty. 
At the time of writing, the new strategy is being drafted, but 
it has been a relatively closed process. CSOs were not invited 
to provide input, and it is, therefore, not possible to comment 
on its content. Moreover, although harm reduction objectives 
are strongly present in the demand reduction area of current 
EU drug policy documents, the recent rollback of EU funding 
opportunities for harm reduction may become an obstacle for 
its sustainability in Europe.
The EU, as a bloc, has traditionally been a strong voice for harm 
reduction at the international level. But recently the EU has 
become increasingly fragmented. This shift can be attributed 
in part to ongoing advocacy from countries that are anti-harm 
reduction (in particular Sweden and Italy) and in part to harm 
reduction being viewed as less important for diplomacy for 
countries that had previously adopted strong leadership roles 
at the international level.ae
ae  See section 1 ‘Policy Development’ for further information on the EU at an interna-
tional level.
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Civil society and advocacy 
developments for harm reduction 
CSOs and organisations of PWUD continue to play a central 
role in harm reduction advocacy and responses in the 
region. National harm reduction networks are active in many 
countries including Germany, the UK, Ireland, France and 
Portugal. Italian harm reduction organisations are currently 
in the process of forming a national network, planned to be 
launched in late 2012. At the time of writing, CSOs in Portugal 
were mobilising a national civil society forum on harm 
reduction to respond to significant funding cuts for harm 
reduction services.60 
Many CSOs are involved at the European level and 
internationally through participation in several networks 
such as the Eurasian Harm Reduction Network, EuroHRN, 
Correlation, the International Drug Policy Consortium and 
others. Regular Europe-wide events bring CSOs together 
to share the latest experiences on harm reduction and drug 
policy. Over the past two years, these have included the first 
European meeting on harm reduction in Marseille,61 the EU 
Civil Society Forum on Drugs,62 the EU Civil Society Forum on 
HIV63 and the final conference of the Correlation Network in 
Ljubljana, Slovenia.64
In April 2010 the European Harm Reduction Network, a project 
funded by the European Commission (EC), was launched with 
the aim of advocating for and sharing knowledge on harm 
reduction within Europe. The project culminated in a meeting 
of network members at a pan-European conference in 
October 2011 in Marseille, France during which the European 
Network of People who Use Drugs (EuroNPUD) was formed. 
The second phase of the project will focus on overdose 
prevention and advocacy, recommendations on the set-up, 
development, study and impact of DCRs in Europe as well as 
supporting harm reduction stakeholders in Europe in sharing 
best practices.
The Correlation Network, established in 2005 and also funded 
by the EC, has undertaken two phases of development. 
Correlation I (2005–2008) identified gaps and inequalities 
in access to health and social services, with a focus on 
marginalised groups. It looked specifically at health issues 
such as HCV and HIV/AIDS within most-at-risk populations, 
particularly drug users and young people at risk. Correlation 
II (2009–2012) built on this experience, focusing on the 
improvement of prevention, care and treatment services and 
targeting blood-borne viruses, in particular HCV and HIV/AIDS, 
among vulnerable and high-risk populations. Correlation has 
recently undergone an organisational restructure and has 
become a more sustainable network.65
Documenting organisations of 
people who use drugs in Europeaf
In 2011, as a part of the European Harm Reduction 
Network (EuroHRN) project, the first comprehensive 
survey of organisations of people who use drugs in the 
European Union was carried out. The aim of the survey 
was to map the current state of drug user organising 
across Europe to inform recommendations for initiating 
such organisations in those countries where they are 
currently lacking, and to strengthen them where they 
are weak. The methodology used to acquire this data 
included the creation of a Directory of Organisations of 
People who Use Drugs in Europe. The second component 
was a detailed report of the state of drug user organising 
in Europe. 
Results of the survey show that more than half of drug 
user organisations are based in Northern Europe (18 
entries out of 30), and six countries from both Northern 
and Southern Europe are totally unrepresented. All 
groups surveyed are people who use/inject heroin, and 
the vast majority of them define themselves as activists 
and lobby groups who primarily represent active drug 
users. Many of the groups that took part in the survey 
came together at the first European meeting on harm 
reduction in Marseille and founded the European 
Network of People who Use Drugs.
Multilaterals and donors: 
developments for harm reduction
Although support for harm reduction from multilateral 
agencies is not targeted towards the high-income countries of 
this region, the EC has been an important donor for regional 
projects relating to injecting drug use and HIV. It has funded 
a range of new projects in recent years including the Access 
to Opioid Medication in Europe (ATOME) project which was 
launched in 2009 and will conclude in 2013. The overall goal 
of ATOME is to develop tailor-made recommendations for 
improving the accessibility, availability and affordability of 
controlled opioid medications, including OST medications. To 
date, the project has identified legal and regulatory barriers 
in the area of prescribing and dispensing opioid medication, 
including OST, in Cyprus, Greece and Turkey, with further 
country reports containing recommendations for legislative 
changes on their way. The EC has also funded a new project as 
part of its Lifelong Learning Programme (Leonardo) which will 
look to develop training guidelines and a professional profile 
for harm reduction outreach workers entitled ‘Prowfile’.
af The directory of organisations of people who use drugs in Europe is available online 
at www.eurohrn.eu.
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Despite a successful record of funding harm reduction 
since the early 1990s, however, the EC’s Health for Growth 
Programme 2014–2020 call for proposals does not address the 
issue of drugs and harm reduction.66 Furthermore, in its Justice 
Programme call for proposals, the EC indicates that in future 
funding it will address drug demand and supply through the 
angle of crime prevention and anti-drug trafficking only.66 
Finally, the Drug Prevention and Information Programme will 
become redundant after 2013, with no plans to replace it with 
alternate funding opportunities for drug demand reduction 
at the regional European level.66 In response to these changes, 
the EU Civil Society Forum on Drugsag appealed to the EC in 
January 2012 and urged for continuation of an effective civil 
society response to HIV/AIDS and drugs.
The WHO Regional Office for Europe, in collaboration with the 
European Centre for Disease Prevention and Control (ECDC), 
continues to collect data and monitor HIV epidemics across 
the region. In September 2011, 53 countries in the WHO 
European Region agreed on a new European Action Plan for 
HIV/AIDS 2012–2015.67 Targets in the new action plan reflect 
those agreed by UN Member States at the 2011 High Level 
Meeting on HIV/AIDS and include reducing the number 
of new infections acquired through IDU by 50% by 2015. 
The EU drugs agency, the EMCDDA, launched its 2012 work 
programme68 and is in the process of developing strategies 
for treatment monitoring and a new strategy for monitoring 
and reporting on drug-related issues in prisons across the 
European region.
Several European governments provide essential funds for 
harm reduction in low- and middle-income countries. These 
include the UK Department for International Development, 
the Netherlands MOFA, NORAD (Norway), GTZ (Germany) 
and the Swedish SIDA, but in this sector, too, budgets are 
becoming tighter.
The recent period of economic crisis has had a considerable 
impact on harm reduction financing at national level across 
the European region. In the UK, a recent survey of 540 UK 
drug service users and providers found that 75% have already 
witnessed cuts in funding for services.69 Other countries such 
as Belgium, Ireland, Germany and Denmark report that funding 
harm reduction programmes is becoming increasingly 
difficult due to recent financial cuts by governments.70 In 
Portugal, where harm reduction programmes were under 
threat of partial closure, funding from the government is 
regularly late, harm reduction programme workers do not 
receive their salaries on time, and financial resources to keep 
clients in programmes are more and more scarce.71 In addition, 
to reduce costs, the Portuguese government plans to abolish 
the national institute for monitoring the drug situation (IDT).71
ag  The Civil Society Forum on Drugs (CSF) meets at least once a year and serves as a 
platform for informal exchanges of views and information between the European Com-
mission and EU civil society organisations.
The financial crisis is likely to lead to greater scrutiny of drug 
service funding, and it will be increasingly important to 
highlight the financial and social implications of HIV outbreaks 
and other likely implications of cuts to services. This is also an 
opportunity to advocate for the most efficient and effective 
drug services. 
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Table 2.4.1: Epidemiology of HIV and Viral Hepatitis, 
and Harm Reduction Responses in Caribbean 
Country/territory with 
reported injecting  
drug usea
People who  
inject drugsb
HIV prevalence 
among people 
who inject drugs 
(%)
Hepatitis C (anti-
HCV) prevalence 
among people 
who inject drugs 
(%)c
Hepatitis B 
(anti-HBsAg) 
prevalence among 
people who inject 
drugs 
(%)c
Harm reduction responsed
 NSPe OSTf
Bahamas nk nk nk nk
Bermuda nk nk  nk  nk
Dominican Republic nk nk nk nk
Haiti nk nk  nk  nk
Jamaica nk nk nk nk
Puerto Rico 29,130 12.9g  89%h  nk  (13)  (6)(M)
Suriname nk nk nk nk
 
nk= not known
a  In 2008 the UN Reference Group found no reports of injecting drug use for Antigua and Barbuda, Barbados, Belize, Dominica, Grenada, St Kitts and Nevis, St Lucia or St Vincent and the 
Grenadines.
b  Unless otherwise stated, data are sourced from Mathers B et al. for the Reference Group to the UN on HIV and Injecting Drug Use (2008) Global epidemiology of injecting drug use and HIV 
among people who inject drugs: a systematic review, Lancet, 372(9651):1733–1745.
c  Nelson PK et al. (2011) Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews, Lancet, 378(9791): 571–583.
d  Unless otherwise stated, data on NSP and OST coverage are sourced from Mathers B et al. for the Reference Group to the United Nations on HIV and Injecting Drug Use (2010) HIV prevention, 
treatment and care for people who inject drugs: A systematic review of global, regional and country level coverage, Lancet 375(9719):1014–28.
e  The number in brackets represents the number of operational NSP sites, including fixed sites, vending machines and mobile NSPs operating from a vehicle or through outreach workers.  
(P) = needles and syringes reported to be available for purchase from pharmacies or other outlets, and (NP) = needles and syringes not available for purchase.
f  The number in brackets represents the number of operational OST programmes, including publicly and privately funded clinics and pharmacy dispensing programmes. (M) = methadone,  
(B) = buprenorphine, (O) = any other form (including morphine and codeine).
g  Estimate from 1998–2001.
h  This figure is sub-national and relates to San Juan only.
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Harm Reduction in the Caribbean
After sub-Saharan Africa, the Caribbean has the highest 
regional HIV prevalence worldwide.1 Seven of the larger 
Caribbean islands have adult HIV prevalence of more than 
1%, the highest being the Bahamas at 3.1%.2 UNAIDS reports, 
that the generalised epidemic slowed significantly between 
2001 and 2011, with HIV incidence declining by 25% in the 
Dominican Republic and Jamaica, and by 12% in Haiti.1 
Injecting drug use (IDU) is rare across most of the Caribbean 
with the exception of Puerto Rico and Bermuda.2 Currently 
only seven countries and/or territories have reported 
IDU.i 3 Reliable data on the number of people who inject 
drugs (PWID) and the prevalence of HIV among injecting 
populations are only available for Puerto Rico, where unsafe 
injecting is a major contributor to the HIV epidemic. In 2006 
it was reported that this mode of transmission accounted for 
40% of new infections among men and 27% among women.4 
The most recent estimate indicates that there are 29,130 PWID 
in Puerto Rico, with HIV prevalence among them reported to 
be 12.9%.j 5 Researchers have found that Puerto Ricans who 
inject drugs tend to inject frequently (on average six times 
a day) and use the same syringe multiple times (on average 
eight times). They are more likely to share drugs and injecting 
equipment and inject in shooting galleries than Puerto Ricans 
who inject drugs living in mainland USA.6 A 2007 study found 
HIV prevalence to be higher among female non-injecting 
heroin users (4.3%) than among their male counterparts 
(0.6%). The researchers called for supportive systems for 
women who use drugs to be made a high-priority public 
health issue in the country.7 
Several Caribbean countries have reported a link between 
sexual HIV transmission and the use of crack cocaine, which 
is widely available and extensively used on some islands.8 
Reported HIV prevalence among people who use crack cocaine 
reach 5% in Jamaica and 7.5% in St Lucia (11.1% among 
women and 6.8% among men).9 Researchers have reported 
that crack cocaine users, particularly women, are more likely 
to sell sex to support their drug use and engage in high-
risk sexual practices. k 2, 10-11 Impaired judgement associated 
with drug use is also reported to contribute to sexual risk 
behaviours in Barbados.12 Research plans in Belize for 2012 
included further investigation into the link between drug 
use and HIV transmission.13 In 2006, UNAIDS recommended 
that countries devise indicators on targeted HIV prevention 
programmes among people who use crack cocaine, to ensure 
these activities are captured in UNAIDS progress reporting.9 
i  Trinidad and Tobago’s progress report to UNAIDS in 2012 stated that it is ‘by and large 
not an injecting society’ and that the few reported cases have been linked to ‘deportees 
returned from abroad’. 
j  Estimate from 1998–2001.
k  In a study conducted in St Croix in 2005 involving 254 drug and alcohol users, women 
not only reported higher levels of crack use (85% compared to 49% of male participants) 
but also significantly more sexual partners in the month previous to the study (5.6 
compared to 2.3) with more unprotected sexual acts (11.2 compared to 6.5). Female 
participants also reported a notably higher HIV prevalence of 8.8%, compared to 1.4% 
in men.
However, few countries have included information on this in 
their latest progress reports.14 
The harm reduction response remains very limited throughout 
the region. Needle and syringe exchange programmes 
(NSPs) and opioid substitution therapy (OST) are only 
available in Puerto Rico.3 Services for people who use drugs 
(PWUD) throughout the rest of the region are predominantly 
abstinence-based, high-threshold interventions, with the 
exception of a small number of drop-in centres in St Lucia, 
the Dominican Republic, Trinidad and Tobago and Jamaica.8 
With the initiation of a Round 9 Global Fund programme in the 
region, there are planned activities related to harm reduction 
in Jamaica, the Dominican Republic and Trinidad and Tobago, 
including the development of a harm reduction training 
programme.15 There are also efforts underway to include drug 
use and harm reduction within peer education curriculum for 
sex workers and men who have sex with men (MSM), as part 
of the Global Fund programme.15
There have been no significant policy developments related 
to harm reduction in the Caribbean in the past two years. 
Developments in harm reduction 
implementation
Needle and syringe exchange programmes (NSPs)  
Regional NSP coverage is very low, with a reported 
distribution of 0.3 syringes per PWID per year.3 Puerto Rico 
is the only territory with NSPs, with currently 13 active NSP 
sites based in communities around the capital city of San 
Juan, equal to 0.4 NSP sites per 1000 PWID.3 Although Law 
110 that classified syringes as illegal injecting paraphernalia 
was amended in 1997, there are anecdotal reports of law 
enforcement authorities entering el punto (shooting galleries) 
and destroying the available sterile injecting equipment.16
Despite reports of IDU in six other Caribbean countries and/
or territories, no NSP services have been established outside 
Puerto Rico. In the Dominican Republic, it is reported that 
sterile syringes can be purchased in pharmacies.15 
Opioid substitution therapy (OST)
Puerto Rico remains the only territory in the region that has 
any OST provision. There are reported to be six operational 
OST sites (five in the community and one in a prison), which is 
equal to 0.2 OST sites per 1000 PWID.3 In 2007, there were an 
estimated 5570 people receiving methadone in Puerto Rico, 
representing 19% of the injecting population.3 Despite opiate 
use reported in the Dominican Republic, there are no OST 
sites operating in the country.15 
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In Puerto Rico a majority of PWID report starting to inject 
at a very young age. In contrast to many other countries 
outside the Caribbean, there are currently no legal restrictions 
inhibiting anyone under eighteen from accessing available 
NSP and OST services.17 
Anecdotal reports indicate that harm reduction coverage in 
Puerto Rico is negatively impacted by funding restrictions. 
Since 2010 the Punto Fijo programme of Iniciativa Cominitaria 
that previously worked across twenty five communities in 
the northeastern part of the island, now covers only fifteen 
communities in the San Juan municipality, with no renewed 
services in the other ten areas.16 The situation in Puerto Rico is 
not captured by UNAIDS reporting processes as it is a territory 
of the USA but unfortunately not included within the 2012 
USA report.18 
Harm reduction for people who use crack cocaine
A small number of drop-in centres primarily for people who 
use drugs (PWUD) have been established across the region. 
Programmes advocating a harm reduction approach have 
been set up in Santo Domingo (Dominican Republic), Port 
of Spain (Trinidad), Kingston (Jamaica) and Vieux Fort and 
Castries (St Lucia).19 The Castries facility offers shelter and 
other services for homeless crack cocaine users living with 
HIV, providing adherence support for residents receiving 
antiretroviral therapy (ART). Although it does not distribute 
cannabis, the centre advocates the use of the drug for residents 
as a method of combating crack cocaine addiction and the 
nausea that is often a side effect of ART.19 In Jamaica, the 
National Council on Drug Abuse (NCDA) provides homeless 
PWUD with HIV treatment, prevention and care services as 
well as rehabilitation and detox services and links to services 
providing food, shelter and primary health care.20 
While countries have not developed indicators specifically 
related to targeted prevention for people who use crack 
cocaine,19 several UNAIDS progress reports in 2012 include 
mention of this group as a vulnerable population. Jamaica, 
for example, now includes responding to HIV among crack 
cocaine users within its National Strategic Plan.20 
Hepatitis C
There is very limited information available on hepatitis C 
(HCV) among PWUD in the Caribbean. The national HCV 
prevalence among PWID in Puerto Rico is not available. 
However, sub-national data relating to San Juan indicate that 
HCV prevalence among PWID is very high (89%).21 Positive 
HCV status has been found to be strongly associated with the 
number of years of IDU, use of shooting galleries, receiving 
a tattoo while incarcerated and having a history of sexually 
transmitted infections (STIs).21 HCV treatment is currently not 
being distributed by the Puerto Rican Health Department due 
to prohibitive cost.17 Obtaining treatment from private health 
providers remains the sole option for people living with 
HCV, with associated costs prohibiting most from accessing 
treatment services.17
Tuberculosis
Data on the extent of tuberculosis (TB) infection among 
Caribbean PWUD are lacking. However, TB remains an 
important public health issue in the region, particularly among 
people living with HIV. In Puerto Rico, one study reported that 
TB incidence was highest among PWID living with HIV.22 A 
recent visit to Puerto Rico by the Centers for Disease Control 
and Prevention (CDC) was prompted by a reported outbreak 
of TB within a ‘drug addiction centre’ in the village of Trujillo 
Alto.23 The extent to which TB prevention and treatment is 
available to PWID in Puerto Rico is not known. 
Antiretroviral therapy (ART)
Alongside Latin America, the Caribbean leads globally in ART 
coverage among low- and middle-income countries; Belize, 
Haiti and Jamaica are reported to have ART coverage of 40–
59%, with Cuba reporting to reach 80% of people who require 
ART.1 Increased access to ART has led to a considerable drop 
in the number of people dying of AIDS-defining illnesses, 
with an estimated 26,000 averted deaths.2 While there 
are programmes in place on some islands to provide ART 
adherence support to PWUD,15 there are no estimates of the 
numbers of PWUD receiving ART in the Caribbean.3 A regional 
synthesis of UNAIDS progress reports from 2008 emphasised 
the need for the region to quickly increase the meaningful 
involvement of its most vulnerable populations within the 
HIV response. It also called for more targeted prevention, 
as currently HIV prevention efforts primarily target the 
general population and reach a very low percentage of MSM, 
male and female sex workers and PWUD.9 Similarly, there 
is a need for increased access to HIV treatment, care and 
support programmes among populations with elevated HIV 
prevalence including PWUD and prisoners. 
Harm reduction in prisons
Drug use is highly criminalised and incurs severe sentences 
across the Caribbean region, resulting in the incarceration 
of large numbers of PWUD and subsequent overcrowding 
within prisons. The criminalisation of sex between men and 
drug use, and high-risk sex within prisons, contribute to high 
HIV prevalence among Caribbean prisoners. While estimates 
of HIV prevalence within prisons are limited to results from 
routine HIV screening and seroprevalence studies (i.e. no 
systematic research has yet been undertaken), there is 
evidence of elevated HIV prevalence in prisons from several 
countries and/or territories, ranging from 2% in St Lucia to 
4.9% in Belize and 5.24% in Guyana.24 
There are no NSPs operating within prisons in the Caribbean, 
and only one OST programme operating in one prison in 
Puerto Rico. There are no systematic data on access to HIV 
prevention, treatment, care and support within prisons, but 
indications are that service provision remains limited. 
Caribbean
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Overdose 
Data on overdose prevalence among PWUD in the Caribbean 
are lacking. One cross-sectional survey in Puerto Rican prisons 
found that almost half of 1179 prisoners had witnessed an 
overdose in prison, and one-third had known someone to 
have died of an overdose while incarcerated.25 The likelihood 
of witnessing an overdose incident was associated with age, 
being male and using drugs in prison (particularly poly-drug 
use).25 Of those reporting IDU before incarceration, 60.6% had 
witnessed an overdose incident and 44.9% had known of an 
overdose death.25 The majority of participants who injected 
drugs in prison reported high-risk injecting practices.25
The researchers note the need to develop and improve 
appropriate responses within prison settings.25 They 
also highlight the need for further investigation into the 
structural factors and staff attitudes that facilitate or hinder 
the implementation of overdose prevention programmes in 
prisons.25 
Policy developments for harm 
reduction
There have been few developments in harm reduction policy 
at either national or regional levels in the Caribbean during 
the past two years. Harm reduction is included within Trinidad 
and Tobago’s National Anti-Drug Plan for 2008–2012 as a 
key component of the national response to drugs,26 but this 
remains the sole national policy related to HIV or drugs in the 
region which includes harm reduction. 
Local respondents have reported an increase in discussions 
surrounding the decriminalisation of cannabis in the 
Caribbean, but as yet there has been no actual legislative 
action.15
The awarding of a regional bid from Round 9 of the Global 
Fund to fight AIDS, Tuberculosis and Malaria, entitled 
‘Fighting HIV in the Caribbean: a Strategic Regional Approach’, 
signified an important advance for harm reduction in the 
Caribbean.27 A total of US$29,812,507 will be disbursed to the 
Pan Caribbean Partnership Against HIV/AIDS (PANCAP) over a 
period of five years, from January 2011 to December 2015.27 
The programme includes harm reduction initiatives for people 
who use crack cocaine both in the community and in prisons. 
Priority area 3 of the Caribbean Regional Strategic Framework 
(CRSF) 2008–2012 is ‘to achieve universal access to targeted 
prevention interventions among the most-at-risk populations 
(such as, MSM, SW [sex workers], drug users, prisoners, and 
migrant populations).’28 An expected result articulated in the 
Grant Application is that six countries will report adoption of 
HIV prevention programmes among cocaine users with harm 
reduction measures by 2014 (up from two in 2008 – St Lucia 
and Jamaica).27
As reported in the Global State of Harm Reduction 2010, the 
involvement of government representatives within Country 
Coordinating Mechanisms (CCMs) for Global Fund grants 
provides some indication of national support for a harm 
reduction approach from Caribbean governments. 
Civil society and advocacy 
developments for harm reduction
The few drop-in centres with a harm reduction approach 
operating in the region are primarily implemented by civil 
society organisations (CSOs). The civil society initiative within 
the PANCAP Round 9 Global Fund programme continues 
to play a significant role in the regional HIV response. It 
is jointly led by the Caribbean Vulnerable Communities 
Coalition (Jamaican coalition of civil society actors known 
as CVC) and El Centro de Orientación e Investigación 
Integral (Dominican Republic-based CSO COIN). They work 
to challenge the structural drivers of the epidemic, focusing 
on socially marginalised populations affected by HIV.29 CVC/
COIN provides technical support to community partners to 
help scale up and develop innovative programme models 
targeting key population groups that include PWUD.30
The Caribbean Drug Abuse Research Unit (CDARI) continues 
to support research into the public health risk of hidden 
populations by assessing prevention, treatment and legislative 
methods as well as promoting a public health approach to 
substance use and dependency issues.31 
The 2011 Caribbean HIV conference was held in the Bahamas 
to discuss the forging of a sustainable response to the regional 
HIV epidemic, highlighting critical issues of sustainability and 
evidence-based interventions.32 The conference attracted 
more than 2000 participants from across the region, with 
individuals from vulnerable population groups, members of 
community organisations and representatives of regional and 
international governments.32
Caribbean civil society will have some involvement in the 
upcoming 6th Latin American & Caribbean Forum on HIV/AIDS 
and STIs to be held in Sao Paolo, Brazil, in August 2012. The 
theme of the conference will be ‘health systems, community 
networks and the challenge of prevention’, and it will offer an 
opportunity to strengthen regional dialogue on key objectives 
in the prevention of STIs, AIDS and viral hepatitis throughout 
the two regions.33
At the international level, civil society engagement in the 
Commission on Narcotic Drugs (CND) remains limited, with 
only a small number of Caribbean countries sending CSO 
representatives to participate and/or observe the CND.34
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Multilaterals and donors: 
developments for harm reduction
The most significant advance in harm reduction funding 
within the region has been the regional Global Fund grant. 
The five-year programme includes US$1.2 million allocated 
for HIV prevention, treatment and care among drug users and 
prisoners.19 Harm reduction activities within the programme 
focus on HIV transmission among people who use crack 
cocaine and as such do not include implementation of the 
comprehensive package of interventions for PWID.19 
The US President’s Emergency Program for AIDS Relief 
(PEPFAR) has continued to fund HIV programmes within the 
region. A five-year collaborative framework between the USA 
and the Caribbean to support the implementation of strategic, 
regional efforts to combat HIV/AIDS was confirmed in 2010.19 
Although it is potentially a mechanism to provide financial 
and technical support for harm reduction initiatives across the 
region, recent changes to PEPFAR funding restrictions prohibit 
the funding of NSPs. The current USAID grant is administered 
by the Caribbean HIV/AIDS Alliance (CHAA) and currently 
covers sex workers, MSM and people living with HIV in some 
of the smaller Caribbean territories.15 As yet, no international 
programmes target PWID in the region.
A new Strategy on Substance Use and Public Health was 
approved at the WHO/PAHO 50th Directing Council meeting 
in September 2010.35 While advocating a primary health 
care approach with integrated service delivery networks, the 
strategy directly articulates the benefits of evidence-based 
health initiatives that include harm reduction and preventive 
interventions targeting vulnerable population groups.35
A recent initiative of the Organization of American States 
(OAS) involved the training of 40 Caribbean delegates on 
the Drug Treatment Courts (DTCs) model that has proved 
an effective alternative measure to incarceration for drug 
use.36 The delegates included judges, prosecutors, defence 
attorneys, treatment providers and health care and justice 
professionals from Trinidad and Tobago, Jamaica, Barbados, 
the Bahamas and Grenada.
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Table 2.5.1: Epidemiology of HIV and Viral Hepatitis, 
and Harm Reduction Responses in Latin Americaa 
Country/territory with 
reported injecting  
drug use
People who  
inject drugsb
HIV prevalence 
among people 
who inject drugs 
(%)b
Hepatitis C (anti-
HCV) prevalence 
among people 
who inject drugs 
(%)1
Hepatitis B 
(anti-HBsAg) 
prevalence among 
people who inject 
drugs 
(%)1
Harm reduction responsec
 NSPd OSTe
Argentina
65,829          
(64,500–67,158)
49.7 (35.4–64) 54.6 8.6 (25)
Bolivia nk nk  nk nk 
Brazil 540,500 48 (18–78) 63.9 2.3 (150–450)
Chile 42,176 nk  nk nk 
Colombia nk 1f nk nk (4)
Costa Rica nk nk  nk  nk
Ecuador nk nk nk nk
El Salvador nk nk nk nk
Guatemala nk nk nk nk
Honduras nk nk nk nk
Mexico nk 3 (1.9–4.1) 97.4 (96–98.7) nk (19) (21–25)(M)
Nicaragua nk 6 nk nk
Panama nk nk nk nk
Paraguay nk 9.35 (3.7–15) 9.8 nk (3)
Peru nk 13g  nk nk
Uruguay nk nk 21.9 4.5
Venezuela nk nk nk nk
 
nk= not known
a Latin American civil society respondents reviewing the data above expressed concern that many of the estimates were outdated and did not accurately represent the current national situa-
tion in relation to the number of PWID and HIV among PWID. Where more recent alternative estimates were available, these are included in the text of this chapter. Similar concern was expressed 
regarding the number of NSP and OST within countries, but in most cases up-to-date figures were not available.
b Unless otherwise stated, data are sourced from Mathers B et al. for the Reference Group to the UN on HIV and Injecting Drug Use (2008) Global epidemiology of injecting drug use and HIV 
among people who inject drugs: a systematic review, Lancet, 372( 9651):1733–1745.
c Unless otherwise stated, data on NSP and OST coverage are sourced from Mathers B et al. for the Reference Group to the United Nations on HIV and Injecting Drug Use (2010) HIV prevention, 
treatment and care for people who inject drugs: A systematic review of global, regional and country level coverage, Lancet, 375(9719):1014–28.
d The number in brackets represents the number of operational NSP sites, including fixed sites, vending machines and mobile NSPs operating from a vehicle or through outreach workers.  
(P) = needles and syringes reported to be available for purchase from pharmacies or other outlets, and (NP) = needles and syringes not available for purchase.
e The number in brackets represents the number of operational OST programmes, including publicly and privately funded clinics and pharmacy dispensing programmes. (M) = methadone,  
(B) = buprenorphine, (O) = any other form (including morphine and codeine).
f Estimate from 1999: UN Reference Group.
g   Estimate from 1994–1995: UN Reference Group.
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Map 2.5.1: Availability of needle and syringe exchange programmes (NSP) 
and opioid substitution therapy (OST)
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Harm Reduction in Latin America 
HIV continues to affect marginalised populations across 
the Latin American region, including people who use drugs 
(PWUD). Though widely under reported, injecting drug use 
(IDU) is a significant route of HIV transmission in the region, 
especially in the southern cone of South America and in 
Mexico.2 The Reference Group to the United Nations on HIV 
and Injecting Drug Use estimates that there were over two 
million people who inject drugs (PWID) in Latin America in 
2008, with the largest number residing in Brazil (540,000). 
Where data on HIV prevalence among PWID are available, 
there are wide variations among and within countries. Latest 
UN Reference Group estimates are that over one quarter 
(580,500) of the 2 million PWID in Latin America were living 
with HIV.3 The highest HIV prevalence among injecting 
populations was reported in Brazil and Argentina at 48% and 
49.7%, respectively (see Table 2.5.1).
Further insights into the HIV epidemic among PWID in the 
region can be obtained from national reports to UNAIDS and 
WHO. For example, the following Latin American countries 
reported to WHO on HIV prevalence among PWID: Brazil (6%), 
Colombia (2%), Mexico (4%) and Paraguay (9%).2 In Colombia, 
reported HIV prevalence among PWID ranged from 1.9% in 
Pereira to 9% in Cucata.4 There are plans for further studies 
on HIV and injecting drug use in Cali, Armenia and Bogota, 
three areas where injecting heroin use is on the rise.5 While 
unprotected sex between men remains the dominant mode 
of transmission in Mexico, intersections between IDU and 
sex work are reported to play an important role in Mexico’s 
epidemic.6 
There is increasing research into the prevalence and harms 
related to non-injecting use of cocaine and its derivatives 
within the Latin American region.7 As in the Caribbean region 
(see Chapter 2.4), studies in several Latin American countries 
indicate that HIV prevalence among people who use crack 
cocaine is often elevated when compared with the general 
population.7-10 In addition, the use of coca paste, bazuco or 
paco is of increasing concern in Colombia, Argentina, Bolivia, 
Chile, Ecuador, Peru and Uruguay.11-12
Civil society organisations continue to be the primary 
implementers of harm reduction initiatives in Latin America. 
Six countries are currently implementing harm reduction 
programmes: Argentina, Brazil, Colombia, Mexico, Paraguay 
and Uruguay. No additional countries have adopted a harm 
reduction approach in the past two years.13 The vast majority 
of needle and syringe exchange programmes (NSPs) operate 
in Brazil, with projects also running in Argentina, Mexico, 
Paraguay and Uruguay. Opioid dependence is uncommon 
throughout much of Latin America, with most heroin use 
concentrated in Mexico and Colombia. Consequently, opioid 
substitution therapy (OST) coverage is low with services only 
available in these two countries (see Table 2.5.1). 
Harm reduction programmes targeted towards people who 
use crack cocaine are operating in some countries but in 
general, these experiences are yet to be documented. 
Across the region, there are very limited comprehensive care 
programmes available for those living with HIV, viral hepatitis 
or TB. Few health services target or address the specific needs 
of PWUD and linkages or referral systems between existing 
services for PWUD and other health services are often poor.13 
However, in Colombia there are indications that they intend 
to ‘[move] forward in the integration of the agenda of HIV 
with the agenda of drugs, which have historically worked very 
separately.’5
Latin America is at the forefront of a growing global movement 
to decriminalise drug use. Civil society advocacy in several 
countries has been instrumental in bringing about preliminary 
changes in national drug policy.13 While these developments 
have clear implications for PWUD and harm reduction policy 
and practice, in no country have legal reforms been followed 
up with an increase in harm reduction services. Civil society 
organisations continue to be the primary service providers of 
harm reduction initiatives throughout the region. However, in 
the absence of state support they are frequently confronted 
with funding difficulties and are increasingly forced to rely on 
international resources.13 
Multilateral agencies and international donors such as the 
Global Fund to Fight AIDS, Tuberculosis and Malaria and the 
World Health Organization’s Pan American Health Organization 
(PAHO) continue to provide limited support to harm reduction 
initiatives throughout the region.13 However, the absence of 
adequate government support and poor financing for harm 
reduction continues to inhibit the introduction and/or scale-
up of services in many Latin American countries.13 
Developments in harm reduction 
implementation
Needle and syringe exchange programmes (NSPs)
Estimates of NSP coverage are very limited for Latin America. 
Where available, data indicates extremely low coverage with 
only 2% of PWID accessing NSP services across the region and 
0.3 syringes received per PWID per year.14 only five countries 
currently operate NSP programmes, leaving twelve that have 
reported injecting drug use with no available NSP facilities. No 
new countries have introduced NSP sites in the past two years, 
and there has been very little scale-up of established NSP 
services.13 Brazil still reports the highest number of active NSP 
sites, with between 150 and 450 currently in operation14 (see 
Table 2.5.1). Recent national reporting to UNAIDS indicates 
that 54.3% of PWID reported to have used sterile injecting 
equipment the last time they injected.4 
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In Paraguay this figure is reported at 92.11% despite there 
being only three NSP sites in operation.4
In Mexico, there are reported to be 0.4 NSP sites per 1000 
PWID, providing equivalent to 2.7 syringes per PWID per year;2 
significantly higher than the regional average. State funds 
subsidise the distribution of sterile injecting equipment to 
Centres for Youth Integration (CIJ) and some CAPASITS (State 
Coordinating of HIV/AIDS/STIs).13 In Ciudad Juarez, the NGO 
intervention Companeros Program distributes equipment 
packs containing sterile needles and HIV and hepatitis C 
prevention information.13 
There are still no NSP programmes in Colombia, despite 
widespread heroin use and high-risk injecting practices. A 
recent study found that 40% and 60% of PWID in Medellin and 
Pereira respectively reported sharing injecting equipment.4 
The majority of participants reported using tap water to 
clean syringes, with a small number using alcohol. The 
interconnection between PWID and their sexual networks in 
HIV transmission has also been highlighted.4 Approximately 
22.9% of PWID in Medellin and 22.7% in Pereira reported 
giving a used syringe to a casual partner.4 
The criminalisation of drug use and strict law enforcement 
across the region remains a significant barrier to PWID 
accessing health services. There are anecdotal reports from 
Mexican civil society of the frequent seizing of used injecting 
equipment from PWID to be used as evidence against them.15 
The registration requirements of Mexican NSPs are also 
reported to deter many PWID from accessing these services.
Prohibition policies in Colombia have given rise to high levels 
of stigma, social discrimination and exclusion of PWUD.13 
Discrimination against PWUD from health service providers is 
reported.16 Studies in Medellin and Pereira revealed that, while 
the majority of PWID participants had purchased syringes 
in pharmacies, most reported discrimination by pharmacy 
employers.4
In those countries that offer limited harm reduction facilities, 
restricted access hours, waiting times, insufficient resources 
and inadequately trained service providers deter many PWID 
from accessing services.13 The Brazilian NGO, Viva Rio, in 
coordination with the Department of Mental Health of Rio 
de Janeiro, is working to improve service access in the area, 
training community health operators who work in the favelas 
in harm reduction intervention.h 13 The Intercambios Civil 
Association, in coordination with the governments of various 
provinces and the support of the Levi Strauss Foundation, 
is also developing training in Argentina under the project 
‘Reducing stigma and discrimination of drug users’.17
h  Favelas are poor and precarious housing settlements.
Further research and programme-monitoring in countries 
implementing NSPs is required to determine accurate levels of 
coverage across the region. Although concentrated epidemics 
within key populations are reported throughout Latin America, 
services targeting the needs of vulnerable population groups 
are limited. More harm reduction initiatives that actively 
engage with networks of PWUD and include community and 
interdisciplinary interventions are required.
Further developments for harm reduction targeting PWID 
include the investment of US$500,000 of the National Drug 
Council of Uruguay to open two crisis centres for PWUD, 
based in the Maciel and San Jose Hospitals.13 In Paraguay, 
the National Centre on Addiction Control with the National 
HIV/AIDS and STI Control Programme and regional NGOs, is 
developing harm reduction initiatives, although it is not yet 
clear what these will involve.13 An Advisory and HIV Testing 
Centre has recently opened in Argentina.4 The National Policy 
for the Reduction of Substance Abuse in Colombia is leading 
localised harm reduction developments for people who inject 
heroin.13 Street-based outreach services are being initiated 
in accordance with local authorities to deliver educational 
activities and monitored distribution of condoms and sterile 
syringes. Pilot schemes have been established in the Cucata, 
Pereira, Santander de Quilichao, Cali, Armenia and Medellin 
areas.13
Harm reduction for people who use crack cocaine 
As the association between HIV transmission and non-
injecting drug use in the region is being increasingly 
reported, 4, 7 there is a need for guidance on the development 
of interventions that specifically aim to prevent HIV for those 
drug users who do not inject. This is of particular urgency in 
South American countries where researchers and CSOs have 
called for increased access to HIV prevention and voluntary 
counselling and testing (VCT) for crack cocaine users.18
Some harm reduction initiatives in the region are tailored 
toward people who use crack cocaine, but these need to be 
more systematically documented. One such programme 
was developed in 2010 in Rio de Janeiro. The ‘crack-land’ 
project provided a safe place for young people to congregate 
and smoke crack cocaine in the Rio favela of Yacarecinho.13 
Pipes, lip balms, condoms and syringes were provided by 
the scheme, which was run by health workers specifically 
trained in the needs of crack cocaine users. Though initially 
supported by a number of government and state bodies as 
well as UNODC, funds supporting the project have since been 
suspended.13
Latin America
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Opioid substitution therapy (OST)
Opioid use is rare throughout most of Latin America. Mexico 
and Colombia remain the only countries with OST programmes 
in operation (see Table 2.5.1).14 There have been limited 
developments in OST service provision in the past two years. 
In 2010, the estimated number of active services in Mexico was 
between twenty-one and twenty-five sites and in Colombia, 
four operational services were reported to be providing 
methadone maintenance treatment (MMT) across three 
districts.14 In 2012, local respondents reported there being 
eight public OST programmes in operation across Colombia, 
each serving an average of 100 patients, with an additional 
four privately run institutions offering OST services.13 It is also 
reported that expanding the range of available OST doses and 
forms is being considered in Colombia.13 
Viral hepatitis 
Population prevalence of HCV in Latin America varies by 
country but averages less than 1% across the region.19 
Contaminated blood products are responsible for most HCV 
infections in Latin America.19 Injecting drug use is an important 
risk factor in parts of the region, most notably major urban 
areas and northern Mexico.19 Data on viral hepatitis among 
PWID remains limited for the Latin America region. Estimates 
of hepatitis C antibody (anti-HCV) prevalence among PWID 
range from 9.8% in Paraguay to 97.4% in Mexico. Estimates 
for hepatitis B surface antigen (anti-HBsAg) are only recorded 
for three countries, and range from 2.3% in Brazil to 8.6% in 
Argentina (see Table 2.5.1). HCV prevalence is also elevated 
among non-injecting cocaine users in Brazil and Argentina. 
Studies have indicated high levels of HIV/HCV co-infection 
among PWID in the region.19
With the exception of one programme in Brazil,13 there 
are currently no integrated HIV, tuberculosis (TB) and viral 
hepatitis testing and treatment programmes in Latin America. 
Attempts have been made to address this situation. The 
Ministry of Health and the Social Security (CCSS) in Costa Rica 
and Panama have pledged to guarantee access to testing and 
treatment services for HIV and viral hepatitis to all.20 In 2011, the 
Ministry of Health of the province of Buenos Aires (Argentina) 
launched the Programme for Prevention and Detection of 
Viral Hepatitis to work in conjunction with the HIV/AIDS and 
Sexually Transmitted Infections (STIs) Programme. 
Tuberculosis
Brazil is one of the twenty-two countries recognised as having 
a high TB burden, reporting forty-eight TB cases per 100,000 of 
the population in 2010.21 Infections with drug-resistant strains 
are beginning to occur in areas of Central America. While 
research on TB prevalence among PWUD in Latin America 
is lacking, there is evidence to suggest that both injecting 
and non-injecting drug use are associated with elevated TB 
infection rates.21 
Most countries in the region offer an HIV test to anyone 
presenting with TB.13 Similar diagnosis services are, in theory, 
available for people who use drugs, though compliance to 
such practices is not always consistent.13 Integrated TB and HIV 
programmes are beginning to emerge in the region, including 
in Uruguay, Argentina and parts of Central America. However, 
there are currently no services that specifically target PWUD.20 
Overdose
Data on the prevalence of overdose in Latin America is very 
limited. Research in Colombia reported 25% and 33.3% 
of PWID in Pereira and Mendellin respectively to have 
experienced a non-fatal heroin overdose.4 In both cities, six 
out of ten revealed that they would not access health services 
if they had another overdose episode for fear they would be 
referred to law enforcement authorities.4 
There are currently no overdose prevention programmes 
established in the region.13 Naloxone is registered in a number 
of South American countries including Argentina, Brazil, Peru, 
Chile, Uruguay, Mexico, Paraguay and Venezuela. However, 
it is not yet available to PWUD or for medical emergencies 
in any of these areas. In Colombia, where heroin and opiate 
use is more widely reported, naloxone is available and its use 
included in regional health care plans.13 
Prevailing laws and the criminalisation of drug use continue to 
inhibit the introduction of overdose prevention and treatment 
initiatives in the region.
Antiretroviral therapy (ART)
Latin America and the Caribbean continue to lead globally in 
ART coverage levels for low- and middle-income countries.22 
In December 2010, it was reported that ART was being 
provided to 521,000 of the 820,000 (710,000–920,000) in need 
of treatment, which equated to 63% ART coverage.2 Coverage 
varied between countries, from less than 70% in Ecuador and 
Guatemala to above 80% in Chile and Nicaragua.22 Brazil is the 
only country with estimates for the number of PWID living 
with HIV and receiving ART. While past estimates have been 
much higher, the UN Reference Group found only 2,974 PWID 
to be receiving treatment: between one and four of every 
hundred PWID living with HIV in Brazil.14
Latin America reports twenty-four ART facilities per 100,000 of 
the population.2 Yet at 11%, the region reported the smallest 
percentage increase in the number of people receiving ART 
between 2009 and 2010.2 While ART coverage is generally 
high in the region, this figure may also reflect challenges 
in scaling up VCT and in early HIV diagnoses.2 Significant 
improvements in access to adequate diagnosis and care 
services are necessary to reach all those in need of ART in the 
region, particularly vulnerable populations.23
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The criminalisation of drug use continues to greatly inhibit 
service access and treatment adherence among key 
populations. Attitudes among health professionals that 
patients must stop the use of illegal drugs or alcohol to receive 
ART is also reported to be impeding the success of many ART 
treatment programmes.
Limited medical resources and the cost of ART are of growing 
concern in Latin America. In a survey conducted by PAHO/WHO 
in 2011, eight out of twelve countries in the region reported 
episodes of ART shortages, which required people to change 
treatment regimens or to have treatment interruptions, 
increasing the risk of HIV resistance and treatment failure.24
Harm reduction in prisons
In most Latin American countries, the cultivation, distribution 
and personal use of drugs remains a criminal offence. The 
predominant ‘war on drugs’ approaches in the region have 
led to large proportions of the drug-using population being 
incarcerated. While there are a lack of data on the prevalence 
of HIV, viral hepatitis and TB within Latin American prisons, 
it is clear that prison populations are at an increased risk of 
infection. In Argentina, for example, TB patients with a history 
of incarceration were six and 18 times more likely to test 
positively for HBV and HCV infection, respectively.25
More thorough and systematic research is required to 
provide an accurate analysis of the current situation of HIV, 
viral hepatitis and TB epidemics and drug use within prisons 
in Latin America. There are currently no prison-based harm 
reduction services operating in the region.13
Policy developments for harm 
reduction
As reported in 2010, six Latin American countries include 
harm reduction within their national policies on HIV and/
or drugs: Argentina, Brazil, Colombia, Mexico, Paraguay and 
Uraguay. The extent to which this indicates government 
support for harm reduction varies. For example, though 
harm reduction is now recognised as part of national public 
health policy in Paraguay, it is implemented only by non-
governmental organisations and often without the support 
of the state.13 While there has been little development in the 
specific inclusion of harm reduction within national policy 
across the region, there has been a notable increase in the 
debate about drug policy and legislation at both national and 
international levels. In most Latin American countries, and 
particularly in Central America, drug policy and legislation 
remains focused on supply reduction and combating drug 
trafficking. These policies are largely determined by security 
and justice ministries and incorporate extensive military 
and policing operations.26 However, during the ‘Strategic 
Meeting of Public Security and Drug Policy’, held in Rio de 
Janeiro in November 2011, law enforcement representatives 
from eighteen countries expressed concern at the negative 
consequences of the current ‘war on drugs’ strategy and called 
for more effective and constructive policy approaches.27
Moreover there is a growing awareness within policy circles 
of the vulnerability of key affected population groups. The 
47th Regular Session of the Inter-American Drug Abuse 
Control Commission (CICAD/OAS) in May 2010 saw the 
approval of the new Hemispheric Drug Strategy.28 Although 
there are no explicit mentions of harm reduction initiatives, 
the strategy does call for comprehensive evidence-based 
prevention programmes targeting key vulnerable and socially 
marginalised populations as well as a stronger institutional 
presence to establish and implement new policy initiatives.28
In September 2011, the 51st Directing Council of PAHO 
endorsed the Plan of Action on Psychoactive Substance Use 
and Public Health Strategy aimed at reducing the burden of 
drug use while strengthening an integrated public health 
response.29 Shortly afterwards, delegations from the twelve 
UNASUR nations of the regional bloc met for the 2011 
South American Council to discuss the ratification of the 
Drug Action Plan to reduce narcotic supply and demand. 
Prevention initiatives and treatment programmes for high-
risk populations were addressed as well as institutional 
strengthening and the harmonising of anti-drug legislation to 
create mechanisms for regional coordination.30
In January 2011, representatives of The Latin American 
Commission on Drugs and Democracy (comprised of 17 drug 
policy campaigners, including former presidents of Brazil, 
Colombia and Mexico) presented an initiative to create the 
Global Commission on Drug Policy. The first meeting and 
official launch of the Global Commission was held in Geneva, 
June 2011. Chaired by Fernando Henrique Cardoso, the Global 
Commission condemns the global ‘war on drugs’ as a failure 
and advocates a paradigm shift towards harm reduction, 
decriminalisation of drug use and the legal regulation of 
certain substances. It seeks to create space for a debate on 
evidence-based drug policies.13, 31
There have been several developments in drug policy in the 
region that have implications for harm reduction, some of 
which are summarised below. For more information on these 
and other developments globally, refer to Chapter 3.4.
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Civil society and advocacy 
developments for harm reduction
Civil society organisations (CSOs) have continued to play 
an important role in advocating for drug policy reform at 
both regional and national levels. A second edition of the 
Latin America Conference on Drug Policy was held in Rio 
de Janeiro in 2010, and a third in Mexico City in September 
2011.13 Organised by Intercambios Civil Association and its 
respective local partners, Psicotropicus and CUPIDH, the 
events brought together key representatives from across 
the region to promote and continue discussions on drug 
policy and reform.13 Various satellite events were held at 
each conference to encourage further dialogue between 
governments and society. The 2011 Mexico convention 
incorporated a ‘Drug Policy in Latin America’ seminar for 
journalists, sponsored by PAHO, to generate a critical mass of 
i For more information about this topic, see TNI Publication, Drugs and Conflict, Debate 
Documents, Nº 13, May 2006, ‘Coca Yes, Cocaine No’ Legal Options for the Coca Leaf, 
http://www.tni.org/briefing/coca-yes-cocaine-no.
trained reporters engaged with advocating for inclusive, harm 
reduction policy development in line with human rights.13 
Contact between regional civil society organisations and the 
International Network of People who Use Drugs (INPUD) led 
to the formation of the LANPUD (Latin American Network of 
People who Use Drugs)13 which has plans to hold a further 
strategic meeting in October 2012.35
Such dialogues on drug policy, initiated in 2007 by the 
Transnational Institute (TNI) and Washington Office on 
Latin America (WOLA), to promote the free and confidential 
exchange of ideas between officials and nongovernmental 
experts, have continued to further the debate on current 
trends and how existing contradictions within international 
drug policy might be resolved.13 In recent years informal 
dialogues have been conducted in Rio de Janeiro (February 
2009 and 2010), Buenos Aires (October 2009), Montevideo 
(February 2011) and most recently in Lima (February 2012).36
Drug policy developments in Latin America
In June 2011, the Bolivian government announced its 
formal withdrawal from the UN Single Convention on 
Narcotic Drugs of 1961. This followed the rejection of a 
proposal to amend Article 49 to remove the coca leaf from 
the list of classified drugs as identified by the Convention. 
Despite its withdrawal, Bolivia indicated its intention to 
adhere to the main outlines of the Convention with the 
exception of the prohibition of the traditional use of coca 
leaf. It remains explicitly in favour of criminalising the use of 
cocaine – ‘Coca Yes, Cocaine No’.13
The Chilean government  has decided to use  Drug 
Treatment Courts for those convicted for problematic 
drug use. The initiative allows the accused to participate 
in a voluntary rehabilitation programme under the 
direct supervision of the judge, and on completion of 
the treatment, the case is dismissed and criminal records 
erased.13
In Argentina, the Mental Health Law now prohibits 
involuntary internment, previously a common practice for 
PWUD. It also denotes the rights of patients to be adequately 
informed of care options and to receive treatment that does 
not infringe on their personal freedoms. The regulation is 
still pending but the enactment of the law marks a step 
towards addressing addiction within mental health policy.13 
Ecuador has some of the toughest drug laws in the 
region, resulting in the incarceration of many small-
scale drug traffickers. The Constitution drawn up by the 
National Constituent Assembly in 2008 declared that drug 
consumption should be decriminalised and substance 
dependency addressed as a public health issue. A complete 
review of the judicial system has since been put forward by 
the Ministry of Justice and Human Rights. The proposed 
legislation distinguishes between small and large-scale 
drug trafficking and street distribution, and introduces 
proportional sentences. Yet there is still no guarantee 
that either the broader reforms or drug legislation will be 
implemented.13
In November 2010 in Mexico, the Law for Integral Support 
to Psychoactive Substance Use was approved. This law 
proposes an alternative justice model focusing on the 
prevention and treatment of addictions through public 
services.32 However, drug policy in Mexico has continued to 
adhere to the ‘war on drugs’ approach. 
The Brazilian government is to invest US$2 billion toward 
creating a public health network for the treatment of PWUD, 
with a particular focus on crack cocaine use. Funds are to 
be used to establish 300 health centres and 600 temporary 
shelters for drug dependency.33 
In June 2012, Colombia’s constitutional Court approved 
the government proposal to decriminalise the possession 
of small amounts of cocaine and marijuana for personal 
use.34 The recent court ruling stated that anyone caught 
with less than 22g of marijuana, or less than one gram of 
cocaine, may receive physical/psychological treatment 
depending on their level of intoxication, but may not be 
prosecuted or detained.34
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The RAISSS network of institutions includes many community-
based organisations committed to addressing the problems of 
drug use and harm reduction in conditions of social inequality 
across the continent.13 It currently comprises organisations 
throughout Latin America and the Caribbean, in Brazil, Chile, 
Haiti, Guatemala, Honduras, El Salvador, Nicaragua, Costa Rica, 
Panama, Bolivia, Mexico and Colombia. RIOD is a similar non-
profit organisation network of Latin American NGOs working 
on prevention, treatment and social inclusion within the drug 
field.13 
At the national level, CSOs continue to play a key role in 
advocating for drug law reform and the increase of harm 
reduction service provision. CSOs in Colombia are calling 
for a reform of the national drug statute to align drug policy 
with human rights and public health.13 Advocating a rejection 
of compulsory treatments and the repression, persecution 
and criminalisation of PWUD, they have demanded that the 
government readdress the failure of the punitive policies of 
previous years.13 Civil society advocacy for harm reduction 
and the involvement of drug users remains weakest in Central 
America, although some NGOs cover these issues in their 
work.13
Multilaterals and donors: 
developments for harm reduction
Multilateral agencies and international donors have continued 
to support several harm reduction initiatives in Latin America 
in recent years.13 As in other regions, the most significant 
donor has been the Global Fund. Over the past five years, 
close to US$90 million has been allocated to programmes in 
Argentina, Panama, Peru, Uruguay, Colombia and Honduras.13 
However, the 2011 selection of proposals was made in the 
context of a global financial crisis. With imposed restrictions 
on the access to resources for middle-income countries, the 
sustainability of many of the projects in Latin American is now 
at risk.
UNAIDS and WHO recently investigated the challenges 
specific to Latin America of engaging PWID in HIV prevention 
trials. Information collated at the regional consultation 
held in Buenos Aires in 2011 has been used to supplement 
previous guidance on ethical considerations in biomedical 
HIV prevention trials initially conducted in 2007.13, 37 WHO, 
UNODC and UNAIDS have also produced a region-specific 
draft of their Technical Guide for countries to identify and 
set targets for universal access to HIV prevention, treatment 
and care for PWID.13, 38 The modified document addresses 
HIV transmission risks and interventions for PWUD in the 
regional context of Latin America and the Caribbean. The 
HIV/STI Project of PAHO/WHO held a regional consultation in 
April 2010 in El Paso, Texas. Experts met to discuss research, 
policy and intervention strategies to address HIV transmission 
associated with or resulting from drug use in the region of the 
Americas. A draft for discussion to review the state of harm 
reduction in Latin America and the Caribbean was produced.13 
In June 2011 the Global Commission on HIV and the Law 
hosted a Regional Dialogue to discuss the experiences and 
perspectives of individuals, communities, policy makers and 
law enforcement officials in the Latin American region. 
Open Society Foundations (OSF) continues to support 
advocacy activities of regional CSOs in drug policy reform 
and advocacy for harm reduction.13 Caritas (Germany) has 
provided support to the RAISSS network activities and the 
Levis Straus Foundation has continued its support for projects 
in Argentina.13
Government support is essential for sustainable harm 
reduction programmes within the region. In addition, and 
particularly given the global economic crisis, support from 
international donors and multilateral agencies in the region 
remains critical to ensuring that harm reduction forms an 
integral part of drug policy and public health responses 
throughout the region.
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Table 2.6.1: Epidemiology of HIV and Viral Hepatitis, 
and Harm Reduction Responses in North America 
Country/territory 
with reported 
injecting  
drug usea
People who  
inject drugsb
HIV prevalence 
among people 
who inject drugs 
(%)
Hepatitis C (anti-
HCV) prevalence 
among people 
who inject drugs 
(%)1
Hepatitis B 
(anti-HBsAg) 
prevalence among 
people who inject 
drugs 
(%)1
Harm reduction responsec
 NSPd OSTe DCRf 
Canada
286,987         
(220,690–
375,173)
5.82 64 (51–77) nk  (>775)g (S) (P)3  (B,M)
United States
 1,857,354 
(1,294,929–
2,589,858)
 15.57c
(8.74–22.4)
73.4 (69.7–77) 11.8 (3.5–20)  (186) (P)  (1,433) (B, BN,M)
nk= not known
 
a    There are no identified reports of injecting drug use in Greenland.
b   Unless otherwise stated, data are sourced from Mathers B et al. for the Reference Group to the UN on HIV and Injecting Drug Use (2008) Global epidemiology of injecting drug use and HIV 
among people who inject drugs: a systematic review, Lancet, 372( 9651):1733 – 1745.
c   Unless otherwise stated, data on NSP and OST coverage are sourced from Mathers B et al for the Reference Group to the United Nations on HIV and Injecting Drug Use (2010) HIV prevention, 
treatment and care for people who inject drugs: A systematic review of global, regional and country level coverage, Lancet, 375(9719):1014–28.
d   The number in brackets represents the number of operational NSP sites, including fixed sites, vending machines and mobile NSPs operating from a vehicle or through outreach workers.  
(P) = needles and syringes reported to be available for purchase from pharmacies or other outlets, and (NP) = needles and syringes not available for purchase.
e   The number in brackets represents the number of operational OST programmes, including publicly and privately funded clinics and pharmacy dispensing programmes. (M) = methadone,  
(B) = buprenorphine, (BN) = buprenorphine-naloxone combination, (O) = any other form (including morphine and codeine).
f   DCR = Drug consumption room, also referred to as safer injection facility (SIF).
g   This figure represents the number of sites in two Canadian provinces: British Columbia and Quebec. The number of sites in other provinces was not known at publication in July 2012.
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Map 2.6.1: Availability of needle and syringe exchange programmes (NSP) 
and opioid substitution therapy (OST)
Both NSP and OST available
OST only
NSP only
Neither available
Not known
DCR available
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Harm Reduction in North America
More than 10% of all people who inject drugs (PWID) 
worldwide reside in Canada and the USA.4 The USA, after China 
and Russia, has one of the highest estimated populations of 
PWID globally.4 Injecting drug use (IDU) accounted for about 
17% of HIV cases in Canada at the end of 20085 and 9% of 
new HIV cases in the USA in 2009.6 The HIV epidemic among 
PWID in both countries mirrors broader disparities in the HIV 
epidemic, with racial and ethnic minorities in the USA and 
Aboriginals in Canada disproportionately affected.5, 6 There 
are no data available on IDU in Greenland. 
Although key harm reduction programmes such as needle and 
syringe exchange programmes (NSPs) and opioid substitution 
therapy (OST) are in place in both countries, provision remains 
uneven across smaller cities and rural areas. Coverage of NSPs 
and OST in North America remains below that in Australia and 
several countries in Western Europe7 (see Chapter 2.3). Since 
last reported in 2010, overdose prevention and response 
programmes, including distribution of community-based 
naloxone, have become increasingly widespread across the 
continent. Prison NSPs remain unavailable in North America, 
while provision of methadone for substitution therapy is 
offered in federal and provincial prisons in Canada and on a 
very limited basis in some US jails.
Significant policy developments with implications for harm 
reduction have occurred since last reported in 2010. The 
Supreme Court of Canada ruled that the Minister of Health 
had violated Canada’s Charter of Rights and Freedoms by not 
allowing InSite, the country’s only safe injecting facility (SIF), 
to remain open, and ordered its continuing operation.8 On 16 
December 2011, US Congress reinstated the ban on US federal 
funding for NSPs.9 In a context of global financial uncertainty, 
this policy decision contributes to critical concerns around 
the expansion of HIV prevention programmes to meet global 
targets and commitments on coverage for PWID.10 
Civil society organisations (CSOs) in the USA and Canada have 
actively engaged in activities around overdose prevention 
and community naloxone distribution in the last two years, 
as a result of which there has been growing awareness of the 
issue at various levels of policy and programme delivery. The 
Canadian Drug Policy Coalition (CDPC), an independent civil 
society network of organisations and individuals advocating 
to improve Canada’s drug policies, is the newest addition to 
the strong civil society presence working for harm reduction 
in the region. 
Developments in harm reduction 
implementation
Needle and syringe exchange programmes
National-level estimates of NSP coverage are not collected in 
Canada or the USA, making it difficult to accurately monitor 
service provision levels.h The latest available data, as reported 
in 2010, indicate that an average of 23 syringes are distributed 
per PWID per year across North America, amounting to 
low coverage by international targets,i 11 and placing North 
America behind other high-income regions such as Europe 
(59 syringes) and Australasia (202 syringes).12 
Civil society reports since 2010 suggest that funding is one 
of the most significant barriers to service provision and scale-
up in both countries. The reinstatement of the US federal 
funding ban for NSPs in December 2011 comes just two 
years after the 21-year-old ban was repealed by President 
Barack Obama.9 While the lifting of the ban in 2009 mobilised 
funders to consider access to sterile injecting equipment for 
financial support, and propelled advocacy efforts by harm 
reduction funders to reach out to other potential donors, 
the recent move undermines programme scale-up and 
marginalises existing programmes away from mainstream HIV 
policy and funding.13 Since individual states determine the 
legality of syringe exchange or distribution, some US states 
have only underground NSPs, or none at all, which is largely 
the case throughout the southern region of the USA.14 In 
Canada the lack of federal support for NSPs means that harm 
reduction services are delivered by community agencies, 
NGOs, municipalities, provinces and territories. Although 
programmes are available in most major cities, individual 
jurisdictions may independently prohibit the provision of 
harm reduction services, including NSPs and safe-injection 
sites, within the city limits.j 
Anecdotal evidence indicates that a small number of 
programmes in the USA have closed in the past two years, 
largely due to financial limitations and shifting political 
priorities. For example, when the Washington State 
government reallocated HIV funding away from primarily 
government-supported programmes, the survival of rural 
services was threatened.13 As NSP implementation is a state 
rather than federal responsibility, the impact of the shifting 
funding landscape varies across the country. In some states 
such as California, new bills passed as of 1 January 2012 
enabling the expansion of access to needles and syringes 
and allowing pharmacists to sell syringes without requiring a 
prescription.15 Likewise, Colorado expanded its NSP provision 
following an authorisation bill from the state, while syringe 
access legislation in Nevada has stalled.13   
h    The HRSA HIV/AIDS Bureau in the USA began tracking client-level data on utilisation of 
services in 2011, but data were not available at the time of writing.
i    According to the 2009 WHO, UNODC, UNAIDS target-setting guide, <100 syringes 
distributed per person who injects drugs per year is considered low coverage; 100–200 is 
medium coverage, and >200 is high coverage.
j    See, for example, The Canadian Press: ‘End Needle Exchange Ban’, Advocates Tell B.C. 
city, 5 July 2012, CTV News.
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The limited geographical reach and opening hours of 
available sites also pose barriers to access, especially for 
women who inject drugs, who experience added stigma and 
fear of exposure to authorities in light of strict child custody 
and welfare laws. In Canada, confidentiality and fear of stigma 
pose a barrier to access in rural and remote areas and on 
Aboriginal reserves, where those accessing harm reduction 
services may be easily identified. 
Safer crack use kit distribution
A significant increase in crack use, particularly among PWID, 
has been documented in Canada over the past decade.16 
People who smoke crack are particularly vulnerable to the 
transmission of viral hepatitis (B and C), tuberculosis (TB) 
and HIV through sharing crack use paraphernalia.17, 18 Safer 
crack use kit distribution programmes have resulted in health 
benefits to individuals who use drugs and communities in 
Canada, including a decreased need among users to share 
paraphernalia, increased health awareness and improved 
personal and community safety.19 
Safer crack smoking supplies have been available in a number 
of cities across Canada for over a decade. Recently, however, 
negative media attention around a new pilot to distribute 
free crack kits in Vancouver’s Downtown Eastside20 has led to 
the slow implementation of this initiative and to the shutting 
down of Safeworks, a programme providing crack smoking 
equipment since 2008 in Calgary.21 Despite these challenges, 
new initiatives are being discussed in some settings.22 For 
example, a comprehensive approach to the distribution of 
safer crack kits, including an evaluation of the proposed 
programme, is being considered in Alberta for roll-out in 
August 2012.23 Continuing barriers to programme initiation 
and scale-up include lack of resourcing, public opposition,23 
limited geographical reach, interference by the police as well 
as the need for further research to evaluate the impact of this 
intervention.19
Opioid substitution therapy (OST)
Provision of OST has increased steadily in both countries, 
although it is by no means universal. Over 1,433 licensed 
facilities provide OST in the form of methadone, 
buprenorphine and buprenorphine-naloxone combination 
across the USA. The most recent available data indicate 
that in the USA in 2009 there were 640,000 individuals on 
buprenorphine or buprenorphine-naloxone combination for 
maintenance therapy (up from 96,000 in 2005) and 266,818 
on methadone (up from 236,836 in 2005).24 All ten Canadian 
provinces deliver methadone maintenance therapy (MMT) 
services through a variety of models, including government-
funded programmes, for-profit private clinics and family 
practice, but the number of sites is unknown due to lack of 
monitoring as part of national surveillance.25 Only one of three 
Canadian territories provides MMT, and buprenorphine is not 
widely used due to its prohibitive cost.25 In Canada, there has 
also been an increase in demand, including in First Nations 
communities and prisons.25 However, the lack of physicians 
who can prescribe methadone and limited provision 
through low-threshold services remain a significant barrier to 
addressing the increasing demand for MMT in Canada. 
Several developments related to OST provision and access 
have occurred in North America since 2010. Limited funding 
options and budget cuts threaten the quality of service 
provision in Canada. For example, in December 2011, as part of 
broader budget cuts, the Canadian province New Brunswick’s 
Department of Social Development placed an 18-month limit 
on the time period during which methadone clients can receive 
travel subsidies (for example, bus passes or reimbursements 
for petrol and taxis) to attend a dispensing pharmacy as part of 
a new MMT benefit programme.26, 27 Benefits were also capped 
at C$200 per month, potentially restricting access to the 1,328 
people who use drugs (PWUD) who used the travel subsidy 
to access OST in 2011.28 Additional obstacles to OST access in 
Canada include geographical distance from sites, stigma and 
misconceptions around drug dependence at every level of the 
treatment system and, as with NSPs, issues of confidentiality, 
especially in small cities and remote areas. Furthermore, there 
is often powerful community resistance to the establishment 
of new programmes, with some cities amending their zoning 
by-laws to restrict or limit programmes (such as Coquitlam 
and Surrey, BC).k Civil society reports highlighted a need for 
more low-threshold services and diversification of service 
models, as well as provision of integrated psychosocial and 
mental health support, especially in First Nation communities.
The clinical trial ‘Study to Assess Longer-term Opioid 
Medication Effectiveness’ (SALOME) is currently underway 
in Vancouver.29 The trial will investigate the effectiveness of 
hydromorphone, the active ingredient in heroin, as compared 
to injectable medical-grade heroin (diacetylmorphine), at 
benefiting people with chronic opioid dependence for whom 
other maintenance treatments have not been successful. 
In the USA, growing concerns about the diversion of 
buprenorphine30 have the potential to decrease access to 
the medication. For example, newly imposed restrictions as 
a result of diversion concerns include mandatory counselling 
and urine toxicology tests, as well as requirements by 
insurance companies for prior approval for each patient, 
placing greater time demands on physicians who administer 
buprenorphine maintenance therapy.31 Additional barriers 
to OST access in the USA include uneven Medicaid coverage 
across states, leaving many uninsured PWUD unable to 
access the medication, as well as many physicians opting to 
k    Examples include Coquitlam, BC, where a by-law regards methadone clinics as 
‘undesirable businesses’ and limits the location of their operation to five small areas; 
Surrey, BC, which prohibits methadone clinics in business parks, commercial, special 
care housing, single family residential and multiple residential commercial zones; 
Abbotsford, BC, which has amended its zoning by-laws to limit harm reduction services 
including fixed NSPs and mobile dispensing vans as well as supervised injection sites in 
its municipality; and Kelowna, BC, where a municipal by-law restricts possession of harm 
reduction supplies in any park or public space. 
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discharge patients for poor attendance, active drug use or not 
participating in counselling. Methadone clinics in the USA are 
rarely low-threshold, with waiting lists of at least six months to 
a year, or longer outside major cities. Barriers are compounded 
for pregnant women who use drugs or those with children, as 
they are at risk of being reported to Child Protection Services 
and losing custody of their children for enrolling in treatment 
or actively using drugs. The need for frequent attendance (in 
some cases, seven days a week) can be further complicated by 
child care and increased stigma. 
Restricting prescription 
opiates in Canada
Diversion of the prescription time-release opiate 
OxyContin, and adverse effects arising from its illicit use, 
have risen considerably in Canada in the past few years. 
A 2009 study linked the introduction of OxyContin to 
the market in 2000 with a five-fold increase in painkiller-
related deaths during the following five years.32 The 
problem is particularly widespread in First Nations 
communities, where more than 50% of adults on some 
Canadian reserves are dependent on the medication.33 
The knee-jerk response from several Canadian provinces, 
including Prince Edward Island, Nova Scotia, Ontario, 
Manitoba, Saskatchewan and British Columbia, has 
been to either delist OxyContin entirely or restrict its 
availability under provincial health care coverage plans.34, 
35 In February 2012, the federal government announced 
that it would no longer pay for OxyContin for patients 
under the Non-Insured Health Benefits Program (NIHB).36 
Purdue Pharma Canada, the pharmaceutical company 
behind OxyContin, plans to replace it with a new version, 
OxyNEO, but several provinces have already announced 
that this, too, will have restricted access. Without 
providing support for people who may be going into 
withdrawal, individuals may turn to other narcotics such 
as heroin, increasing the potential for switching to less 
regulated, potentially more harmful opioids.k
Antiretroviral therapy (ART)
An estimated 40,334 PWID in Canada and 308,208 PWID in the 
USA were living with HIV as of 2008.5 In the USA, 9% of new HIV 
infections are among PWID.6 According to the US Centers for 
Disease Control, African-American PWID are ten times more 
likely to be diagnosed with HIV than white PWID.14 In Canada, 
Aboriginal (composed of First Nations, Inuit and Métis) PWID 
are more likely to acquire HIV than non-Aboriginal PWID, and 
IDU accounts for more HIV cases among Aboriginal women 
l    Public health officials in Ontario have already warned that their treatment programmes 
are overwhelmed. See The Toronto Star (2012) Ontario must boost addiction services and 
treatment programs to help OxyContin addicts, 2 April 2012.
than among Aboriginal men.37, 38 This group comprises 
only 3.8% of Canada’s overall population but represents a 
disproportionately high number of new HIV cases (12.5%) and 
all prevalent infections (8%) at the end of 2008.39 
There are no national-level data on antiretroviral therapy 
(ART) coverage among PWID in either Canada or the USA. 
Differing approaches, targets and implementation structures 
across states, provinces and jurisdictions impact the ability to 
monitor service provision. It can be inferred that a sizeable 
proportion of those who may need treatment could be 
unaware of their HIV status. As of 2008, 26% of the estimated 
65,000 Canadians living with HIV were unaware that they 
were infected.39 A majority of these individuals represent key 
populations at higher risk of HIV, including PWID. Although 
recent data indicate that 85.5% of PWID took an HIV test and 
received their results in the past 12 months,2 this proportion is 
substantially lower among sub-groups at higher risk, such as 
Aboriginal people and women who inject drugs.6, 37
Civil society reports in the USA cite the lack of access to 
antiretroviral drugs, especially in the southern region of the 
country where there is a growing waiting list40 for the AIDS 
Drug Assistance Program, as a major barrier to PWID starting 
ART.41 Additionally, some physicians are reported to initiate 
treatment only when the patient abstains from drug use.
Viral hepatitis
The USA and Canada have significant numbers of people co-
infected with HIV and hepatitis C (HCV).39 A recent systematic 
review reported rates of over 60% and 70% HCV prevalence 
among PWID in Canada and the USA, respectively (see 
Table 2.6.1). High lifetime prevalence of HCV (91%) was also 
detected among transgender people who inject drugs.6 Rates 
of hepatitis B (HBV) are unknown in Canada, and exceed 10% 
in the USA.1 
In 2011 the US Department of Health and Human Services 
released its Viral Hepatitis Action Plan.42 The Plan included 
strong language on strategies for PWUD, with a separate 
chapter dedicated to HCV prevention, treatment and research 
for PWID. In particular, the Plan commits to expanding access 
to syringes as a critical prevention strategy.
The extent of testing and treatment for viral hepatitis among 
PWID is not clear. In the USA, access to testing and treatment 
services for viral hepatitis is limited by several factors, including 
the prohibitive cost of treatment, geographic distance from 
centres that may offer the service, and the current lack of 
an effective test that can determine current infection status 
instead of history of exposure. In Canada, comprehensive HIV 
and viral hepatitis services are available in some jurisdictions 
but remain limited in most places where populations at 
higher risk may need them most, such as on Aboriginal 
reserves.23 A recent study estimated that approximately 
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137,000 PWID will experience HCV-related disease each year 
until 2026, and it will cost C$3.96 billion to provide them with 
treatment, highlighting the urgent need to develop targeted 
HCV prevention strategies and ensure adequate allocation of 
resources for future treatment needs in Canada.43
Tuberculosis
Integration of TB, viral hepatitis and HIV services vary from 
region to region across Canada and the USA. The lack of 
free TB testing and treatment targeted at PWUD and poor 
awareness of the relevance of TB for PWID hinder many of 
them from seeking these services. The US Centers for Disease 
Control and Prevention have recently launched a Program 
Collaboration and Service Integration (PCSI) mechanism to 
promote increased collaboration and integration of testing, 
treatment and surveillance for HIV, viral hepatitis, sexually 
transmitted infections (STIs) and TB in the USA.44 The impacts 
of this initiative are yet to be determined.
Overdose
Drug overdose death rates have increased steadily in the USA 
since 1990. Currently, overdose is the most frequent cause 
of death among PWID,45 and the number of these deaths 
has overtaken motor vehicle fatalities in the USA.46 In 2008, 
a total of 36,450 drug overdose deathsm were reported, 
with prescription opioid analgesics such as oxycodone, 
hydrocodone and methadone, as well as cocaine and 
heroin, most commonly involved.47 Research has detected 
fatal overdose rates two to three times higher among First 
Nations Canadians compared with the general population.48 
Although national estimates for lifetime non-fatal overdose 
are rare, high rates have been detected at the local level (for 
example, 41% in Baltimore49 and 42% in New York City).50 
Community-based programmes in the USA have increasingly 
offered opioid overdose prevention services to PWUD, 
their families and service providers, including the opioid 
antagonist naloxone hydrochloride. As of October 2010, 50 
community-based opioid overdose prevention programmes 
distributing naloxone were known in the USA.51 Since the first 
opioid overdose prevention programme began distributing 
naloxone in 1996, kits with naloxone have been distributed 
to 53,032 persons, and programmes received reports of 
10,171 overdose reversals. These 50 programmes operate in 
15 US states and the District of Columbia and include nearly 
200 sites where naloxone is distributed in the community to 
PWUD, their friends and family. New Mexico, New York and 
Massachusetts operate state-wide naloxone distribution 
programmes through their state Departments of Public 
Health. North Carolina has recently agreed to make naloxone 
available state-wide through its Medicaid health insurance 
programme to patients who are prescribed opioids for pain 
management or dependence treatment, and others at risk of 
an opioid overdose. The US Army also distributes naloxone 
m    Including unintentional, intentional (suicide or homicide) or undetermined intent.
to soldiers on active duty who are at risk of overdose from 
prescription opioids or heroin, as part of a pilot project on 
one of its largest bases.52
Since 2010, there has been growing activity in Canada 
around the implementation of overdose death prevention 
programmes through the delivery of naloxone. Several 
provinces are considering implementing initiatives for 
distributing naloxone in collaboration with local NGOs. One 
such example, the Harm Reduction Program at the BC Centre 
for Disease Control, is developing an initiative to increase 
access to naloxone across BC. Working alongside its many 
partners, the Harm Reduction Program hopes to increase 
the public’s awareness of and accessibility to naloxone, as 
well as have naloxone made available at community service 
organisations.53 Education and overdose prevention training 
are implemented through some NSPs and methadone 
clinics across the country, with varying availability across 
provinces. Streetworks in Edmonton has operated a naloxone 
distribution programme since 2005,54 and a new programme 
was initiated by Toronto Public Health in late 2011.55 In Canada, 
naloxone distribution through peers in the community is only 
implemented in Edmonton and Toronto. 
New evidence has emerged suggesting that among other 
health benefits, Canada’s SIF in Vancouver has had a positive 
impact on the number of overdose deaths in its vicinity. A 
2011 study observed a 35% reduction in overdose deaths 
in the city’s Downtown Eastside after the SIF opened in 
September 2003, while overdose deaths in the rest of the city 
declined only 9% over the same period (see chapter 3.6 for a 
Vancouver-based case study which includes Insite).56
The legal battle over InSite
In the autumn of 2011 the Canadian Supreme Court 
ordered the federal Minister of Health to continue 
the Section 56 exemption to the Controlled Drugs 
and Substances Act that permits InSite, Canada’s only 
supervised injection site (SIF), in Vancouver, BC, to 
continue to operate.8 Extensive research has proven that 
InSite reduces crime, overdose deaths and transmission 
of HIV and other blood-borne viruses, and has helped 
people access treatment when they were ready to do 
so.56-59 The Court found that the Minister of Health had 
violated Canada’s Charter of Rights and Freedoms in not 
allowing the project to remain open, and ordered the 
Minister to remedy the situation. Several Canadian cities 
are in the process of discussing the implementation of 
supervised injection sites including Victoria, Montreal, 
Ottawa, Toronto and Quebec City. 
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Harm reduction in prisons
Despite high levels of IDU,60, 61 high rates of HIV and high 
prevalence of viral hepatitis and TB among inmates, particularly 
among those who are released and re-incarcerated,62 harm 
reduction initiatives within these settings remain limited in 
North America. 
There are no NSPs operating in prisons in either Canada or 
the USA. MMT is available in federal correctional facilities and 
provincial prison systems in Canada,25 and minimal access 
to substitution treatment is offered in some jails in the USA. 
Other HIV and viral hepatitis prevention strategies, such as 
safe tattooing programmes, were abolished by Canada’s 
current Conservative government in one of the first actions 
after it attained office in 2007.
Policy developments for harm 
reduction
Significant developments have occurred at the national 
level in Canada and the USA since last reported in 2010. On 
16 December 2011, US Congress reinstated the ban on US 
federal funding for NSPs,9 just two years after it was repealed 
and signed into law by President Barack Obama. In the 
precarious global economic context, the US government’s 
policy shift on NSPs is a significant step backward in meeting 
international commitments to halve HIV transmission among 
PWID by 2015.10 Concerns around essential harm reduction 
programmes being discontinued or scaled back within the 
USA have also since increased. 
Several developments have taken place on the Canadian 
drug policy landscape. Following public consultations on 
its Marihuana Medical Access Program,n Canada’s federal 
government announced a series of proposed changes that 
would see an end to licences for individuals to produce 
medical marijuana for personal use or the use of others.63 
These changes would limit the cultivation and supply of 
medical marijuana to commercially licensed producers. The 
potential impacts of these changes on the quality, variety and 
accessibility of medical cannabis have yet to be determined. 
In March 2012 the Canadian federal government passed into 
law changes that implement mandatory minimum sentences 
for drug crimes as part of the Safe Streets and Communities 
Act, which will come into effect in November 2012.64 Drawn 
from the US approach to drug policy, these harsher penalties,o 
many focused on youth and Aboriginals, are among several 
‘anti-crime’ approaches which were recently introduced 
into Canadian law. The changes prioritise punishment as an 
objective of criminal law rather than access to treatment and 
health programmes. 
n    See, for instance, http://www.hc-sc.gc.ca/dhp-mps/consultation/marihuana/_2011/
program/consult-eng.php.
o    For example, these include mandatory minimum sentences of one year in a provincial 
jail for possession of five cannabis plants, and an increase in sentences for larger 
quantities of marijuana and other drugs. 
Amid more conservative developments at the federal level, 
the debate at the provincial and local levels in Canada appears 
to be broadening. For example, despite opposition to the 
decriminalisation of currently prohibited drugs by the federal 
government, in the autumn of 2011, the Health Officers 
Council of British Columbia released a revised version of its 
public health model for a regulated market for all currently 
prohibited substances.65 Another example is the Thunder 
Bay Drug Strategy, an official community plan to address 
substance use in Thunder Bay, Ontario. Ratified by the City 
Council in September 2011, the Thunder Bay Drug Strategy 
Implementation Panel explicitly supports harm reduction and 
includes in its three-year action plan the investigation of harm 
reduction services for youth.66
Civil society and advocacy 
developments for harm reduction 
CSOs working for harm reduction and drug policy advocacy in 
North America have been increasingly active during the past 
two years. For example, a joint working group, comprising 
government representatives and NGOs organised by the 
Substance Abuse and Mental Health Services Administration 
(SAMSHA), and an all-NGO Naloxone Overdose Prevention 
Education Working Group have increasingly mobilised around 
overdose prevention and community naloxone distribution in 
the USA. Notable civil society events since 2010 include the first 
conference of the Peer Delivered Syringe Exchange Network 
in New York in 2011, the annual Harm Reduction Coalition 
conference in Austin in November 2010 and the Drug Policy 
Alliance conference in November 2011. Although drug user 
organising remains uncommon in the USA, there is a growing 
awareness and legitimacy around the distinct expertise 
provided by PWUD, and the need to meaningfully involve 
this group in the planning and execution of programmes that 
affect them.
Organisations of PWUD operate in a number of cities and 
regions in Canada. They are active in Vancouver (VANDU), 
Victoria (SOLID) and Toronto (TODUU). Two groups – the BC/
Yukon Association of Drug War Survivors and AAWARE in 
Alberta – operate at the regional level. Most organisations of 
PWUD remain small and have minimal budgets. In the past 
two years, smaller groups have been initiated at the local 
level in some cities and provinces, including around InSite, 
Canada’s SIF.23 A national meeting of groups of PWUD around 
the country is being planned for later in 2012. 
In Vancouver, BC, a group of former patients in the North 
American Opiate Medication Initiative (NAOMI)p have joined 
efforts to advocate for better integrated services in the 
p    The findings of the NAOMI trials conducted in Vancouver indicated that medically 
prescribed diacetylmorphine, the active ingredient in heroin, was more effective than 
methadone therapy for individuals with chronic opioid dependence who were not 
benefiting from other conventional treatments. The results showed that patients treated 
with injectable diacetylmorphine were more likely to stay in treatment and to reduce 
their use of illegal drugs and other illegal activities than patients treated with oral 
methadone. 
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wake of clinical trials of heroin-assisted therapy. After the 
research trial was completed, participants were not offered 
medically prescribed heroin. For some of these individuals, 
discontinuation of treatment precipitated a downward slide 
in their health and other outcomes. The NAOMI Patients 
Association (NPA) has now released its own study of the 
experience of participating in this research trial.67 The NPA 
has also made recommendations for future ‘experimental 
drug maintenance programmes’ including the provision of 
an umbrella of support and services and the continuation of 
heroin-assisted treatment after the end of research trials. This 
group challenged future research programmes to consider 
the context of consent when a prohibited drug is offered as 
a treatment. The NPA has been supported by VANDU (see 
chapter 3.6 for a Vancouver-based case study which includes 
the NAOMI trial). 
Other significant CSOs working for harm reduction in 
Canada include the Canadian Harm Reduction Coalition, a 
virtual forum for information exchange for individuals and 
organisations working in the areas of harm reduction and 
drug policy,q and the HIV/AIDS Legal Network, a national 
organisation actively engaged in advocacy on legal and 
human rights issues surrounding HIV, including among PWID 
in communities and in prisons.
The Canadian Drug Policy Coalition
The Canadian Drug Policy Coalition (CDPC), a new 
independent civil society network of organisations and 
individuals advocating to improve Canada’s drug policies, 
was launched in 2011. It envisions a safe, healthy and 
just Canada in which drug policy and legislation as well 
as related institutional practice are based on evidence, 
human rights, social inclusion and public health. 
The CDPC is focused on five key policy areas: a 
comprehensive health, social and human rights approach 
to drug policy; scaling up harm reduction; challenging 
criminalisation as a barrier to belonging for people who 
use drugs; moving beyond prohibition; and promoting 
human rights both inside Canada and globally.
A 15-member steering committee extending across the 
country through partnerships and networks oversees the 
work of CDPC, which is based at the Centre for Applied 
Research in Mental Health and Addictions at Simon 
Fraser University in Vancouver, BC. 
q    For more information, see http://canadianharmreduction.com/.
Though not explicitly focused on harm reduction, a civil society 
group – Stop the Violence BC (STVBC) – has formed a coalition 
of law enforcement officials, legal experts, medical and public 
health officials and academic experts concerned about the 
links between cannabis prohibition in BC and the growth 
of organised crime and related violence in the province. This 
coalition has released several reports that examine the context 
of marijuana production in BC and explore options for its 
regulation. Its campaign has received intense media scrutiny 
as well as support from currently serving and former mayors, 
former provincial attorney generals and key supporters in the 
USA. 
Multilaterals and donors: 
developments for harm reduction
Harm reduction in Canada is largely funded by provinces and 
territories, as well as municipalities, and covers programming, 
community-based research and direct service delivery. Other 
sources of funding include MAC AIDS Fund and the Open 
Society Foundations. 
A number of foundations consistently support harm reduction 
implementation and advocacy in the USA, with the largest 
percentage of funding being directed to direct services. In 
the absence of federal funding, the Syringe Access Fund 
(SAF) is the largest private funding source for syringe access 
in the country and is comprised of AIDS United, Elton John 
AIDS Foundation, Levis-Strauss Foundation, Open Society 
Foundations, Tides Foundation, Irene Diamond Fund (closed 
in 2011) and the North American Syringe Exchange Network. 
In 2010, the total reported funding for NSPs in the USA totalled 
$21,674,495, over 60% of which was provided by state (43.1%), 
city (27.8%) and county (10.7%) governments.68
In addition to the contributions made by the SAF, as well as 
separate funding provided by individual SAF partners, MAC 
AIDS, amfAR, Ford Foundation, Broadway Cares/Equity Fights 
AIDS and the Comer Foundation have provided ongoing 
support to both harm reduction implementation and policy 
advocacy projects. In response to the reinstatement of the 
federal funding ban, community and corporate foundations 
that fund harm reduction services reported an increase in 
grant requests from public health departments looking to 
offset projected loss of federal funding.13
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Table 2.7.1: Epidemiology of HIV and Viral Hepatitis,  
and Harm Reduction Responses in Oceania 
Country/territory with 
reported injecting  
drug use
People who  
inject drugsa
HIV prevalence 
among people 
who inject drugs 
(%)
Hepatitis C (anti-
HCV) prevalence 
among people 
who inject drugs 
(%)1
Hepatitis B 
(anti-HBsAg) 
prevalence among 
people who inject 
drugs 
(%)1
Harm reduction responseb
 NSPc OSTd DCRe 
Australia
149,591
(89,253–
204,564)
1.02 54.6  (41.2–68) 4 (2.9–5)  (1372) (P)  (2132) (B,M)
Fiji nk nk nk nk
New Zealand
20,163         
(13,535–26,792)
0.42 51.9 2.8 (1.2–4.4)  (>200)4 (P)  (B,M)
Papua New Guinea nk nk nk nk
Samoa nk 0 nk nk
Timor Leste nk nk nk nk
nk= not known
 
a   Unless otherwise stated, data are sourced from Mathers B et al. for the Reference Group to the UN on HIV and Injecting Drug Use (2008) Global epidemiology of injecting drug use and 
HIV among people who inject drugs: a systematic review, Lancet, 372( 9651):1733 – 1745.
b   Unless otherwise stated, data on NSP and OST coverage are sourced from Mathers B, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, Myers B, Ambekar A & Strathdee SA for the 
Reference Group to the United Nations on HIV and Injecting Drug Use (2010) HIV prevention, treatment and care for people who inject drugs: A systematic review of global, regional and 
country level coverage, Lancet, 375(9719):1014–28.
c   The number in brackets represents the number of operational NSP sites, including fixed sites, vending machines and mobile NSPs operating from a vehicle or through outreach workers.  
(P) = needles and syringes reported to be available for purchase from pharmacies or other outlets, and (NP) = needles and syringes not available for purchase.
d   The number in brackets represents the number of operational OST programmes, including publicly and privately funded clinics and pharmacy dispensing programmes.  
(M) = methadone, (B) = buprenorphine, (BN) = buprenorphine-naloxone combination, (O) = any other form (including morphine and codeine).
e   DCR = Drug consumption room, also referred to as safer injection facility (SIF).
f   This figure represents the number of sites in two Canadian provinces: British Columbia and Quebec. The number of sites in other provinces was not known at publication in July 2012.
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Harm Reduction in Oceania
The Oceania region includes Australia, New Zealand and 
the Pacific island countries and territories (PICTs).g There are 
approximately 170,000 people who inject drugs (PWID) in 
Australia and New Zealand combined, a low proportion of 
whom (0.4–1.0%) are living with HIV,2 and over half of whom 
have hepatitis C (HCV).1 The prevalence of injecting drug use 
(IDU) is higher and accounts for a greater proportion of HIV 
transmission (18%) among Aboriginal Australians than among 
non-Aboriginals (3%).3 Few recent, reliable and representative 
data exist on population size estimates of people who use and 
inject drugs, or on the prevalence of blood-borne viruses and 
other drug-related harms in the PICTs.4 
Although the early implementation of harm reduction 
programmes in Australia has been widely credited with low 
levels of HIV among injecting populations, available evidence 
points to significant ethnic disparities and uneven coverage 
regionally and among affected groups. No significant 
changes have occurred in Australia or New Zealand in terms 
of harm reduction service coverage since 2010. Civil society 
reports suggest that engagement with the federal and some 
state governments in Australia has become increasingly 
challenging around issues such as the need for increased 
funding for needle and syringe exchange programmes (NSPs), 
diversification of opioid substitution therapy (OST) options 
including heroin-assisted treatment and improvement in the 
range of service provision for people who inject drugs other 
than heroin.5 Culturally sensitive, integrated services targeting 
Aboriginal and Torres Strait Islander Australians, particularly in 
remote and rural areas, and the meaningful involvement of 
these communities in service delivery and evaluation, remain 
important gaps.3  
With the exception of Papua New Guinea, which has a 
generalised HIV epidemic, epidemics in the PICTs have 
remained small.6 IDU is a minor route of transmission in this 
sub-region. For instance, in French Polynesia approximately 
12% of the cumulative reported HIV cases have been 
attributed to IDU.7 Poly-drug use, particularly involving 
alcohol – both legally and illegally produced homebrew – 
as well as cannabis, inhalants, kava (for example, on Samoa, 
Tonga and Vanuatu) and emerging markets for amphetamine-
type stimulants, are more common in the PICTs than injecting 
drug use.4 Anecdotal evidence indicates that levels of licit 
and illicit drug use and the availability of new drugs may be 
increasing in the region.8
Responses to drug and alcohol use in the PICTs have relied 
largely on abstinence-based approaches and law enforcement 
methods focused on supply reduction. Some broader public-
g    The PICTs comprise 22 countries and territories subdivided into Micronesia, Polynesia 
and Melanesia. They are American Samoa, Cook Islands, Federated States of Micronesia, 
Fiji, French Polynesia, Guam, Kiribati, Marshall Islands, Nauru, New Caledonia, Niue, 
Northern Mariana Islands, Palau, Papua New Guinea, Pitcairn Islands, Samoa, Solomon 
Islands, Tokelau, Tonga, Tuvalu, Vanuatu, and Wallis and Futuna.
health-focused approaches, including multisectoral education 
and awareness campaigns and integration of drug services 
with the mental health system, have been implemented to 
some degree in individual Pacific island states.4 However, 
these have not been systematically evaluated, and a clear 
framework for addressing drug use in this sub-region is yet to 
be developed.
The engagement of civil society organisations (CSOs) and 
organisations of people who use drugs is integral to the 
harm reduction response in Australia. In the PICTs, the lack 
of resources and of reliable, active data collection continue 
to pose barriers to understanding the extent of drug use and 
designing appropriate policies and responses.  
Developments in harm reduction 
implementation
Needle and syringe programmes (NSPs)
There are over 1372 NSP outlets across Australia operating 
through a diverse range of service provision models such 
as needle-syringe vending machines and pharmacy-
operated sites. Approximately 203 syringes per person per 
year were distributed to PWID in 2011.9 The low rate of HIV 
among PWID in Australia has often been attributed to the 
early implementation and scale-up of NSPs. Recent cost-
effectiveness analyses have estimated that between 2000 and 
2009 over 32,000 HIV infections were averted, and for every $1 
invested in NSPs $4 were returned in health care cost savings.10 
Along with Australia, New Zealand has one of the highest NSP 
coverage rates in the world, having distributed 2.7 million 
needle-syringes from the approximately 200 outlets across 
the country at an estimated rate of 270–280 needle-syringes 
per person per year.2
Despite relatively high coverage rates by international 
standards,h recent estimates indicate that only 12.4% of PWID 
in Australia and 70% in New Zealand reported using sterile 
injecting equipment the last time they injected.2 Evidence 
suggests that the use of non-sterile equipment and re-use 
of injecting paraphernalia may be relatively high among 
key sub-groups of PWID, such as Aboriginal Australians, who 
also tend to experience a multiplicity of health and socio-
economic disparities compared with their non-Aboriginal 
counterparts.3 Access to NSP services by these groups is 
limited by inadequate provision in remote and rural areas, 
the lack of culturally sensitive service delivery or service 
models that recognise the Aboriginal definition of healthi and 
h    The 2009 WHO, UNAIDS, UNODC Technical Guide for countries to set targets for universal 
access to HIV prevention, treatment and care for injecting drug users categorises NSP 
coverage levels as follows: low (<100 needles/syringes per injector per year), medium 
(>100–<200 needles/syringes per injector per year) and high (≥200 needles/syringes per 
injector per year).
i    Aboriginal community-controlled health services (ACCHS) in Australia consider three 
different social dimensions: the individual, the family, and the community. For more 
information, see Australian National Council on Drugs (2011) Injecting drug use and 
associated harms among Aboriginal Australians. Canberra: Australian National Council on 
Drugs.
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stigma and discrimination by the community and by medical 
personnel.3, 10
A recent survey by the Australian Injecting and Illicit Drug 
Users’ League (AIVL) found that not only does much of the 
general population discriminate against people who use drugs 
(PWUD), but many feel that discrimination may deter people 
from using drugs, and as such is a positive event.11 Additional 
barriers to access are posed by legislation limiting the 
distribution of injecting equipment.12 For example, it is illegal 
for a person to provide injecting equipment to a peer, which 
often translates into services placing limits on the amount 
of equipment distributed per person. The limited range of 
equipment supplied at NSPs is also a challenge in many states 
in Australia, particularly for people injecting drugs other than 
heroin. In most states, for example, equipment such as sterile 
water, large-sized barrels, filters and winged-tip syringes are 
not supplied by state health departments, and service users 
must purchase them from pharmacies or other suppliers.10
NSPs do not operate in any PICTs, and it is not known whether 
needle-syringes can be purchased from pharmacies in these 
settings. Where drug and alcohol services for PWUD exist, 
these tend to be abstinence-based and are often located 
within mental health services.4
Legal status for Australia’s only 
medically supervised injecting 
centre
Australia’s only medically supervised injecting centre 
(MSIC) originally began operating for a trial period of 
18 months in Sydney in May 2001 and continued to 
operate as a ‘trial’ project for over a decade, during which 
it underwent numerous evaluations.13 The MSIC has 
provided sterile injecting equipment for use alongside 
a range of additional services to all people who inject 
drugs, with the exception of pregnant women who inject 
drugs or young people under the age of 18.5 
On 1 November 2010 the MSIC was ultimately awarded 
legal status through the enactment of the Drug Misuse 
and Trafficking Amendment (Medically Supervised 
Injecting Centre) Bill 2010 into law.14 This allows the 
facility to operate as other health services – without 
requiring an extension from the State Parliament to 
continue operation every four years. Although the MSIC 
has strong support within the local community, plans 
to trial or open similar facilities are not currently on the 
agenda anywhere else in Australia. 
Opioid substitution therapy
Over 2132 outlets provide OST across Australia.7 A key change 
in the provision of OST in Australia since 2010 has been the 
introduction of buprenorphine-naloxone film to replace 
buprenorphine and buprenorphine-naloxone combination 
pills for substitution therapy.5 Presently, pills are being phased 
out over a two-year period, following which they will cease 
to be covered through the government scheme. However, 
some clinics, pharmacies and doctors have reportedly been 
forcing a shift to the film without prior consultation or patient 
involvement in the decision.5 
As reported in 2010, a major barrier to accessing OST remains 
the cost prescribed by dispensing pharmacies and private 
clinics,j with people on OST paying between A$40 and A$85 
per week for the medication.15 Qualitative research has shown 
that the high costs of OST services may compel some people 
to choose between basic necessities such as food and their 
medication, while others report engaging in crime or selling 
takeaway doses to pay for OST.13 While demand for OST 
has increased in Australia in recent years, the availability of 
treatment has remained the same, resulting in frequent delays 
and waiting lists, particularly in remote and rural areas.16 In 
some regions, where one prescribing doctor or dispensing 
pharmacist often covers a wide geographical area, clients have 
reported travelling more than two hours daily or several times 
per week to access OST.5 Pregnant women and women with 
children who use opiates are often hesitant to access services 
for fear that Child Protection Services may potentially take 
their children into protective care.5 Guidelines for prescribing 
and administering pharmacotherapies in Australia were being 
reviewed at the time of writing. 
In New Zealand, approximately 4600 individuals are receiving 
OST, mostly in the form of methadone.17 Significant waiting 
times and restrictions on takeaway doses have been reported 
among the top three perceived barriers to OST.11 Resource 
constraints pose an additional obstacle in the transfer of OST 
provision from specialist OST sites and its integration into 
primary care settings.17
There is generally a lack of treatment options, and no OST 
provision, in the PICTs. Existing responses to drug and alcohol 
use are usually abstinence-based and largely delivered 
through mental health and counselling programmes.4 A 2008–
9 situational analysis by the Burnet Institute identified a focus 
on prevention-focused education and training programmes 
around drug and alcohol use for young people; however, it is 
unclear whether these interventions have had an impact on 
behaviour change in the sub-region, and there has been little 
evaluation of their effectiveness.4 
j    Methadone and buprenorphine are provided free to pharmacies and clinics in Australia 
by the federal government under the Pharmaceutical Benefits Scheme (PBS). These 
services then charge the client for dispensing, often charging more for takeaway doses.
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Antiretroviral therapy
HIV prevalence among PWID remains low in Australia (1.0%) 
and New Zealand (0.4%) (see Table 2.7.1). However, the drug-
related HIV burden is not consistent across sub-groups of 
injectors. In 2011, a higher proportion of HIV cases among 
Aboriginal and Torres Strait Islander people (19.4%) were 
attributed to IDU compared with new HIV diagnoses among 
non-Indigenous people (2.5%),7 and HIV rates within these 
sub-populations who inject drugs are high by comparison. 
It is estimated that in Australia the total number of people 
prescribed antiretroviral therapy (ART) increased from 9463 in 
2006 to 11,523 during 2010.10 It is unclear how many of these 
people are PWID.
New data indicate that almost half (47.6%) of PWID in Australia 
accessed HIV testing in the last year. This proportion is lower 
than in New Zealand, where 80% of PWID reported having an 
HIV test in 2009.2 
In 2010, Australasia was reported to have the second highest 
level of ART coverage among PWID after Western Europe.18 
Papua New Guinea, Fiji, Timor Leste and states in Micronesia 
provide ART, but it is unknown how many PWID living with 
HIV are receiving treatment.
Viral hepatitis
In contrast to low HIV prevalence among PWID in the region, 
viral hepatitis rates are high and increasing in key areas of 
the region. Australia and New Zealand both have HCV rates 
over 50% among PWID.1 Liver disease, most commonly as 
a result of viral hepatitis, has become the most common 
cause of mortality among ageing people who are dependent 
on opioids.19 For example, incidence of HCV among PWID 
enrolled in the Hepatitis C Incidence and Transmission Study 
community (HITS-c) in Sydney increased from 5.0 per 100 
person years in 2009 to 9.3 in 2010.10 In some regions, such 
as South Australia and Western Australia, levels of HCV are 
substantially higher in the Aboriginal and Torres Strait Islander 
population than in the non-Aboriginal population.10
Hepatitis B (HBV) prevalence among PWID has remained 
stable over the past decade – 2.8% in New Zealand and 4% in 
Australia, according to a 2011 systematic review.1 Surveillance 
studies show that there has been an increasing number of 
newly diagnosed HBV cases among Aboriginal Australians, 
despite vaccination programmes,3 with IDU reported as the 
most frequent source of exposure.10
Targeted, integrated HIV and viral hepatitis programmes 
operate free of charge across Australia and are particularly 
common in capital cities. Despite high levels of provision, the 
AIVL estimates that less than 10% of people living with chronic 
HCV access treatment every year.20 Barriers to HCV testing and 
treatment among PWID include stigma and discrimination in 
the health care sector, lack of housing, treatment and post-
treatment support.5
In Christchurch, where the largest population of PWID in New 
Zealand resides, a specialised pilot programme dedicated 
solely to addressing HCV testing, treatment and support 
has operated since January 2009, enrolling more than 530 
clients as of November 2011.21 The Christchurch Hepatitis C 
Community Clinic operates as an integrated model attached 
to an NSP and liaises with various local agencies, including 
OST programmes, hospitals offering antiviral therapy and 
general practitioners (GPs). Its low-threshold services and 
accessible community setting have attracted PWID who may 
feel stigmatised by mainstream health services. 
Little is known about the prevalence of viral hepatitis in the 
PICTs. HBV is highly endemic in Tonga, where more than 10% 
of the population is estimated to have active HBV infection.22 
The WHO Western Pacific Regional Office (WHO-PRO) has 
also documented HBV in Guam, Kiribati, Solomon Islands, Fiji, 
Vanuatu, New Caledonia, Federated States of Micronesia and 
Samoa.23 Low HCV prevalence has previously been recorded 
among Samoans and American Samoans, with tattooing 
practices potentially contributing to infection.24 It is unclear 
what role drug and alcohol use plays in the viral hepatitis 
context in the PICTs. 
Tuberculosis
The incidence of tuberculosis (TB) cases is low at between 5–6 
cases per 100,000 people in Australia, or 1062 bacteriologically 
confirmed cases of TB in 2009.25 Incidence rates in New Zealand 
are higher than those in Australia at around 10 per 100,000 
people, representing approximately 350–400 cases per year.26 
Foreign-born individuals are disproportionately affected: 
for instance, all cases of multidrug-resistant TB (MDR-TB) in 
Australia in 2009 were among individuals from Papua New 
Guinea and the Torres Strait Islands cross-border region, and 
over two-thirds of all TB cases in New Zealand are in foreign-
born individuals, particularly among people from the PICTs. 
It is estimated that 11,000 people across 22 PICTs acquire TB 
every year, 50% of whom are infectious cases.27 
It is not known what proportion of PWID across the region 
have had TB diagnosed and treated successfully, or to what 
extent TB/HIV co-infection occurs among PWUD.
Overdose
A recent meta-analysis showed that among other world 
regions, Australasia had the lowest pooled crude mortality 
rates (CMRs) among people who use opioids, with overdose 
reported most commonly as the cause of death.28 Non-fatal 
heroin overdose is highly prevalent,29 while drug overdoses 
attributed to prescription drugs are overrepresented in 
remote and rural areas of Australia.30 Recent evidence has 
shown the positive effect of the Sydney MSIC on overdose-
deaths: calls to ambulance services to attend to opioid-related 
overdoses declined significantly in the vicinity of the Sydney 
safe injecting facility (SIF) after it opened, compared to the 
rest of New South Wales.31 
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Naloxone is a prescription-only drug administered to reverse 
the effects of overdose by ambulance paramedics and other 
medical staff through registered health services in Australia. 
In late 2011 the first trial piloting distribution of naloxone for 
peer administration was launched in Canberra.32 The two-year 
training programme seeks to make naloxone more widely 
available by training 200 PWID, their families and friends to 
respond to drug overdoses. This will include training on the 
administration of naloxone, which will be funded by the 
government.31 
Harm reduction in prisons
Drug use and injecting are common in Australasian prisons. 
Almost half of participants (48–49%) in the 2011 Australian 
Needle and Syringe Program Survey reported a lifetime history 
of imprisonment, and 10% reported incarceration in the last 
year.33 One in three (31–37%) of those who reported having 
been incarcerated in the past year had injected drugs while 
in prison.33 Studies have shown that Aboriginal Australians, 
and Aboriginal women in particular, are overrepresented in 
prisons and tend to experience elevated rates of HIV, HCV and 
other blood-borne viruses.34 Previous research in Australian 
prisons has suggested that prisoners are more likely to share 
injecting equipment in custody than people in the general 
community, and found that HCV rates among prisoners were 
higher than 20%.35
There are currently no NSPs in prisons in the Oceania region. 
However, OST is available in most Australian and New 
Zealand prisons. In 2011 the Australian Capital Territory (ACT) 
government invited public submissions on a proposed NSP 
trial at the Alexander Maconochie Centre (AMC) in Canberra.36 
At the time of writing, plans to initiate the NSP had been 
placed on hold amid debates among key stakeholders, with 
an implementation date yet to be determined.5 
Policy developments for harm 
reduction 
Although no significant changes to harm reduction policy have 
occurred at the national level in Australia, the debate around 
drug policy reform and decriminalisation has broadened 
considerably. In response to the Global Commission on 
Drug Policy’s 2010 report,37 Australia 21,k an independent, 
multidisciplinary NGO, brought together 24 former senior 
state and federal politicians, experts in drug policy and public 
health, young people, a business executive and former law 
enforcement officers to discuss Australia’s present drug policy 
and explore moving toward a decriminalisation approach 
to illicit drugs. The report that followed the 21 January 2012 
high-level roundtable, The prohibition of illicit drugs is killing 
and criminalising our children and we are all letting it happen, 
k    For more information, visit http://www.australia21.org.au.
has since called for a review of Australia’s drug law toward a 
decriminalisation and regulation approach of illicit drugs.38 
Despite more open debate around drug policy reform, there 
has been increased interest by some state governments 
and funders in the ‘New Recovery’ movement, which in the 
Australian context has promoted abstinence as an externally 
enforced goal for people who use opiates, and limits the time 
period during which a person may be able to access OST.5 
In 2010, Australia released its Third National Hepatitis 
C Strategy 2010–201339 and accompanying National 
Surveillance and Monitoring Plan.40 The inclusion of concrete 
targets and dedicated resources in the new document is a 
significant improvement on the previous strategies between 
1999 and 2008, as it will allow for monitoring and evaluation of 
its effectiveness.41 Targets to be measured include increasing 
access to sterile injecting equipment through NSPs, and 
reducing the burden of disease attributed to chronic HCV in 
Australia.
An extensive review of New Zealand’s drug law began in early 
2010. In June 2011 an independent, government-funded law 
advisory body, the Law Commission, tabled in Parliament 
its final report and 144 recommendations for reforming the 
Misuse of Drugs Act 1975. The review called the current policy 
‘outdated’ and recommended greater investment in harm 
reduction, education and addiction treatment, amendment 
of drug paraphernalia laws and decriminalisation of small 
amounts of drug possession.42 
Many of the same concerns as in 2010 are still applicable 
to the context of the PICTs. Responses to drug use in the 
region have generally been law-enforcement-centred.4 
However, recent reports have cited the development of a 
broadening perspective that takes into account public health 
and development approaches.4 Increased engagement in 
the region from agencies such as WHO-PRO, the Secretariat 
of the Pacific Community (SPC) and the Pacific Drug and 
Alcohol Research Network (PDARN) have increasingly brought 
attention to drug and alcohol issues in the PICTs. For instance, 
a significant concern emerging out of the 2011 meeting of 
PDARN remains the lack of national frameworks to address 
the production of homebrew alcohol, which has been linked 
to increased crime, particularly violence against women.4, 
40 The lack of data and resources to conduct comprehensive 
research continues to hamper the design and implementation 
of appropriate policy responses.43 
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Civil society developments for harm 
reduction
Civil society organisations (CSOs) and organisations of 
people who use drugs have been integral to Australia’s harm 
reduction response at the national and state levels. Although 
advocacy on behalf of PWUD remains underfunded, the AIVL 
and its member organisations across the country regularly 
engage in advocacy within academic, community and policy 
forums. AIVL recently completed its Online Discrimination 
Survey as part of the broader National Anti-Discrimination 
Project which aims to reduce stigma and discrimination, 
improve access to services and reduce social exclusion among 
PWID and those on OST.10 A report summarising the findings 
and exploring the history of stigma and discrimination against 
PWUD was published in July 2011.8 
In August 2011 the New Zealand Drug Foundation and the 
New Zealand Society on Alcohol and Drug Dependence 
organised a Drug Policy Symposium that brought together 
experts from New Zealand and overseas. The aim of the 
symposium was to engage policymakers and funders in a 
conversation around integrated and effective treatment for 
drug dependence in light of the government’s commitment 
to provide additional funding for treatment.44
Although civil society in the PICTs has established a more 
visible presence in recent years, its engagement in regional 
forums around harm reduction has remained very limited. 
Activities have largely been hindered by inadequate 
resources. The Pacific Regional Rights Resource Team (RRRT) 
is active in the region, providing training, technical support 
and policy and advocacy assistance on issues of governance, 
democracy and human rights. PDARN is the only research 
and information network in the Pacific Region with a specific 
focus on substance use and related issues. The network first 
met in 2005 in response to a lack of data describing drug and 
alcohol issues in the PICTs, and held its most recent meeting 
in 2011 in Fiji. The gathering brought together government 
officials, NGOs, representatives from multilateral agencies, 
researchers and law enforcement representatives to exchange 
information and collaborate on joint activities.8 Among the 
priorities identified for the region are the urgent need for 
technical and financial support to develop effective national 
alcohol policies and action plans, the need for adequate 
funding for conducting comprehensive research to inform 
responses and the need for ongoing support to strengthen 
networks within countries and the region.8 
Multilaterals and donors: 
developments for harm reduction
Bilateral funds from Australia and New Zealand remain 
an important source of support in the PICTs.4 Multilateral 
agencies such as WHO-PRO have increasingly worked with the 
SPC and PDARN to improve the level of engagement in the 
region. The Australian government, through the Australian 
Agency for International Development (AusAID), is also 
an important source of bilateral support for HIV and harm 
reduction programming across Asia and the Pacific. 
Support for harm reduction services and for organisations 
of PWUD in Australia has long been provided by the federal 
government and state governments, generally via health 
departments. In the past two years, a competitive funding 
model has been introduced whereby a larger number of 
NGOs compete for a smaller pool of funding in one-year 
cycles, resulting in increasingly insecure funding year to year.5 
The level of funding for harm reduction programmes such as 
NSPs and OST nationally has remained the same as reported 
in 2010. No significant changes in funding or support for harm 
reduction were reported in New Zealand. 
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Table 2.8.1: Epidemiology of HIV and Viral Hepatitis, 
and Harm Reduction Responses in Middle East and North Africa 
Country/territory with 
reported injecting  
drug use
People who  
inject drugsa
HIV prevalence 
among people 
who inject drugs 
(%)
Hepatitis C (anti-
HCV) prevalence 
among people 
who inject drugs 
(%)1
Hepatitis B 
(anti-HBsAg) 
prevalence among 
people who inject 
drugs 
(%)1
Harm reduction responseb
 NSPc OSTd
Algeria nk nk nk nk
Bahrain nk nk nk  nk
Egypt 85,0002 (s) 6.5–6.82 e (s) 49.4 (35.8–63) 13.5 (10.9–16)  (2) (P)
Iran
170,000 – 
230,0003
15 (9.5 - 22.9)4 50.2 (34.5–65.9) 17.3 (3.7–30.9)  (421)3 (P)  (3,373)3 (B,M)
Iraq nk nk nk nk  (P)
Israel nk 2.94 (2.07–3.81) 67.6  2.8 (0–5.5)  (5)3  (B,M)
Jordan nk nk nk nk  (P)
Kuwait nk nk nk  nk
Lebanon nk 05 52.86 2.5 (0–5)  (1–5) (P)  (1)(B)
Libya 1685 877 (s) nk nk 
Morocco 18,5002 11.4 (0.4–21.8)3 nk nk  (6)3 (P) (3)3 (M)
Oman nk 11.8 (5–18.6) nk nk  (1)
Palestine nk 08 (s) 38.28 (s) 6.4  (1)
Qatar nk nk nk  nk
Saudi Arabia 10,0002 0.6h 3 49.8 (14.1–85.4) 18.5
Syria 10,0002 nk 60.5 nk  (P)
Tunisia nk 2.43 nk nk  (3)3
United Arab Emirates (UAE) nk nk nk nk 3 (BN)
Yemen nk nk nk nk  (NP)
a b c d e f g h i 
nk= not known
(s) = sub-national data
a   Unless otherwise stated, data are sourced from Mathers B et al. for the Reference Group to the UN on HIV and Injecting Drug Use (2008) Global epidemiology of injecting drug use and 
HIV among people who inject drugs: a systematic review, Lancet, 372(9651):1733–1745.
b   Unless otherwise stated, data on NSP and OST coverage are sourced from Mathers B, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, Myers B, Ambekar A & Strathdee SA for the 
Reference Group to the United Nations on HIV and Injecting Drug Use (2010) HIV prevention, treatment and care for people who inject drugs: A systematic review of global, regional and 
country level coverage, Lancet, 375(9719):1014–28.
c   The number in brackets represents the number of operational NSP sites, including fixed sites, vending machines and mobile NSPs operating from a vehicle or through outreach workers. 
(P) = needles and syringes reported to be available for purchase from pharmacies or other outlets, and (NP) = needles and syringes not available for purchase. 
d   The number in brackets represents the number of operational OST programmes, including publicly and privately funded clinics and pharmacy dispensing programmes. (M) = metha-
done, (B) = buprenorphine.
e   Sub-national data from 2010 behavioural/biological surveillance conducted in two cities: Alexandria and Cairo.
f   Year of estimate: 2007.
g   Includes sites in the community and in prisons. 
h   2010–2011 estimate based on people who inject drugs (n=3441) enrolled in the detoxification centre at Al-Amal Hospital in Riyadh, and may not be representative of out-of-treatment 
and other populations of people who inject drugs.
i   Population size estimate reported by NAP for 2011, but no information was available at the time of writing as to how this size estimate was arrived at.
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Harm Reduction in the Middle East and 
North Africa
The Middle East and North Africa (MENA) is one of two regions 
in the world where HIV rates continue to increase.9 People 
who inject drugs (PWID), men who have sex with men (MSM) 
and female sex workers (FSWs) remain the most affected 
groups. Estimates of the numbers of PWID across the region 
vary from over 300,00010 to approximately 1 million,11 a wide 
range that is complicated by the lack of reliable size estimates 
for populations of PWID in most countries in this region. 
Although important progress has been made in improving 
monitoring and surveillance to inform data gathering, 
and to target prevention and treatment efforts among key 
populations at higher risk of HIV, availability of reliable data 
remains extremely poor. 
Available  data indicate that injecting drug use (IDU) 
contributes to HIV epidemics in most MENA countries, is 
increasing in some (for example, Syria, Egypt, Libya, Oman and 
Bahrain) and is driving the HIV epidemic in others (Iran, Libya). 
Since 2010 there have been significant policy developments 
and scale-up of harm reduction programmes as an HIV 
prevention strategy in several countries in the region, pointing 
to an increased willingness from governments to address 
key populations at higher risk of HIV, including drug-related 
epidemics among PWID. 
Eight countries in the region implement needle and syringe 
exchange programmes (NSPs) to varying degrees, and five 
provide opioid substitution therapy (OST) (see Table 2.8.1). 
The reach of harm reduction programmes has expanded 
in Iran and Morocco. In 2010, Morocco started prescribing 
methadone for substitution therapy at three pilot sites in 
Tangier, Salé and Casablanca, with plans to scale up its 
methadone maintenance therapy (MMT) programme to 
seven additional sites.3 Significant scale-up of harm reduction 
programmes have occurred in the community and in prisons 
in Iran, where programmes covered an estimated 42.6% of 
PWID as of 2010, and expanded provision to 3,373 MMT sites 
in public and private treatment centres and in prisons as of 
August 2011, compared with 680 to 1100 sites reported 
in 2010.3 Despite these positive developments in service 
provision, the scope and coverage of existing services remain 
insufficient to have a marked impact on reversing HIV and viral 
hepatitis epidemics among PWID. Where programmes already 
exist, improvements in scale and quality are urgently needed 
to ensure that interventions achieve the greatest impact. 
Poly-drug use is common across the region, particularly 
with pharmaceutical prescription drugs, as well as other 
substances such as hashish. A recent increase in use of 
amphetamine-type stimulants (ATS) among people who use 
drugs (PWUD) in the community, those enrolled in MMT and 
those in prisons has been documented in recent years in some 
countries, with potential for these substances to be injected.3 
Overlaps between IDU and the exchange of sex for money – 
but also for drugs, food and shelter – have been increasingly 
documented in the region (for example, in Syria and Egypt).3 
Improved monitoring systems at the local and national 
levels in most countries are urgently required to gain a more 
nuanced understanding of local drug-related epidemics and 
intersections with other populations at high risk of HIV such 
as sex workers and MSM, and inform integrated, targeted 
responses across sectors.
A significant concern in the MENA region remains the high 
prevalence of viral hepatitis and tuberculosis (TB) among 
inmates, particularly those who engage in IDU in prisons and 
other closed settings. Harm reduction initiatives in prison 
settings are only available in Iran, despite evidence that 
injecting equipment is commonly shared in prisons across 
the region, including in Iran, Jordan, Kuwait and Lebanon. 
Improving the coverage of TB and HIV co-treatment is a 
persisting challenge for the region and is particularly relevant 
to addressing the needs of the most marginalised populations 
of PWID.12 
Severe levels of marginalisation and criminalisation of PWID 
across the MENA region pose substantial barriers to effective 
service provision and outreach. Women who inject drugs 
comprise a small proportion of all PWID in the region but 
tend to experience higher levels of HIV, hepatitis C (HCV) 
and other blood-borne viruses and increased levels of stigma 
and discrimination. They are also less likely than men who 
inject drugs to access harm reduction programmes.5, 13, 14 
Gender-sensitive harm reduction programming remains a 
considerable gap, with the notable exception of Iran, the 
only MENA country to have successfully developed female-
operated harm reduction services targeted at women.15 
Since the first female drop-in centre was opened in 2007, the 
gender-specific programme been has expanded to 27 sites 
in several major cities in Iran.15 Strengthening the response 
among PWID in the MENA region will require a reorientation 
of laws and policies that continue to criminalise PWID and 
hinder the implementation of evidence- and human-rights-
based HIV prevention and treatment services.
Several countries in the region now explicitly mention key 
populations at higher risk of HIV, including PWID, as part of 
their national HIV strategies, including Jordan, Syria and 
Tunisia since last reported in 2010. This suggests a slight shift 
in the regional policy environment toward greater acceptance 
of harm reduction as a core strategy for HIV prevention among 
PWID. The Middle East and North Africa Harm Reduction 
Association (MENAHRA) has been an important catalyst for 
increased government and civil society attention to harm 
reduction since its founding in 2007. Regional momentum 
for harm reduction implementation and policy has increased 
further following MENAHRA’s multi-country Round 10 grant 
from the Global Fund to Fight AIDS, Tuberculosis and Malaria, 
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which has been implemented beginning in January 2012. 
The US$6.2 million grant awarded to MENAHRA in 2010 is 
the first regional Global Fund grant exclusively dedicated 
to support harm reduction and civil society activities. The 
grant came into effect in 2012, and over the next five years 
MENAHRA will work together with the Global Fund and other 
international, regional and national stakeholders to advocate 
for an improved policy environment for implementing harm 
reduction programmes, and to build the capacity of civil 
society organisations (CSOs) working for harm reduction in 12 
countries in the region.j 
Developments in harm reduction 
implementation
Needle and syringe exchange programmes (NSPs)
As reported in 2010, eight countries in the MENA region have 
operational NSPs (see Table 2.8.1). Iran continues to have the 
highest level of provision in the region, with a total of 6,022,834 
free needles and syringes distributed through 421 sites across 
the country over a one-year period ending in September 
2011.3 There has been an increase in service provision in 
Morocco, where six NGO-run sites are now operating in Nador, 
Al Hoceima, Rabat, Oujda, Tangier and Tetouan. Although 
no formal harm reduction programmes distribute sterile 
injecting equipment in Oman, anecdotal evidence of small-
scale, unofficial syringe distribution has been reported in the 
Muscat area.3 Importantly, Syria’s new 2011–2015 National 
Strategic Plan on HIV and AIDS prioritises prevention among 
populations at higher risk of HIV including PWID.3 As of early 
2012, plans were underway to initiate an NSP pilot with 
support from the Global Fund channeled through MENAHRA. 
Sterile needles and syringes are extremely difficult to obtain 
in Bahrain, where pharmacy provision is only possible on 
prescription. PWID are highly criminalised, with reports of 
arrest for possession of drug paraphernalia including new 
needles and syringes.16 
Estimates of NSP service coverage are sparse in the region, 
due largely to the lack of reliable size estimates of numbers 
of PWID and inadequate monitoring of existing services. 
Global AIDS progress reports submitted by governments to 
UNAIDS suggest that coverage remains extremely limited. 
Iran has the highest NSP coverage in the region, distributing 
26–35 syringes per PWID per year3 – a slight decrease from 
the average 41 syringes per person per year reported to be 
distributed in 2010.17 In Morocco 13 syringes were distributed 
per person per year in 2011, a minor improvement compared 
with 7 syringes per person per year distributed in 2010,3 
but still far below levels needed to have a positive impact 
j    Iran, Pakistan, Libya, Lebanon, Syria, Jordan, Bahrain, Morocco, Egypt, Afghanistan, 
Oman, and West Bank and Gaza.
on HIV and viral hepatitis epidemics in this population.k 9 
During the same period, three NGOs with support from the 
Global Fund in Tunisia distributed 137,000 free needle syringes 
to 9000 PWID, amounting to similarly low coverage at 15.2 
syringes per person per year. No national data on coverage 
are available for Lebanon, but reports from Soins Infirmiers et 
Développement Communautaire (SIDC), an NGO providing 
this service, indicate that coverage was exceptionally low 
at 1.6 syringes per person per year.3 The majority of PWID in 
Tunisia, and nearly half in Jordan (49.8%) and Iran (48.6%) 
access injecting equipment from pharmacies.3 
Research indicates that there is a high prevalence of sharing 
syringes and other injecting equipment such as cookers, 
vials, containers, filters or rinse water in MENA countries.18 
For instance, 63% of PWID in Jordan report engaging in the 
high-risk practice of ‘frontloading’,l and almost three-quarters 
report sharing injecting paraphernalia.3 Where figures are 
available, high rates of syringe-sharing are also reported in 
Lebanon (21%),19 Bahrain (53.4%)16 and Syria (46%).20 
The criminalisation of PWUD and acute stigma, discrimination 
and human rights violations against them pose significant 
obstacles to accessing existing services. For example, in a 2011 
study among 300 PWUD in Northern Morocco, 87% reported 
experiencing police violence, and 50% reported human rights 
violations by medical personnel; when asked to elaborate on 
the type of police abuse, 83% reported recurrent harassment 
and 65% reported illegal practices.21 
Opioid substitution therapy (OST)
In 2012, five countries in the MENA region provide OST to 
varying degrees: Iran, Israel, Lebanon, Morocco and the United 
Arab Emirates (UAE). The most significant programme scale-
up occurred in Iran, where there were 3373 sites in public and 
private treatment centres and in prisons providing MMT as of 
August 2011 – a considerable increase in provision compared 
with 680 to 1100 sites reported in 2010.3 Buprenorphine and 
opium tincture are also offered as maintenance therapies in 
Iran, with 3500 persons receiving the latter as of February 
2012.3 
Progress was also made in Morocco, where methadone was 
approved for substitution therapy in November 2009, and OST 
pilot sites in three cities – Tangier, Salé and Casablanca – began 
prescribing in June the following year. Responding to positive 
results from a 2011 evaluation, the government of Morocco 
approved the scale-up of the MMT programme to a further 
seven sites in Oujda, Rabat, Marrakech, Tetouan, Nador, Al 
Hoceima and Agadir.3 Information on the availability of OST in 
k   The 2009 WHO, UNAIDS, UNODC Technical Guide for countries to set targets for universal 
access to HIV prevention, treatment and care for injecting drug users categorises NSP cover-
age levels as follows: low (<100 needles/syringes per injector per year), medium (>100-
<200 needles/syringes per injector per year) and high (≥200 needles/syringes per injector 
per year).
l    ‘Frontloading’ is a drug-sharing ritual that involves injecting with a syringe after 
someone else has squirted drugs into it from his/her used syringe, either by removing the 
plunger (backloading) or needle (frontloading) from the receiving syringe.
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the UAE was unknown in 2010, yet since then the government 
has confirmed that there are eight patients receiving 
buprenorphine-naloxone combination for substitution at 
the National Rehabilitation Centre, a drug treatment facility 
run by the Dubai police in Abu Dhabi.3 A decree on OST 
implementation was signed by Lebanon’s Ministry of Health 
and a national OST taskforce put in place to provide technical 
support for developing OST clinical guidelines in September 
2010. By March 2012, 120 clients were reported to be receiving 
buprenorphine as substitution therapy from two government 
hospitals in Beirut.3 Authorities in Oman have recently 
approved the implementation of an OST pilot, but it is as yet 
unclear when it will start.3 Methadone is available in Bahrain 
but used only for detoxification on an inpatient basis, rather 
than maintenance. Saudi Arabia has established the first OST 
committee and agreed to initiate MMT services through one 
pilot site in Al-Amal Psychiatric Hospital in Riyadh.22 
OST coverage estimates are almost non-existent in the MENA 
region, with the exception of Iran. Bio-behavioural surveillance 
in Iran in 2010 indicated that at the time of study 42.6% of 
people who had injected in the last year were receiving 
MMT.4 Women who inject drugs in Iran, as women injectors 
in other settings,23 experience higher levels of HIV, HCV and 
other blood-borne viruses and increased levels of stigma and 
discrimination but are less likely than men who use/inject 
drugs to access harm reduction programmes.13, 15 A clinic 
for women who use drugs that provides a range of services 
including MMT was established in Tehran in 2007 and has 
now expanded to 27 sites around the country.24 Subsequent 
research showed that women who use drugs respond well 
to MMT: within six months of initiating MMT, decreases 
were observed in heroin use, levels of dependence and 
engagement in high-risk injecting behaviour and criminality.15 
A gender-sensitive setting designed and operated for women 
was key to engaging this population in harm reduction and 
drug treatment services.13 
HIV testing and antiretroviral therapy (ART) for 
people who inject drugs
Although an increasing number of countriesm in the 
region now conduct bio-behavioural surveillance among 
populations at higher risk of HIV, including PWID,3 data on 
HIV prevalence, testing and antiretroviral therapy (ART) in 
the region are largely based on detoxification services, police 
registers and prison records. As such, available figures in many 
countries tend to be underestimated, are highly susceptible 
to reporting bias and are unlikely to be representative of the 
broader population of PWID. 
Voluntary counseling and testing (VCT) is available in 
several MENA countries, yet where it exists, there are few, 
if any, facilities specifically targeted at PWID. Mandatory 
m    Tunisia, Morocco, Jordan, Iran, Egypt, Algeria, Libya, Oman (planned) and Syria 
(planned).
testing is widely implemented across the region, with the 
exception of Morocco, the only country with explicit national 
policies prohibiting mandatory testing.12 In early 2012, the 
government of Libya announced plans to establish eight 
VCT centres targeted at key populations at higher risk 
of HIV, including PWID.25 The UAE has recently reviewed 
existing policies on mandatory HIV screening, allowing for 
the introduction of VCT for the first time.3 Testing for drug 
users is mandatory on entering treatment or on arrest/
imprisonment in several countries, including the UAE, Iraq 
and Bahrain. Available estimates reported by countries to 
UNAIDS in March 2012 indicate that only a small proportion 
of PWID are getting tested and following up their test results: 
19.5% in Tunisia, 11% in Morocco, 26.9% in Jordan, 40.9% in 
Egypt and 24.8% (16.9% among PWID under 25 years old) in 
Iran.3 In Syria, uptake of existing VCT services was generally 
low (1541 clients in 2011), representing only 0.23% of all tests 
conducted that year. However, it is unknown what proportion 
of VCT clients are PWID, since there are no VCT services 
targeting this population.3 In Bahrain, a country where HIV is 
primarily driven by IDU, mandatory testing of HIV, hepatitis B 
(HBV), HCV and TB is routinely performed, particularly among 
migrants and mobile populations, all of whom are deported 
upon a positive diagnosis. Most newly identified HIV cases in 
Bahrain are among males, three-quarters of whom are non-
Bahraini migrants, with 58.1% of these attributed to IDU.3 
Regionally, recent estimates of HIV prevalence among PWID 
range from 0.6% in Saudi Arabian to over 10% in Iran, Libya, 
Morocco and Oman.3 However, much higher rates of HIV 
have been detected at the local level within some countries. 
A surveillance survey conducted by the Liverpool School of 
Tropical Medicine with the support of the European Union in 
the Libyan capital, Tripoli, detected 87% HIV prevalence among 
PWID.25 In the past, IDU has accounted for as many as 90% of 
HIV cases in Libya.26 In Iran, HIV estimates range considerably, 
from 2.2% to 44.4%, with the highest prevalence documented 
in Tehran, Fars and Lorestan provinces.4 Increases in prevalence 
have been documented in some parts of the region, particularly 
in Tehran, Khuseztan, Fars and Sistan-Baluchestan provinces in 
Iran, as well as in Egypt, where HIV prevalence among PWID 
rose sharply from 0.6% in 2006 to 6.7% in 2010.3, 27 
Despite improved access to ART in some countries at the end 
of 2010, including Lebanon (37%), Morocco (30%) and Oman 
(45%), the estimated regional coverage remains low at 13% 
in 2011.2 It is unknown what proportion of ART recipients 
are PWID and how ART coverage in this population fares 
compared with regional coverage among all people living 
with HIV. In Libya, ART is currently provided for free to an 
estimated 2000–2500 people living with HIV from four sites 
including hospitals in Tripoli, and one each in Benghazi and 
Sabha, but information on the proportion of ART recipients 
n    Estimate based on mandatory testing among clients enrolled in detoxification at 
Al-Amal Hospital in Riyadh, and cannot be generalised to the entire population of people 
who inject drugs in Saudi Arabia.
109
Middle East and North Africa
who are PWID is unavailable.o 3 According to the World Health 
Organization (WHO), nine of 11 countries surveyed in the 
MENA region in 2010 reported ART availability for PWID; 
however, data on the scope and reach of treatment were 
not known.2 In Iran in 2010, 580 PWID were reported to be 
receiving ART.28 Estimates of ART coverage among PWID are 
very limited across the region. 
Viral hepatitis
According to a 2011 global systematic review, figures on 
HBV and HCV prevalence among PWID are available for only 
a fraction of MENA countries.1 The large ranges for available 
figures suggest that the quality of estimates in the region 
is limited, and existing estimates are inexact at best (see 
Table 2.8.1). All seven countries that reported data had HCV 
prevalence close to or above 40% among PWID. In Israel and 
Syria, HCV rates among PWID exceed 60%. Prevalence of 
HBV ranges from 2.5% in Lebanon to 18.5% in Saudi Arabia. 
Additionally, a local study in Tehran, Iran, found that co-
infection with HBV and HCV was significant in PWID living 
with HIV: up to 61.2% and 85.1%, respectively.29
Information on the extent of the response to viral hepatitis 
among PWID in MENA is limited. In 2011, the WHO reported 
that among 11 countries surveyed in the region, seven 
provided viral hepatitis diagnosis, treatment and vaccination 
services for PWID.9 However, the scope and coverage of such 
interventions among PWID are unknown. The high prevalence 
of HBV in the region highlights the need for intensified efforts 
to increase provision and uptake of HBV vaccination targeting 
this population. 
Tuberculosis
There are no systematic data on rates of TB, multi-drug-
resistant TB (MDR-TB) and TB/HIV co-infection among PWID in 
the MENA region. Data from Libya indicate that there were 731 
new TB cases in 2011, 128 of which were TB/HIV co-infected.3 
However, people living with HIV are not routinely screened for 
TB, and there is no information on rates among PWID. In Iran, 
approximately 14,000 people were affected by TB in 2010, 
50 of whom had MDR-TB; it is not known what proportion of 
these also used drugs.30 
According to UNAIDS 2011 Universal Access reporting, 
coverage of treatment for people with TB/HIV co-infection 
in the region ranges from less than 10% in five countries 
to between 22% and 55% in another four, and nearly full 
coverage in Oman (100%) and Algeria (99%).27 However, 
disaggregated data by population are not available, and as 
such the proportion of PWID with TB/HIV co-infection among 
those receiving treatment is not known. Similarly, in 2011, six 
countries in the region reported availability of prevention, 
o    Interruptions in treatment for over six months in 2011 due to internal conflict in Libya 
led to an increased number of people living with HIV reporting to Tripoli Central Hospital 
in very advanced stages of disease, high mortality and potentially increased risk of devel-
oping resistance to existing ART regimens. 
diagnosis and treatment of TB among PWID, but the scope 
and reach of these interventions are unclear.2
National treatment policies and guidelines in some countries 
may pose barriers to accessing treatment for the most 
vulnerable sub-populations of PWID. For example, current 
policy in Libya does not allow for simultaneous treatment 
with ART and TB medications for patients with TB/HIV co-
infection,p despite international guidelines advising against 
this practice.31 A significant challenge in MENA countries 
remains the strengthening of data collection and monitoring 
systems to obtain a true picture of the extent of TB and 
HIV among marginalised groups, and the required scale of 
prevention and treatment. 
Overdose
Data on the occurrence of fatal and non-fatal overdose remain 
largely elusive in the MENA region. Where data are available, 
rates of overdose appear to be substantial. A study examining 
overdose prevalence among PWUD across 29 provinces in Iran 
detected significantly higher non-fatal overdose rates among 
the sub-group of injectors (56.1%) compared to pooled rates 
for all drug users (injecting and non-injecting) participating 
in the study (42.1%). Lifetime experience of overdose was 
highest in those whose primary substance was Norgesic, a 
type of locally produced illicit opioid vial (53.9%) and heroin 
(50.2%).32 Previous research has suggested that opium is the 
dominant cause of overdose in Tehran, Iran.33 In Oman, more 
than two-thirds of the current and former PWID participating 
in a recent qualitative research study reported overdosing at 
least once in their lifetime, with a range of 1–30 overdoses per 
respondent.3 
Responses to overdose in MENA countries are very limited. 
Naloxone, a highly effective opioid antagonist that 
reverses the effects of overdose, is not available for peer 
distribution in the community anywhere in the MENA region. 
Isolated initiatives addressing overdose as part of broader 
interventions have been documented in some instances. 
For instance, the Association for Justice and Mercy (AJEM), a 
Lebanese NGO comprised of social workers and nurses, has 
recently launched a one-year campaign in partnership with 
MENAHRA and supported by the Global Fund with the aim of 
sensitising policymakers, prison managers and 300 inmates 
across six prisons to harm reduction approaches.34 As part 
of the campaign, AJEM will conduct a series of information, 
education and communication (IEC) activities with inmates 
which include overdose prevention and management.
Harm reduction in prisons
A high proportion of PWID have spent time in detention, 
and IDU is a common practice in prisons across many 
MENA countries. In Syria, for instance, half of the 336 PWID 
p    If a person living with HIV on ART is diagnosed with TB, treatment is discontinued and 
only re-started after the six-month TB treatment has been completed. 
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participating in a local survey in the Greater Damascus area 
had previously spent time in prison, and almost half reported 
using drugs while incarcerated.20 Among 300 PWUD in three 
cities in Northern Morocco, 82% reported they had been 
incarcerated, and 6% reported inhumane treatment while in 
detention.21 At Roumieh prison in Lebanon, 34% of inmates 
surveyed in 2011 had newly started using drugs, with 37% of 
those injecting them.34 Qualitative data from Oman have also 
indicated that many PWID spend time in prison, with most 
continuing to inject and share needles, syringes and other 
injecting paraphernalia while incarcerated.3 
Inmates who inject drugs in MENA countries tend to 
experience high rates of viral hepatitis and TB, and 
comparatively low levels of HIV. Bio-behavioural surveillance 
across 13 correctional facilities in Jordan in 2011 found 1.5% 
HBV, 3.6% HCV prevalence and no cases of HIV among inmates, 
and an observed (but not necessarily causal) association 
between IDU and viral hepatitis infections.3 A recent study in 
Iran corroborates this observation: in addition to a history of 
tattooing and sharing needles and syringes, having a history 
of incarceration was a significant predictor of high HCV 
prevalence in PWID.35 Surveillance among both male and 
female inmates in Iran also found an overall HIV prevalence of 
2%; however, this figure reached 8.1% in prisoners who had a 
history of IDU (2.1% to 12.5%).4 At Roumieh prison in Lebanon 
a significantly higher prevalence of HBV (2.4%) and HCV (3.4%) 
was found among 580 prisoners, compared with only one 
case of HIV.34 The majority (89%) of inmates with HCV injected 
drugs and reported a previous history of imprisonment. In 
Kuwait, HCV was detected in approximately 10% of the total 
prison population, and 75% of cases were among inmates 
who engaged in IDU.3 
Iran remains the only country in the region to implement NSPs 
and OST in prison settings. By February 2012, more than 38,000 
inmates were receiving MMT out of an estimated 120,000 
inmates who use both injecting and non-injecting drugs and 
have been deemed eligible for OST.3 Other responses to harms 
associated with IDU in prison settings in the region include 
HIV prevention education and awareness programmes for 
prisoners and managers in Morocco and social and medical 
support for prisoners in Qatar. Morocco is presently exploring 
strategies to introduce OST in prisons in the future.22 In Egypt 
a multisectoral Prisons Health Steering Committee has been 
established to initiate activities and coordinate integrated 
health services in prisons, including joint responses (other 
than OST and NSP) to illicit drug use, HIV and TB.3 In Libya, 
UNODC, with funding from the Libyan government, recently 
re-launched the second phase of an HIV awareness project 
suspended in 2011 due to the security problems, focusing 
on PWID in prison settings. The project, funded by the Libyan 
government, was interrupted and is now being resumed.
Policy developments for harm 
reduction
Seven countries in the region – Iran, Israel, Lebanon, Morocco 
and, since 2010, Jordan, Tunisia and Syria – explicitly support 
a harm reduction approach to drug use as part of their 
national strategy documents on drugs and HIV. In 2010, Tunisia 
developed a harm reduction strategy for the first time, with 
support from UNAIDS. During the same year, Syria developed a 
national strategic plan which was the basis for the first successful 
Round 10 application to the Global Fund to implement harm 
reduction interventions. Morocco’s new five-year AIDS strategy 
launched in April 2012 retains a focus on key populations at 
higher risk, including PWID, and is closely aligned with targets 
in the 2011 Political Declaration on HIV/AIDS.36
At the 57th session of the WHO’s Regional Committee for the 
Eastern Mediterranean in August 2010, Ministers of Health 
endorsed the WHO Regional Strategy for the Health Sector 
Response to HIV 2011–2015.37 The strategy includes a set of 
priorities relevant to strengthening the response among PWID 
in the region, including strengthening surveillance systems and 
improving access to VCT and prevention and care services for 
key populations at increased risk of HIV. 
In March 2012, at the 37th Session of the Council of Arab 
Ministers of Health in Jordan, member country representatives 
of the League of Arab States launched the Arab AIDS Initiative, 
aimed at accelerating responses to HIV in the region to achieve 
the targets set in the 2011 Political Declaration on HIV/AIDS.38 
A technical committee will develop a regional roadmap to 
reach global targets – including reducing transmission among 
PWID by 50% – by 2015, and work with states to monitor and 
implement the new strategy. 
Although the policy environment in the region appears to have 
moved towards greater acceptance and acknowledgement 
of harm reduction as a core strategy for HIV prevention for 
PWID, a significant proportion of MENA countries still have no 
explicit policies on harm reduction. Many countries continue to 
promote abstinence-based approaches to drug use and remain 
politically opposed to introducing NSPs and OST. In a significant 
number of states, drug-related offences are subject to severe 
penalties, including the death penalty, which is upheld in most 
of the region.q 39 
The criminalisation of populations at higher risk of HIV such as 
PWID and MSM and the lack of an enabling policy environment 
in many parts of the MENA region severely limit the 
implementation of current interventions and the introduction 
of public health and human-rights-based approaches.
q    The death penalty for drug offences is present in legislation in the following countries, 
although some countries have not carried out executions for drug offences in recent 
years: Iran, Saudi Arabia, Egypt, Syria, Yemen, Libya, Kuwait, Iraq, Oman, UAE, Bahrain and 
Qatar. 
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Bringing the 22nd International 
Harm Reduction Conference to 
Lebanon
In 2011, Harm Reduction International staged the 
International Harm Reduction Conference in Beirut – 
the first time the event was held in the Middle East. This 
represented a significant success for harm reduction in 
the region. The five-day conference brought together 
over 800 delegates from 79 countries to discuss, debate, 
share and advocate for harm reduction policies and 
practices.
The event included three days of practical training 
workshops and demonstrations, many presented in 
local languages, to help build harm reduction capacity 
in the region. Highlights included training on overdose 
prevention, implementing harm reduction in prisons and 
developing and improving hepatitis C treatment services. 
A ‘dialogue space’ was offered to provide delegates with 
an opportunity to engage in a less formal and more 
interactive programme of events.
During the closing ceremony, the Middle East and North 
Africa Network of People Who Use Drugs, which had 
coalesced during the conference, was officially launched. 
This newly formed network aims to promote the health 
and defend the rights of people who use drugs in and 
around the MENA region, and will work closely with the 
International Network of People who Use Drugs.
Civil society developments for harm 
reduction
CSOs in the MENA region have played an increasingly active 
role in advocating for and implementing harm reduction 
approaches in the last two years. MENAHRA, a regional 
network of CSOs, governments and researchers founded in 
2007 and composed of three knowledge hubs in Iran, Lebanon 
and Morocco and a secretariat based in Lebanon, has acted 
as a catalyst for civil society strengthening, cooperation and 
mobilisation across 20 MENA countries. CSOs participating 
in training and advocacy workshops through the knowledge 
hubs report that these information-sharing activities have 
contributed to increasing acceptance of both harm reduction 
policy and practice. 
In 2010, the Global Fund awarded US$8.3 million as part of 
Round 10 to a multi-country project coordinated by MENAHRA 
– the first regional Global Fund grant exclusively dedicated to 
support harm reduction and civil society activities. Over the 
next five years, MENAHRA will work together with its partners 
through the Global Fund to advocate for a conducive policy 
environment for implementing harm reduction programmes, 
and build the capacity of CSOs to scale up the provision of 
harm reduction services in 13 countries in the region: Iran, 
Pakistan, Libya, Lebanon, Syria, Jordan, Bahrain, Morocco, 
Egypt, Afghanistan, Oman, Tunisia, and Palestine.
In March 2011, the International Drug Policy Consortium, in 
collaboration with the National Rehabilitation Centre in Abu 
Dhabi, organised the first seminar on drug policy in the MENA 
region. The event was attended by over 150 participants 
from 12r different countries and provided a rare forum for 
dialogue on existing law enforcement approaches to drug 
policy prevalent in MENA countries, as well as the benefits of 
evidence-based alternatives such as harm reduction.
MENAHRA will be organising a regional meeting for religious 
leaders on advocacy and harm reduction in September 2012, 
to sensitise them towards harm reduction strategies. 
In Morocco, the CSO Association de Lutte Contre le Sida (ALCS) 
in collaboration with RDR, ASCMP clinic and the National 
Council of Human Rights, organised a conference entitled 
‘Towards a new approach for drug users based on health and 
human rights’ in October 2011. Findings from a community 
study led by ALCS documenting widespread human rights 
abuses against PWUD by the police, the justice system and the 
health care system were presented,10 after which participating 
organisations adopted the Rabat Declaration, calling for 
policy change on the human rights of PWUD in Morocco. 
Despite significant developments, in many settings across 
the MENA region, the work of CSOs working with populations 
at higher risk of HIV is impeded by high levels of stigma and 
discrimination, repressive laws and limited government 
support for harm reduction. 
r    Afghanistan, Egypt, Gaza, Iran, Jordan, Lebanon, Pakistan, Saudi Arabia, Tunisia, the 
United Arab Emirates, the West Bank and Yemen.
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Multilaterals and donors: 
developments for harm reduction
The role of multilateral agencies and donors remains crucial 
in the MENA region. The Global Fund is the most significant 
source of financial support in the region, having committed 
approximately US$24 million to date (see Table 2.8.2), 
including $6.2 million of committed funds for the MENAHRA 
multi-country grant and separate grants for eight countries or 
territories.s 40 The majority of countries in the region rely on 
external funds to finance at least 50% of their harm reduction 
responses. Although recognition of harm reduction and its 
role in addressing drug-related epidemics among PWID has 
increased, national funding commitments for programmes 
remain limited. 
Table 2.8.2: Approved Global Fund investments targeting 
people who inject drugs in the Middle East and North Africa 
Round 1 (2002) to Round 10 (2010)40
Country / territory totAL (uS$)
Algeria 500,000  
egypt 800,000  
iran 8,200,000 *
Jordan 300,000  
MenAHrA 6,200,000 * †
Morocco 4,600,000 *
Syrian Arab republic 1,200,000 *
tunisia 1,400,000  
West Bank and Gaza 800,000  
totAL 24,000,000
Notes
Figures are rounded. Data are correct as of March 2012. Data are based on 
detailed grant budgets submitted to the Global Fund, and may not reflect 
actual expenditures.
* Figure includes projections for future years of grants that have not yet been 
formally committed.
† MENAHRA received a multi-country grant that covers Afghanistan, Bahrain, 
Egypt, Iran, Jordan, Lebanon, Libya, Morocco, Oman, Pakistan, Syrian Arab 
Republic, Tunisia, and the West Bank and Gaza.
The WHO Eastern Mediterranean Regional Office (EMRO) 
is directly involved in the provision of technical support to 
civil society in the region through MENAHRA and directly 
to country missions. Moreover, WHO is directly involved 
with countries in building their capacities and providing 
the necessary technical assistance to collect, analyse and 
report strategic information, including epidemiological 
and programme monitoring information on IDU and harm 
reduction.
s    Algeria, Egypt, Iran, Jordan, Morocco, Syria, Tunisia, and West Bank and Gaza.
UNODC supports harm reduction in 18 Arab countriest 
through a new five-year project launched in 2010 largely 
focused on criminal justice reform.41 UNODC has recently 
restarted the four-year ‘Drugs and HIV’ project in post-
conflict Libya with financial support of US$6 million from the 
government. The project will involve establishing two drug 
treatment centres for PWUD, providing capacity-building 
for local CSOs to engage in outreach to key populations at 
higher risk and conducting an HIV assessment in prisons, 
including training and awareness among prison staff and 
inmates.
t    Algeria, Bahrain, Egypt, Iraq, Jordan, Kuwait, Lebanon, the Libyan Arab Jamirihiya, 
Morocco, Oman, Qatar, Saudi Arabia, Sudan, the Syrian Arab Republic, Tunisia, UAE, Ye-
men and Palestine.
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Table 2.9.1: Epidemiology of HIV and Viral Hepatitis, 
and Harm Reduction Responses in Sub-Saharan Africa 
Country/territory with 
reported injecting  
drug usea
People who  
inject drugsb
HIV prevalence 
among people 
who inject drugs 
(%)b
Hepatitis C (anti-
HCV) prevalence 
among people 
who inject drugs 
(%)1
Hepatitis B 
(anti-HBsAg) 
prevalence among 
people who inject 
drugs 
(%)1
Harm reduction responsec
 NSPd OSTe
Côte D’Ivoire nk nk nk nk
Djibouti nk nk  nk  nk
Gabon nk nk nk nk
Ghana nk nk  40.1  nk
Kenya 49,1672 18.32 51.4  (42.2–60.6) 6.4  (M,O)f
Malawi nk nk  nk nk  (P)
Mauritius
9,253
(5,699-10,444)3
47.43 97.33 9  (52) (P)  (16)(M,O)
Nigeria nk 4.24 nk nk
Senegal nk 9.24 nk nk  (B,O)
Seychelles
1,671
(673–1,706)4
5.8g 53.5 0.1
Sierra Leone nk nk nk nk nk
South Africa 67,0005 19.44 nk nk  (1)(P)5  (6)(M,B)
Uganda nk nk nk nk
Tanzania 25,000-50,00058 4258 22.2 3.8  (1) (P)  (1)
Zambia nk nk nk nk
a b c d e f 
nk= not known
a  The countries included in the table are those which have reported injecting drug use (IDU) and/or NSP or OST according to the latest UN Reference Group systematic reviews. However, HRI 
data collection in 2007/08 also identified IDU reports in Angola, Benin, Burkina Faso, Cameroon, Cape Verde, Ethiopia, Gambia, Guinea, Liberia, Mali, Mozambique, Niger, Rwanda, Seychelles, 
Somalia, Togo, Zanzibar and Zimbabwe.
b  Unless otherwise stated, data are sourced from Mathers B et al. for the Reference Group to the UN on HIV and Injecting Drug Use (2008) Global epidemiology of injecting drug use and HIV 
among people who inject drugs: a systematic review, Lancet, 372(9651):1733–1745.
c  Unless otherwise stated, data on NSP and OST coverage are sourced from Mathers B, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, Myers B, Ambekar A & Strathdee SA for the Refer-
ence Group to the United Nations on HIV and Injecting Drug Use (2010) HIV prevention, treatment and care for people who inject drugs: A systematic review of global, regional and country level 
coverage, Lancet, 375(9719):1014–28.
d  The number in brackets represents the number of operational NSP sites, including fixed sites, vending machines and mobile NSPs operating from a vehicle or through outreach workers.  
(P) = needles and syringes reported to be available for purchase from pharmacies or other outlets, and (NP) = needles and syringes not available for purchase.
e  The number in brackets represents the number of operational OST programmes, including publicly and privately funded clinics and pharmacy dispensing programmes. (M) = methadone,  
(B) = buprenorphine, (O) = any other form (including morphine and codeine).
f  Methadone is available on a very limited basis from private clinics only.
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Available estimates suggest that there may be 1,778,500 
people who inject drugs (PWID) in sub-Saharan Africa 
(range: 534,500–3,022,500).6  Among them, an estimated 
221,000 (range: 26,000–572,000) may be living with HIV.6 
However, since this estimate is based on only 13 out of 47 
countries in sub-Saharan Africa, it is likely that current figures 
underestimate the true extent of injecting drug use (IDU) and 
HIV among injecting populations in the region. In 2009, the 
prevalence of IDU across the region was estimated at 0.2% in 
the general population.7 
Available estimates of HIV prevalence among PWID in sub-
Sahara Africa range from 4.2% in Nigeria to 51.6% in Mauritius, 
among a small number of countries for which data exist (see 
Table 2.9.1).3 Unsurprisingly, HIV prevalence among PWID is 
higher than in the general population; for example, in 2011 
HIV rates among PWID in Zanzibar were approximately 25%, 
compared to less than 1% among the general population.8 
Significant proportions of PWID in Kenya, Tanzania, Mauritius, 
Mozambique and South Africa engage in high-risk injecting 
practices, including sharing of needles, syringes and other 
injecting paraphernalia.9-11
The growing number of PWID in sub-Saharan Africa has 
been closely associated with the emergence of many African 
countries as key transit points in the global trafficking of 
heroin, cocaine and other drugs.7, 13 For example, the Indian 
Ocean coastal regions of Tanzania and Zanzibar are situated 
on the path of multiple trafficking routes.7 South Africa and 
several countries in Western Africa likewise act as key transit 
points for cocaine trafficking routes from Latin American 
producers.7 Ineffective border controls, limited cross-border 
and regional cooperation and deficiencies in the criminal 
justice systems allow for relatively easy access to heroin from 
Afghanistan, Thailand, India and Pakistan.58 
Sub-Saharan Africa remains significantly behind global efforts 
to implement and scale up harm reduction interventions 
as part of a comprehensive HIV response for PWID. Existing 
needle and syringe exchange programmes (NSPs) have been 
scaled up in Mauritius, and new programmes have been 
established in South Africa and Tanzania. In South Africa, 
provision is small-scale, based in Cape Town only and targeted 
specifically at men who have sex with men (MSM), whereas 
in mainland Tanzania the opioid substitution therapy (OST) 
programme is backed by the government and has been in 
operation since February 2011. 
Existing interventions are largely restricted to major cities and 
coastal regions where IDU appears to be more concentrated.9 
Although anecdotal evidence suggests that IDU may also 
occur in rural areas and smaller towns,14 existing programmes 
in Kenya and Tanzania are focused in and around Mombasa, 
Nairobi and Dar es Salaam.9 In all cases, the scale of existing 
services remains far below estimates needed to reverse the 
HIV epidemic among this population.15
There are substantial evidence gaps on the epidemiology of 
HIV and viral hepatitis among PWID, particularly for Central 
and Western African countries. Since 2010 there have been 
attempts to address the dearth of population-based studies 
among PWID and injecting-related HIV infection in the sub-
Saharan Africa region,9 with bio-behavioural surveillance 
projects now being conducted in the major drug consumption 
cities of Nairobi and Mombasa in Kenya.10 However, even 
in East and Southern African countries that conduct such 
surveillance projects, these assessments are not conducted 
regularly enough to track trends in IDU and HIV. As a result, 
in most countries there is still insufficient understanding 
of the size and distribution of key affected populations, 
rendering calculations of intervention needs and coverage 
very challenging.16 Further investigation is urgently needed 
to understand the extent to which existing interventions 
effectively meet the needs of PWID to determine the scale of 
the response required.17 
Major legal and policy barriers, including criminalisation of 
people who use drugs (PWUD), present significant barriers 
to accessing existing programmes where these do exist and 
exacerbate unsafe injecting practices and HIV transmission 
among PWID.7, 18 Although there has been an increasing 
awareness of the need to address IDU-related HIV in region 
since 2010, approaches in many countries in the region 
continues to focus on supply reduction and rely on law 
enforcement rather than public health approaches.
Developments in harm reduction 
implementation
Needle and syringe exchange programmes
Provision of NSPs in sub-Saharan Africa is limited to isolated 
efforts by non-governmental organisations (NGOs) in a small 
number of countries. In June 2012 the Kenyan government 
announced that it will begin distributing sterile needles 
and syringes to PWID across the country.19 At the time of 
writing, the proposed NSP was still in the early phases of 
discussion, and potential implementation sites in Kenya 
had yet to be identified.20 A small NSP programme was also 
launched in Cape Town, South Africa, in August 2010 as part 
of Health4Men, a Cape Town project providing free sexual 
health care to MSM.21 However, its reach remains very limited 
to a small number of MSM. There are plans to open a second 
site in Gauteng in South Africa.21 In late 2010 Médecins du 
Monde-France (MdM-F) initiated the first NSP site in Tanzania, 
in the Temeke district of Dar es Salaam.8 Although still in the 
early stages of development with a relatively small reach, by 
September 2011 the MdM team had made contact with 1307 
PWID, distributing a total of 32,700 needle and syringes.
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The number of operational NSP sites in Mauritius, the first 
country in the region to implement NSPs, was scaled up 
from 39 sites in 2010 to 52 sites in 2012.5 Despite increases 
in the number of sites, coverage of existing NSP services in 
Mauritius remains low compared to international standards,15 
with 30 syringes distributed per PWID per year.22g Some 
NGOs in Seychelles distribute needles, syringes and other 
injecting equipment sporadically; however, these efforts are 
not officially recognised or accounted for by government 
authorities.23 
In countries where data are available, sharing of injecting 
equipment among PWID appears to be common. In Nigeria, 
the percentage of PWID reported to have used sterile 
equipment for their last injection has decreased over the past 
two years, from 89.2% in 2010 to 70.8% in 2012.24 More than 
a third of the 540 participants in a Kenyan study reported 
sharing injecting equipment with close friends or primary sex 
partners.2 Reasons for sharing injection equipment included 
lack of personal needles when required (23%), difficulty in 
accessing new needles or cost (17%), pressure from peers 
(14%) and being in prison (2%).2 HIV prevalence was six times 
higher (30%) among those that reported ever having shared 
needles and syringes than among those that never shared 
(5%), and 47% reported sharing a needle or syringe in the 
past month.2 In South Africa, 86% of PWID reported sharing 
needles and syringes, with some reporting re-using injecting 
equipment up to 15 times.25 
Legal barriers and social stigma present major barriers to 
accessing sterile injecting equipment, often forcing PWUD to 
hide injecting equipment and engage in unsafe injecting.10, 26 
Even in places where it is legal to purchase needles and syringe, 
fear of discrimination or disapproval from the community 
often deters PWID from accessing the services they need.5 In a 
study from Kenya, an average of 31% of respondents reported 
having been confronted by the police or having injecting 
equipment confiscated by law enforcement authorities 
within the past six months.2 The threat of arrest for possessing 
residual traces of heroin in the syringe barrel when returning 
used injecting equipment remains a significant deterrent to 
those seeking to access NSP facilities.27 
An emerging concern is the overlap between the injecting 
and sexual networks of several key populations at higher risk 
of HIV, including PWID, MSM and sex workers. Research from 
South Africa highlighted a significant intersection between 
IDU and high-risk sexual practices.28 A 2010 study of 509 MSM 
in Zanzibar reported that 60% used a needle after someone 
else had used it, with 68% passing a needle on to someone 
else after injecting.58  Effective responses to overlapping 
high-risk behaviours require both the mainstreaming of harm 
reduction services within broader HIV prevention services 
as well as the inclusion of population-specific needs, such 
g If the 4728 clients on Methadone Maintenance Therapy are excluded from the calcula-
tion, the number of syringes distributed per PWID per year would be 60.
as those of women or MSM, within existing harm reduction 
programmes. It is unclear whether and to what extent such 
integrated services are available in countries within this 
region. 
As in other parts of the world,29-30 women who inject drugs 
in the region experience disproportionately higher levels 
of negative health outcomes than their male counterparts.2, 
8, 31 Though fewer in number compared with their male 
counterparts, women who inject drugs have consistently 
higher HIV prevalence than male injectors.10 In a 2011 Kenyan 
study, HIV prevalence was 47% among women injectors 
compared with 17% among male injectors.10 Flashblood,h 
which has previously been documented among women who 
inject drugs in Tanzania and Zanzibar,32 is now also evident 
along the Kenyan coastal towns of Mombasa and Malindi,33 
indicating cross-border influences of drug consumption 
trends among countries in the same geographical region.
Opioid substitution therapy
OST remains largely unavailable throughout sub-Saharan 
Africa (see Table 2.9.1). Tanzania is the only country in the 
region that has initiated a pilot OST programme since 
2010, in addition to those already operating in Mauritius.17 
Located within Muhimbili University Hospital, Tanzania’s OST 
programme began operating in February 2011.8 Although 
the outreach capacity of the existing single facility is limited, 
175 PWID received treatment through this programme as of 
September 2011.8 Plans to open an additional site were in 
progress at the time of writing. 
Limited OST services are available in South Africa and Senegal, 
but there is very limited government support. In South Africa, 
legal restrictions for using methadone for substitution therapy 
have been lifted, and buprenorphine is also available for 
substitution, only in the private health sector.34 This effectively 
limits access to these medicines for the vast majority of 
people who use opiates who are not covered by private health 
insurance and cannot afford the medicines. 5 Despite evidence 
that access to OST could prevent 14% of new HIV infections 
projected to occur in Nairobi between 2010 and 2015,35 legal 
restrictions in Kenya still prohibit the introduction of OST.
Antiretroviral therapy
In December 2010, an estimated 5,064,000 people were 
receiving antiretroviral therapy (ART) in the sub-Saharan 
Africa region. This represented almost half of the people 
living with HIV that were eligible for ART. Coverage differed 
significantly between Eastern and Southern Africa (56%) and 
West and Central Africa (30%).31 
h  Flashblood is high-risk practice that involves blood-
sharing by injecting the blood of the person who got the 
main hit to experience some of the effect of the drug.
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National reporting to WHO in 2010 on the availability of HIV 
prevention, treatment and care services for PWID revealed 
that only nine out of thirty-five reporting sub-Saharan African 
countries had services in place providing ART to PWID.31 There 
remain very limited data on the numbers of PWID that may 
be accessing ART within the region. The Reference Group to 
the UN on HIV and Injecting Drug Use reported that thirty-
eight PWID in Kenya and 138 PWID in Mauritius were receiving 
ART in 2008. These estimates were equal to less than 1% of 
HIV-positive PWID in Kenya and 1.1% (range 0.4–9.2%) of HIV-
positive PWID in Mauritius receiving ART.17 The global average, 
according to the UN Reference Group was 4% of HIV-positive 
PWID receiving ART.17 Despite the significant caveats on these 
calculations,i it is clear that the response to HIV among PWID 
is much further developed in Mauritius than in the rest of the 
region. While more data are necessary to accurately assess the 
situation, with an absence of targeted HIV interventions for 
PWID, along with substantial barriers to accessing health care 
services,36 the overwhelming majority of PWID eligible for ART 
in sub-Saharan Africa are currently unlikely to receive it. 
Where services providing ART are available to PWID, there are 
significant factors which may impede service access. These 
include, but are not limited to, institutionalised stigma and 
discrimination against PWID within health care systems, a 
perceived or real lack of confidentiality and subsequent fear 
of health care professionals reporting drug use to the police, 
as well as treatment providers refusing access to ART on the 
basis of drug use.36
Viral hepatitis
The prevalence of hepatitis C (HCV) among the general 
population in sub-Saharan countries varies but is generally 
high.37-38 Similarly, the majority of countries in the region have 
considerable hepatitis B (HBV) epidemics among the general 
population.39 
There is a paucity of available data on viral hepatitis among 
PWID across sub-Saharan Africa. In the five countries where 
estimates were available, they suggest that HCV prevalence 
may be significantly higher than HIV prevalence among 
PWID. Estimates were available for Tanzania (22.2%), Ghana 
(40.1%), Mauritius (97.3%), Kenya (51.4%, range 42.2–60.6%)1 
and Seychelles (53.5%)40 (see Table 2.9.1). In a Tanzanian 
study, HCV prevalence was 28% among PWID compared with 
2% in their non-injecting peers.8 Data on HBV among PWID 
are similarly limited, with estimates only available for four 
countries: Tanzania (3.8%), Kenya (6.4%), Seychelles (0.1%) and 
Mauritius (9%).1 For many countries in the region, the failure 
to acknowledge the existence of PWIDs continues to thwart 
systematic surveillance efforts to monitor viral hepatitis and 
other IDU-related harms among this population.
i Not all HIV-positive people who inject drugs will be eligible for ART. The calculation of 
the ratio of PWID receiving ART is based on the UN Reference Group (C grade) estimate 
of 130,748 PWID in Kenya and an estimated HIV prevalence of 42.9% among them. More 
recent data suggests both the number of PWID and the HIV prevalence among PWID to be 
significantly lower (see Table 2.9.1).
While the cost and quality of HCV treatment regimens 
may change in the near future, at present the cost and 
complexity of treatment delivery pose substantial barriers to 
implementation in high-prevalence, low-resource settings.1,41 
The significance of viral hepatitis among populations 
engaging in IDU needs considerably more recognition in the 
region. Targeted messaging for hepatitis prevention must 
be integrated within comprehensive HIV prevention and 
treatment services.58 There are indications that such services 
may be developed in Zanzibar, where plans include the 
establishment of integrated HIV/viral hepatitis facilities that 
will target key affected populations.58 
Tuberculosis 
Tuberculosis (TB) prevalence in the sub-Saharan region is 
notably high. Where available, TB rates per 100,000 in the 
population were reported to be highest in South Africa 
(981) and Zimbabwe (633), with Mozambique (544) and the 
Democratic Republic of Congo (327) also reporting substantial 
rates.42 South Africa currently reports the third highest TB 
burden in the world, with TB incidence having increased 
by 400% over the past fifteen years.25 An estimated 80% of 
South Africa’s population are currently infected, and TB/HIV 
co-morbidity is estimated to reach 60% among people living 
with HIV.25  While the majority of people infected with TB will 
not develop active TB disease, PWUD and prisoners are more 
vulnerable to progressing to active TB disease.42 
Although integrated TB/HIV testing and treatment is 
beginning to emerge in South Africa25 and other parts of the 
region, there are no known interventions specifically targeting 
PWID. The challenges posed by TB/HIV co-infection among 
PWID are intensified by incarceration, with TB prevalence 
amongst prison populations much higher than prevalence 
in the general population.43  High rates of TB in prisons are 
further exacerbated by overcrowding, poor sanitation, late 
diagnosis, inadequate treatment of infectious cases, high 
transfer rates and gaps in continuity of care upon release.
Overdose
Data on the prevalence of and responses to overdose in sub-
Saharan Africa are extremely scarce. Available data indicate 
that risk of overdose is high in some parts of the region. For 
instance, overdose cases in Kenya are estimated to be 83–90% 
higher in Nairobi than in the coastal areas, and approximately 
58% of PWID in Kenya reported knowing at least one person 
who had experienced a fatal overdose.10 
Naloxone, a highly-effective opioid antagonist used to reverse 
the effects of overdose, has been approved and is available 
for the management of overdose in hospital emergency 
departments in Tanzania.9 However, in the context of 
significant stigma and criminalisation of PWID, who may 
be reluctant to access services for fear of being reported, 
managing overdose remains a challenging feat in countries 
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in the region.44 Community distribution of naloxone through 
peers is unknown to operate in any countries within the 
region.44 Given the paucity of data available on this issue, 
further investigation is required to better understand the 
extent of overdose in countries in sub-Saharan Africa and 
to expand access to overdose prevention programmes that 
include peer distribution of naloxone among PWID, their 
families and communities. 
Harm reduction in prisons
Criminalisation of drug use and possession and drug-related 
crime contribute to a high proportion of PWID among sub-
Saharan African prison populations.10 Anecdotal evidence 
suggests that prison settings may be contributing considerably 
to accelerating HIV transmission due to the high availability of 
drugs and the lack of sterile injecting equipment.7
IDU has been documented in prisons in Côte d’Ivore, Mauritius, 
Kenya and Ghana.10 Kenyan prisons are predominantly 
populated by adult males, with a significantly smaller number 
of female and juvenile inmates.45 Drug trafficking and 
trading in prison is reported to be common, with drugs often 
brought in by inmates attending court dates or by corrupt 
security officers either supplying the drugs or facilitating 
their entry.2 HIV prevalence in the Kenyan prison population 
is 8.2% compared with a national prevalence of 6.4%, and is 
significantly higher (19%) among female inmates than among 
male inmates (6%).45 
Access and take-up of testing services is limited, particularly 
for TB and viral hepatitis. Approximately 77% of Kenyan 
inmates reported ever being tested for HIV, 23% for TB and 
less than 2% for viral hepatitis.45 In neighbouring Uganda, HIV 
prevalence in the prison population is nearly twice as high as 
the national prevalence in adults.46 Where data are available, a 
high percentage of PWID report sharing injecting equipment 
while incarcerated. The overwhelming majority of PWID (81%) 
surveyed in Nairobi and coastal provinces in Kenya report 
having been previously incarcerated.2 Approximately 7% 
reported injecting drugs while in prison, and of these, 61% 
reported sharing needles or syringes.2
NSP and OST are not implemented in any prisons in the 
sub-Saharan Africa region. Although Nigerian government 
objectives outline a commitment to increased access for PWID 
to a full range of harm reduction measures, planned services 
in prisons are limited to drug treatment, telephone hotlines 
and drop-in centres for providing information and referrals.47
Policy developments for harm reduction 
Progress in terms of the development of a conductive 
policy environment for harm reduction remains limited 
across the region, with a few notable exceptions. Harm 
reduction is mentioned in the Tanzanian National Strategy 
for Non-Communicable Diseases (NCD) 2009–2015, with 
key objectives on the most-at-risk populations outlined 
in the National Multisectoral Strategic Framework on HIV/
AIDS.48 In Kenya the recently launched national HIV strategy 
similarly denotes a national response to emerging evidence 
of changing epidemiological dynamics, affirming universal 
access to HIV prevention, treatment, care and support.46 
Recent steps have also been taken to increase the engagement 
of provinces, districts and local communities in HIV service 
planning across the country.46 Ongoing strategic objectives 
in Mauritius include dialogue and sensitisation with the Anti-
Drug Smuggling Unit to improve the running of the NSPs, 
advocacy for the decriminalisation of the distribution and 
carrying of syringes, the implementation of harm reduction 
programmes in prisons and the implementation of awareness-
raising programmes in the community to mitigate stigma and 
discrimination.22 
Despite these advancements, for the majority of countries 
in the region, relevant policies continue to focus on supply 
reduction and the criminalisation of PWUD, impeding efforts 
to implement evidence-based harm reduction interventions.2 
For instance, despite progress with the implementation 
of the first NSP in Tanzania, the possession of needles is 
still illegal across some jurisdictions.8, 49 Although HIV-
related discrimination is now prohibited in Kenya, national 
legislation and policy fail to offer legal protection for certain 
key populations.46 Furthermore, although reference to harm 
reduction appears in Nigeria’s National Policy on HIV and 
AIDS,50 the country’s National Drug Law Enforcement Agency 
(NDLEA) continues to focus on supply control and demand 
reduction via seizures and arrests. PWID are routinely harassed, 
raided and detained in the already overcrowded prisons in the 
attempt by the NDLEA to control drug availability.47 
While there is an increasing awareness of the need to address 
IDU-related HIV in region, as can be seen above, drug policy 
continues to focus on supply reduction and rely on law 
enforcement rather than public health approaches, with very 
few exceptions. Progress toward the overhaul of current drug 
policies and regulations in favour of harm-reduction-based 
strategies is impeded by the lack of political will and support. 
Increased advocacy efforts are essential to strengthen 
political support for public health and human-rights-based 
approaches to addressing HIV related to IDU in the region.
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Civil society and advocacy 
developments for harm reduction
Although civil society organisations (CSOs) with a focus on 
PWID and harm reduction are limited in number within the 
region, there has been a marked increase in the number of 
local CSOs working alongside international organisations 
to advocate for the introduction and/or scale-up of harm 
reduction services since 2010. 
In the continuing absence of local government support for 
harm reduction, regional CSOs remain the main advocates for 
harm reduction. A meeting of civil society groups was held at a 
pre-conference event during the 16th International Conference 
on AIDS and Sexually Transmitted Infections (STIs) in Ethiopia 
in December 2011. Among the outputs of this meeting was 
the formation of a sub-regional harm reduction and drug 
policy network to be hosted by Kenya AIDS NGOs Consortium 
(KANCO). The objectives of the network include strengthening 
links between local harm reduction networks in sub-Saharan 
Africa, promoting awareness and facilitating the adoption of 
harm reduction initiatives across the continent. The network 
will continue to work together with national harm reduction 
networks and organisations in Uganda and Kenya, as well as 
focal points in Tanzania, Mauritius, Nigeria and Ethiopia. 
There are a number of newly formed national networks in the 
region including those based in Kenya and Uganda. Formed in 
January 2011 by current and former PWUD based in Kampala, 
the Ugandan Harm Reduction Network (UHRN) is a national 
non-profit organisation that works to promote the health 
of individuals and communities affected by drug use. UHRN 
engages in advocacy, information sharing and dissemination 
and capacity-building, and seeks to act as a coordinating body 
for member associations representing marginalised groups in 
the country. Similarly the Kenyan Harm Reduction Network 
was formed in 2011 and is made up of harm reduction 
organisations that aim to advocate for a harm reduction 
approach to drug use and drug policy.
Other new initiatives include those in the Seychelles; while 
key groups are still not directly targeted in national prevention 
programmes, NGOs have attempted to become more 
proactive in addressing the specific needs of key populations 
at higher risk of HIV, including PWID.23 Moreover, several 
programmes in Zanzibar are currently being developed to 
strengthen and extend the capacity of the public health 
system, community-based organisations and associated peer-
education initiatives.58 
In June 2012 INPUD developed and led capacity-building 
workshops for drug user advocates in Kenya as part of the 
CAHR project, and in Tanzania in partnership with MdM. The 
overall aim of the workshops was to determine existing and 
potential platforms for PWUD to input into the development, 
implementation and evaluation of programming and 
decision-making around national-level services and policy 
that impact upon PWUD. Activities included information 
dissemination around harm reduction, training in drug user 
organising and capacity-building to deliver peer education. 
As a result of these workshops, national drug user networks 
were founded in each country.51 
The region held its second harm reduction conference in 2011, 
hosted by Collectif Urgence Toxida (CUT), a network of NGOs 
and individuals working in the field of drug use and HIV/AIDS 
mainly in Mauritius and the Indian Ocean. The conference was 
attended by participants from all of the Indian Ocean states as 
well as Kenya, Tanzania, Zanzibar, Mozambique and Morocco, 
among others. The theme of the conference was ‘Towards a 
client-centred approach’ and aimed to engage the participants 
in dialogue around the improvement of the quality of harm 
reduction services delivered in Mauritius. Importantly, the 
conference emphasised the human rights and public health 
principles that underscore harm reduction.
Multilaterals and donors: 
developments for harm reduction
Multilateral agencies and donor NGOs provide the majority 
of HIV/AIDS spending in sub-Saharan Africa. The German 
Society for International Cooperation (GIZ) provides technical 
assistance to exchange initiatives in parts of the region 
including Mauritius, Sierra Leone and Kenya. 
Open Society Foundations, through the International Harm 
Reduction Development Program (IHRD) and the Open 
Society Initiative for Eastern Africa (OSEA), has supported 
organisations working with PWUD in Kenya and Tanzania to 
increase knowledge and capacity on harm reduction, health 
and human rights protections. Support has included: study 
visits for NGO representatives to harm reduction programmes 
in Africa (Mauritius) and North America; support for legal 
empowerment, including legal aid, paralegal training and NGO 
support for PWUD at police stations, in pre-trial detention and 
in prisons; training on naloxone provision, needle exchange 
and harm reduction basics; presentations and participation 
at national, regional and international conferences and 
advocacy to increase awareness of harm reduction principles, 
decrease rights abuses, secure national and international 
funds for harm reduction, and network with other community 
organisations working with PWUD.
The short-lived 2009 US Congressional decision to allow the 
use of federal funds for such programmes and subsequent 
revisions to HIV prevention guidance from the President’s 
Emergency Plan for AIDS Relief (PEPFAR)52 represented an 
opportunity to expand and develop existing harm reduction 
interventions and to rally support for evidence-based 
approaches targeting PWID.9 However, the reinstatement of 
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the ban on the use of US federal funds for NSPs53 in December 
2011 greatly undermined bourgeoning efforts to expand 
harm reduction in the region. 
The Global Fund to Fight AIDS, Tuberculosis and Malaria 
explicitly supports harm reduction as part of its commitment 
to fund evidence-based, cost-effective interventions.54 
However, of the 55 countries and territories supported by the 
Global Fund since its inception, only three African countries 
with generalised HIV epidemics – Burundi, Kenya and Nigeria 
– were included (see Table 2.9.2).55 
Table 2.9.2: Approved Global Fund investments targeting 
people who inject drugs in sub-Saharan Africa, Round 1 (2002) 
to Round 10 (2010)56
Country / territory totAL (uS$)
Burundi 600,000 *
Cape Verde 700,000 *
Kenya 1,900,000 *
Madagascar 1,300,000 *
Mauritius 1,500,000 *
nigeria 1,300,000 *
Zanzibar 500,000 ‡
totAL 7,800,000
Notes
Figures are rounded. Data are correct as of March 2012. Data are based 
on detailed grant budgets submitted to the Global Fund and may not 
reflect actual expenditures.
* Figure includes projections for future years of grants that have not 
yet been formally committed.
‡ Zanzibar, a semi-autonomous part of Tanzania, receives separate 
grants from the Global Fund.
Despite the major concerns posed by IDU-related HIV in 
these epidemiological settings,7, 31 no funds were allocated 
for PWID in countries with generalised epidemics in past 
rounds, a situation largely influenced by limited technical 
support, advocacy and political commitment in most settings 
in the region.57 Since 2010 the dedicated funding reserve for 
HIV proposals that focus on most-at-risk populations created 
as part of Round 10 includes funding support to implement 
harm reduction programmes planned in Kenya.55 In total, the 
Global Fund has provided US$7.8 million for harm reduction 
programmes targeting PWID in the region. 
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Chapter 3.1
Developing effective 
harm reDuction 
services for women 
who inject Drugs
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Introduction
Despite evidence of important differences in drug use 
experiences and access to harm reduction services for 
women and men, gender-sensitive interventions have not yet 
been fully integrated into these services around the world. 
However, research and experience suggest that the provision 
of enhanced harm reduction services for women can increase 
uptake and improve the outcomes of these interventions.  
This chapter provides an overview of the risks and harms 
experienced by women who inject drugs, and of women’s 
access to harm reduction and related health services.a 
Drawing on programmes from around the world, the chapter 
proposes a ‘menu’ of gender-sensitive services for women who 
inject drugs.b These services aim to provide more accessible, 
comprehensive and effective care for women by addressing 
their needs in an holistic way and respecting their human 
rights and freedom of choice. The chapter concludes with 
recommendations for policies that support gender-sensitive 
harm reduction.
Risks and harms experienced by 
women who inject drugs
Due to a mix of social and biological factors, women and men 
have different experiences of injecting drug use (IDU) and its 
accompanying risks and harms.1-2 A recent systematic review 
of international research on the risks, experiences and needs 
of women who inject drugs found the following major themes:
 » Compared to their male counterparts, women who inject 
drugs experience significantly higher mortality rates; an 
increased likelihood of injecting-related problems; faster 
progression from first drug use to dependence; higher 
rates of HIV; and higher levels of risky injecting and/or 
sexual risk behaviours.1 
 » For women who inject drugs, there is greater overlap 
between sexual and injecting social networks than there 
is for men who inject drugs. This may increase women’s 
risk of acquiring HIV through sexual transmission as well 
as through unsafe injecting. Women who inject drugs are 
more likely than their male counterparts to have a sexual 
partner who injects drugs, and to be dependent on them 
for help acquiring drugs and injecting. Relationship 
dynamics can make it difficult for women to access harm 
reduction services, enter and complete drug treatment (if 
desired) or practise safer drug use and safer sex.1
a    The scope of this article is limited to women who inject drugs, rather than all women 
who use drugs. It should be noted that there is also a significant amount of research 
on women who use drugs without injecting. For a discussion of the general literature 
on women who use drugs and the implications for future HIV prevention efforts, see El 
Bassel N, Wechsberg W and Shaw S (2012) Dual HIV risk and vulnerabilities among women 
who use or inject drugs: no single prevention strategy is the answer, Current Opinion on 
HIV/AIDS (7):326–331.
b    For reasons of space, the scope of this article does not address the specific needs of 
transgender people who use drugs.  
 » Intimate partner violence (IPV) is more commonly 
reported among women who inject drugs than among 
women in the general population.1 Violence has an 
immediate effect on a woman’s ability to practise safer 
sex and safer drug injecting, and can contribute to 
continued drug use. 
 » There is significant overlap between women’s 
engagement in IDU and in sex work, especially street-level 
sex work. Participation in sex work has been associated 
with syringe sharing and inconsistent condom use, as 
well as other risks posed by the dangerous circumstances 
in which sex work often takes place.1
 » There are a number of differences between men’s and 
women’s motivations to enter and complete opioid 
substitution therapy (OST) and other drug treatment 
modalities, and in the personal dynamics that play a part 
in treatment success. Many women cite pregnancy as a 
central reason for entering treatment, although punitive 
policies that separate women who use drugs from their 
children can deter pregnant women and mothers from 
entering drug treatment. A partner’s entry into treatment 
is another key factor that can facilitate treatment entry for 
women. OST and certain other types of drug treatment 
have been found to be especially effective in helping 
women to reduce their drug use, while detoxification 
alone is significantly less successful for women who 
inject drugs than for men.1 
A systematic review of studies from 14 countries found a 
significantly higher prevalence of HIV among women who 
inject drugs than among their male counterparts in settings 
with high HIV prevalence.3 Studies in nine EU countries found 
that the average HIV prevalence was more than 50% higher 
among women who injected drugs than among their male 
counterparts.4 
Access to services
The intense social stigma attached to women’s IDU and HIV 
infection can pose a formidable barrier to their access to harm 
reduction services, drug treatment, HIV treatment, sexual 
and reproductive health care, and other medical services, 
especially in culturally conservative societies.5-6 As a minority 
of people who inject drugs (PWID), women are not always 
included in medical or social programmes for drug users. 
For example, anti-retroviral treatment (ART) and OST are 
sometimes available in men’s penal institutions, but not in 
women’s.5, 7, 8 Many programmes for drug users do not respond 
to the specific needs of women.
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Limited data on injecting drug use among women 
Women have been estimated to represent roughly 40% of 
people who use drugs in the USA and some parts of Europe, 
and 20% in Eastern Europe, Central Asia and Latin America.9, 
10 However, data on women as a percentage of people who 
inject drugs are sparse, due in part to the difficulties of 
estimating the size of a hidden population engaged in an 
illicit activity. There has been no systematic analysis of the 
prevalence of IDU among women internationally. While data 
on the prevalence of IDU and HIV among PWID are available 
for more than 148 countries, for the most part these data are 
not disaggregated by gender. In the global data holdings on 
IDU and HIV maintained by the Reference Group to the UN on 
HIV and Injecting Drug Use, none of the countries that report 
IDU have data disaggregated by gender. This failure to collect 
gender-disaggregated country-level data on IDU makes it 
difficult to evaluate the precise scope and nature of needs 
among women who inject drugs, and should be remedied. 
Similarly, the Reference Group’s global data holdings show 
that countries that provide HIV prevention, treatment, care 
and support services for PWID generally fail to report on 
the number of women served by OST, ART and needle and 
syringe programmes (NSPs). This lack of data is disquieting, as 
it makes it difficult to assess whether at a country level there 
are gendered disparities in access to these essential services, 
or the degree to which available services are responsive to 
women’s needs. This may have a negative impact on efforts to 
improve harm reduction service coverage and, consequently, 
on efforts to curtail the HIV epidemic within this population. 
Despite these significant data gaps, evidence suggests that 
there is indeed a substantial population of women who inject 
drugs worldwide. In Europe, the European Monitoring Centre 
for Drugs and Drug Addiction (EMCDDA) reported that, while 
precise data on women as a proportion of out-of-treatment 
PWID were not available, women comprised 22% of new 
patients for OST and 33% of new patients for amphetamine 
dependence treatment.11 This suggests that women are a 
sizable minority of PWID in the region as a whole. Estimates 
of the gender balance among PWID in various countries (see 
Table 3.1.1) show that women are a very sizable minority of 
PWID in Russia, home to 1.8 million PWID, of whom 37% are 
HIV-positive;12 China, home to 2.35 million PWID, of whom 
12% are HIV-positive;12 and Ukraine, which has the highest HIV 
prevalence in Europe and an epidemic largely concentrated 
among PWID.13 This points to the importance of addressing 
the needs of the large populations of women who inject drugs 
in these areas. The wide variation among and within countries 
also points to the importance of geographical difference, and 
the need for services that are adjusted accordingly.
Table 3.1.1: Women as percentage of all people who inject 
drugs in selected countries
Country/territory
Women as an estimated (%)  
of all PWID14 
Cambodia 10
Canada 3315
China 20
Estonia 911c  
Georgia 10
Indonesia 11
Kenya 11
Kyrgyzstan 10
Malaysia 10
Russian Federation 30
South Africa 27
Ukraine 26
Vietnam 18
c
Sexual and reproductive health and pregnancy 
While harm reduction programmes usually include 
condom distribution, information on sexual health and 
sexually transmitted infections (STI) testing and sometimes 
treatment, many do not address other aspects of sexual and 
reproductive health, even though many women who inject 
drugs experience unplanned pregnancies.5, 6, 8, 16 Some women 
do not realise they are pregnant until relatively late, making 
it more difficult for them to access appropriate prenatal care, 
harm reduction services, drug treatment (if desired) or other 
support, or to terminate their pregnancies safely if they so 
choose.6, 8, 17 
Faced with pressure to have abortions and high levels of 
stigma, women who inject drugs sometimes have reduced 
access to prenatal care.5, 6, 8 This can lead to reduced levels of 
prevention of mother-to-child transmission (PMTCT) services 
among women living with HIV who inject drugs, among 
other negative effects. A 10-year study in Western and Central 
Europe of ART during pregnancy found that a history of IDU 
was associated with the risk of not receiving ART, and with 
being diagnosed with HIV late in pregnancy.18 
The comprehensive package for the prevention, treatment 
and care of HIV among people who use drugs, produced 
by the World Health Organization (WHO), United Nations 
Office on Drugs and Crime (UNODC) and the Joint United 
Nations Programme on HIV/AIDS (UNAIDS), does not include 
contraceptive methods other than condoms; pregnancy tests; 
pre- and post-natal care; or links between harm reduction, 
drug treatment and prevention of vertical transmission of 
HIV.19 Adding these services to the comprehensive package 
could help women who inject drugs to better manage 
c    Based on estimated 10:1 ratio of male to female drug users, based on IDU estimates from 
HIV reference laboratory, police arrests, overdoses and drug treatment.
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their sexual and reproductive health, thus preventing 
unplanned pregnancies and improving pregnancy outcomes, 
including through improved access to prevention of vertical 
transmission of HIV. 
Pregnant women who inject drugs may wish to begin OST or 
other forms of drug treatment, and prompt, easy access to 
these services is essential in improving outcomes for these 
women and their children. While there has been some scale-up 
of OST worldwide, information and protocols on OST provision 
during pregnancy and post-partum (including during stays in 
maternity hospitals) are not always in place.5, 6, 8, 20 This risks 
treatment interruptions and makes it difficult for women to 
access the ‘treatment of choice’ during pregnancy.9 Long waits 
to enter OST and other drug treatment programmes in some 
countries, and the complete lack of OST in others (notably 
Russia), threaten the health of all PWID, but are especially 
troubling in the case of pregnant women.9
Sexual and intimate partner violence
Problematic drug use among women is often associated 
with a history of sexual abuse,6, 9 and women who inject 
drugs experience elevated rates of IPV.1 Violence has an 
immediate effect on a woman’s ability to practise safer sex 
and safer drug use, and contributes to continued drug use. 
A history of violence can make women feel uncomfortable 
in certain situations – for example, in a support group where 
the majority of participants are men, or when receiving pelvic 
examinations.23 Where a history of trauma contributes to 
problem drug use or risky behaviours, it is important that harm 
reduction and drug treatment programmes take this into 
account and that staff are aware of how to deal appropriately 
with these issues.9 
Women, injecting drug use and prisons
Just as women’s experience of drug use often differs from 
that of men, women occupy a different stratum of the drug 
economy. A meta-synthesis of qualitative literature found 
that the drug economy is gender-stratified and hierarchical, 
with women mainly confined to the lower levels.24 Low-level 
dealers and drug ‘mules’ are easier to arrest than higher-level 
traffickers. In addition, they often have fewer resources for 
legal defence. This, combined with the low thresholds for 
criminal responsibility for drug possession in many countries, 
means that low-level players (many of them women) receive 
long prison sentences. 
An increasing number of women are being incarcerated for 
drug-related offences worldwide.25-30 A recent study found 
that more than one in four female prisoners in Europe and 
Central Asia had been convicted of a drug offence, and that 
the number of women incarcerated for drug-related offences 
in Russia is more than double the total number of female 
prisoners in all EU countries combined.31 In Tajikistan, up to 
70% of all female prisoners have been incarcerated for drug-
related crimes.31 The dual criminalisation of sex work and drug 
Comprehensive care for women and their children 
Vancouver, Canada  
Recognising that women’s social and economic environment 
has the greatest impact on maternal and foetal health, 
Sheway brings together representatives from the 
government and the community to provide comprehensive, 
non-judgemental health and social services to pregnant and 
parenting women with current or past issues with substance 
use. Sheway provides education, referrals and support to 
help women access prenatal care and reduce risk behaviours 
– in particular, reducing or ceasing the use of alcohol and 
other drugs during pregnancy. It also supports the health, 
nutrition and development of participants’ children for up 
to 18 months after their birth. The programme is absolutely 
voluntary, and based on the choices women make for 
themselves.
Sheway’s services include: 
 » Outreach and drop-in services
 » Hot lunch, food bags and coupons, formula, clothing, 
infant items
 » Accompaniment to appointments, transportation 
assistance (taxi vouchers, bus tickets)
 » Assistance with securing housing, day care, emergency 
funds
 » 12 transitional housing units 
 » Pre- and post-natal health care
 » Advocacy and counselling
 » Needle and syringe exchange (NSP)
 » Methadone maintenance therapy (MMT)
Sheway works in partnership with the combined care unit 
at the Fir Square British Columbia Women’s Hospital, which 
provides flexible, non-judgemental services for pregnant 
women with a history of drug use. It offers continuous 
care for mother and child before, during and after birth, 
including help stabilising and withdrawing from substances 
if necessary. The multidisciplinary team includes physicians, 
a senior practice leader, nurses, a social worker, an addictions 
counsellor, a nutritionist and a life skills/parenting counsellor. 
Fir Square aims to improve perinatal outcomes, increase 
the percentage of mothers able to safely retain custody of 
their babies, increase the number of women seeking drug 
treatment and their readiness to enter treatment, and increase 
access to medical services for substance-using women.21, 22
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possession puts sex workers who use drugs at exceptionally 
high risk of police harassment, extortion and arrest.26 
In multiple settings, rates of IDU and problematic drug used 
have been found to be higher among incarcerated women 
than among their male counterparts.32, 33 In some settings, HIV 
prevalence among women prisoners is higher than among 
men.34 However, health programmes for male prisoners 
sometimes do not extend to women’s facilities. Because of 
financial constraints and logistical or bureaucratic obstacles, 
programmes sometimes prioritise male prisoners, operating 
only in men’s prisons and leaving women without essential 
care.5, 7, 8 For example, a 2008 survey of women’s access 
to OST in prisons found that in Georgia, methadone was 
available in some men’s prisons but not in women’s prisons.8 
In Kyrgyzstan, though methadone programmes were planned 
for women’s prisons, funding cuts have meant that they are 
still unavailable, and as a result OST is available only in men’s 
prisons.5 
Increased advocacy is urgently needed to ensure that all 
prisoners, regardless of gender, have access to necessary 
interventions (including NSP, OST, and ART) while 
incarcerated, including during pre-trial detention, and that 
no interruptions of ART and OST occur in these settings.27 
Other needs of incarcerated women who inject drugs include 
d    The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) defines 
‘problem’ drug use as “injecting drug use or long duration or regular use of opioids, 
cocaine and/or amphetamines.”  Definitions of ‘problem’, ‘hard’ or ‘heavy’ drug use can 
vary, but generally fit this basic description.  
general medical care, mental health care and vocational 
preparation.35 Decriminalisation of personal possession of 
drugs would substantially reduce the number of women 
who are incarcerated unnecessarily, thus eliminating harms 
associated with incarceration for women as well as for their 
children and other family members. 
Designing harm reduction services for women 
who inject drugse
To date, there has been limited research on the efficacy of 
interventions specific to women who inject drugs. This is 
partly because gender-sensitive services often mix multiple 
approaches, are tailored to the individual and are relatively 
long-term. Services that combine structural, biomedical and 
behavioural interventions can be more difficult to evaluate 
through randomised controlled trials (RCTs) measuring HIV 
incidence, the current ‘gold standard’ of research on the 
efficacy of HIV prevention interventions, especially given large 
data gaps on the epidemiology of drug use and HIV among 
women. Limited research funding poses another obstacle. 
Finally, even simpler services, such as NSP, need to achieve 
considerable coverage before they can have a substantial 
impact on HIV incidence or prevalence.36 In some cases, lack 
of evidence of impact may reflect external limitations, such as 
e   Case study information provided by Anna Ivanova, Programme Coordinator, 
Humanitarian Action.
Reaching out to women who inject drugs  
St. Petersburg, Russia  
Humanitarian Action provides preventive health services to 
PWID in St. Petersburg. Of 5,000 annual clients, about 2,000 
are women, 51% of whom are living with HIV and 30% are 
supporting their drug use through sex work. (In 2011, there 
were an estimated 15,000 women who inject drugs in the 
city.) Russia’s extremely punitive drug policies drive drug 
users underground, incarcerate them en masse, and pose 
major obstacles to harm reduction services. OST has never 
been legal in Russia, and NSP faces mounting opposition. 
Most donors no longer fund NSP in Russia, compromising 
the crucial first point of contact between drug users and 
medical services.
In 2008 Humanitarian Action developed a project promoting 
equal access to prevention, treatment, care and support for 
women who inject drugs. Mobile street outreach in a special 
bus provides safer injection and safer sex supplies, including 
sanitary napkins and women-specific information materials; 
consultations with doctors, psychologists and social workers; 
express HIV and pregnancy tests; STI tests; and referrals. 
Legal aid helps respond to the frequent loss of parental 
rights, physical and sexual violence and discrimination 
in medical settings experienced by clients. Project staff 
members accompany women to appointments and help 
them navigate medical and social services. A network of 
trusted doctors provides women with low-threshold care 
in a non-judgemental atmosphere. In the past five years, 
11,346 women have received services from the project, with 
in-depth case management for 372 women.
There are no rehabilitation centres in St. Petersburg for 
women with children, and the city’s shelters do not accept 
women living with HIV or those who actively inject drugs. 
Because this group of women often faces unstable housing 
and domestic violence, Humanitarian Action opened a ‘Crisis 
Apartment’ where women can live for up to three months. 
Pregnant women and mothers of small children have 
priority, since they are most vulnerable and have the most 
difficulty finding work. Women receive structured assistance 
with medical, legal, bureaucratic and family problems and in 
seeking employment and permanent housing.e
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a cap on the number of syringes provided daily, rather than a 
problem with the intervention design.37 
These limitations have led some experts to push for new 
methodologies to assess the impact of health promotion 
programmes, arguing that a lack of data on HIV incidence 
should not deter programmes that have positive results in 
practice and could be essential to reducing HIV risk and other 
harms.38 Alternative measures of effectiveness could include 
baseline-to-follow-up reductions in reported risk behaviours 
and incarceration rates; improvement in health status, family 
relations, housing, self-efficacy and well-being as reported by 
clients; and increased uptake of medical and social services. 
Such indicators are easier to measure, though they cannot 
be used as proxies for reduced HIV transmission. Community 
randomised trials that compare a basic intervention to an 
enhanced intervention pose fewer ethical problems than 
standard RCTs, and help reduce the biases of observational 
studies by randomising by group.37 Some of these methods 
and indicators were used in evaluating the programmes 
described below.
To date, HIV risk-reduction interventions among women who 
inject drugs have been more successful in reducing drug-
related risks than unsafe sexual behaviours, likely because 
of structural factors that shape sexual relationships and limit 
condom use among vulnerable women.39-41 This points to a 
need for interventions that address these broader, structural 
factors, increasing self-efficacy and autonomy as well as 
awareness of the importance of safer sex.
The following interventionsf have documented success 
among women who inject drugs:g
 » A woman-focused intervention in an inpatient 
detoxification programme in St. Petersburg, Russia, 
found that in comparison with the control group (which 
received nutritional counselling), women receiving the 
HIV-focused intervention reported a lower frequency of 
partner intoxication during their last sexual act and a 
lower average number of unprotected vaginal sex acts 
with their main sexual partner who injects drugs. Both 
groups reported lower levels of injection frequency. 
The two-session intervention consisted of educational 
activities, skills-building demonstrations, guided practice 
and roleplaying, covering topics including drug use 
and relationships; physical and sexual abuse; rape and 
violence prevention; ways of discussing and negotiating 
f   A review of the evidence for harm reduction interventions in general is outside the 
scope of this article. For information on harm reduction interventions in general, see, for 
example: WHO (2004) Effectiveness of sterile needle and syringe programming in reducing HIV/
AIDS among injecting drug users. Evidence for action technical papers. Geneva: WHO; WHO/
UNODC/UNAIDS (2004) Joint Position Statement: Substitution maintenance therapy in the 
management of opioid dependence and HIV/AIDS prevention. Geneva: WHO; International 
Harm Reduction Development Program (2007) Delivering HIV Treatment and Care to 
People Who Use Drugs. New York: Open Society Institute; Hunt N (2003) A review of the 
evidence-base for harm reduction approaches to drug use, http://www.forward -thinking-
on-drugs.org/review2-print.html. 
g    For other examples, see Gay J, Hardee K, Croce-Galis M et al. (2010) What Works for 
Women and Girls: Evidence for HIV/AIDS Interventions. New York: Open Society Institute. 
www.whatworksforwomen.org.
safer sex; and developing a personalised action plan to 
help women reduce alcohol and drug use and HIV risk 
and avoid sexual and physical violence.42 
 » In Baltimore, USA, the JEWEL intervention combined HIV 
prevention education and skills building with economic 
enhancement to reduce HIV risk among women who use 
drugs (injecting and non-injecting) who traded sex for 
drugs or money. The HIV component aimed to increase 
women’s knowledge about HIV, STIs and drugs, improve 
their risk reduction knowledge and skills, and enhance 
self-efficacy and negotiation and communication skills 
to support safer sex. The economic component taught 
women how to make and sell jewellery, giving them 
practical skills while aiming to increase their self-efficacy 
in relation to licit employment. Self-reports three months 
after the intervention showed significant reductions 
in the exchange of drugs or money for sex, the median 
number of sex trade partners per month, daily drug use 
and daily crack use, the amount of money spent on drugs 
daily, and IDU. There was also a small increase in the 
percentage of women reporting that they never shared 
needles (from 86.7% to 93.7%). Income from jewellery 
sales was associated with a reduction in the number of 
sex trade partners at follow-up. The study suggested 
that exposing women to the possibility of gaining legal 
employment could support positive behaviour change, 
and that sustainability of these positive behaviours would 
likely require women’s access to job training programmes 
and job opportunities.43 
 » In Miami, USA, a study with female sex workers who 
traded sex for drugs and used heroin or cocaine regularly 
compared a standard HIV prevention intervention 
for drug users with a new sex-worker focused (SWF) 
intervention. The standard intervention provided 
pretest counselling on HIV, Hepatitis B and C (HBV/HCV), 
transmission routes, risky drug use, unsafe sex practices, 
male and female condom use, disinfection of injection 
equipment, and the benefits of drug treatment. The SWF 
intervention was developed through a collaborative 
process with sex workers, including focus groups and 
engaging sex workers as outreach workers. It covered 
many of the topics in the standard intervention but 
discussed them in language recommended by sex 
workers themselves, addressing specific misconceptions 
and needs identified during the focus groups – notably, 
the need to avoid violence. Both study groups reported 
significant decreases in the number of days using alcohol 
and other drugs between baseline and three- and six-
month follow-ups. Mean occasions of sex work while 
drunk or high declined significantly for both groups at 
six-month follow-up. Group averages for unprotected 
vaginal and unprotected oral sexual contact decreased 
significantly at both follow-up time points for both 
intervention protocols. Both physical and sexual 
victimisation were reduced significantly at three and 
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six months among participants in both intervention 
protocols. The SWF intervention was significantly more 
effective in reducing sexual violence at the six-month 
contact, with participants nearly twice as likely as those 
in the standard intervention to report a decrease in 
sexual abuse/victimisation.44
 » In 2005, Family Health International Bangladesh 
established drug treatment services especially for 
women, leading to increasing numbers of women 
accessing treatment. Because OST was not available, 
treatment consisted of clonidine-assisted detoxification 
followed by three months of in- or outpatient care 
and follow-up. Women received HIV risk-reduction 
counselling and VCT; screening and treatment of STIs; 
overdose prevention education; and information on HBV 
and HCV. Counselling services were based on cognitive 
behavioural therapy and client-centred approaches. 
The services were free of charge, targeting homeless 
women with a history of drug-related harms. They were 
provided by specially trained female staff members 
and included childcare, prenatal care and vocational 
rehabilitation. Treatment for male drug-using partners 
was offered to reduce barriers to treatment and poor 
treatment outcomes. A study of the programme found 
that participation was significantly associated with 
correct use of condoms, use of condoms during the last 
sexual act, HIV testing, and correct assessment of risk. 
A possible association was found between programme 
participation and reduced borrowing or lending of 
injecting equipment during the last injection, correct 
knowledge about where to receive STI treatment, and 
correct knowledge about where to get VCT for HIV.45 
 » One review analysed studies of alcohol and drug 
treatment programmes for women that included 
childcare, prenatal care, women-only programmes, 
supplemental services and workshops that addressed 
women-focused topics, mental health programming and 
comprehensive programming. These components were 
positively associated with better treatment outcomes, 
reduced mental health symptoms, improved birth 
outcomes, employment, improved self-reported health 
status, and HIV risk reduction. One randomised study 
of pregnant methadone clinic patients who received 
prenatal care, therapeutic childcare during visits and 
relapse prevention support found improved outcomes 
at delivery and a threefold increase in the number of 
prenatal visits.46 
 » A qualitative meta-synthesis of studies of US and 
Canadian integrated drug treatment programmes for 
pregnant or parenting women and their children found 
that these programmes, which combined medical and 
social support, increased women’s sense of self and 
personal agency, engagement with the programme staff 
and sense of giving and receiving support, openness 
about feelings, recognition of patterns of destructive 
behaviours and goal setting. These psychosocial 
processes were reported to play a role in women’s 
recovery and contribute to favourable outcomes. The 
motivating presence of children during treatment was 
also found to support women in their recovery. Perceived 
outcomes of programmes included improved maternal 
and child well-being and enhanced parenting capacity.47 
h
h    Case study information provided by Ian Bromage, HIV Programme Manager, MCNV.
Women supporting women 
Hanoi, Vietnam  
In Vietnam, PWID are highly stigmatised. Many are forced 
into rehabilitation centres that violate international human 
rights law, and where relapse rates are very high. Women 
who inject drugs are even more marginalised than men, 
since drug use runs counter to cultural ideals of motherhood 
and femininity. Women are also a minority of PWID. They are 
often neglected by interventions, have less access to harm 
reduction services and are at greater risk of HIV.  
In 2005 the Medical Committee Netherlands-Vietnam 
(MCNV), in partnership with the Red Cross and others, 
established a support group for women who inject drugs. 
Called the ‘Cactus Blossoms’, the group originally consisted 
of 10 women with a history of IDU, and aimed to provide 
mutual support, help give women access to the services they 
required, and raise public awareness of this issue. Today the 
group has over 200 members who conduct outreach work 
with other women who use drugs and sex workers, meet 
with women in compulsory rehabilitation centres and work 
with providers to ensure that health services are delivered in 
a non-discriminatory manner. The Cactus Blossoms provide 
information within the rehabilitation centres and a mutually 
supportive environment after release, helping to reduce 
relapse rates. The group has organised high-profile media 
events to fight stigma and discrimination within society. 
Since the group began, 130 women have received help in 
finding employment. Women have reported increased self-
esteem and confidence. One member said, “After coming 
back from a rehabilitation centre and going home, I had no 
rope to cling to. But joining the group provided me with 
support. Now I feel reborn.”h
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Greater involvement of women  
who use drugs  
In recognition of the need for more active involvement 
of women who use drugs in the international harm 
reduction and drug policy reform community, two 
international networks are now in operation.  
The International Network of Women Who Use Drugs 
(INWUD) represents the interests of women who use 
drugs in the International Network of People Who Use 
Drugs (INPUD). INWUD actively seeks to collaborate with 
relevant UN and other international groups and bodies 
to give greater voice to issues affecting women who use 
drugs. INWUD helps channel the views and experiences 
of women who use drugs into advocacy efforts.
The Women and Harm Reduction International Network 
(WHRIN)i is a global platform that seeks to reduce 
harms for women who use drugs and to develop an 
enabling environment for the implementation and 
expansion of harm reduction resources for women. 
WHRIN provides a forum to discuss the needs of and 
challenges faced by women who use drugs. It advocates 
for national, regional and international bodies to adopt 
and implement policies and programmes that promote 
and support harm reduction interventions for women 
and girls. It also aims to provide access to high-quality 
resources (including educational material) to help 
women who use drugs and/or the people who work 
with them to improve access to gender-sensitive harm 
reduction services.
i
i   To register, visit www.talkingdrugs.org/user/register.
Developing a ‘menu’ of services for 
women who inject drugs
The following table draws on examples of existing gender-
sensitive harm reduction services to provide a ‘menu’ of 
options to improve and expand care for women who inject 
drugs. Ideally, services should be targeted according to the 
documented needs of women in a given context. Women 
who use drugs should always be involved in the design 
and implementation of these programmes, to ensure that 
programmes are effective, appropriate, and respectful of the 
human rights of women who use drugs.j 
It should be noted that the establishment of gender-sensitive 
harm reduction services depends on the pre-existence of 
standard harm reduction services, which remain unavailable 
in many settings. Basic harm reduction services should 
be provided on a scale adequate to need and based on 
internationally endorsed WHO, UNODC and UNAIDS coverage 
targets necessary for an impact on HIV transmission rates.36 
Gender-sensitive services should then be added as required.
Because the resources available in different settings vary 
widely, the services are sorted into three groups based 
on the rough magnitude of cost, time and effort required 
for implementation.k It should be noted that some of the 
proposed services do not require any additional expenditure 
– for example, establishing staff gender balance, designating a 
time when only women visit the drop-in centre, or organising 
self-help groups specifically for women. 
j    Recommendations on service provision and advocacy goals are also provided 
in Pinkham (2007) op cit.; EHRN (2011) op cit.; Global Coalition on Women and AIDS 
(2011) Women who use drugs, harm reduction and HIV. Geneva: GCWA http://www.
womenandaids.net/news-and-media-centre/latest-news/women-who-use-drugs--
harm-reduction-and-hiv.aspx Accessed 27 June 2012; and International Harm Reduction 
Development Program (2011) By Women, For Women. New York: Open Society Institute.
k    These are very rough estimates; real costs would vary widely depending on location.
133
Chapter 3.1
Service
Adjustments and small 
additions to existing 
services: 
Added commodities 
distributed, additional 
staff training, 
designation of special 
activities for women 
clients
 » Addition of women-specific items to basic harm reduction kits (women’s hygiene materials 
and female condoms along with syringes, male condoms, wipes, lubricant)6, 48, 49
 » Additional basic services/material assistance for women at harm reduction sites (pregnancy 
tests; diapers and other supplies for children; short-term babysitting while women get 
counselling/participate in support groups; informational materials specific to women; help 
learning to inject oneself and thereby eliminate dependence on partners) 6, 48, 49
 » Staff training on gender issues (counselling techniques for women, needs of women who 
use drugs etc.)9, 48, 49
 » Gender balance in harm reduction staff, including active involvement of women drug users 
in service provision and design48, 49 
 » Special time for women only (‘Ladies’ Night’)k
 » Women-only support groups, women-specific counselling programmes (including 
structured HIV prevention counselling interventions)42
 » Relationships with trusted gynaecologists, obstetricians and other specialists for client 
referrals49
 » Secondary-syringe exchange programme focusing on expanding coverage of women26 
 » Training OST providers and OB-GYNs on drug use and drug treatment in pregnancy9
 » (For OST programmes/policymakers): take-home doses, flexible clinic hours5, 9 
 » Basic training on drug use for primary care and women’s healthcare providers, to enable 
effective and prompt referrals to harm reduction and related services when needed50
 » Links between services for people who use drugs and for sex workers, including discreet 
provision of harm reduction for sex workers unable to openly visit a harm reduction site26, 35
New services added by 
existing organisations: 
Hiring a new staff 
member, adding new 
types of services to an 
existing programme, 
designating permanent 
space or significant 
equipment to women
 » Specialist to work with women’s children and give counselling on parenting skills9, 21, 35
 » Counselling services to respond to sexual violence, IPV, other trauma, and to address the 
links between trauma and risky behaviours9, 35, 48  
 » Women-only drop-in centre or space in the harm reduction centre devoted specially to 
women9, 51 
 » Appointments with a gynaecologist, other medical specialists at the harm reduction site6, 51
 » Multidisciplinary case management for women and their children, including pregnant 
women6, 52
 » Mobile harm reduction, OST, basic medical services for women unable to visit service-sites6, 53
 » Legal aid to help women resolve problems with documents, access to social support, legal 
problems etc.6, 49
 » Free, low-threshold sexual and reproductive healthcare, including PMTCT
 » Job training, job placement assistance and economic empowerment programmes to 
increase women’s economic independence35, 43
 » Social support for women released from prison, including support related to parenting35
New stand-alone 
services: 
Creation of an entirely 
new centre/service site
 » Open separate rehabilitation centres for women (if possible, where children can also stay)9
 » Establish comprehensive maternity and post-natal services for pregnant women who use 
drugs52
 » Provide short-term/transitional housing for homeless women and their children21, 35
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Building a supportive policy 
environment l
Access to services depends on a supportive policy 
environment. The following actions are recommended to 
support effective health and social services for women who 
inject drugs:
 » Whenever feasible, collect gender-disaggregated data 
on the epidemiology of drug use and HIV; coverage and 
uptake of essential HIV and harm reduction services such 
as NSP, OST and ART; health service provision in prisons 
and incarceration for drug-related crimes; and other 
relevant subjects.
 » Continuously and meaningfully engage women who use 
drugs in policy and programme design, monitoring and 
evaluation.
 » Establish a system that guarantees free or low-cost, non-
judgemental sexual and reproductive health services, 
including PMTCT, for vulnerable women, including 
women who use drugs.
 » Provide NSP, OST, psychosocial support and ART in 
women’s prisons and pre-trial detention centres, as well 
as sexual and reproductive healthcare and other forms of 
gender-sensitive care. 
 » Eliminate punitive approaches toward pregnant women 
who use drugs; introduce policies that improve access to 
voluntary, evidence-based drug treatment on demand 
and to perinatal care and other supports.
 » Establish clinical protocols on OST and other care for 
pregnant women who use drugs, and provide OST in 
maternity hospitals.
 » Eliminate laws that make drug use, a history of drug use 
or participation in an OST programme (as opposed to 
negligence or abuse) grounds for the removal of parental 
rights, as this is a strong deterrent to mothers in need of 
care.
 » Support links between harm reduction programmes and 
primary and women’s healthcare systems.
 » Establish stronger protections for patient confidentiality.
It has become clear that the HIV epidemic demands an 
approach that addresses multiple health and social factors, 
on the structural as well as individual level. This lesson should 
be applied to harm reduction for women who inject drugs. A 
gender-sensitive approach to harm reduction will benefit not 
only women but their children, families and communities. 
l    See Magee C & Huriaux E (2008) Ladies’ night: Evaluating a drop-in programme for home-
less and marginally housed women in San Francisco’s Mission district. International Journal 
of Drug Policy 19, 113–121.
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Introduction
UNICEF estimates that there are nearly 2.2 billion children 
and young people under 18 years of age, accounting 
for more than a third of the world’s population.1 The UN 
Convention on the Rights of the Child requires that state 
parties take ‘appropriate measures’ to protect this age group 
from the illicit use of drugs. However, the ‘war on drugs’ often 
trumps young people’s rights.2,3 This chapter will provide a 
global snapshot of the harms experienced via injecting drug 
use (IDU) among young people aged under 18 and existing 
harm reduction responses targeted at this population. 
Alcohol, cannabis and ‘club drug’ use remain much more 
prevalent than IDU among this population. However, this 
chapter focuses specifically on youth injecting, which 
continues to represent a significant blind-spot in terms of 
research and public health responses. The chapter begins 
by outlining recent trends in IDU among young people. As 
part of the Global State of Harm Reduction 2012 survey, 
new international data were collected from civil society 
and researchers, and this chapter reports our analyses 
of these data to provide a unique and timely study of 
legal age restrictions and other barriers to young people 
accessing harm reduction services. This chapter also 
highlights case studies of best practice for meeting the 
needs of this population in different settings, to inform our 
recommendations for improving policies and services to 
reduce drug-related harm.
Young people who inject drugs: 
prevalence and harms
Although overall levels of youth drug use appear to be 
stabilising or decreasing in many high-income countries4,5,6  
surveys of the general population conceal the drug-related 
harms experienced by the most vulnerable groups of young 
people. This includes young people who are not in education 
and street-involved youth – populations whose drug use is 
less likely to be transitory and more likely to progress onto 
more problematic patterns of use, such as IDU.7 The impact 
of current economic recessions is likely to further increase 
the vulnerability of young people,8 and record levels of child 
poverty and youth unemployment have already led some 
commentators to describe a new ‘lost generation’ of young 
people devoid of jobs and hope. 9
Furthermore, drug use is a universal and globalising 
phenomenon. Young people in Western Europe and North 
America represent a small fraction of the total global youth 
population: more than four-fifths of the world’s children and 
young people aged 18 years and younger live in low- and 
middle-income countries in Eastern Europe, Asia, Africa 
and South America. Recent reports have drawn attention 
to a ‘historic high’ in youth drug use globally,10 and IDU has 
spread to new regions. For example, the Pangaea Global 
AIDS Foundation estimates that there are now over 25,000 
people who inject drugs (PWID) in Tanzania, and that over 
40% of this population is living with HIV.11 HIV transmission 
via unsafe injecting in sub-Saharan Africa is a relatively new 
phenomenon, and young people are likely to be among the 
most vulnerable.12
While IDU still only represents a small proportion of drug 
use reported by under-18s overall, in many regions of the 
world the age of initiation of injecting now appears to be 
decreasing.13 Those young PWID who are sharing injecting 
equipment can transmit blood-borne viruses including 
HIV and Hepatitis C. These youth are also at greater risk of 
other preventable diseases such as tuberculosis. Research 
consistently shows that young injectors are more likely 
than older ones to report sharing equipment with other 
injectors and less likely to access needle and syringe 
exchange services.14,15  Young people also often have a lack of 
knowledge and misconceptions about HIV transmission.16
According to UNICEF in 2011,16 globally young people 
account for 2,500 new HIV infections every day. Failures to 
meet targets on reducing HIV transmission among young 
people is in a large part due to unsafe injecting practices 
and the criminalisation of these behaviours. It is estimated 
that in countries such as Belarus, China, Italy, Poland, Spain 
and Russia more than half of HIV infections are due to unsafe 
injecting,17 much of this among youth. More generally, 
young people are also often the first to experiment with new 
substances, and are often highly connected to dense drug-
supply networks, making them highly susceptible to new 
drug-related harms. 
Young people who inject drugs: 
current responses and data gaps
Despite increasing global coverage of harm reduction 
services,18,19 there remains a lack of youth-focused harm 
reduction services, and a potential gap between the age 
of initiation of injecting and the age at which services are 
accessible to young people. Current responses remain 
dominated by prevention and punishment discourses. 
In some regions, strict age restrictions on access to these 
services have been highlighted as a major barrier, as young 
people are denied access to evidence-based interventions 
such as needle and syringe exchange programmes (NSPs) 
and opioid substitution therapy (OST). Criminal laws 
increase that risk and other barriers to young people 
accessing harm reduction services have also been identified, 
including appointment-based service provision and a lack 
of youth-work expertise and training among practitioners.20 
Furthermore, youth participation in the design of policies 
and programmes remains rare. 
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However, to date, there have been no attempts to map out 
and synthesise these barriers globally. The Global State 2012 
data collection questionnaire offers a novel lens through 
which to study age restrictions and other barriers to NSP and 
OST access among the youth population. Data were collected 
by surveying civil society organisations and key researchers 
working in the harm reduction field around the world to 
explore region-by-region developments in harm reduction 
since the previous Global State report was released in 2010. 
In the 2012 survey, specific questions were asked for the first 
time about the barriers to young people accessing services 
and legal age restrictions in different countries and regions 
(for more information see the Introduction to this report). 
Data on young people were available from all the Global 
State regions except for the Middle East and North Africa, 
which is, therefore, not included in these analyses.
Harm reduction services for young 
people: a global snapshot
Overall, of 85 countries reporting at least one NSP or OST 
site, data on the existence of age restrictions were available 
for 77 countries. Of those countries that reported data on 
age restrictions, 18 countries reported an age restriction for 
accessing NSPs, and 29 for accessing OST. Most commonly 
the age restriction was 18 years, but in some cases it was 
much higher (e.g. Georgia, Norway and Sweden). Even in 
countries with no legal age restrictions, the application of 
other requirements, such as compulsory parental consent 
or evidence of previous failed attempts at detoxification or 
other drug treatment modalities, and ‘aiding and abetting’ 
laws limit access to harm reduction services for young 
people. Table 1 provides more information on the existence 
of age restrictions by country, and the survey responses have 
also been synthesised in narrative form and are presented, 
region-by-region.a
a  Please see section 2: Regional Overviews for a comprehensive list of countries 
considered as part of each of the world regions. 
Country/territory with at 
least one reported NSP 
or OST site
Legal age restriction for 
accessing NSP  
(age in brackets)
Legal age restriction for 
accessing OST services 
 (age in brackets)
ASIA
Afghanistan Data n/a No
Bangladesh Data n/a Yes (18)
Cambodia No Yes (18) 
China Yes (18) No 
Hong Kong No NSP No 
India Yes (18) Yes (18)
Indonesia Data n/a Yes (18)
Macau No No
Malaysia No No 
Maldives No NSP No
Mongolia Data n/a No OST
Myanmar No No 
Nepal No Yes (18)
Pakistan Yes (18) No OST
Philipinnes Data n/a No OST
Taiwan Data n/a Data n/a
Thailand No No 
Vietnam Yes (18) Yes (18)
LATIN AMERICA
Argentina No No OST
Brasil No No OST
Colombia No NSP No
Mexico No No
Paraguay No No OST
Uruguay No No OST
CARIBBEAN
Puerto Rico No No
SUB-SAHARAN AFRICA
Kenya Data n/a Data n/a
Mauritius Yes (18) Yes (18)
Nigeria No NSP Data n/a
Senegal No NSP Data n/a
South Africa Yes (18) Data n/a
Tanzania No No
EURASIA
Albania No No
Armenia No Data n/a
Azerbaijan Data n/a Yes (18)
Belarus No Yes (18)
Bosnia  and 
Herzegovina
No No 
Bulgaria No Yes (18)
Croatia No No
Czech Republic Yes (15) Yes (15)
Estonia Yes (18) No
Georgia No Yes (21)
Hungary No Yes (18)
Kazakhstan No Data n/a
Kosovo No No 
Kyrgyzstan No No
Latvia Data n/a Data n/a
Lithuania Yes (18) Yes (18) 
Macedonia Yes (18) Yes (16)
140
Country/territory with at 
least one reported NSP 
or OST site
Legal age restriction for 
accessing NSP  
(age in brackets)
Legal age restriction for 
accessing OST services 
 (age in brackets)
Moldova Data n/a Yes (18)
Montenegro Data n/a Data n/a
Poland No No
Romania Yes (18) Yes (16) 
Russia No No OST
Serbia Yes (15) Yes (15)
Slovakia No Yes (18)
Slovenia No Yes (16) 
Tajikistan No No
Turkmenistan Data n/a No OST
Ukraine Yes (14) Yes (14)
Uzbekistan Data n/a No OST
WESTERN EUROPE
Austria Data n/a Data n/a
Belgium No Yes (18)
Cyprus No No 
Denmark No No
Finland No No
France Yes (18) Yes (15)
Germany Yes (18) Yes (18) 
Greece Data n/a Data n/a
Iceland No NSP Data n/a
Ireland No No
Italy No No 
Luxembourg Data n/a Data n/a
Malta Data n/a Data n/a
Netherlands No No
Norway Data n/a Yes (25)
Portugal No Yes (18)
Spain Yes (18) Yes (18)
Sweden Yes (20) Yes (20)
Switzerland No No
Turkey No NSP Data n/a
United Kingdom No No
OCEANIA
Australia No No
New Zealand Yes (16) No 
NORTH AMERICA
Canada No No 
United States No Yes (18) 
Asia
Despite a scale-up in services overall in the last two years, 
it was reported that harm reduction services in Asia almost 
always target male, adult PWID. A major barrier to service 
provision targeted at youth in the region appears to be their 
relative invisibility as a drug-using population. Few or no 
data are collected on this population in most countries in 
the region at present. Young people are, therefore, rarely a 
focus for intervention, and the vast majority of programmes 
lack any clear strategy for reaching and engaging under-18s. 
Even in Bangladesh, which has relatively high levels of NSP 
coverage in South Asia according to recent reviews,19,21 there 
are no data on, or provision for, younger PWID. Furthermore, 
many young injectors in Asia are using methamphetamine 
and pharmaceutical drugs (e.g. benzodiazepines), and their 
needs will not be addressed through OST.22
Legal age restrictions are also a barrier in the region. For 
example, in Nepal and Pakistan harm reduction projects can 
only work with those aged 18 and above, despite Article 33 of 
the UN Convention on the Rights of the Child requiring that 
state parties take ‘appropriate measures’ to protect under-
18s from drug-related harms. This is of particular concern in 
Pakistan, where the age of initiation into drug injecting is 
decreasing, according to a recent rapid assessment exercise.23 
Meanwhile, in China and Vietnam, despite an expansion of 
harm reduction service provision overall, age restrictions 
prevent under-18s from accessing these new services.
It was reported that legal age limits are a common reason 
for refusal by services, as they provide an objective way 
of rationing limited supply in the region. Stigma was also 
reported to be a major barrier, and many young PWID in 
the region deny they are dependent on drugs and need 
harm reduction services. At present, there is a mandate 
to disclose one’s identity, and service-users often have to 
effectively ‘register’ with authorities, as is the case in China. 
This is a clear impediment to accessing OST services and 
may disproportionately affect younger people. Furthermore, 
most OST clinics have yet to be integrated into general 
health services, with the consequence that those accessing 
treatment can easily be identified and stigmatised. 
141
Chapter 3.2
bLatin America 
Sporadic and isolated efforts largely characterise the 
development of harm reduction services in Latin America 
at present. Similar to Asia, a lack of harm reduction services 
for young people under 18 was reported in this region. 
Youth-focused approaches to reducing the harms associated 
with IDU are rarely an acceptable public health strategy in 
either South or Central American countries, and national 
drugs policies do not support this approach. Harm reduction 
responses which do emerge are normally led by NGOs, 
and it was reported that even where these do exist stigma, 
discrimination and criminalisation pose significant barriers to 
service use, especially for young people.
Despite these barriers, new examples of youth-focused harm 
reduction projects were reported. For example, in Rio de 
Janeiro a project was established in 2010 in an area known 
as ‘crack land’ where young people gather to use drugs. Work 
so far has focused on sensitising the health care system to 
the needs of these young PWID, including the development 
of a new course to train health workers, and the provision 
of syringes, pipes, lip balms and condoms. This project was 
supported by the federal government, the National Health 
Ministry, the Secretariat of State for Rio de Janeiro, the 
Federal University of Rio and the UN Office on Drugs and 
Crime. Also, in Mexico, the state authorities now buy and 
b   The ‘Opening Doors’ project has developed a toolkit on enhancing youth-friendly 
harm reduction, available at: http://ndarc.med.unsw.edu.au/resource/opening-doors-
enhancing-youth-friendly-harm-reduction-toolkit. 
distribute syringes through centres for youth integration 
and in some CAPASITS (state provider of HIV, AIDS and STI 
services) sites.
Sub-Saharan Africa
Even more so than in Asia and Latin America, Africa is 
a region characterised by a paucity of both data on the 
number of young PWID and harm reduction services for this 
group. In East Africa, there are major concerns at present 
of both increasing IDU in general and also earlier initiation, 
with reports of young people as young as 11 in Kenya 
and as young as six in Tanzania injecting drugs.26 Harm 
reduction services that target young people in East Africa, 
particularly in the coastal areas where IDU is concentrated 
(e.g. Mombasa, Dar es Salaam and Zanzibar) are urgently 
needed. Such services must also meet the needs of young 
women who are injecting drugs, who are subject to multiple 
vulnerabilities.27 Although there is no official data on the 
prevalence of IDU and service provision for young people, 
anecdotal information from some parts of West Africa 
suggests a rapid rise in IDU among youth and a severe harm 
reduction service provision gap.28 As HIV infection through 
IDU increases in sub-Saharan Africa, young people are a 
particularly vulnerable population.12 
The ‘Opening Doors’ project: increasing access to 
youth-friendly harm reduction in Asiab
‘Opening Doors’ is a response to current legislation across 
Asia which mostly prohibits access to harm reduction 
services for young people, as well as the stigmatising and 
punitive nature of current treatment approaches which 
exacerbate social exclusion. The project is funded by Aids 
Fonds, a Dutch NGO, and is a partnership between Access 
Quality International and the National Drug and Alcohol 
Research Centre, University of New South Wales, Australia.
Where community options do exist, young people have 
tended not to engage with these adult-oriented services. 
Informed by the World Health Organization’s model of 
‘youth-friendly health services’,24 the primary aim of the 
project is to increase access to harm reduction services for 
young PWID and those who are at risk of initiating IDU. The 
target age group is 10–25, with special attention paid to 
the engagement of difficult-to-reach young people. The 
project has been implemented in three sites so far: Bangkok, 
Thailand; Kunming, China; and Kathmandu, Nepal. 
In all three sites, participatory focus group research with 
young PWID has been used to identify local needs, engage 
them in service design and increase access to locally 
appropriate harm reduction services. For example, in 
Kunming, the main drug of concern remains heroin, with 
significant unmet needs identified following consultation 
with young people. The project site in Kunming has aimed 
to increase participation in ‘youth-friendly’ methadone 
maintenance therapy (MMT), alongside other activities such 
as counselling groups, employment assistance, visits and 
recreation.25 
An evaluation undertaken by Youth Vision in Nepal in 2010 
suggested that there had been a significant increase in the 
engagement of young people with harm reduction services 
after adopting the ‘Opening Doors’ approach. Young people 
accessing the services also reported improved mental 
health, less involvement with crime, a reduction in sharing 
of injection equipment and increased condom use. The 
projects have helped to establish new partnerships between 
the health, education, vocational training and employment 
sectors, building greater capacity for youth-focused harm 
reduction interventions in the region in the long term. 
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Eurasia
Many countries in Eastern Europe report high HIV prevalence 
rates among young people through the sharing of injecting 
equipment and unsafe sexual practices.29 Some positive 
legislative changes which aim to improve harm reduction 
services for young people were reported in this region. For 
example, in Serbia a new law allows juveniles aged 15 and 
over to have exclusive privacy over their medical records and 
consent rights regarding their health issues, which means 
no parental consent will be required to access NSP and 
OST. There are now no legal age restrictions for accessing 
NSP in Albania, Bosnia and Herzegovina, Bulgaria, Croatia, 
Hungary, Kosovo, Slovakia or Slovenia. However, since NSPs 
are often anonymous and client ages unrecorded, it is hard 
to assess whether PWID under 18 are being reached by these 
services.30
In other countries in the region, age restrictions remain a 
barrier to accessing harm reduction services. The Czech 
Republic and Macedonia both have legal age limits for NSPs, 
allowing only PWID who are at least 15 and 18 years old, 
respectively, to access sterile injecting equipment. Access 
to OST is also often subject to strict age regulations. For 
example, in Bulgaria and Hungary the minimum age for 
participation in OST is 18, and it is 21 in Georgia. The written 
consent of a legal representative or a parent of a minor is 
required prior to starting OST in Bosnia and Herzegovina, 
Romania and Kosovo, which also poses a significant obstacle. 
Additional barriers to service access in the region include 
stigma, fear of the police, and a lack of funding. NSPs are also 
rarely, if ever, tailored to young people’s needs. There are also 
a lack of youth-focused OST programmes, and to become 
eligible in many countries young people have to prove they 
were not successful in previous detoxification treatment.
Western Europe
The prevalence of injecting heroin and other drugs remains 
rare among young people in this region – typically only 
being reported by 1–2% or less of young people in general 
population surveys – while alcohol and cannabis remain the 
primary drugs used by young people.5,6 The incidence of 
new cases of HIV among PWID is also low in Western Europe, 
although incidence is still relatively high in some countries 
(e.g. Portugal), and recent increases have been observed 
in others such as Sweden.30 Furthermore, the burden of 
morbidity associated with IDU is not evenly distributed: 
certain groups of vulnerable young people are most at risk 
of transmission of HIV or Hepatitis C and other drug-related 
harms due to social and structural factors such as poverty 
and social exclusion.8 
There is a mixed picture in terms of the application of age 
restrictions to accessing harm reduction services in Western 
Europe (see Table 1). For example, legal age restrictions 
were reported to limit access to evidence-based harm 
reduction services for vulnerable young people in Belgium, 
Germany, Norway, Portugal and Sweden. Alternatively, in 
countries such as the UK, specialist services to safeguard 
children and young people from harm were reported to have 
been developed, and ‘minors’ are not excluded from NSPs 
(although guidelines make it clear that the service providers 
should inform their parents and the local child protection 
agency). Likewise, community-based pharmacological 
interventions such as OST are now available for young 
people in the UK and have been developed to recognise the 
different context of working with young people.31
As in other regions, stigma, marginalisation and law 
enforcement practices were reported as significant barriers 
to HIV prevention, care and treatment for young people who 
use illegal drugs. This included a reluctance from young PWID 
to carry syringes due to social stigma, and who often adopt 
dangerous drug storage and concealment methods for fear 
of consequences of police action. Increasing incarceration of 
young people who inject drugs is also a major public health 
challenge, as access to harm reduction measures is usually 
limited or non-existent and HIV/Hepatitis C risk behaviours 
are more prevalent in prison settings.32
Oceania
In Australia, government support for harm reduction service 
provision and scale-up, and debates on drug policy reform, 
have become increasingly challenging. In most cases there 
are no age, gender-based or other criteria that restrict access 
to NSPs in Australia, although the only operational drug 
consumption room (DCR) in the country, which provides 
injecting equipment for use in its service, prohibits access 
to the service for those under the age of 18. Additional 
barriers which can prevent young people accessing services 
in Australia were also reported, including fear of stigma, the 
limited hours of service operation, limited service availability 
outside of major cities and discriminatory attitudes of staff 
towards younger people. While young people under 18 
are not precluded from OST, doctors are discouraged from 
prescribing pharmacotherapies to ‘minors’ in Australia. 
Furthermore, if a ‘child’, that is a person under 18, is accessing 
injecting equipment or OST, staff are required to report this 
to the local child protection agency, which may be a further 
barrier for some young people. 
In New Zealand, the minimum legal age for accessing NSPs 
is 16. Although there is no legal age restriction for OST, for 
those under 18 parental/caregiver support and consent is 
preferred. For those under 16, assessment and consent are 
also needed from an addiction medical specialist and/or a 
child and youth psychiatrist.
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North America
Injecting drug use often starts at a young age in North 
America.33 Age restrictions and limited access to NSPs for 
under-18s represent significant barriers to access to harm 
reduction services in this region. In the USA, although 
restrictions vary by state and by type of treatment setting, 
anyone under 18 must have undergone at least two 
documented attempts at detoxification or outpatient 
psychosocial treatment within 12 months in order to be 
eligible for OST. This inevitably limits the potential for 
young people to access evidence-based harm reduction 
programmes. 
Cost is also likely to be a barrier to treatment in the USA, as 
Medicaid insurance can only be used to pay for MMT in some 
states, and even then it is often time-limited. It was reported 
that private insurance payment is also usually preferred 
by PWID to avoid exposure and stigmatisation, but this is 
unlikely to be an option for young PWID. Additional barriers 
include lengthy waiting lists for methadone clinics in some 
USA regions (particularly in regions far from urban centres), 
regulations around OST programme attendance and regular 
testing for other drug use, all of which are likely to pose 
barriers for young people.
No legal age restrictions for accessing NSPs or OST in Canada 
were reported. Outreach and frontline workers provide 
sterile equipment to young people who show evidence of 
use or need, although many youth in Canada still go without 
services, particularly in rural regions and central/northern 
Canada. 
The TRIP! Project: Youth-Led Harm Reduction in Canada
TRIP! is a youth-led harm reduction project that has been 
providing peer outreach to the dance music community 
in Toronto, Canada for over 15 years. TRIP! aims to include 
young people who use drugs, street-involved and lesbian, 
gay, bisexual, transgender and queer (LGBTQ) youth in direct 
service development and delivery, and to encourage safer 
drug use and safer sex to reduce associated harms including 
the transmission of HIV, Hepatitis C and other sexually 
transmitted infections (STIs). TRIP! does outreach work via 
a variety of venues, including nightclubs, bars, warehouses, 
bridge parties, house parties, street parades and multi-day 
festivals. During outreach events, young people can pick up 
info-cards on dance drugs, routes of administration and safer 
sex, as well as a variety of harm reduction supplies including 
condoms, lubricant, straws, needles and syringes.
In addition to outreach, TRIP! engages youth through social 
networking to circulate messages about safer partying 
practices. Online surveys are employed to monitor patterns 
of drug use, injecting, and ‘high-risk’ behaviours. TRIP! has 
found that youth tend to be most honest when responding 
to anonymous online survey questions. As a result, an annual 
online survey is used to obtain accurate drug use data 
within this community. Information generated by this type 
of youth engagement allows TRIP! to monitor and identify 
emerging health and safety issues, as well as publish alerts 
about dangerous or new substances and laws affecting the 
communities.
While young PWID represent a minority of those with 
whom TRIP! works, injecting is an emerging trend within 
the Toronto community of young people who use drugs. 
The 2010 TRIP! survey found that 9% of young people were 
injecting drugs, with 3% considering doing it in the future. 
Young people who used crystal meth and ketamine were 
more likely to inject, with 17% of meth users and 13% of 
ketamine users reporting injecting. Furthermore, 83% of 
TRIP! youth reported having tried prescription opioids, often 
to deal with the come-down and other side effects reported 
from chronic ketamine use. 
It is important to recognise the value of such projects in 
both increasing young people’s ‘voice’ and also in building 
the existing network of safer nightlife organisations locally, 
nationally and internationally to share information and 
create a peer support network. According to the 2009 
Toronto Teen Survey, many youth distrust health workers, 
instead turning to their friends (53%), siblings, and infolines 
(55%) for health questions.34 
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Increasing young people’s visibility in 
harm reduction
IDU represents a small minority of youth drug use, but it is 
an acute problem affecting those most at-risk young people, 
and it is a much overlooked aspect of the global response to 
injecting-driven HIV epidemics. Young people are excluded 
from harm reduction services in every region of the world. 
Few NSPs or OST programmes target and work with young 
people. This was a recurring theme in the responses to the 
Global State of Harm Reduction 2012 questionnaire. Young 
people face all the same barriers to accessing harm reduction 
services that adults do – limited coverage, stigma and 
criminalisation – and these are further compounded by legal 
age restrictions and other barriers such as a lack of funding 
for youth-focused services. 
At the international-level, the nine core harm reduction 
interventions recommended by the WHO, UNODC and 
UNAIDS35 are not youth-focused, and it appears that 
key issues regarding young people, IDU and HIV may be 
falling between the priority areas of different international 
organisations such as UNAIDS, UNICEF, UNESCO and the 
WHO. Furthermore, while ‘know your epidemic, know your 
response’ has become the rallying cry of UNAIDS,36 when it 
comes to young people and injecting we do not yet ‘know 
our epidemic’. Where surveys do monitor prevalence and 
trends of drug use among young people, they are almost 
always still based on school samples, and PWID remain 
largely invisible in the official statistics on youth drug use.7
This chapter provides a much-needed global snapshot of 
legal age restrictions and other barriers to harm reduction 
services for young people. However, this picture is 
incomplete, and improved data collection should also be 
an international priority, as should significantly increased 
investment in youth-focused harm reduction. This review 
of harm reduction services for young people suggests the 
following priority areas:
Avoid legal age restrictions: Removing the 
barriers caused by legal age restrictions should be a priority, 
especially where the age of initiation to IDU is decreasing. 
Removing such restrictions is an important first step towards 
developing youth-focused services because, although 
OST provision for young people may raise specific medical 
concerns and abstinence-based treatments may be more 
appropriate in some cases, an age restriction on these harm 
reduction services will likely also mean there is nowhere else 
to go.
Youth-led, youth-friendly harm reduction: 
Young people may not identify with more adult-orientated 
models of treatment and should be involved in designing 
new services to meet their specific developmental needs. Our 
case studies highlight how it is possible to use participatory 
and peer-led methods to engage young PWID to inform 
more appropriate youth-led and youth-friendly services. 
International guidelines for OST (for those using opiates) and 
NSPs for children and young people are also required, as are 
clear child protection protocols and rapidly applicable legal 
tests for capacity to consent to treatment and to receive 
treatment without parental consent.
Improving data collection: Street-based surveys 
of young people should be more widely implemented to 
complement existing monitoring systems (e.g. school-based 
surveys), alongside rapid assessments of youth injecting and 
its adverse health outcomes. Furthermore, it is important that 
data on epidemiology and service coverage among PWID be 
disaggregated by age. To this end, existing recommendations 
by UNAIDS, WHO and other multilateral agencies to improve 
country-level data collection via age disaggregation are 
particularly relevant.35,37   Removing legal age restrictions 
may also allow for an improved understanding of patterns of 
injecting through the collection of age-disaggregated client 
data.
Investment in young people most at risk: It is 
imperative that there is sufficient funding and training to 
support new responses focused specifically on the special 
needs of young people at highest risk from drug use. UNAIDS 
has already identified that this is a major problem in Asia, 
where 90% of the resources for young people are spent on 
low-risk youth, who represent just 5% of those who go on to 
become infected with HIV.
Structural interventions – the holistic 
approach: Social policies and interventions which address 
the broader ‘risk environment’ – for example, by addressing 
poverty, trauma, homelessness and social exclusion – are also 
needed and may have the greatest impact on reducing drug-
related harms at a population level.38 This is also in line with 
a children’s rights-based approach.39 Harm reduction in this 
context is about keeping at-risk youth alive and safe, while 
also addressing the causes of their vulnerability.
Finally, we would also emphasise that context is key: what 
works in the United Kingdom and Canada, where child 
protection services are strong, may not work in Nepal or 
the Ukraine. Irrespective of context, however, failing to find 
solutions represents a missed opportunity to protect and 
improve the health of the next generation of young people 
across the world. To do so, further questions must be asked 
about what information is already available, and where 
further investigation is required about IDU among young 
people and about the most appropriate responses to reduce 
drug-related harm among this population. 
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Introduction
Numerous studies have demonstrated that men who have 
sex with men (MSM) experience disproportionate levels of 
ill-health1-3 compared to the general population, and are one 
of the highest risk groups for HIV in every part of the world.4, 
5 MSM frequently face significant stigma and discrimination 
from their families, communities and, in some countries, 
are the subject of systemic repression and persecution.7 
Often this repression and stigmatisation can make accessing 
appropriate health services, where they exist, problematic.8, 9 
A significant concern among health professionals and 
advocates who work to improve the health and well-being 
of MSM relates to the prevalence of drug use within the 
population, its uses and its associated harms. The chapter 
begins with an overview of the range of drugs taken by MSM, 
followed by a description of prevalence across the world 
(where such data exist) and a discussion of data quality. It then 
assesses the reasons for drug use by MSM and the harms that 
may be associated with such use. The final section highlights 
interventions to help reduce the harms associated with drug 
use among MSM. 
MSM, gay, homosexual, queer?
Terminology to describe men who are attracted to, or 
have sex with, other men is often carefully selected. 
Some men who are attracted to, or have sex with, other 
men may describe themselves as ‘gay’, while others do 
not. Some might use the term ‘homosexual’ (literally 
meaning they have a sexual orientation towards people 
of the same sex) or ‘queer’ (referring to a sexuality that 
deviates from the ‘norm’). ‘Men who have sex with men’ 
(MSM) refers only to the act of sexual contact between 
two men and is rarely used by men themselves to 
describe their sexuality. Health professionals often use 
the term MSM because it relates to behaviour which, 
when considering issues such as HIV, other sexually 
transmitted infections (STIs) or drug use, is more 
important than the identity an individual might assign 
themselves. When working with this population it is 
important that you establish the term with which male 
clients or service users are most comfortable. 
The range of drug use among MSM 
Studies indicate that MSM utilise a broad range of drugs. 
This chapter relates only to non-prescription drugs that 
are considered illegal or otherwise ‘recreational’ in most 
countries. The following is a list of drugs known to be 
used by MSM, and includes street names or regional 
variations.a 
 » Amphetamine (speed, uppers, sulphate, whizz) 
 » Cannabis (marijuana, Mary Jane, dope, pot, spliff, 
hash(ish), weed, puff, grass, herb, draw, wacky 
backy, ganja, hemp)
 » Cocaine (coke, Charlie, C, snow, blow, a toot, 
Bolivian/Peruvian/Colombian marching powder)
 » Crack cocaine (rock, base) – essentially a super-
strength cocaine
 » Crystal methamphetamine (Crystal, Tina, meth, ice, 
crank) – essentially a super-strength amphetamine
 » Ecstasy (E, MDMA, X, XTC) 
 » GHB/GBL (Gina, G, liquid ecstasy) 
 » Heroin (smack, skag, junk, horse)
 » Ketamine (K, special K, vitamin K)
 » LSD (acid, a trip)
 » Mephadrone (MCAT, Meow-meow)
 » Poppers (amyl, butyl, isobutyl nitrate, aromas, liquid 
incense) – the formula frequently changes, but they 
are chemicals from the alkyl nitrite family.
a
Prevalence of drug use among MSM
Establishing the prevalence of drug use among MSM in 
different parts of the world is challenging. In a large number 
of countries, homosexuality, or sex between men, is illegal, 
making the collection of data relating to sexuality challenging 
and complex. Even where research about MSM and drug 
use has been conducted, it is often difficult, or impossible, 
to compare because of inconsistent methodologies, such as 
different recruitment methods, a focus on different drugs or 
use in different settings or across varying time frames (e.g. 
within the last month, the last three months, within the past 
12 months or drug use ever in life). In addition, the use of 
drugs may vary wildly not only from one region of the world 
to another but from one country to the next, between cities 
in the same country or even among different venues within 
the same city. As is the case with other populations, drug use 
among MSM in various areas can change significantly within 
short spaces of time, meaning that data collected can quickly 
become redundant.
The literature review that follows is written with the best data 
publicly available in English. 
a    For a detailed account of these drugs commonly used by MSM and their effects, see 
http://www.drugfucked.tht.org.uk/. 
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Africa
There has been relatively little research in general conducted 
with MSM in African nations, and only a small number of 
studies that have specifically explored drug use. Much of the 
research that has been conducted relates solely to injecting 
drug use (IDU), with rates among MSM ranging from 3.4 to 12% 
in Malawi and 8% in Namibia,10 all within the last six months, 
and 14% within the last year among MSM in Zanzibar.11 Drug 
use among MSM in South Africa has received more attention 
than in other countries, with one study reporting that 11% of 
men described having sex while under the influence of drugs 
within the previous 12 months,12 and further mixed-method 
research suggesting significant regional variation in drug use 
across different cities in the country.13, 14 For example, crystal 
methamphetamine was the most commonly used drug 
among MSM in Cape Town, but dipipanone hydrochloride was 
more common in Durban. 
Asia
The 2010 Asian MSM Internet Sex Survey15 included 10,861 
respondents recruited online from China, Singapore, 
Malaysia, Taiwan, Hong Kong, Thailand, Japan, Indonesia, the 
Philippines, Korea and Vietnam. Table 1 displays the levels of 
reported drug use within the past six months (findings are 
not publicly available at country level). Data from this survey 
also indicate that drug use was significantly higher among 
MSM with diagnosed HIV, particularly with respect to crystal 
methamphetamine, ketamine and ecstasy. A 2009 study in 
Thailand identified an association between HIV prevalence 
and a history of drug use.16
Table 1: Levels of drug use among respondents in the Asian 
MSM Internet Sex Survey
Stimulant drugs % Use in last 6 months
Crystal meth 4.0
Ecstasy 8.1
Cocaine 1.8
Poppers 6.1
Cannabis 3.6
GHB 2.3
Ketamine 5.3
Several other studies across the continent have explored 
lifetime usage of drugs, with levels ranging from 6% in 
Vietnam17 and 11.7% in Taiwan18 to nearly 65% in Japan19 
(although much of this variation can be accounted for by 
differences in sampling and recruitment).
Levels of IDU among MSM in Asia have generally been low.17, 
20, 21 There are currently no data publically available on the 
prevalence of drug use among MSM living in Central Asian 
Republics. 
Australasia
Frequent gay community surveys in Australia and New 
Zealand provide a detailed picture of drug use among MSM in 
these countries, as displayed in table 2. 
In Australia, the proportion of men reporting any IDU in 
the previous six months has remained stable at around 
5–6% for the last ten years.26 While the percentage of men 
using poppers has fallen slightly over the last nine years, 
still in 2009 an average of 31.8% of MSM across the country 
reported use within the previous six months. The Australian 
surveys typically identify higher rates of all drug use in Sydney 
compared to other parts of the country.
Table 2: Prevalence of drug use among MSM in Australasia within the previous 6 months
Cocaine % Poppers % Cannabis % Ecstasy % Methamphetamine % Ketamine % Source
Australia 
(Sydney)
20.6 40.4 27.9 29.8 11.1 9.6
2011 Gay Community Periodic 
Survey Sydney22 
Australia 
(Melbourne)
12.4 35.4 27.6 21.5 8.9 6.0
2011 Gay Community Periodic 
Survey Melbourne23 
Australia 
(Adelaide)
7.1 21.9 34.6 17.2 9.5 2.1
2011 Gay Community Periodic 
Survey Adelaide24 
New Zealand 
(Auckland)
7.3 40 37.5 21.2 7.9 5.7
2006 Gay Auckland Periodic 
Sex Survey25
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Caribbean
Prevalence data for drug use among MSM in the Caribbean 
is extremely scarce. Secondary analysis of a representative 
general household survey data collected in Puerto Rico27 
reported lifetime use of cannabis (63.4%), amphetamines 
(20%) and heroin (20%). A quarter of MSM reported using 
cannabis (24.4%) and cocaine (24.4%) in the past 12 months.
The UNAIDS-sponsored Caribbean Men for Men Internet Sex 
Survey (CARIMIS) is underway at the time of writing and will 
report its findings in the summer of 2012. This survey will 
provide drug use data for each of the Caribbean nations and 
territories and will be a useful source of information for the 
development of future interventions.b 
b    See  http://www.carimis.org
Europe
Comprehensive data on drug use among MSM was collected as 
part of the European Man for Man Internet Sex Survey (EMIS). 
This online survey was open for completion in 25 languages 
in the summer of 2010 and recruited a total of 181,495 men. 
It asked questions about use of a range of drugs within the 
previous 4 weeks (as displayed in table 3). While country-level 
data will become available in the near future, at present EMIS 
data are reported on a European sub-regional level. 
Research in the UK29 that explored drug use levels among 
MSM within the previous 12 months reported levels ranging 
from 39.4% for poppers, 27.7% for cannabis, 18.5% for ecstasy 
and 4.7% for methamphetamine (with significant regional 
variations evident and highest usage in London.)30 Drug 
use among MSM in Catalonia, Spain, within the previous 12 
months followed a broadly similar pattern (poppers 40.8%; 
cannabis 26.0%; ecstasy 10.2% and methamphetamine 
3.0%.)31 
Table 3: Use of drugs among MSM across Europe within the previous four weeks
Region of residence
poppers use in last 4 
weeks
cannabis (or LSD) use in 
last 4 weeks
Heroin/crack use in last 
4 weeks
party drugs* use in last 
4 weeks
West: Belgium, France, Rep. 
of Ireland, the Netherlands, 
the UK
28.3 13.8 0.4 10.6
North West: Denmark, 
Finland, Norway, Sweden
13.8 6.2 0.3 3.1
Central-West: Austria, 
Switzerland, Germany, 
Luxembourg
22.0 10.1 0.2 4.9
South West: Greece, Spain, 
Italy, Portugal
10.9 13.6 0.4 6.6
North East: Estonia, 
Lithuania, Latvia
6.2 4.9 0.2 2.3
Central-East: Czech 
Republic, Hungary, Poland, 
Slovenia, Slovakia 
15.2 10.2 0.3 4.9
South East (EU): Bulgaria, 
Cyprus, Malta, Romania
7.9 5.9 0.3 3.0
South East (non-EU): 
Bosnia & Herzegovina, 
Croatia, Macedonia, Serbia, 
Turkey
7.7 8.6 0.4 2.5
East: Belarus, Moldova, 
Russia, Ukraine
8.3 5.2 0.3 2.4
* Party drugs include ecstasy, amphetamine, methamphetamines, mephadrone, GHB, ketamine and cocaine. Adapted from EMIS 
Network.28
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North America
There are no publically available national MSM drug use 
prevalence data for the USA: prevalence is reported only at 
a city or state level. This approach is appropriate in terms of 
influencing local harm reduction interventions but makes 
country-level comparison difficult. Table 4 provides a snapshot 
of drug use prevalence in different cities, established via 
multiple surveys. 
Similar levels of poppers use among MSM have been observed 
in Canada.35 
A significant body of research has addressed 
methamphetamine use among MSM in the USA. This drug 
is commonly associated with euphoria, decreased sexual 
inhibition and hypersexual behaviour.36, 37 Analysis of data 
collected annually between 1996 and 2007 in Los Angeles 
found levels of methamphetamine use within the last 12 
months varying from 11% to 53%.38 A longitudinal study of 
club drug using gay and bisexual men in New York found that 
64.6% of their sample reported using methamphetamine 
within the previous four months.39 
Levels of IDU among MSM in both Canada and the USA have 
typically been very low.2, 40, 41, 42 
South America
Between 1999 and 2002 a series of 19 sero-epidemiological 
cross-sectional surveys43 were conducted among MSM in 
seven different South American nations: Argentina, Bolivia, 
Colombia, Ecuador, Paraguay, Peru and Uruguay. These 
surveys asked about history of drug use (ever) and analysed 
such usage in light of national HIV prevalence to identify 
significant associations. The surveys recruited a total of 13,847 
MSM participants by opportunistic, community sampling, 
although the number of participants varied considerably 
between countries. Reported data from Peru appear 
incomplete; therefore, Peru is not included in Table 5.
Table 4: Prevalence of drug use among MSM across the USA
City/region 
(Year of data 
collection)
Methamphetamine 
%
Cannabis 
%
Ecstasy 
%
Cocaine 
%
Poppers 
%
Study type
Time 
frame of 
drug use
Reference
New York 
(2007)
6.2 27.9 8.38 12.03 24.46
Community survey of 
MSM (n=740)
Within 
the last 3 
months
Carpiano et 
al. (2011)32
Chicago  
(2002–2003)
6 28 13 12 -
Household survey. Data 
from HIV-negative MSM 
(n=151)
Within 
the last 6 
months
Fendrich et 
al. (2010)33
San Francisco 
(1999–2001)
23* - - 19 37
Randomised behavioural 
intervention of MSM 
accessing counselling 
(n=736)
Lifetime 
use
Colfax et al. 
(2005)34
* Includes speed and any form of methamphetamine
Table 5: Reported drug use (ever) among MSM from six South American countries
Drug used (ever) Colombia % Ecuador % Bolivia % Argentina % Uruguay % Paraguay %
Cannabis 31.2 17.4 21.4 15.4 14.8 42.4
Heroin 2.4 0.6 0.0 0.4 0.2 4.3
Cocaine 14 4.9 17.2 6.7 21.9 26.4
[Adapted from Bautista et al.]43
Chapter 3.3
152
Broad patterns of drug use among all 
MSM
In reviewing this broad literature from across the globe, 
several patterns in MSM drug use emerge. Firstly, most 
drug use among MSM appears to be episodic, with weekly 
or monthly use far higher than daily.15, 29, 44 This might 
suggest that most MSM who report drug use are not drug-
dependent but instead use drugs for specific purposes (such 
as when partying, socialising or when seeking or having sex).45 
Episodic drug use may also reflect specific periods of stress or 
uncertainty, such as an HIV diagnosis, struggles in the process 
of ‘coming out’, or may occur in combination with periods of 
depression or anxiety. 
Secondly, MSM, or gay men, are not a homogenous group in 
terms of drug use. Prevalence of use was very often higher 
among further marginalised or minority groups, such as ethnic 
minority gay men in the USA,46-48 and is often higher among 
younger men.42, 49, 50 Use of most drugs (except cannabis) 
tends to be higher among MSM living in large urban centres, 
particularly those with large gay populations such as Berlin, 
Sydney, London and San Francisco than it is among men in 
more rural areas.26, 30 
Thirdly, polydrug use (taking more than one drug during the 
same session or within a fixed time frame) is common among 
MSM, particularly with regards to stimulants (‘party drugs’) 
such as ecstasy, cocaine, amphetamines or ketamine.34, 51 
Fourthly, across the world, the prevalence of IDU, especially 
heroin, was generally very low. Other than in South Africa, 
reported levels of IDU in non-purposive samples rarely 
exceeded 5%. Previous authors52 have suggested that the 
reason insufficient attention has been paid to drug use 
among MSM is specifically because levels of heroin use – 
often the focus of drug harm reduction services – have been 
comparatively low. In the absence of heroin-related health 
concerns, and those social or community harms such as crime 
which are often associated with problematic heroin use, the 
harm reduction needs of gay men have not always featured 
on the radar of policymakers. 
Harms associated with drug use 
among MSM
Harms to physical and mental health
The physical and mental health harms associated with 
cocaine, heroin, ecstasy, cannabis, LSD and amphetamines are 
well documented, and are likely to be similarly represented in 
MSM. 
Crystal methamphetamine is a super-strength amphetamine 
stimulant, which results in high-energy feelings of confidence, 
invincibility or impulsiveness. Continuous stimulation of the 
nervous system by crystal methamphetamine has been 
known to cause anxiety, depression, confusion, insomnia, 
psychosis and suicidal ideation,53 and long-term use may also 
result in a loss of motor control or memory.54
GHB/GBL (Gamma-butyrolactone) is a party drug that brings a 
sense of euphoria. It is usually sold diluted in water, although 
just an extra millilitre of GBL over a moderate dose can result in 
an overdose, the effects of which are often unconsciousness, 
coma or death by respiratory depression. GBL can be addictive 
(although this usually only develops over longer periods 
of time) and, therefore, can result in significant withdrawal 
effects. 
After-effects of inhaling poppers can include headaches, skin 
rashes, sinus pains and burns, but only if the liquid comes 
into contact with the skin. They have also been known to 
cause nausea and vomiting. Inhaling poppers after taking 
anti-impotence drugs, such as Viagra or Cialis, can result in a 
dangerous drop in blood pressure.55 This may be more likely 
to occur if also taking a protease inhibitor as part of HIV anti-
retroviral therapy (ART). 
There is evidence to suggest that the use of a range of drugs, 
particularly methamphetamines, GBL and ecstasy, might have 
a detrimental impact on adherence to ART.56, 57
Harms to sexual health and well-being
The association between drug use (particularly 
methamphetamine, ecstasy and cocaine) and sexual risk 
behaviours is complex, and a comprehensive analysis of this 
literature is beyond the scope of this chapter (for a review, 
see Corsi et al.58 or Romanelli et al.59). It is possible to say that 
there is a clear association between certain drug use and sex 
that carries a risk of HIV transmission. However, it is not clear 
whether this is causal or simply co-relational. 
Significant attention has been paid to the role of 
methamphetamine in HIV transmission risk behaviours, 
particularly in the USA. This drug can cause feelings of 
hypersexualisation and is commonly utilised as part of 
sexual marathons (protracted periods of sexual activity) 
and group sex activities.60-62 Ensuing rectal trauma facilitates 
the transmission of HIV. Numerous studies have suggested 
that the use of methamphetamine causes high-risk sexual 
behaviour,63-65 perhaps via a myopic mechanism or the 
removal of sexual inhibitions. However, other studies have 
challenged this causal pathway.66, 67
Other associations with high-risk sexual behaviour have been 
identified in relation to ecstasy,68 GHB/GBL69 and ketamine.70 
Men who reported polydrug use in the recent past (up to 
three months) are more likely to report HIV risk behaviours 
than men who took only one drug.44, 47 
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Poppers cause blood vessels to dilate and also relax the 
anal sphincter muscle. This can make receptive anal 
intercourse more comfortable for some men. The process of 
vasodilatation, and the fact that sex may be rougher or last for 
longer while using poppers, means that their use during sero-
discordant anal intercourse can increase the probability of HIV 
transmission by a factor of three.71, 72 
Motivations for drug use
There has been relatively little research exploring the reasons 
or motivations for drug use among MSM or the personal and 
social context within which drug use occurs, particularly 
outside North America, Western Europe and Australia. 
Numerous authors52, 73 have highlighted that in most settings 
the majority of venues to meet other men for social and/
or sexual interaction are those where alcohol is served and 
drug use is common. Clubs and bars are the centre of most 
‘gay scenes’, and drug use itself is normalised within this 
environment. Drugs often serve a very deliberate purpose 
in helping individuals to relax, to socialise, to mitigate social 
unease and to gain confidence in seeking sexual partners.74 
The value of these actions and activities should not be 
underestimated by those seeking to support MSM to reduce 
any harm that may be associated with their drug use.
Further to this, a significant body of research indicates that 
(crystal) methamphetamines are often used by MSM to 
psychologically enhance sexual experience, to maintain 
sexual activity over long periods of time and to facilitate 
sexual desires by dissipating sexual inhibitions.75-77 Drugs may 
also help MSM with diagnosed HIV, in particular, to ‘cognitively 
escape’ from fear of rejection and negative self-perception 
and to cope with broader emotional and physical demands of 
living with HIV on a daily basis.78
The best indicator of whether drug use is problematic, or 
is in danger of becoming so, is if the individual concerned 
considers their use in this way. As already discussed, drug use 
among MSM in general tends to be episodic in nature, but 
dependency can still develop and significant harm can result. 
For many men, drug use becomes problematic when the costs 
or side-effects associated with usage impinge on their ability 
to live the life they are comfortable or content with.
Harm reduction interventions to meet 
the needs of MSM
Drug use interventions for MSM need to empower men with 
honest information about what the possible effects (both 
positive and negative) might be of taking a range of drugs. 
They should seek to support men, and those around them, 
to control or limit their use, or to limit the harms associated 
with such use, at times when they consider their drug 
use is causing harm to themselves or others. This can be 
accomplished in a number of ways, ranging from provision 
of educational information to psychotherapeutic support 
and pharmacological interventions. Whatever the setting, 
interventions should take into account each man’s personal 
circumstances, acknowledging that drugs can serve a useful 
purpose in their lives, particularly in terms of mitigating 
psychological unease or by facilitating social or sexual 
contact. Health professionals should take account of these 
motivations and work with men to identify what level or type 
of drug use they are comfortable with, and help to reduce 
harms associated with this use.
Numerous civil society organisations in Australia, Canada, 
Germany, Poland, the UK and USA have developed websites or 
printed information booklets that explain the effects of drugs 
commonly used by MSM, and describe ways in which any 
associated harms might be mitigated. They often also include 
information about the legal status of each drug, and provide 
referral information for direct contact services if readers 
consider their use problematic. 
Provision of psycho-therapeutic services or counselling 
specifically designed to address problematic drug use 
among MSM varies considerably across the world and 
within individual countries. They are known to currently 
exist in Australia, Canada, Germany, New Zealand, Norway, 
South Africa,79 Spain, Sweden, the UK and USA. A service 
in Hong Kong ran between 2007 and 2009. Such therapy 
includes drop-in advice, motivational interviewing, support 
groups and cognitive behavioural therapy. Many of these 
interventions appear grounded in evidence from evaluations 
of the general population (for review, see Shearer80), although 
there have been a number of evaluations of behaviour change 
interventions related to methamphetamine use specifically 
among MSM.81-83 In many instances, such evaluated 
programmes focus on reducing harms to sexual health and 
the likelihood of contracting or transmitting HIV, with mixed 
success (for review, see Rajasingham et al.57). In a very small 
number of settings, primarily the UK and USA, pharmacologic 
interventions exist to address methamphetamine use, but 
their effectiveness is still uncertain.84, 85
In Australia, and in many parts of Europe and North America, 
harm reduction services are situated within the HIV prevention 
sector, largely because of the association with sexual risk 
behaviours and because this sector is well established with 
strong links to the gay communities they serve. There is 
currently no provision of any harm reduction interventions 
specifically targeting MSM in Africa (except the Republic of 
South Africa), Asia, the Caribbean or South America. While 
MSM could access services for the general population (where 
they exist), previous research has reported that they often 
feel uncomfortable or unwelcome in such environments.52 
Drug use among MSM is frequently associated with ‘gay scene’ 
social activity or with sex, and many services for the general 
population may not be sufficiently knowledgeable, skilled or, 
indeed, accepting to help address drug use that occurs within 
these contexts. 
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Case study: 
antidote @ London friend
This organisation works exclusively with lesbian, gay, 
bisexual and transgender (LGBT) people who use drugs, 
the majority being gay men in their 20 and 30s, mostly 
employed and financially self-supporting. In the past 
three to four years the drug use profile of their clients 
has shifted towards crystal meth and GHB/GBL, with 
many people using them in sexual contexts. There 
has been a trend to inject crystal, and for GBL use to 
rapidly escalate to dependence levels (dosing around 
every two hours), so the type of intervention has had to 
extend to medical (mainly prescribing for GBL detox), 
having been mainly psychosocial. This typically involves 
administering benzodiazepines in high doses (often 
> 100mg/24hrs),6 which they offer in partnership with 
the NHS Club Drug Clinic, to help clients deal with 
withdrawal symptoms. Dependence on GBL is an entirely 
new phenomenon for members of the community, who 
have used other drugs, often without major problems, 
for many years.
Most service users do not fit the typical profile of 
mainstream UK drug services or the typical drug 
patterns presenting there. By offering a targeted service 
they are able to remove many of the barriers of users not 
identifying with generic support. Being an LGBT service 
means that people feel less judged and more able to talk 
about their full range of associated problems, which they 
may feel inhibited to do in generic services, particularly 
as it may involve talking about sexual behaviours they 
feel ashamed of. 
They work around reasons for using, dealing with 
cravings and trigger situations, negotiating safer 
boundaries and improving well-being overall; these are 
all typical substance misuse interventions, but it is their 
provision in a safe and understanding LGBT environment 
which sets the service apart. c 
c
Conclusions
This review has highlighted the extent of drug use among 
MSM and summarised the range of harms that can be 
associated with their use. Drug use is common among MSM 
and is well established in gay social and sexual environments. 
Given the significant harms associated with many of the drugs 
that MSM use, harm reduction interventions that meet the 
specific needs of MSM should be prioritised in all parts of the 
world.
 
c    See http://www.londonfriend.org.uk
Establishing the prevalence of drug use among MSM living 
in Central Asian Republics, South America, the Caribbean 
and Africa is a research priority. Systematic population and 
local-level estimations for MSM populations are a necessary 
precursor to this. There is a need for more qualitative research 
in many parts of the world that explores the reasons why MSM 
use drugs and the personal and social context of this use. 
Harm reduction practitioners should seek to understand 
variations in drug use among MSM in their local area and 
tailor interventions accordingly. They should attend to 
changes in such use over time, and be accepting of the social 
and sexual environments in which drug use often occurs. 
Harm reduction practitioners should also attend to ethnic or 
sexuality variation within MSM communities, acknowledging 
that further marginalised sections of the population are more 
likely to use drugs and for such use to be problematic. As the 
evidence base for prevalence, motivations, context and harms 
associated with drug use among MSM evolves, so it would be 
beneficial to develop toolkits for effective interventions for 
rollout in various settings. 
As long as homosexuality – or acts of sex between men – is 
criminalised, and as long as MSM face stigma and persecution, 
it will remain a significant challenge to develop and deliver 
effective interventions to meet the complex needs that this 
review identifies. Legal and policy reforms relating to MSM are 
required in a large number of countries if prevention of HIV 
transmission and a reduction in other harms associated with 
drug use is to be realised. 
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Introduction
Decriminalisation of drug possession or use can be defined as 
‘the removal of sanctions under criminal law, with optional use 
of administrative sanctions, such as the application of civil fines 
or court-ordered therapeutic responses.’2 Decriminalisation is 
often mistakenly understood to mean complete removal or 
abolition of possession offences, or confused with ‘legalisation’ 
(legal regulation of drug production and availability).3 Under 
decriminalisation regimes, possession and use of small amounts 
of drugs are still unlawful but not criminal offences. 
The first half of this chapter examines the harms associated 
with criminalising people who use drugs (PWUD) and outlines 
key considerations for the implementation of decriminalisation 
of drug possession. The second portion considers models of 
decriminalisation of drug possession adopted by different 
countries around the world. It also provides recommendations 
that should be taken into account when implementing 
decriminalisation of drug possession and highlights the growing 
support for adopting such a model. 
International drug treaties 
and decriminalisation of drug 
possession
The modern international drug control framework was 
established under the 1961 UN Single Convention on 
Drugs,4 but the criminalisation of personal possession 
was first explicitly introduced by the 1988 UN Convention 
against Illicit Traffic in Narcotic Drugs and Psychoactive 
Substances.5 Article 3(2) of the 1988 convention states: 
‘...each Party shall adopt such measures as may be 
necessary to establish as a criminal offence under 
its domestic law, when committed intentionally, the 
possession, purchase or cultivation of narcotic drugs or 
psychotropic substances for personal consumption.’ 
The commentary on the 1988 convention says explicitly 
that this paragraph ‘amounts in fact also to a penalisation 
of personal consumption.’ Over 180 States are parties to 
the three UN drug conventions (1961, 1971 and 1988), and 
the punitive paradigm they establish has subsequently 
been translated into domestic policy and law across the 
world.
However, the 1988 convention does not specify the 
nature of the sanction and additionally provides a caveat 
to the presumption that States must criminalise drug 
possession. Article 3(2) begins with the statement that any 
measures adopted shall be ‘subject to its constitutional 
principles and the basic concepts of its legal systems.’ 
State parties can, therefore, adopt a less punitive criminal 
justice approach to drug possession and use without 
breaching their international obligations.6, a 
a
a   For further discussion, see Bewley-Taylor D & Jelsma M (2012) The UN drug control 
conventions: The Limits of Latitude, Series on Legislative Reform of Drug Policies No. 18. 
Amsterdam: Transnational Institute.
Criminalisation as a risk factor in 
drug-related harm
The criminalisation of PWUD (directly criminalising use, or 
indirectly through criminalising possession) has been a central 
pillar of illicit drug control for over a century. 
This punitive approach has come under increasing scrutiny 
as it has been identified as a key structural risk factor for a 
range of drug-related harms for people who inject drugs 
(PWID).7 More commonly higher rates of HIV infection among 
PWID8 are seen in environments in which injecting drug use 
(IDU) and other associated practices such as the provision of 
sterile needles are criminalised.8 The following approaches 
contribute to exacerbating drug-related harms in a number 
of ways: 
 » encouraging needle sharing and hurried and higher-risk 
injecting – all of which increase the risk of contracting 
HIV, viral hepatitis and other blood-borne viruses8
 » pushing use into unhygienic marginal environments and 
thus increasing the risk of infection and overdose death
 » increasing the prison population of people who use 
and inject drugs – a high-risk environment usually with 
poor provision of harm reduction and HIV prevention 
services.9
Criminalisation is intended to stigmatise drug use 
and generate social disapproval. This has resulted in 
discrimination against PWUD10 and can further increase 
risks by: 
 » undermining drug education, prevention and harm 
reduction efforts by alienating and marginalising key 
populations at higher risk of acquiring HIV, including PWID
 » deterring individuals from approaching services for help 
or volunteering information about drug use in emergency 
situations such as overdose11
 » creating informal barriers that effectively deny 
antiretroviral or hepatitis C treatment to people who use 
drugs12, 13, 14 
 » negatively impacting on wider life opportunities, including 
access to housing, personal finance and employment, 
that are all positively linked to improved health and well-
being15,  b 
 » justifying the continuation of counterproductive 
enforcement approaches, with opportunity costs for public 
health elements of designated drug policy budgets.
Conversely, claims for a positive deterrent effect from user-level 
punitive enforcement are not well supported by the limited 
empirical research and comparative analysis available.16, 17 
Many of the groups most vulnerable to drug-related harms 
b   McLaren & Mattick (2007) compared the outcomes of individuals given a non-criminal 
sanction in South Australia and individuals given a criminal sentence in Western Australia 
(pre-decriminalisation) and found that the individuals given criminal penalties were more 
likely to suffer negative employment, relationship and accommodation consequences as a 
result of their cannabis charge and were more likely to come into further contact with the 
criminal justice system than the (non-criminalised) individuals in South Australia.
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(including young people, PWID, those from lower socio-
economic backgrounds, those with existing criminal records, 
and those with mental health vulnerabilities) are also likely to 
be among the least deterred by criminalisation.18
Definitions of ‘decriminalisation’
‘Decriminalisation’ is not a strictly defined legal term, but its 
common usage in drug policy (and the definition used here) 
refers to the removal of criminal sanctions for possession of 
small quantities of currently illegal drugs for personal use, 
with optional use of civil or administrative sanctions.2 Under 
this definition of ‘decriminalisation’, possession of drugs 
remains unlawful and a punishable offence (albeit not one 
that results in a criminal record).
A distinction is also made between de jure decriminalisation, 
involving specific reforms to the legal framework, and de 
facto decriminalisation, with a similar outcome but achieved 
through non-enforcement of criminal laws that technically 
remain in force. With the exception of some of the more 
tolerant policies for cannabis possession (for example, in 
Spain, the Netherlands and Belgium), people caught in 
possession under a decriminalisation model will usually have 
the drugs confiscated. 
Policy variables
There is considerable variation in how decriminalisation 
models function in different jurisdictions, making 
international comparisons and generalisations about impacts 
on key indicators problematic. Each of these variables can 
have a significant impact on the measurable outcomes. These 
include:1
Threshold quantities 
Many but not all decriminalisation policies use maximum-
quantity thresholds to distinguish between trafficking or 
supply offences and personal possession or use offences.19 
Mexico, for example, allows possession of up to 0.5g of 
cocaine without prosecution, while Spain allows up to 7.5g, 
a fifteen-fold difference.20 Since cocaine is usually sold in 1g 
units, Mexico’s permissible possession level of 0.5g means it 
is likely that virtually everyone will exceed that threshold and 
be liable for criminal prosecution.
Types of administrative penalties
Non-criminal sanctions in different jurisdictions include: 
fines, community service orders, warnings, mandatory 
treatment or education sessions, driver’s or professional 
licence suspensions, travel bans, property confiscation, 
associational bans, mandatory reporting, mandatory drug 
testing, termination of public benefits, administrative arrest, 
or no penalty at all. 
Roles of the judiciary and police
Some jurisdictions, such as the Czech Republic and the 
Australian states with civil penalty schemes, allow the police 
to issue fines in the field for minor drug offences, similar to 
issuing a traffic violation. Other jurisdictions, such as Brazil 
and Uruguay, require individuals arrested for drug offences to 
appear before a judge in court to determine the charge and 
receive an appropriate sentence, if any.
Policy implementation
Role of medical professionals and harm reduction 
programmes 
The effectiveness of decriminalisation of drug possession 
is also dependent on a number of other key considerations 
including investment in a wide range of harm reduction and 
treatment options. The relationship between a country’s 
public health and law enforcement systems can significantly 
change an individual’s experience following an arrest for 
a drug offence. For example, the significant investment in 
Portugal’s harm reduction interventions and treatment in 
2001 (see Page 5), coupled with the new decriminalisation 
model, saw an increase in the numbers accessing services. 
Many commentators have highlighted that the reduced 
stigma associated with drug use, due largely in part to the 
decision not to impose criminal sanctions, contributed to this 
increase.21 As the current report shows, jurisdictions also vary 
greatly in the resources allocated to and availability of harm 
reduction and treatment programmes.
Data availability and quality
Data availability and quality are important to assess the impact 
for a country that has adopted decriminalisation. Incomplete, 
inaccurate or inconsistent data on key indicators assessing 
the impact of decriminalisation pose important challenges 
to evaluation. For example, long reporting periods between 
national surveys on prevalence or the manner in which drug-
related deaths are recorded can make it difficult to ascertain 
the actual impact of the policy. 
Implementation challenges
Despite the existence of a statutory, judicial or regulatory 
decriminalisation policy, a jurisdiction’s inability or 
unwillingness to implement that policy in practice can make 
it difficult to assess a policy’s merits. In Peru, for example, 
researchers report that police regularly arrest and detain 
individuals for long periods without charge for decriminalised 
drug offences. In practice, for those in detention, such 
a system does not resemble decriminalisation, despite 
Peruvian law instructing no penalty for certain minor 
possession offences. Furthermore, in some jurisdictions the 
impact of decriminalisation has had a ‘net-widening’ effect, 
so that while the intention of the policy is to decriminalise 
certain behaviour, in practice more people get caught up in 
the system.22
160
Social, cultural, economic and religious 
characteristics
A community’s – or individual’s – relationship to drug use is 
impacted by much more than a country’s drug laws. Public 
health capacity, religiosity, cultural history, employment, 
inequality23 and various other measures of social and personal 
well-being significantly impact drug-using behaviours in a 
given society. It is important to recognise that impacts and 
implementation of drug decriminalisation policies cannot be 
evaluated in a vacuum.
Growing support for decriminalisation
High-level support for decriminalisation has grown in 
recent years in parallel with the growing trend towards 
its adoption by states and jurisdictions. Alongside the 
development of the wider mainstream drug policy reform 
movement (focused primarily on recreational cannabis use), 
support for decriminalisation of drug possession and use in 
the context of HIV and other blood-borne viruses among 
PWID has also grown significantly among key voices in the 
public health community. This includes journals such as the 
British Medical Journal24 and Lancet,25 non-governmental 
organisations (NGOs) including the Red Cross/Red Crescent26 
and International AIDS Society (IAS),27 and high-profile 
individuals including Anand Grover (UN Special Rapporteur 
on the Right To Health),28 Michel Sidibé (UNAIDS Executive 
Director),29 Ban Ki-Moon30 (UN Secretary-General) and Michel 
Kazatchkine31 (former Executive Director, the Global Fund to 
Fight HIV, Tuberculosis and Malaria). Among the UN family of 
agencies, UNAIDS32 and UNDP have shown cautiously worded 
support in principle (but remaining reluctant to overtly use 
the language of ‘decriminalisation’). The executive summary 
of the 2012 UNDP Global Commission on HIV and the Law 
report, for example, highlights the need to:
Reform approaches towards drug use. Rather than 
punishing people who use drugs but do no harm 
to others, governments must offer them access to 
effective HIV and health services, including harm 
reduction programmes and voluntary, evidence-
based treatment for drug dependence. 33
Even the historically conservative UN Office on Drugs and 
Crime (UNODC) has increasingly adopted the narrative that 
‘drug use is a health problem, not a crime,’34 and in a 2012 
discussion position paper the UNODC make clear that:
Responses to drug law offences must be 
proportionate. Serious offences, such as trafficking 
in illicit drugs must be dealt with more severely and 
extensively than offences such as possession of drugs 
for personal use. For offences involving the possession, 
purchase or cultivation of illicit drugs for personal use, 
community-based treatment, education, aftercare, 
rehabilitation and social integration represent a more 
effective and proportionate alternative to conviction 
and punishment, including detention.35
One of the highest-profile public expressions of support, 
in terms of signatories and media coverage, has been the 
Vienna Declaration,36 which states ‘The criminalisation of 
illicit drug users is fuelling the HIV epidemic and has resulted 
in overwhelmingly negative health and social consequences. 
A full policy reorientation is needed’ and includes a call on 
‘governments and international organisations, including the 
United Nations,’ to ‘decriminalise drug users.’ 
In June 2012 the Global Commission on Drug Policy launched 
its second report, The War on Drugs and HIV/AIDS: How the 
Criminalization of Drug Use Fuels the Pandemic.37 It highlighted 
that fear of criminalisation led to increased HIV risk behaviour 
in certain countries and that mass incarceration fuelled HIV 
transmission rates within prisons. The Commission, which is 
made up of several former presidents and other high-profile 
individuals, has repeatedly called for the decriminalisation of 
drug possession. 
Decriminalisation systems around the 
worldc 
It is estimated that around 25–30 countries have 
now implemented some form of decriminalisation. 
Decriminalisation approaches are found mostly in Europe, 
Latin America and, to a lesser extent, Eurasia, as well as 
some parts of the USA (cannabis only) and Australia. The 
precise number of countries implementing such an approach 
depends on which definition is used, with additional 
problems in quantifying more localised or informal de facto 
decriminalisation policies, as well as challenges of incomplete 
country data. Some Southeast Asian states, such as Vietnam, 
nominally espouse decriminalisation of use but are not 
included here because, instead of criminal sanctions, they 
often forcibly detain drug users in ‘drug detention centres’ 
largely indistinguishable from prisons and associated with 
serious human rights violations.38, 39
The following survey is adapted from the Release report, A 
Quiet Revolution: Drug Decriminalisation Policies in Practice 
Across the Globe.1
c    This information is largely taken from the report by Release: Rosmarin A & Eastwood 
N (2012) A Quiet Revolution: Drug Decriminalisation Policies in Practice Across the Globe. 
London: Release. 
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Western Europe
 » Belgium decriminalised small-scale cannabis possession 
in 2003.40
 » German federal law has contained decriminalisation 
elements since the early 1990s.41 There is variation 
between different Länder (German states) in 
application.42, d
 » Italy first decriminalised drug possession in 1975. Since 
then, laws and policies around drug possession have 
fluctuated between harsh and lenient penalties.43 
d   For the different thresholds, see: http://www.drug-infopool.de/gesetz/nordrhein-
westfalen.html.
 
 » Spain formally decriminalised possession and private 
use of small amounts of drugs in 1982, following a 1974 
Supreme Court ruling.44, 45
 » The Netherlands has had a de facto decriminalisation 
policy since 1976. While remaining technically criminal, 
possession offences of up to 5g of cannabis (30g prior to 
1996)46 or ‘one dose’ of ‘hard’ (non-cannabis) drugs for 
personal use are not prosecuted.47 
 
Case Study: The Portuguese decriminalisation experience
Portugal provides a useful case study, with over a decade 
of detailed evaluation to draw on and a policy developed 
and implemented in response to a perceived national drug 
problem with public health priorities at the fore from the 
outset. Notably, Portugal coupled its decriminalisation 
with a public health reorientation that directed additional 
resources towards treatment and harm reduction.48 Those 
caught in possession are referred to a ‘dissuasion board’ that 
decides whether to take no further action (the most common 
outcome), direct the individual to treatment services if a 
need is identified, or impose an administrative fine.  
The useful volume of data collected during and since the 
reform offers considerable scope for filtering through 
different political and ideological lenses;49 contrast 
the evaluation of Portugal’s prohibitionist ‘anti-drug’ 
organisations who see it as an unmitigated disaster50 with that 
of the high-profile but overwhelmingly positive Greenwald 
report51 from the libertarian-leaning Cato Institute. A more 
rigorous and objective academic study of the Portuguese 
experience from 20082 summarises the changes observed 
since decriminalisation as: 
 » small increases in reported illicit drug use among 
adults
 » reduced illicit drug use among problematic drug users 
and adolescents, at least since 2003
 » reduced burden of drug offenders on the criminal 
justice system
 » increased uptake of drug treatment
 » reduction in opiate-related deaths and infectious 
diseases 
 » increases in the amounts of drugs seized by the 
authorities
 » reductions in the retail prices of drugs.
In conclusion the authors note: 
[Portugal’s experience] disconfirms the hypothesis 
that decriminalisation necessarily leads to increases 
in the most harmful forms of drug use. While small 
increases in drug use were reported by Portuguese 
adults, the regional context of this trend suggests 
that they were not produced solely by the 2001 
decriminalisation. We would argue that they are less 
important than the major reductions seen in opiate-
related deaths and infections, as well as reductions in 
young people’s drug use. The Portuguese evidence 
suggests that combining the removal of criminal 
penalties with the use of alternative therapeutic 
responses to dependent drug users offers several 
advantages. It can reduce the burden of drug law 
enforcement on the criminal justice system, while 
also reducing problematic drug use.
Supporting these conclusions has been a more recent Drug 
Policy Profile of Portugal48 from the European Monitoring 
Centre on Drugs and Drug Addiction, which observed that: 
While some want to see the Portuguese model 
as a first step towards the legalisation of drug use 
and others consider it as the new flagship of harm 
reduction, the model might in fact be best described 
as being a public health policy founded on values 
such as humanism, pragmatism and participation.
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Latin America
 » Argentina’s Supreme Court declared criminalisation 
of drug possession for personal consumption 
unconstitutional in 2009.52, 53 A process of formally 
incorporating this decision into law is underway.54
 » Chile decriminalised possession in 2007;55 sentencing 
judges can administer fines, mandatory treatment, 
community service requirements and/or suspension 
of driver’s licence.56 Although the majority of cases 
end in the suspension of sentences or administrative 
sanctions, many people caught with small quantities do 
go to prison. Chile is assessing possible further changes 
to its laws, including full decriminalisation.56 
 » Colombia decriminalised possession following a 
Constitutional Court ruling in 1994.57 This decision 
has been subject to more recent ongoing legal and 
constitutional argument between the government and 
Supreme Court.58, 59, e While these tensions leave the 
situation in flux, de facto decriminalisation continues, 
with a formal new government decriminalisation 
proposal reported.60
 » Mexico decriminalised possession of small amounts 
of drugs in 2009, replacing criminal sanctions with 
treatment recommendations, and mandatory treatment 
for repeat offenders.61 The quantity thresholds 
have, however, been criticised as being too low and 
ambiguous, leaving implementation vulnerable to 
police corruption.62
 » Paraguay decriminalised small-scale possession in 
1988.56
 » Peru decriminalised drug possession in 2003,63 but 
research reveals a disconnect between policy and the 
reality of police practices in the country.64
 » Uruguay has never criminalised possession of drugs 
for personal use.56 The principle formally entered 
Uruguayan law in 1974. Concerns have been raised 
about high levels of pre-trial detention without charge 
for more serious drug offences.65
 » Decriminalisation laws are also pending in Brazil and 
Ecuador.f
Eurasia
 » In Armenia possession of small quantities of drugs 
has been decriminalised since 200866 and is subject to 
administrative fines. However, the high level of fines 
(100 to 200 times the minimum wage for first-time 
offenders) can still result in incarceration of those 
unable to pay.  
e   The dose is not the only factor the Court can look at when considering if drugs are for 
personal use.
f   For updates, see: http://www.druglawreform.info/en/country-information/item/261-
regional-overview-of-drug-law-reform-in-latin-america.
 » In Estonia possession of small quantities of drugs for 
personal use has been decriminalised since 2002,47, 67 
subject to court-ordered administrative fines or 30 days 
administrative detention (in a local police jail). 
 » In Kyrgyzstan small-scale possession offences have 
been decriminalised and subject only to administrative 
responses since 1998.68
 » In Poland since May 2011 prosecutors have had 
discretion not to prosecute small-scale possession 
offences69 or if the individual is judged to be drug-
dependent. 
 » The Czech Republic formally decriminalised possession 
of all drugs for individual use in 2010.70
 » Russia nominally decriminalised possession in 2005. 
Article 228 of Russia’s criminal code provides that 
possession of less than a ‘large amount’ of illegal 
drugs face only administrative sanctions. However, 
since then the threshold amount that determines a 
‘large’ quantity of drugs has oscillated from very low 
thresholds to slightly higher thresholds and back again, 
making decriminalisation in Russia an inconsistent and 
effectively unrealised policy.71
Other countries
 » Between 1987 and 2004 four Australian states 
decriminalised possession and use of cannabis. Two 
of these, Northern Territory72 and South Australia,73 
have additional treatment diversion schemes for those 
found in possession of other drugs for personal use 
(completion of the designated programme avoids a 
prosecution). 
 » Since 1973, 14 US states and a number of other local 
jurisdictions have decriminalised cannabis possession. 
Recommendations for 
implementation of decriminalisation 
of drug possession
When adopting a decriminalisation policy, a number of 
factors have to be considered to ensure the framework is 
meaningful in its goal of not criminalising those caught in 
possession of drugs for their own personal use. The following 
section details points for consideration in terms of the actual 
policy/legislation and implementation of the policy: 
 » Thresholds – where threshold amounts are adopted 
to determine whether someone is in possession for 
personal use the level needs to reflect market realities 
and be flexible enough to ensure that the principle of 
decriminalisation of personal possession is properly 
achieved. 
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 » Response – the State can either decide to take no 
action against someone caught in possession of drugs 
(for example, the Netherlands or Belgium) or can 
respond using civil sanctions. 
 
If a system of fines is to be adopted, they must be set at 
a reasonable level and not result in the imprisonment 
of large numbers of people for non-payment. Other 
forms of civil penalties, such as seizure of passport or 
driving licence, should be avoided, as these can have a 
disproportionately negative impact on a person’s life.  
In terms of those who are dependent on drugs, 
Portugal’s approach, in which the police work with 
treatment agencies to offer an individualised referral 
route (with a range of treatment options available, 
including harm reduction), appears to be a pragmatic 
option. Also, failure to meet the conditions of treatment 
should be addressed by involving the person in their 
treatment programme and should certainly not 
result in criminal sanctions. In particular, ‘drug-free’ 
conditionality is also potentially setting up a person to 
fail, given the relapsing nature of drug dependence. 
 » Disproportionate sentencing for cases involving 
possession above the threshold or supply offences 
– it is critical that governments recognise the principle 
of proportionality in sentencing for drug offences. 
Too often those convicted of non-violent drug supply 
offences receive custodial periods which are much 
harsher than other violent offences, such as rape and 
even murder. 
 » Public health interventions and treatment – 
countries that wish to reduce the potential harms of 
problematic drug use and limit long-term health costs 
by introducing programmes that tackle HIV transmission 
and other blood-borne viruses should consider coupling 
the decriminalisation model with such a public health 
investment. 
 » Net-widening – policymakers must work to ensure that 
decriminalisation does not result in more people coming 
into contact with the criminal justice system. Whether 
this comes as a result of expanded police powers or low 
thresholds, decriminalisation policies must be targeted 
at reducing the number of individuals who suffer from 
the consequences of a criminal conviction, not merely 
the enactment of decriminalisation in name only.
Discussion
Given the wide variation in models around the world, there 
are relatively few general conclusions that can be made about 
the impacts of decriminalisation beyond the observation that 
it does not lead to the explosion in use that many fear. Critics 
of decriminalisation will often cite drug tourism as a risk 
associated with the introduction of such a policy. However, 
there is no evidence to suggest that this occurs. More often 
than not, countries or states that have adopted this approach 
will see similar rates of prevalence as their neighbours.22, 74-77, g
Research from Europe,78 Australia,72 the USA22 and globally17 
suggests changes in intensity of punitive user-level 
enforcement appear to have only a marginal influence on 
determining prevalence of use, although, as noted earlier, 
there are significant impacts on risk behaviours. 
Increasingly, more countries are joining the drug policy 
reform debate. Latin and Central American countries such 
as Colombia79 and Guatemala80 are some of the leading 
proponents calling for a reform of drug laws. Australia81 has 
set up a new enquiry to consider the implementation of 
decriminalisation of possession of all drugs. It is not surprising 
that this growing momentum for change is occurring; the 
harms caused by criminalising those who use drugs are well 
documented, but added to this is a global economic crisis 
which is seeing cuts in police budgets all over the world. In 
California the decriminalisation of cannabis saw the total cost 
of enforcement decline from $17 million in the first half of 
1975 to $4.4 million in the first half of 1976.22
Some research has shown that beyond ending the 
criminalisation of PWUD there can be other positive benefits. 
In Portugal, the increased numbers in treatment have been 
linked to the reduced stigmatisation created by a non-
criminal approach to drug use.82 Research from Australia 
compared individuals who had been criminalised for 
cannabis possession against those who had received a non-
criminal response. It found that individuals given criminal 
penalties were more likely to suffer negative employment, 
relationship and accommodation consequences as a result 
of their cannabis charge and were more likely to come into 
further contact with the criminal justice system.15
Decriminalisation is clearly no ‘silver bullet’; it can only aspire 
to reduce harms created, and costs incurred, by criminalisation 
in the first place and does not reduce harms associated with 
the criminal trade on which it has little direct impact. If 
inadequately devised or implemented, decriminalisation will 
have little impact, even potentially creating new problems 
such as net-widening.1, 83 A more critical factor appears to be 
the degree to which decriminalisation is part of a wider policy 
reorientation and resource reallocation away from harmful 
punitive enforcement and towards public-health-oriented 
and human-rights-based approaches targeted at PWUD, 
particularly young people and PWID. Decriminalisation can 
be seen as a part of a broader harm reduction approach, as 
well as a key to creating an enabling environment for other 
public health interventions.  
g   These studies showed that there were no statistically significant differences in preva-
lence of cannabis use in states throughout Australia, even though three states had de-
criminalised cannabis possession and cultivation.
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Introduction 
In the 25 years since the development of the first harm 
reduction programmes, a harm reduction approach has been 
adopted in policy or practice to varying degrees in 94 countries 
worldwide.a The majority of these countries, however, do not 
have comprehensive harm reduction programmes1 operating 
at the scale necessary to impact on HIV,2 or even more 
challenging, hepatitis C epidemics. Those countries that are 
containing or reducing HIV epidemics among drug-injecting 
populations are largely high-income and overwhelmingly 
European. There are notable successes in implementation in 
a variety of political, religious and economic contexts, but the 
vast majority of low and middle-income countries around the 
world lack adequate harm reduction responses.2
Threats to sustained harm reduction responses are multiple 
and vary within and across countries, but the financial and 
political contexts are often the underlying factors that 
determine the life or death of a programme. Although 
harm reduction interventions are evidence-based,3 cost-
effectiveb and a fundamental element of the international HIV 
response,4 government investment in low and middle-income 
countries remains limited.5 Of the $160 million estimated to 
be invested in HIV-related harm reduction in low and middle-
income countries in 2007, approximately 90 per cent came 
from a small number of international donors5 (see the Global 
Overview section of this report for a more in-depth analysis of 
global financing for harm reduction). Bilateral and multilateral 
funding for harm reduction has been crucial to introducing 
and sustaining the response to some of the most severe HIV 
epidemics among people who inject drugs (PWID) around the 
world. However, reliance on international funds is becoming 
increasingly insecure as the global economic crisis impacts 
upon development and HIV funding. Middle-income countries 
with large numbers of PWID and governments hostile to 
harm reduction have been left particularly vulnerable. With 
recent developments at the Global Fund, and depleting funds 
available from several other major donors, the sustainability of 
harm reduction is under threat like never before. 
a    As reported in Section 1 of this report, 94 countries and territories worldwide now 
employ a harm reduction approach (compared to 93 and 82 countries in 2010 and 2008, 
respectively). This support is explicit either in national policy documents and/or through 
the implementation or tolerance of harm reduction interventions such as needle and 
syringe exchange programmes (NSPs) or opioid substitution therapy (OST).
b    For example: National Centre in HIV Epidemiology and Clinical Research (2010) Return 
on Investment 2: Evaluating the cost effectiveness of needle and syringe programs in Australia 
2009. Sydney: University of New South Wales.
Political support for harm reduction remains key to ensuring 
that investments are strategic and proportionate to need, 
particularly in the current financial environment. Many 
countries continue to emphasise drug control over public 
health, resulting in policy and legal contexts which hinder 
public health responses, increase potential for infections and 
lead to overburdened prison systems. While this approach is 
being questioned and openly debated by governments more 
than ever before, poor political backing for harm reduction 
remains one of the most crucial barriers to an effective response 
to epidemics among PWID. In addition to the countries where 
political support has long been lacking, the phenomenon of 
regression or backsliding in support for harm reduction in 
policy and practice is beginning to emerge in several countries 
where programmes have been long established and enjoyed 
long-standing government support. Given this backdrop, it is 
important to investigate the ways in which harm reduction 
programmes can be scaled up, or continue to operate to scale 
while adapting to changing policy and funding environments. 
This chapter presents a series of case studies to examine 
the different strategies and responses that have emerged to 
secure the survival of harm reduction policies and practices. It 
will explore, through these case studies, strategies for 
ensuring sustainability in harm reduction programmes. Two 
of the case studies focus on protecting harm reduction during 
periods of wider political change, while a further two examine 
ways of overcoming stalled implementation or ‘death by pilot’. 
Overall they look to encapsulate the interplay between harm 
reduction, local and national policies and politics. The final 
section of the chapter summarises these developments and 
attempts to identify successful and innovative strategies for 
overcoming the barriers to the survival and scale-up of harm 
reduction programmes.
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c
Official policy language labels PWUD as patients;10 however, 
practice at the community level in Thailand suggests that 
they continue to be treated as criminals. The government’s 
response to drugs, guided by principles of prohibition 
and repression, has been consistently implemented with 
little regard to the health and human rights of PWUD.11-14 
Law enforcement initiatives have led to incarceration and 
compulsory detention with accompanying abuse of PWUD, 
both in community and closed settings.15 The recently elected 
Pheua Thai party announced a new ‘war on drugs’16, 17d with 
objectives of rehabilitating 400,000 ‘users’ in compulsory 
‘treatment’ centres, primarily run by military and law 
enforcement agencies.18 The Thai government’s reluctance to 
address drug-related issues through public health measures 
is embodied in the absence of national harm reduction policy 
instruments, mechanisms and measures beyond the national 
HIV/AIDS strategy. The Thai Office of Narcotics Control Board 
(ONCB) drafted a national harm reduction policy in 2010, but 
this has not yet been deployed. In spite of this unsupportive 
environment, some level of harm reduction services have 
been delivered in Thailand at least since 2003.
c   This figure refers to men who inject drugs only.
d   The 2003 campaign in particular illustrates the scale of the Thai government’s ap-
proach to the war on drugs, including human rights violations and arbitrary killings that 
took place as a result, for more information: Human Rights Watch (2004) Thailand: Not 
Enough Graves. The War on Drugs, HIV/AIDS, and violations of Human Rights, Vol. 16, No. 8, 
http://www.hrw.org/reports/2004/thailand0704/thailand0704.pdf.
At present, the national response to HIV transmission 
among PWID is essentially limited to the CHAMPION-IDU 
project, supported by the Global Fund Round 8 grant and 
implemented by PSI Thailand alongside civil society partners 
including Raks Thai Foundation, the Thai AIDS Treatment 
Action Group, the Thai Drug Users’ Network, Alden House 
and the Thai Red Cross. This grant is for an approved total of 
US$17 million for the period 2009–2014 – US$6 million for the 
first phase of funding, and US$11 million for ‘Phase 2’ – and 
covers 19 of the 76 Thai provinces. Earlier, in 2003, the Global 
Fund also provided a US$1 million grant to Thai civil society 
groups to address HIV transmission among PWID.e Without 
support from the Global Fund, the national response to HIV 
transmission among PWID would be limited to small-scale 
community-led programmes whose operations have been 
under continued threat from police and government crack-
downs. 
During the first two years of operations, the CHAMPION-IDU 
project reached over 6,000 PWID across Thailand, providing 
them with education, information and behaviour change 
communication, safer injecting kits, condoms, referrals to 
voluntary HIV counselling and testing (VCT), diagnosis and 
treatment for sexually transmitted infections (STIs), and opioid 
substitution therapy (OST). In parallel, over 130 health service 
providers and approximately 50 prison guards received 
training to be sensitised to the needs of PWID, while over 1500 
people have participated in advocacy activities to improve the 
operating environment. Meanwhile, CHAMPION-IDU supports 
12D – a civil society coalition working to improve the drug and 
HIV policy environment – in coordinating and implementing 
additional advocacy activities, as well as the Foundation for 
AIDS Rights to develop effective legal aid services for PWID. 
The successes of the CHAMPION-IDU project largely belong to 
active and recovering PWID who comprise a large proportion 
of the implementing field teams.
However, the sustainability of these successes is constantly 
under threat. There continues to be a lack of support from 
all government sectors for effective and evidence-based 
interventions to address HIV transmission among PWID, 
which undermines the project. Government agencies have 
not signed identity cards that would protect field teams from 
arrest, which leads to peer outreach workers being routinely 
harassed and arrested by law enforcement officers. There 
are also anecdotal reports from implementing agencies in 
Thailand suggesting that law enforcement officers can benefit 
from financial incentives for drug seizures and the arrest of 
PWUD, as well as penalties if quotas are not met.
A further challenge has been posed by target-setting 
following the CHAMPION-IDU grant’s mid-term review in 
2011. As the Global Fund is a funding (rather than technical) 
e    For a more nuanced discussion of the challenges around this grant, please refer to Kerr 
T et al. (2005) Getting Global Funds to Those Most in Need: The Thai Drug Users’ Network, 
Health and Human Rights, 8(2) 170–186.
ThaIland 
HIV was first reported among PWID in Thailand in
the late 1980s, and the epidemic increased dramatically 
within this population in a few years. Despite successes 
in other areas of HIV prevention, the Thai response to HIV 
and drugs has failed to have an impact on this epidemic. 
The latest data indicate that between 40,3006 and 
160,5287 people inject drugs in Thailand. HIV prevalence 
among PWID remains among the highest in Asia at 21.9 
per cent.8c The majority of PWID in Thailand are living 
with hepatitis C (89.8 per cent).9 The Thai government’s 
response has focused on criminal justice approaches 
centred on the incarceration and compulsory detention 
of people who use drugs (PWUD) and characterised 
by several ‘wars on drugs’. This case study outlines the 
acquisition and implementation of a Global Fund grant 
since 2009 and the challenges that have been faced by 
implementing civil society organisations operating in an 
environment that remains hostile to harm reduction.  
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body, it follows the agreed normative guidance to assess the 
quality of programmes – in this case the UN target-setting 
guide for PWID.1  However, this guidance is ‘primarily intended 
for national target-setting’1 whereas the CHAMPION-IDU 
programme is a nongovernmental initiative that operates in 
just 19 provinces. The guidance also states that interventions 
should be implemented ‘in an enabling environment created 
by supportive legislation, policies and strategies’1: this is 
clearly not the case in Thailand. In negotiations between PSI 
and the Global Fund to agree targets for Phase 2, the Global 
Fund requested high coverage levels in the 19 provinces 
in line with the UN target setting guide (i.e. 60% for NSP 
and 40% for VCT). The performance based funding (PBF) 
model is based on the principle that ‘to receive subsequent 
financing, [projects] must demonstrate results against defined 
performance targets’.   This has raised concern that, despite 
its successes in health service provision, the CHAMPION-IDU 
programme may struggle to meet its performance targets and 
would therefore be rated by the Global Fund as ‘inadequate’ or 
‘unacceptable’ (see Table 1).f
Table 1: CHAMPION-IDU key indicator targets (October 2011 
– June 2014)19
Indicator 
Phase 1 
Targets
Phase 1 
Performance
Phase 2 
Targets
Increase 
between 
Phase 1 and 
2 targets 
(%)
Number of PWID 
reached
6,574** 6,191 9,762*** 148
Number of people 
trained (and 
retrained)# to 
implement HIV 
prevention activities 
for PWID
223** 137 258*** 115
Number of condoms 
distributed to PWID 
319,879* 170,411 986,364* 308
Number of needles/
syringes distributed 
to PWID
1,151,495* 319,879 5,698,315* 495
Number of PWID 
referred for 
HIV testing and 
counselling (and 
have received their 
results) 
602* 351 6,391*** 1062
Number of STI 
cases referred 
and received their 
diagnosis result
577* 411 8,171*** 1988
# In Phase 2, CHAMPION-IDU partners were allowed to count people re-trained, whereas 
in Phase 1, once a person received training, they could not be re-counted against indica-
tor performance.
* Not cumulative
** Cumulative over project life
*** Cumulative annually
f   See Global Fund (2012) Performance-based Disbursements, www.theglobalfund.org/
en/performancebasedfunding/grantlifecycle/3.
A further concern is that the Government, already 
unresponsive to harm reduction efforts, could potentially 
use this assessment as further justification to avoid deploying 
future interventions to reduce HIV among PWID. The 
Global Fund is a leading source of international support for 
harm reduction programmes20 and remains the sole and 
best possible option for supporting the response to HIV 
transmission among PWID in Thailand. In order to maximize 
the Global Fund’s significant investment in HIV prevention 
among PWID in Thailand, it will be critical to balance the 
quantitative results of the CHAMPION-IDU project against 
the hostile operating environment. At the same time, it is 
important to provide flexibility to implementing agencies to 
re-program funds to support advocacy efforts towards the 
deployment of an evidence-based policy, while efforts are 
also needed to harmonize law enforcement and public health 
objectives so that these challenges can be transformed into 
genuine successes for the benefit of Thai society as a whole.
AUSTRALIA
Australia has benefitted greatly from the early adoption of 
harm reduction as an effective way to reduce the impact of HIV 
and other blood-borne viruses such as hepatitis B and C that 
can result from sharing contaminated injecting equipment. 
Harm reduction initiatives including the implementation 
and rapid scale-up of NSPs and OST began in the mid- to late 
1980s. These effective programmes have helped maintain low 
HIV prevalence of approximately 1 per cent among PWID in 
Australia for almost 30 years.21 
In the early days of harm reduction, drug use was seen as a 
criminal issue to be stamped out by police arrests and customs 
seizures of imported drugs. The adoption of harm reduction 
shifted much of the rhetoric to one of drug use as a health 
issue. Language became an important way to convey ideas 
about ‘managing drug use’ and ‘reducing harm’. However, the 
ausTralIa 
There are an estimated 149,591 PWID in Australia.7 
Early adoption and high coverage of harm reduction 
interventions is often credited for the consistently low 
HIV prevalence among them (1 per cent).8 This case 
study outlines the important role of user organisations 
in shaping Australia’s harm reduction response, both 
historically and in the face of recent shifts in government 
policy agendas.
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rhetoric did not entirely reflect the reality. Examining funding 
for drug-related interventions in Australia reveals a very 
different picture of the priorities of the country’s leaders. The 
majority of funding goes to supply and demand reduction 
measures, and just 3 per cent of funding has consistently been 
allocated to harm reduction.22
Despite this disparity, just one of the harm reduction measures, 
NSP, is recognised as one of the most cost-effective health 
interventions ever funded. For every $1 spent on NSP, $27 
is saved just on health care costs,23 and increased spending 
would result in a corresponding further reduction in blood-
borne virus transmissions, other adverse health outcomes for 
PWID and overall health care costs, with the maximum benefit 
being achieved at increasing funding by 150 to 200 per cent 
of its current levels.23 
To assess their impact, the Federal Department of Health 
commissioned two major cost–benefit analyses of NSPs in 
Australia. The first of these showed overwhelming evidence 
for the financial and health benefits of investing in NSPs in 
the first decade and a half of their existence. According to the 
second Return on Investment Report, published in 2010, these 
savings have continued to grow. Between 2000 and 2009, 
NSPs alone directly prevented approximately 32,000 HIV 
transmissions and almost 100,000 hepatitis C transmissions, 
and saved the Australian government over $1 billion in health 
care costs.23
Integral to the success of the Australian harm reduction 
response has been the involvement of PWUD in providing 
services, conducting formal and informal peer education, and 
representing the needs of PWUD in Australian policy dialogue. 
From the earliest days of implementing the first pre-legal NSP 
to today, PWUD have done everything they can to be part of 
Australia’s harm reduction response. PWUD have challenged 
stereotypes by developing their own organisations, advising 
on policies and procedures, developing resources and working 
in every area relevant to PWUD, from NSPs to outreach to 
government health departments. They have proved that 
not all illicit drug use is problematic and chaotic, and that 
PWUD have valuable skills and care about their peers and 
communities. Without the voluntary and paid work of these 
people, and the willingness of PWUD to take the necessary 
steps to look after themselves and their peers, Australia’s 
response to HIV would have had a far less successful outcome. 
Drug users were organising themselves even before the 
identification of HIV and hepatitis C as potential concerns 
for PWUDs. The recognition that PWUD might pose a ‘threat’ 
to the ‘general community’ through sexual transmission of 
HIV meant that the drug user organisations that had been 
operating voluntarily began to receive some funding. 
As drug user organisations at the state and national level 
gained experience and proved their worth by developing 
successful programmes and resources, more funding was 
made available to allow these organisations to educate the 
PWUD community about blood-borne viruses. Australia, 
unlike many other countries, can rely on neither international 
donors nor philanthropic organisations to support community 
work. Almost all community organisations, including all harm 
reduction and drug treatment services, are primarily funded 
by the government, and the government is not very interested 
in funding organisations to look critically at its policies. Most 
of the advocacy work and lobbying for policy change remains 
unfunded, limiting the opportunities drug user organisations 
can take outside programmes to prevent transmission of 
blood-borne viruses. 
Australia has rightly been proud of its record on implementing 
brave programmes in the mid-1980s that prevented an 
HIV epidemic. It has also been proud of what is called the 
‘partnership approach’,24 referring to the inclusion of affected 
communities such as PWUD organisations in the response to 
HIV. The Australian response has been promoted and modelled 
in Australia’s aid development programmes around the world, 
particularly in Asia where HIV has devastating impacts on the 
lives of millions of PWUD and their communities. 
Australian aid has funded many harm reduction programmes 
in Asia where the health and human rights of PWUD had 
previously not been considered. Meanwhile, in Australia, 
drug user organisations have despaired at government 
and community attitudes to PWUD and the lack of forward 
movement in our own programmes. More frightening is the 
fact that Australia appears to be going backwards towards 
denial and abstinence-oriented programming. 
An 11-year conservative rule of the country from 1996, 
led by Prime Minister John Howard, produced the ‘Tough 
on Drugs’ strategy. Howard portrayed himself as a strong 
conservative, frequently talking about the evils of drugs and 
what he wanted to do about it. The ‘Tough on Drugs’ strategy 
emphasised supply reduction measures and language 
that pandered to stigma about PWUD. Increasing stigma is 
obviously damaging, particularly for already marginalised and 
criminalised communities such as PWUD. However, the ‘Tough 
on Drugs’ rhetoric was accompanied by continued harm 
reduction funding, and in some cases increased funding, 
although few new harm reduction programmes.
It was hoped that the election of a Labour government in 
2007 might make the language and policies more progressive 
and compassionate. Instead, rhetoric around harm reduction 
and drug use has regressed further. A recent report 
developed by prominent Australians including politicians, 
medical professionals and parents of children who had died 
of overdose called on Australia to rethink the ‘war on drugs’ 
and reform drug policy.25 The report, entitled The Prohibition 
on Drugs is Killing and Criminalising Our Children and We Are All 
Letting It Happen, received a lot of media and public attention. 
The only people unwilling to even acknowledge the idea, 
172
let alone engage in a conversation about drug law reform, 
seemed to be the politicians responsible for the well-being 
of its citizens. Media questions about the report were met 
by blanket refusals from the ruling parties to discuss either 
the report or the ideas contained in it. Labour’s silence has 
created confusion about where PWUD stand, and changes to 
budgeting have been even worse for many PWUD and harm 
reduction organisations.
The ‘Tough on Drugs’ strategy has gone, but it is being replaced 
by something drug user organisations are finding equally 
disturbing. ‘New Recovery’, following an agenda implemented 
in the United Kingdom (UK) in recent years, seems to be the 
new Australian strategy. ‘New Recovery’ promotes many ideas 
that seem positive such as increasing treatment programmes 
for PWUD. It sounds like people will have more choices in their 
treatment options. However, a closer reading of the current 
Australian National Drug Strategy, 2010–2015: A framework for 
action on alcohol, tobacco and other drugs reveals an increasing 
emphasis on abstinence-based outcomes for people who use 
drugs. It lists demand reduction as its ‘First Pillar’ and supply 
reduction as its ‘Second Pillar’ for responding to issues related 
to drug use. It also includes ideas such as ‘outcomes-based 
funding’, and ‘episodes of care’, which, experience from the 
UK shows us, can lead to rewarding numbers rather than 
quality outcomes. The number of times a person is told to see 
a particular professional does not mean they will enjoy quality 
or relevant treatment for their needs. 
Harm reduction is slipping further into the background. 
Although evidence-based programmes are frequently 
mentioned, the actual objectives of the drug strategy 
concentrate far more on programmes that have proved to be 
costly and ineffective such as education campaigns to prevent 
young people trying drugs. The language used for people 
who are dependent on drugs emphasises ‘reducing and/ or 
ceasing the use of drugs (to) … help them lead more stable, 
healthy and productive lives’.26
Characterising any drug use as ‘problematic’ and linking 
drug use and mental health issues is appearing as a 
dominant discourse in both health and political forums. In 
this environment, we are seeing services and programmes 
for PWID moved into the mental health sector and harm 
reduction quickly losing its place in Australia’s health sector. 
We are also already seeing the first major signs of the effect 
such pathologising of drug use may have on the ability of drug 
user organisations and PWUD to be involved in the decisions 
being made around their lives and choices. Although drug 
user organisations have been a part of Australia’s harm 
reduction response, the future is not assured. The Canberra 
Alliance for Harm Minimisation and Advocacy (CAHMA) has 
been integral to the newest initiatives in Australia including 
advocating for, designing and receiving funding to run 
Australia’s first naloxone peer distribution programme. The 
first training sessions for PWUD and their friends and family 
were held a few weeks before CAHMA was told that its 
2012–2013 funding application for the organisation had been 
rejected by the Federal Department of Health, along with 
many other significant but small community organisations. It 
was only through intense lobbying by the national drug user 
organisation, the Australian Injecting and Illicit Drug Users 
League (AIVL), CAHMA and supportive local and national 
agencies that CAHMA’s funding was reinstalled and its ability 
to implement these new programmes realised. 
Australia has not yet regressed to the time when drug 
users could not advocate for their communities for fear of 
imprisonment, but complacency could have devastating 
effects. The pathologising of drug use seems to be dominating 
policy and legislation, whereas harm reduction, involvement 
of the people affected by the issues, and evidence-based 
policy used to have a much stronger place. This is a time when 
drug user organisations are more important than ever. 
CANADA
Beginning in the mid-1990s, Vancouver’s Downtown Eastside 
neighbourhood became the focus of unprecedented levels of 
harms related to illicit drugs, including an explosive outbreak 
of HIV transmission and an extremely high fatal overdose 
rate.27 In response, a broad coalition of PWID, community-
based advocates, public health professionals and elected 
officials coalesced around support for the implementation 
of a broad range of harm reduction interventions,28 most 
notably establishing Insite, North America’s first medically 
VancouVer 
There are reported to be 286,987 PWID in Canada. HIV 
prevalence among them is estimated to be 13.4 per cent. 
Coverage of key harm reduction interventions such as 
NSP and OST remains lower than in Australasia and most 
Western European countries.2 The current government has 
prioritised a law enforcement approach to drugs, which 
has overshadowed public health responses. Vancouver 
is home to two projects not only crucial for the local 
community of PWUD but also for their contributions 
to the international evidence base for two important 
harm reduction interventions – safer injecting facilities 
and heroin-assisted treatment. This case study outlines 
these two very different projects, the structural barriers 
they have encountered and the reasons why, despite 
substantial evidence of effectiveness, these pilots have not 
been scaled up in the Canadian context.
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supervised safer injecting facility (SIF)29 and conducting the 
North American Opiate Medication Initiative (NAOMI) study, 
a randomised clinical trial of heroin-assisted treatment for 
severe heroin addiction.30 However, despite the impressive 
body of scientific evidence generated attesting to the positive 
impacts of these programmes on the health and well-being of 
local vulnerable and marginalised illicit drug users, they have 
yet to be scaled up or implemented in a fashion consistent 
with their benefits and cost-effectiveness.31, 32
Insite opened in 2003 in a low-threshold facility located 
within the epicentre of the neighbourhood’s open illicit drug 
market. A joint initiative of a social services agency and the 
local health authority, Insite obtained the necessary federal 
government-issued exemption from criminal prosecution by 
being set up as a pilot project to study the effects of a SIF in 
the Downtown Eastside.33 The scientific evaluation produced 
a wealth of peer-reviewed research describing the facility’s 
benefits, including lower levels of syringe sharing,34 increased 
uptake of addiction treatment35 and significant reductions in 
fatal overdoses in the area around the facility.36 In addition, 
Insite enjoys broad support from its clientele, members of 
the surrounding community including merchants and civic 
leaders, as well as the Vancouver Police Department and 
current and former city mayors and provincial premiers. 
Despite these successes, the agency operating Insite and two 
Insite clients were forced to take Canada’s federal government 
to court to prevent it from shutting the facility shortly before 
the exemption expired in 2006. Subsequently, the Supreme 
Court of Canada ruled in 2011 that the facility could remain 
open indefinitely, and plans are underway to try to expand 
the service by creating supervised injecting environments 
elsewhere in Vancouver and in other regions in Canada.
In light of the successful implementation of heroin-assisted 
treatment in several European countries,37 the NAOMI study 
recruited over 200 out-of-treatment long-term opioid 
injectors and randomly assigned them to receive standard 
medical care (oral methadone) or a diacetylmorphine (heroin) 
(DAM) plus flexible doses of methadone.38 After 12 months, 
individuals in the DAM group were more likely to remain in 
treatment, less likely to be engaged in illicit heroin use or 
other criminal activity, and enjoyed greater improvements 
in social functioning than patients receiving methadone.39 
Additional analyses concluded that treatment with DAM 
was cost-effective.31 Despite these findings, DAM has not 
been added as a treatment modality for opioid dependence, 
and all participants in the DAM group were transitioned to 
methadone or detoxification, making the NAOMI project the 
only heroin prescription study to discontinue heroin-assisted 
treatment upon conclusion.40 
Although it is important to note the fundamental differences 
between Insite and the NAOMI trial, both interventions share 
similar structural barriers to implementation and scale-up. 
First, both interventions were the subject of numerous rules 
and regulations rooted in political or legal considerations. 
For example, the City of Vancouver restricted NAOMI 
participation to individuals residing within one kilometre 
of the study site, limiting recruitment.38 Clients at Insite are 
not permitted to share drugs within the facility nor assist in 
injections, limiting its effectiveness for a small but vulnerable 
group of clients.41 Second, both interventions exist within a 
federal policy environment that is explicitly hostile to harm 
reduction interventions.42 First elected in 2006, Prime Minister 
Stephen Harper has removed harm reduction from the federal 
government’s official anti-drugs strategy and has pursued a 
strict prohibitionist strategy, including the implementation 
of mandatory minimum sentences for minor drug offences 
and expansion of the correctional system. Finally, the recent 
history of the NAOMI trial and Insite reveal the importance 
of community and academic advocacy in planning and 
implementing interventions for illicit drug users. In many 
respects, the establishment and continued existence of 
Insite is a result of the efforts of the broad coalition of 
clients, researchers, advocates and officials operating within 
legal, political, social and cultural contexts.43 The NAOMI 
investigators were not similarly engaged with the community 
and other supporters, and patients in this study have not 
benefitted from similar advocacy efforts, resulting in the 
NAOMI intervention being halted without public education or 
legal efforts to prevent this outcome. 
In a recent report on their experiences prepared by the 
NAOMI Patients Association,44 one participant identified 
the marginalised status of illicit drug users as a reason for 
the failure to create a permanent heroin-assisted treatment 
programme: ‘If they give you a drug for — they’re experimenting 
with a drug for cancer and it starts working. I mean, what are 
they going to do? Oh, no. You can’t have it any more; we’re going 
to back off here.’
These examples, with the success of the Insite programme 
resulting from collaboration between scientists, community 
groups and the legal and public health communities, and the 
closure of the NAOMI programme in the setting of researchers 
working largely in isolation from external stakeholders, 
demonstrate the importance of coalition-building between 
the research community, the non-profit sector, service 
providers and those with legal expertise to ensure that 
effective harm reduction programmes and other evidence-
based approaches to prevent and treat harmful substance use 
can expand in a sustainable way.
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RUSSIA
The decade between 1996 and 2005 was a time full of hope 
for harm reduction in Russia. The country’s first pilot harm 
reduction projects funded by the Open Society Institute (OSI) 
and Médicins du Monde (MdM) opened in 1996 and delivered 
high-quality results.45 In 1997, Médecins Sans Frontières 
(MSF) Holland and OSI launched an ambitious programme 
to introduce harm reduction in Russia, in cooperation with 
the HIV/AIDS Department of the Russian Ministry of Health. 
As part of the new programme, MSF trained 300 doctors and 
NGO representatives from all over Russia in providing needle 
and syringe and outreach services, and OSI funded over 30 
pilots.46 To ensure sustainability, the Russian government 
agreed to gradually increase co-funding of the pilots, with 
a view to eventually fully fund and continue to scale up the 
project.46 However, this did not transpire – the government 
continued to postpone the takeover of harm reduction 
services, encouraging international donors to step in and 
bridge the gap.47 
In 2001 a new donor emerged – the UK Department for 
International Development (DFID). Its funds intended to 
‘bridge’ the ending OSI grant programme and to fill the gap 
until a looming World Bank loan to meet the country’s urgent 
health needs was agreed and signed off.48 The DFID support 
included a large research project examining the effectiveness 
of harm reduction in Russia; it matched the funding for the 
30 existing pilot projects and provided for significant scale-
up of harm reduction services in two selected Russian regions 
looking to prove the impact of harm reduction on the HIV 
epidemic. However, by the end of 2003, DFID decided to 
move its funding to post-war development in Iraq, changing 
its priorities abruptly; funds were withdrawn, and scaling up 
did not take place.48 
However, there was hope that the government would support 
harm reduction efforts within the upcoming World Bank loan. 
Negotiations on the loan took place for almost five years; the 
World Bank conducted numerous assessments, research and 
consultations – all with a promise that the loan would support 
30 harm reduction projects.49 However, by the time the loan 
was accepted, both the government and the World Bank 
dismissed their written plans and agreements to take over 
harm reduction, reallocating the money towards purchases 
that were more convenient for the Russian officials, such 
as laboratory equipment and furniture for the state AIDS 
centres.49 
In 2003 a consortium of five major NGOs took the decision to 
stop waiting for government support and submitted Russia’s 
first application to the Global Fund (Round 3). The grant was 
successful and went on to support 22 harm reduction projects. 
A year later, support for 30 more projects was received through 
the Global Fund Round 4, and again in 2006 another 33 
projects were funded through the Round 5 grant. As a result, 
the period between 2005 and 2008 saw the beginning of scale-
up for harm reduction, with over 80 projects implemented.50 
Many of the projects, however, operated only as small-scale 
pilots. Scepticism was also increasing around governmental 
support to harm reduction, as government officials became 
increasingly vocal in their opposition to harm reduction. For 
example, government representatives unanimously refused 
to approve harm reduction as part of national applications to 
the Global Fund, meaning that the Round 5 proposal did not 
receive the approval of the Country Coordinating Mechanism 
due to its focus on harm reduction. 
Unexpectedly, in May 2008, at the Eastern European and 
Central Asian AIDS Conference the newly appointed Russian 
Minister for Health, Ms Golikova, announced that the 
government had all the resources to fully take over harm 
reduction projects currently supported by the Global Fund.51 
After her announcement, the audience held their breath for a 
moment and then burst into applause. This was the moment 
harm reduction advocates had been waiting over a decade for.
However, just one year later in September 2009, the same 
Minister, at a meeting with the President and Prime Minister 
in attendance declared that ‘distribution of sterile needles 
and syringes stimulates social tolerance of drug addicts, and 
violates the Criminal Code.’47 This speech marked the end of 
political support, if even only rhetorical, to harm reduction. 
The national ‘Anti-Drug Policy Strategy’, approved another 
year later, ignored significant evidence around major health 
challenges including HIV rates of around 37 per cent52 and 
hepatitis C prevalence of between 49 per cent and 96 per 
cent9 among PWID and even named harm reduction as a 
threat to the strategy.53 
russIa 
An estimated 1,815,000 PWID live in Russia. The HIV 
epidemic in the country is largely driven by injecting drug 
use. Prevalence of HIV and hepatitis C among PWID are 
among the highest in the world at over 37 per cent7 and 
72 per cent,9 respectively. This case study outlines the 
struggles of small-scale harm reduction programmes 
to continue operations in the face of increasingly 
staunch government opposition to harm reduction and 
an overreliance on international donors. It highlights 
various strategies used by civil society actors to attempt 
to overcome the considerable barriers to implementing 
a scaled-up and sustainable harm reduction response in 
Russia.
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At the end of 2011, the last Global Fund-supported 
programmes ceased to function. As a result, by early 2012, 
only six organisations across the country were able to provide 
harm reduction services to PWID, all struggling for small-
scale funding from independent sources.54 This is grossly 
inadequate for the needs of PWID; current estimates in Russia 
are that nearly 2 million people inject drugs, with HIV rates 
around 37.15 per cent among this population and much 
higher in some provinces [for more information see Chapter 
2.1: Harm Reduction in Eurasia]. 
One of these organisations, the Andrey Rylkov Foundation 
for Health and Social Justice (ARF), maintained its outreach 
services supported by the International Crystal of Hope 
Award. However, the organisation has been severely repressed 
by the government. In 2012, after multiple checks by police 
and prosecutors, its website was shut down by the Federal 
Drug Control Service citing ‘drug propaganda’ as its reasoning 
– specifically concerning materials discussing substitution 
treatment.55 Through this action, the Russian government 
suggested that it believed that not only providing services but 
even discussing harm reduction was illegal.
What went wrong with harm reduction advocacy in Russia? 
Why were small but aspirational harm reduction pilots not 
scaled up by the government but, rather, fiercely opposed? 
Traditional advocacy has been undertaken in Russia: 
research and evidence-building, trainings and international 
study tours, publications and debate. However, so far none 
of these activities have had an impact on mainstreaming 
harm reduction into national public health strategies or 
services. The root of this strong ideological government 
resistance is hard to explain, and this opposition has never 
been scrutinised scientifically,47 so more research into policy 
resistance is recommended to determine the causes of this 
ongoing phenomenon. 
Advocates affiliated with the ARF have taken the decision 
to use legal tactics to force the government to change its 
policies. The organisation has taken several cases to national 
and international courts, claiming violations of the right to 
health,56 the right to be protected from torture and inhumane 
treatment,57 the right to receive informationg and the right 
to benefit from scientific progress.58 However, it remains 
uncertain whether this approach will be successful in bringing 
evidence-based programmes to PWID in Russia.
g    Andrey Rylkov Foundation (2012). Information note regarding retaliation of the 
Government of the Russian Federation against the Andrey Rylkov Foundation for 
Health and Social Justice (ARF) for promoting the recommendations made by the UN 
Committee on Economic, Social and Cultural Rights (CESCR) to the Russian Federation in 
its Concluding Observations
conclusion and recommendations
This chapter has brought together a diverse set of case 
studies from around the world to examine the problems of 
sustainability in harm reduction and to highlight successful 
or promising strategies for securing it. All four case studies 
clearly demonstrate the importance of continued advocacy, 
alongside sustained political support for the implementation 
and scale-up of harm reduction services. Although the 
circumstances of the four case studies differ in significant 
respects, there are a number of common issues that can be 
identified.
Each of the case studies and  Vancouver, in particular 
highlights the importance of creating a broad and diverse 
coalition of advocates and supporters to ensure the survival of 
harm reduction services. The example of Insite demonstrates 
that a key element in ensuring the continuation of the facility 
was the broad support it received from community advocates, 
law enforcement officials, academics and clients, as opposed 
to the failed NAOMI trial which worked mostly in isolation. This 
case study also serves as a cautionary example, highlighting 
the marginal social status of PWID and the potential role this 
has in the ‘acceptability’ of rolling back on harm reduction.
The Canadian and Russian case studies highlight the 
importance of legal mechanisms and the value of forging 
connections with legal professionals to protect harm 
reduction. In the case of Insite the ongoing use of legal 
mechanisms bypassed political opposition to harm reduction 
and helped to ensure the survival of the project. Moreover, 
this ruling provided legal cover for the opening of further safer 
injecting facilities in other parts of Canada. Similarly in Russia 
the use of legal mechanisms is now being applied with the 
hope that it will enable NGOs to side-step political resistance 
to harm reduction. While these initiatives are in their early 
stages, it is clear from the Canadian example, in particular, that 
this is a strategy worth exploring further.  
Several case studies highlight the fundamental role of 
funding (or the lack thereof ) in sustaining harm reduction 
programmes, and the significant role of donor advocacy. The 
case study from Thailand emphasised the need for donors to 
balance performance-based quantitative indicators with less 
quantifiable activities such as advocacy, and for international 
donors to take into account hostile political environments and 
adjust indicators and activities accordingly. The Australian 
study highlighted the precariousness of government funding 
and the need for funding mechanisms that are independent 
from the state for civil society strengthening, in particular for 
organisations of PWUD. Autonomous funding mechanisms 
are clearly a common need to allow harm reduction advocates 
to function as ‘community watchdogs’. Moreover, in Russia it 
is clear that international donors are the only hope for the 
survival of harm reduction services, not only as funders but 
also as independent bodies with some influence over resistant 
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governments to put in place evidence-based strategies for HIV 
prevention for PWID.  
Another key theme that emerges from the case studies is 
the importance of involving PWUD in advocacy activities. In 
Australia the scale-up of harm reduction can be attributed 
in part to the activities of networks and organisations of 
drug users, including self-organising, advocating and peer 
support. In Vancouver the Eastside community and service 
users of Insite and drug user organisations such as VANDU 
played a vital role in keeping the facility open. In Thailand 
ongoing advocacy from PWUD has been vital in ensuring the 
expansion of harm reduction services, as well as ensuring that 
the regressive policies and practice of the Thai government 
are recorded and highlighted to donors and the international 
community.
The Australian case study discusses the potential threat 
posed by the emergence of the ‘new recovery’ movement. It 
is particularly threatening to harm reduction in Australia, as 
it uses the language of harm reduction yet deviates from the 
key principles of pragmatism, evidence-based interventions 
and the meaningful involvement of PWUD. It is, therefore, 
extremely important for harm reduction professionals 
internationally to ensure that harm reduction messages are 
delivered in clear and coherent ways to ensure they cannot 
be co-opted. 
The Australian case study also raises concerns about mental 
health providers taking the lead in harm reduction services. It 
notes that, although mental health provision is an extremely 
important component of a comprehensive package for drug 
users, it is dangerous to subsume all drug services under this 
label, as it suggests that PWUD are ‘unwell’ and unable to make 
informed decisions, thereby undermining efforts to support 
active drug users to self-organise and advocate.
In conclusion, threats to the continued implementation of 
programmes at a level that can impact on epidemics among 
PWID are a challenge to harm reduction practitioners and 
advocates in various political and economic contexts. The 
strategies to overcome these threats are multiple and varied, 
but all require strong and strategic advocacy for harm 
reduction, particularly in the current context of uncertain 
international financing and wavering or poor political support 
for harm reduction in many parts of the world. These case 
studies underline the importance of donors, governments 
and civil society organisations themselves recognising and 
prioritising advocacy as key to ensuring sustainable and 
scaled-up harm reduction responses. 
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reduction in challenging 
environments
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INTRODUCTION
The reasons for starting and scaling-up harm reduction 
services are multifaceted, compelling and well established. 
If policy-making were a purely scientific, objective and 
methodical process, harm reduction would already be the 
global norm. However, this is not the case. Section 1 lists 
158 countries that report injecting drug use (IDU), of which 
94 support harm reduction in policy and/or practice to help 
individuals stay safe, manage or end their drug use and 
avoid blood-borne viruses (BBV). The other 64 countries still 
do not support and/or implement harm reduction. What 
accounts for these variations in response? What makes one 
country adopt harm reduction in policy and practice, while 
a neighbour continues to ignore the evidence? 
This chapter highlights four examples from around 
the world where harm reduction has been endorsed to 
varying degrees: from early adoption and nationwide 
scale-up in Switzerland and Macedonia, to opening the 
harm reduction debate in Malaysia and overcoming strong 
ideological resistance in the Caribbean. Each case study 
explores how harm reduction came to be accepted and 
documents the events and actions that were key to this 
process. It is hoped that this chapter will inform ongoing 
advocacy efforts for harm reduction elsewhere in the world 
and provide encouragement to those who are working to 
promote change in their own countries — including those 
in both governmental and nongovernmental positions. At 
the same time, it should be equally relevant for countries 
that are seeing their existing services come under threat 
(see Chapter 3.6  for a more in-depth discussion of this).
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Drug policy in the Caribbean has always been heavily 
influenced by the USA, and its historical antipathy toward 
harm reduction approaches as ‘capitulation’ to drug use. In the 
1990s, any mention of the term ‘harm reduction’ would lead 
to the loss of US State Department funding for drug demand 
reduction programmes. In 1997, the European Commission 
contracted a situational assessment of drug treatment in 
the Caribbean, which remains an influential work to this 
day.1 The following year, Deutsche Orden Hospitaller (DOH) 
International received a grant from the European Commission 
to expand low-threshold programmes for street-engaged 
people who use drugs.
 
In the absence of prevalent drug injecting, harm reduction 
in the Caribbean often refers to services that treat people 
who use drugs with respect and dignity: providing food, 
clothes, showers, referrals and a supportive, listening ear. 
However, when the first drop-in centres began implementing 
this approach, service providers were forced to label them 
as ‘public health approaches’ to address HIV among the 
homeless, rather than harm reduction for people who use 
drugs. The first drop-in centre in the Caribbean was opened 
in Castries (Saint Lucia) in 2000, followed by centres in Santo 
Domingo (Dominican Republic) in 2001, Kingston (Jamaica) in 
2002 and Port of Spain (Trinidad) in 2003. 
Meanwhile, work was being done by leading activists in the 
halls of the Caribbean Community (CARICOM) Secretariat to 
place harm reduction on the agendas of various Councils of 
Ministers. In particular, as a result of the work and advocacy 
efforts of a handful of researchers and service providers, there 
was a growing acceptance by the Pan-Caribbean Partnership 
Against HIV/AIDS (PANCAP), the UNAIDS Regional Office and 
others of an overlap between non-injecting crack cocaine use 
and HIV infection, with five to 10 times the national prevalence 
among this population.2 This countered the common 
argument that ‘Caribbean people do not inject, so there is no 
link with HIV’. 
In 2001, the Foreign and Commonwealth Office commissioned 
an evaluation of demand reduction programmes in the 
Caribbean, which confirmed the link between crack smoking 
and unsafe sexual behaviours, leading to increased HIV 
infections.3 In the Nassau Declaration on Health 2001, 
Caribbean Heads of Government committed to Phase II of the 
Caribbean Cooperation in Health Initiative, which explicitly 
The CaRIbbeaN
Injecting drug use is reported to be rare in 
the Caribbean region, with the notable
exception of Puerto Rico.  The harm 
reduction response in the region remains 
very limited, with needle and syringe exchange and 
opioid substitution therapy only available in Puerto Rico. 
The response in the rest of the region is predominantly 
characterised by abstinence-based, high-threshold 
services. The use of illicit drugs is highly criminalised, with 
harsh sentencing resulting in large numbers of people 
who use drugs in Caribbean prisons. This case study 
illustrates the emergence of harm reduction advocacy in 
the region and describes the various efforts which have 
contributed to its wider acceptance. 
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classified substance use as a mental health and public health 
issue.4,5 A steady stream of US-funded interventions continued 
to undermine harm reduction by focusing solely on drug use 
prevention and high-threshold abstinence-based services. 
However, harm reduction programmes remained successful 
in reaching and supporting ‘hidden’ populations in the region.
Several events led to 2001 being a pivotal year for civil society 
advocacy. A number of Caribbean treatment professionals 
attended the International Harm Reduction Conference 
in Delhi, India, and the US Harm Reduction Conference in 
Miami later that year. At the latter event, the Caribbean Harm 
Reduction Coalition (CHRC) was formed during a special 
satellite meeting. CHRC set out to promote the emerging 
experiences in the region and support research to increase 
the evidence base for interventions. The Caribbean Drug 
and Alcohol Research Institute was then formed to work 
alongside CHRC and provide the necessary evidence to 
support advocacy efforts. In 2004, the Caribbean Vulnerable 
Communities Coalition was formed, of which CHRC was a 
founding member, and allowed for the expansion of harm 
reduction to other vulnerable groups such as sex workers and 
men who have sex with men. 
Despite the weight of US drug policy in the region, 
contributions from a range of international donors and 
partners have proven invaluable for the success of harm 
reduction efforts. The original European Commission funding 
got the ball rolling, while support from the Open Society 
Foundations and the UK Department for International 
Development (via Harm Reduction International) enabled 
the exchange of information, ideas and experiences across 
the region and internationally. In 2008, the Caribbean 
Vulnerable Communities Coalition began work on a successful 
multi-country proposal to the Global Fund to Fight AIDS, 
Tuberculosis and Malaria.6 Although injecting and opioid use 
is less common in the Caribbean than in many parts of the 
world, non-injecting crack cocaine users were included as a 
target population, and programmes began in 2011. As a result 
of a rapid assessment conducted by CHRC that documented 
heroin injecting, efforts are also underway to provide sterile 
injecting equipment and to advocate for the adoption of 
opioid substitution therapy (OST) interventions by Caribbean 
governments. 
Overall, the HIV crisis in the region facilitated the emergence 
of harm reduction as a proven public health response. 
Governments were presented with a harsh economic reality: 
they would experience a significant drop in Gross National 
Product if the HIV epidemic were left unaddressed. With the 
establishment of the Caribbean Vulnerable Communities 
Coalition, CHRC became part of a Caribbean-wide movement 
advocating for the adoption of a human rights-based 
agenda to augment the public health arguments previously 
espoused. Although the HIV epidemic remains, responses 
to HIV are presently more practical and evidence-informed. 
Agencies that previously were resistant to adopting harm 
reduction strategies a decade ago began to embrace and 
implement variations of harm reduction adapted to the 
contextual realities they experienced. Trinidad adopted harm 
reduction as part of its national drug policy, supporting the 
continuation of the drop-in centre started with European 
Development Fund (EDF) funding in 2003. Jamaica carried this 
one step further when the National Council for Drug Abuse 
received support from the Ministry of Health to operate a 
mobile outreach project targeting homeless street-engaged 
crack smokers. As this report shows, three of the countries 
in the region now embrace harm reduction in policy and/or 
practice (see Section 1: Global Overview). Advocacy efforts 
are ongoing, but the Caribbean example shows how harm 
reduction can be promoted even under the shadow of a major 
global detractor such as the USA. 
MACEDONIA
In Macedonia, harm reduction began with the provision of 
OST to a very small group of people from the early 1980s, 
growing into an organised state-run programme from 1990 
onwards. In addition, however, two key milestones stand out 
in the development of broader harm reduction policies and 
programmes.
The first of which was the research of Jean-Paul Grund and 
Dusan Nolimal in 1995 entitled The Heroin Epidemics in 
Macedonia.7 This report for the Open Society Foundations 
was perfectly timed — HIV had not become established in 
Macedonia, but research indicated that widespread high-risk 
injecting behaviours such as syringe sharing could drive the 
emergence of an HIV epidemic among people who inject 
drugs (PWID). One of the report’s recommendations was to 
open needle and syringe exchange programmes (NSPs). As 
MaCeDONIa
The timely introduction of harm reduction interventions 
is credited for averting an HIV epidemic among PWID 
in Macedonia. This case study outlines the antecedent 
factors which contributed to the adoption of a harm 
reduction approach in the country, including well-timed 
research and well-placed civil society actors funded to 
take forward research recommendations. In addition to 
this, international technical assistance and the continued 
engagement of decision-makers, civil society groups 
and people who use drugs have been critical factors in 
developing the national harm reduction response.
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a result, the first service opened in 1996 via the Macedonian 
Association for Socio-Culture Activities (MASKA). This move 
was initiated by people who use drugs and supported by the 
Open Society Institute in Macedonia.
The second key milestone was the founding in 1997 of the 
Healthy Options Project Skopje (HOPS), a nongovernmental 
organisation (NGO) that continued the work undertaken by 
MASKA. Since then, HOPS has developed or supported all 16 
harm reduction programmes in 13 towns across Macedonia. 
Because of this work, harm reduction programmes can be 
seen even in towns with populations of just 20,000 people. 
Harm reduction programmes have also been developed for 
the Roma suburbs, as well as for sex workers who inject drugs.
HOPS has played a key role in promoting harm reduction 
in Macedonia through these services, by promoting and 
respecting the meaningful involvement of people who use 
drugs in all programmes and insisting on a wide spectrum of 
services being made available (beyond just needles, syringes 
and condoms). At present, the majority of harm reduction 
programmes also provide medical, social and psychiatric 
services, and legal aid and court representation in cases of 
human rights violations. Experience has shown that only 
this comprehensive approach can achieve the coverage and 
results that are needed. Annually, these programmes serve 
more than 3,000 PWID — approximately one-third of the 
estimated number of people in need.8 
The feared HIV epidemic in the country has been avoided. This 
has been largely attributed to the immediate implementation 
of harm reduction programmes, according to the latest 
available evidence. Only 10 of the 142 registered HIV cases 
are among PWID, and there have been just two cases of HIV 
among PWID in the last eight years.9 Intolerance of drug use 
and harm reduction programmes was overcome by engaging 
and bringing together decision-makers, authorities, civil 
society groups and people who use drugs. 
A key strategy used to achieve a shift in initially hostile attitudes 
was the inclusion of state and local government bodies in joint 
project activities financed by the Global Fund and the Open 
Society Foundations. Cooperation with the international 
community was also important. Experts and agencies such 
as UNAIDS, WHO, UNICEF and the European Union were all 
involved in advocating for changes to state policies on HIV 
and drugs. Macedonia’s EU candidacy also played a role in 
pushing the finalisation of the National Drugs Strategy 2006–
2012 and its reflection of international guidance on harm 
reduction.10 With this collective support, harm reduction was 
first mentioned in official government documents as part of 
the National Strategy on HIV/AIDS in 2003 and, subsequently, 
as part of the National Drugs Strategy in 2006. In 2011, for the 
first time, small quantities of the needles, syringes, condoms 
and lubricants needed for harm reduction programmes were 
purchased through the state budget. Another important 
element has been the inclusion of state and local government 
bodies such as the Ministry of Health, Ministry of Social Policy, 
the National Drug Coordinator and the Departments for Social 
and Health Protection in activities within local municipalities, 
which has helped to shift the initial attitudes to drug use and 
harm reduction. Local municipalities are also supportive of 
harm reduction approaches, including through the provision 
of local funding for such programmes. Slowly but surely, harm 
reduction is becoming ingrained within national health and 
social care systems. 
For many decades, Malaysia has employed a punitive and 
prohibitionist drug policy, characterised by a statutory 
presumption of trafficking when possessing more than a 
certain quantity of drugs (such as 200g of cannabis and 15g 
of heroin), mandatory death sentences, incarceration for 
personal drug use offences and a vision of a drug-free nation 
by 2015.13 However, since the turn of the century, there 
has been a policy shift toward harm reduction.14 This was 
a response to HIV epidemics among PWID. At the height of 
the epidemic, Malaysia recorded approximately 7000 new 
infections in 2002, 75% of which were due to injecting.15 The 
shift in approach was certainly facilitated by international and 
internal pressure to achieve all eight Millennium Development 
Goals (MDGs), the prerequisites for being categorised as a 
developed nation.16 Malaysia has achieved seven of these 
goals, the exception being the goal related to HIV.
Although the policy decisions were made by the federal 
government, they were clearly influenced by strong voices 
from patient groups and NGOs such as the Malaysian AIDS 
Council (MAC). In 2002, a grant was obtained from the US 
National Institutes of Health for exploratory research and a 
rapid situational analysis on HIV and drug use.17 
MalaysIa
Malaysia is home to an estimated 170,000 PWID4, with 
the latest reported HIV prevalence among them being 
8.7%.4 Hepatitis C prevalence among PWID remains 
high at 67.1%.11 In recent years, Malaysia has refocused 
efforts into scaling up harm reduction services and 
is now reported to have ‘medium’ NSP coverage and 
increasing OST coverage.12 This case study catalogues 
developments leading to the policy shift towards harm 
reduction, including strong civil society advocacy, and 
the important approval of a harm reduction approach by 
Islamic scholars. Also described is the recent movement 
towards evidence-based treatment options in favour of 
drug detention centres. 
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A Harm Reduction Working Group was then formed, hosted 
by MAC, which used the data and findings to advocate to 
the relevant government agencies. The Working Group also 
worked with Islamic scholars to obtain their buy-in, and the 
Institute for Islamic Understanding of Malaysia pronounced 
harm reduction to be a public health issue which did not 
violate shariah law.18  
At around the same time that the MDG results were 
released, the case for NSPs and OST was presented to the 
Prime Minister, Deputy Prime Minister and a governmental 
committee on drugs. Approval was given for methadone 
treatment and later, from the Minister of Health, for needle 
and syringe distribution. Free antiretroviral treatment (ART) 
was introduced in 2004, methadone pilot projects began in 
2005 (and have since been expanded nationwide to include 
community and prison programmes, as well as a pilot clinic 
within a mosque setting), and NSPs began in 2006. Between 
2006 and 2010, Malaysia saw a decline in the annual number of 
recorded HIV cases,19 although this cannot be solely attributed 
to the introduction of the harm reduction programmes. 
Additional factors that may have contributed to the overall 
decline in HIV prevalence include the decreasing purity of 
heroin, which has led some PWID to switch to inhaling or to 
consuming methamphetamine tablets or buprenorphine, the 
increasing influx of amphetamine-type substances from East 
Asia,20 and improved coverage of awareness and prevention 
programmes for other key populations at higher risk of HIV.21
In recent years, dialogue around Malaysian drug policy 
has begun to move away from HIV as the sole reason for 
reform. Arguments are increasingly being made based on 
an understanding that policies focusing on incarceration 
and corporal or capital punishment do not work. Malaysia 
has seen increased cooperation between NGOs and police 
and anti-drug agencies, which has helped to promote the 
humanitarian and health perspectives of drug use and 
dependency. While ‘hard-line’ perspectives and rhetoric still 
obviously exist, they are being broken down over time. Even 
among senior members of the police force there is a growing 
realisation that the ‘war on drugs’ has failed, and an openness 
to discuss alternatives such as police referrals into health 
services. Although HIV remains a concern, it has now become 
easier to argue for harm reduction on the basis of the dignity, 
health and productivity of the individual person who uses 
drugs. 
These approaches contributed to the introduction of state-
run ’Cure and Care’ clinics in early 2010 by the National Anti-
Drugs Agency. These facilities are voluntary clinics which 
provide integrated healthcare for PWID, including methadone 
treatment and counselling. This represents a significant 
paradigm shift for an agency that has traditionally focused 
on compulsory detention centres (or ‘Pusat Serenti’). These 
centres still exist across Malaysia, but the number of people 
held in them is in decline.
Since the introduction of harm reduction programmes, 
Malaysia has seen a positive shift toward evidence-based 
prevention and treatment for people who use drugs. These 
programmes have continued to expand nationwide, and have 
led to increased collaboration between health workers and law 
enforcers. Today, MAC and numerous partner organisations 
continue to work toward reducing HIV infections among PWID 
and raise awareness about harm reduction, safe sex and the 
destigmatisation of people living with HIV. However despite 
these major advances, challenges still remain amidst a legal 
and policy environment that continues to heavily criminalise 
drug use. 
SWITZERLAND
In the 1980s, Switzerland experienced a steady rise in the 
number of people using drugs, the amount of seized drugs, 
drug-related crimes (including organised crime leading to 
higher drug prices, delinquency and prostitution) and deaths 
related to overdose.24 By 1990, the HIV infection rate in 
Switzerland was the highest in Europe.25 Despite the alarming 
trends, prominent psychiatrists and officials remained 
opposed to harm reduction.26 This led to protests from health 
professionals, social workers, some politicians and the media, 
all of whom accused officials of exacerbating the problem. In 
1985, for example, a heated debate broke out when the Chief 
Medical Officer in Zürich prohibited NSPs and threatened 
severe sanctions against any organisation that offered them. 
Around 300 physicians signed a declaration challenging 
this stance.27 A parliamentary investigative committee also 
reproached the Chief General Attorney for remaining passive 
while crime rates and organised crime increased.28 That same 
year, the Swiss AIDS Federation was founded to advocate 
strongly for key services,29 and numerous attempts were made 
swITzeRlaND
There are an estimated 31,653 PWID in Switzerland.22 
The early introduction of harm reduction measures had 
a dramatic impact on the HIV epidemic among PWID, 
which in 1990, was the most severe in Europe. Switzerland 
now maintains a low HIV prevalence among this group 
at 1.4%.23 This case study describes the factors which 
culminated in the development of a pioneering and 
committed harm reduction response, including advocacy 
from professionals in the health and social sectors and 
Swiss professionals taking opportunities to learn from 
international experiences.
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by activists to try to improve the health and social situation of 
people who use drugs. 
Crucially, the Federal Subcommittee on Drug Questions 
(EKDF) published a report in 1989 proposing various 
measures to reduce harm, including widespread OST.30 The 
Federal Office of Public Health (FOPH) sent this report to the 
major stakeholders for consultation.31 In 1990, several Swiss 
professionals attended the first international harm reduction 
conference in Liverpool, and an FOPH delegation to England, 
the Netherlands and Sweden further supported the roll-out of 
harm reduction. The well-documented harm reduction work 
being done in Australia was also a major inspiration.
As a result of this work, at a national drug conference in 
October 1991,32 ‘survival assistance/harm reduction’ was 
confirmed as one of the four pillars of the new Swiss drug 
policy (alongside ‘repression’, prevention and treatment).33,34 
This decision was particularly informed by the measurement 
of various drug-related indicators to compare the efficacy 
of different measures.35 During this process, EKDF helped 
to bridge the gap between activists, professionals and the 
government. Its report proposed viable solutions later 
adopted by the government and implemented by the FOPH, 
while an Advocacy Coalition Framework helped to make the 
decision possible.36
During the last two decades, harm reduction in Switzerland 
has been held up as an example of best practice in the field. 
All levels of government have entrusted public services and 
civil society to provide comprehensive support for people 
who use drugs. The first authorised drug consumption room 
(DCR) opened in 1986 in Berne, and similar facilities soon 
opened in Zürich and Basel, providing contact points, food 
and basic medical care.37,38 Low-threshold OST became widely 
available in most of the country, and methadone prescriptions 
rose steadily from a few hundred in 1975 to 10,000 in 1991, 
and then stabilised at around 17,000 per year.39 The various 
cantons (districts) offer DCRs, NSPs40 (including in pharmacies) 
and night services.41 Heroin assisted treatment is also 
provided (and is considered as treatment rather than harm 
reduction) despite initial opposition from the International 
Narcotics Control Board42 and the WHO. This intervention now 
reaches around 1000 of the estimated 30,000 people who 
use heroin. The FOPH also supported the creation of projects, 
including safer night-life programmes, and cities and cantons 
have assured sustainability by integrating activities into their 
budgets.43
The results of this approach are clear, not least in the downward 
trend in HIV transmission – an estimated 1.4% of PWID are 
currently living with HIV.44 Just 4% of new HIV infections were 
associated with IDU in 2007, compared with the late 1980s and 
early 1990s when this was the primary mode of transmission.45 
Illegal drug use in public spaces is now less of an issue, and the 
number of deaths from overdose has declined markedly over 
the last 20 years.46,47 Whereas public health and public order 
arguments were the most prominent in the early stages of the 
Swiss debates, ethical considerations and human rights were 
also a key part of the discussion. Harm reduction is considered 
a means to save lives and support people to survive their drug 
use, and this overcame the convictions that drug consumption 
violated other fundamental values of Swiss society.48
More than 25 years after opening its first DCR, Switzerland 
has firmly embedded harm reduction within its drug policy. 
The actions of activists, advocates and professionals helped 
to mainstream this approach, while the concrete evidence 
and data provided by researchers empowered the public 
and politicians to agree on pragmatic steps. Harm reduction 
in Switzerland no longer faces opposition from international 
organisations such as the WHO, and numerous referenda and 
popular initiatives have confirmed continuing support from 
the Swiss public (the most recent being in 2008). Although 
many aspects of this example may be considered ‘typically 
Swiss’, there remain numerous lessons that can be applied by 
other countries.49
CONClUsION
This chapter highlights the successes achieved in advocating 
for harm reduction in the Caribbean, Macedonia, Malaysia 
and Switzerland. There are numerous other countries that 
could have also been featured, but the highlighted examples 
successfully draw out several key themes. Across all these 
case studies, it is clear that scientific research and the 
collection and communication of data are essential to make 
strong and evidence-based arguments to policymakers. The 
role of dedicated civil society groups is also clearly pivotal. 
Organisations such as CHRC, HOPS and MAC have all helped 
to engage and convince governments and religious leaders 
through innovative service delivery, organising or attending 
key meetings and events (including the International Harm 
Reduction Conferences) and generating and communicating 
sound evidence.
In all four examples, high rates of HIV transmission among 
people who use drugs was a key factor in the early conversations 
around harm reduction, and this remains the case in many 
countries around the world. While some countries such as 
Malaysia needed to react in order to control and reverse 
existing epidemics, others such as Macedonia were able to 
generate action to avert potential crises. This latter approach 
may be particularly important now for sub-Saharan Africa, 
where injecting-driven epidemics are beginning to emerge. 
Crucially, dialogue around HIV vulnerability, prevention 
and treatment has also helped to open doors to broader 
conversations around human rights, the overall health and 
well-being of PWID and the development of supportive policy 
environments.
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These four case studies also demonstrate the need to carefully 
tailor approaches to the local situation. For example, whereas 
Switzerland embraced heated public debates to negotiate 
the issue in the 1980s, a more subtle approach was taken in 
the Caribbean to allow services to be delivered under the 
watchful gaze of the USA. Effective advocacy has to reflect 
the local context and should ideally be driven by local groups 
who best understand this context (meaning that these groups 
should be appropriately funded and empowered to perform 
this role). The relevant groups, whether governmental or 
nongovernmental, must acknowledge and understand 
the factors that guide policy decisions. Interestingly, these 
examples also allude to a diversity in the motivations of policy 
makers in adopting harm reduction, including ensuring 
national productivity, improving public health and order, and 
achieving MDGs and consequent ‘developing country’ status. 
Crucially, advocates must also decide and focus on which 
factors they can realistically influence or control. Although 
the ultimate ‘tipping point’ may come from factors beyond 
their control (such as changes in political leadership), their 
work will lay the foundations for policy shifts for change. 
Finally, the four examples highlighted here also demonstrate 
the need for patience. In the Caribbean, Macedonia, Malaysia 
and Switzerland, there will undoubtedly have been times 
when it seemed like fighting a losing battle. The policy shifts 
described here happened over a prolonged period and as the 
result of tireless and dedicated activism and advocacy. 
Factors Influencing Successful Local 
Advocacy for Harm Reduction
 » Carefully tailor responses to local contexts
 » Involvement of strong, local civil society 
organisations 
 » Innovative services opened (with or without official 
support or permission)
 » Commissioning or conducting research
 » Evidence made accessible for policymakers and the 
public
 » Clear articulation of costs, benefits, and risks of 
inaction
 » Empowerment and meaningful engagement of 
people who use drugs
 » Key groups united for discussions and debate: 
policymakers, academics, civil society, religious 
groups, the media and people who use drugs
 » Conferences, events and exchanges (international, 
regional and national)
 » Support from international or regional donors and 
organisations
 » Emphasis of international goals, commitments and 
targets (for public health, human rights and other 
issues)
 » Alliances built with other fields and groups
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about this Publication
In 2008  Harm Reduction International released the Global State of Harm Reduction, a report that mapped 
responses to drug-related HIV and hepatitis C epidemics around the world for the first time. The report 
has since been published every two years.
The Global State of Harm Reduction 2012 presents the major developments in harm reduction policy 
adoption and programme implementation that have occurred since 2010, enabling some assessment of 
global progress. It also explores several key issues for developing an integrated harm reduction response, 
such as building effective harm reduction services for women who inject drugs, access to harm reduction 
services by young people, drug use among men who have sex with men, global progress toward drug 
decriminalisation and regulation and sustainability of services in challenging environments.
This report, and other global state of harm reduction resources, are designed to provide reference tools for 
a wide range of audiences, such as international donor organisations, multilateral and bilateral agencies, 
civil society and non-governmental organisations, including organisations of people who use drugs, as 
well as researchers and the media.
tHe Global State
of Harm reduction20
12
Towa r d s  a n  i n T e g r aT e d  r e s p o n s e
If you would like to find out more about Harm Reduction International
and how you can support our work, please contact us at:
Harm Reduction International
Unit 2D12, South Bank Technopark
90 London Road, London, SE1 6LN
Phone:  +44 (0)207 7171 592
Email: info@ihra.net
Web: www.ihra.net
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